id	sid	tid	token	lemma	pos
cord-015922-5wwy0m2k	1	1	key	key	JJ
cord-015922-5wwy0m2k	1	2	:	:	:
cord-015922-5wwy0m2k	1	3	cord-015922	cord-015922	NNP
cord-015922-5wwy0m2k	1	4	-	-	HYPH
cord-015922-5wwy0m2k	1	5	5wwy0m2k	5wwy0m2k	CD
cord-015922-5wwy0m2k	1	6	authors	author	NNS
cord-015922-5wwy0m2k	1	7	:	:	:
cord-015922-5wwy0m2k	1	8	Marty	Marty	NNP
cord-015922-5wwy0m2k	1	9	,	,	,
cord-015922-5wwy0m2k	1	10	Francisco	Francisco	NNP
cord-015922-5wwy0m2k	1	11	M.	M.	NNP
cord-015922-5wwy0m2k	1	12	;	;	:
cord-015922-5wwy0m2k	1	13	Baden	Baden	NNP
cord-015922-5wwy0m2k	1	14	,	,	,
cord-015922-5wwy0m2k	1	15	Lindsey	Lindsey	NNP
cord-015922-5wwy0m2k	1	16	R.	R.	NNP
cord-015922-5wwy0m2k	1	17	title	title	NN
cord-015922-5wwy0m2k	1	18	:	:	:
cord-015922-5wwy0m2k	1	19	Infection	infection	NN
cord-015922-5wwy0m2k	1	20	in	in	IN
cord-015922-5wwy0m2k	1	21	the	the	DT
cord-015922-5wwy0m2k	1	22	Hematopoietic	Hematopoietic	NNP
cord-015922-5wwy0m2k	1	23	Stem	Stem	NNP
cord-015922-5wwy0m2k	1	24	Cell	Cell	NNP
cord-015922-5wwy0m2k	1	25	Transplant	Transplant	NNP
cord-015922-5wwy0m2k	1	26	Recipient	Recipient	NNP
cord-015922-5wwy0m2k	1	27	date	date	NN
cord-015922-5wwy0m2k	1	28	:	:	:
cord-015922-5wwy0m2k	1	29	2008	2008	CD
cord-015922-5wwy0m2k	1	30	journal	journal	NN
cord-015922-5wwy0m2k	1	31	:	:	:
cord-015922-5wwy0m2k	2	1	Hematopoietic	Hematopoietic	NNP
cord-015922-5wwy0m2k	2	2	Stem	Stem	NNP
cord-015922-5wwy0m2k	2	3	Cell	cell	NN
cord-015922-5wwy0m2k	2	4	Transplantation	transplantation	NN
cord-015922-5wwy0m2k	2	5	DOI	doi	NN
cord-015922-5wwy0m2k	2	6	:	:	:
cord-015922-5wwy0m2k	3	1	10.1007/978	10.1007/978	LS
cord-015922-5wwy0m2k	3	2	-	-	HYPH
cord-015922-5wwy0m2k	3	3	1	1	CD
cord-015922-5wwy0m2k	3	4	-	-	HYPH
cord-015922-5wwy0m2k	3	5	59745	59745	CD
cord-015922-5wwy0m2k	3	6	-	-	HYPH
cord-015922-5wwy0m2k	3	7	438	438	CD
cord-015922-5wwy0m2k	3	8	-	-	HYPH
cord-015922-5wwy0m2k	3	9	4_19	4_19	CD
cord-015922-5wwy0m2k	3	10	sha	sha	NNP
cord-015922-5wwy0m2k	3	11	:	:	:
cord-015922-5wwy0m2k	3	12	08c166a51c492af21571f14789db44b27ebe53ae	08c166a51c492af21571f14789db44b27ebe53ae	CD
cord-015922-5wwy0m2k	4	1	doc_id	doc_id	CD
cord-015922-5wwy0m2k	4	2	:	:	:
cord-015922-5wwy0m2k	4	3	15922	15922	CD
cord-015922-5wwy0m2k	4	4	cord_uid	cord_uid	NNS
cord-015922-5wwy0m2k	4	5	:	:	:
cord-015922-5wwy0m2k	4	6	5wwy0m2k	5wwy0m2k	CD
cord-015922-5wwy0m2k	5	1	nan	nan	NNP
cord-015922-5wwy0m2k	5	2	There	there	EX
cord-015922-5wwy0m2k	5	3	are	be	VBP
cord-015922-5wwy0m2k	5	4	three	three	CD
cord-015922-5wwy0m2k	5	5	key	key	JJ
cord-015922-5wwy0m2k	5	6	elements	element	NNS
cord-015922-5wwy0m2k	5	7	of	of	IN
cord-015922-5wwy0m2k	5	8	the	the	DT
cord-015922-5wwy0m2k	5	9	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	5	10	procedure	procedure	NN
cord-015922-5wwy0m2k	5	11	that	that	WDT
cord-015922-5wwy0m2k	5	12	determine	determine	VBP
cord-015922-5wwy0m2k	5	13	the	the	DT
cord-015922-5wwy0m2k	5	14	type	type	NN
cord-015922-5wwy0m2k	5	15	and	and	CC
cord-015922-5wwy0m2k	5	16	timing	timing	NN
cord-015922-5wwy0m2k	5	17	of	of	IN
cord-015922-5wwy0m2k	5	18	the	the	DT
cord-015922-5wwy0m2k	5	19	infectious	infectious	JJ
cord-015922-5wwy0m2k	5	20	risk	risk	NN
cord-015922-5wwy0m2k	5	21	profile	profile	NN
cord-015922-5wwy0m2k	5	22	after	after	IN
cord-015922-5wwy0m2k	5	23	transplantation	transplantation	NN
cord-015922-5wwy0m2k	5	24	[	[	-LRB-
cord-015922-5wwy0m2k	5	25	1	1	CD
cord-015922-5wwy0m2k	5	26	,	,	,
cord-015922-5wwy0m2k	5	27	7	7	CD
cord-015922-5wwy0m2k	5	28	]	]	-RRB-
cord-015922-5wwy0m2k	5	29	:	:	:
cord-015922-5wwy0m2k	5	30	1	1	CD
cord-015922-5wwy0m2k	5	31	,	,	,
cord-015922-5wwy0m2k	5	32	7	7	CD
cord-015922-5wwy0m2k	5	33	a.	a.	NN
cord-015922-5wwy0m2k	6	1	The	the	DT
cord-015922-5wwy0m2k	6	2	duration	duration	NN
cord-015922-5wwy0m2k	6	3	of	of	IN
cord-015922-5wwy0m2k	6	4	neutropenia	neutropenia	NN
cord-015922-5wwy0m2k	6	5	and	and	CC
cord-015922-5wwy0m2k	6	6	mucosal	mucosal	JJ
cord-015922-5wwy0m2k	6	7	injury	injury	NN
cord-015922-5wwy0m2k	6	8	which	which	WDT
cord-015922-5wwy0m2k	6	9	is	be	VBZ
cord-015922-5wwy0m2k	6	10	a	a	DT
cord-015922-5wwy0m2k	6	11	function	function	NN
cord-015922-5wwy0m2k	6	12	of	of	IN
cord-015922-5wwy0m2k	6	13	the	the	DT
cord-015922-5wwy0m2k	6	14	conditioning	conditioning	NN
cord-015922-5wwy0m2k	6	15	regimen	regimen	NN
cord-015922-5wwy0m2k	6	16	selected	select	VBN
cord-015922-5wwy0m2k	6	17	(	(	-LRB-
cord-015922-5wwy0m2k	6	18	myeloablative	myeloablative	NNP
cord-015922-5wwy0m2k	6	19	or	or	CC
cord-015922-5wwy0m2k	6	20	not	not	RB
cord-015922-5wwy0m2k	6	21	)	)	-RRB-
cord-015922-5wwy0m2k	6	22	and	and	CC
cord-015922-5wwy0m2k	6	23	the	the	DT
cord-015922-5wwy0m2k	6	24	stem	stem	NN
cord-015922-5wwy0m2k	6	25	cells	cell	NNS
cord-015922-5wwy0m2k	6	26	'	'	POS
cord-015922-5wwy0m2k	6	27	procurement	procurement	NN
cord-015922-5wwy0m2k	6	28	(	(	-LRB-
cord-015922-5wwy0m2k	6	29	cord	cord	NN
cord-015922-5wwy0m2k	6	30	or	or	CC
cord-015922-5wwy0m2k	6	31	adult	adult	NN
cord-015922-5wwy0m2k	6	32	;	;	,
cord-015922-5wwy0m2k	6	33	peripheral	peripheral	JJ
cord-015922-5wwy0m2k	6	34	or	or	CC
cord-015922-5wwy0m2k	6	35	bone	bone	NN
cord-015922-5wwy0m2k	6	36	marrow	marrow	NN
cord-015922-5wwy0m2k	6	37	acquisition	acquisition	NN
cord-015922-5wwy0m2k	6	38	among	among	IN
cord-015922-5wwy0m2k	6	39	adult	adult	NN
cord-015922-5wwy0m2k	6	40	donors	donor	NNS
cord-015922-5wwy0m2k	6	41	)	)	-RRB-
cord-015922-5wwy0m2k	6	42	.	.	.
cord-015922-5wwy0m2k	7	1	b.	b.	NNP
cord-015922-5wwy0m2k	8	1	The	the	DT
cord-015922-5wwy0m2k	8	2	strategy	strategy	NN
cord-015922-5wwy0m2k	8	3	chosen	choose	VBN
cord-015922-5wwy0m2k	8	4	to	to	TO
cord-015922-5wwy0m2k	8	5	prevent	prevent	VB
cord-015922-5wwy0m2k	8	6	GVHD	gvhd	NN
cord-015922-5wwy0m2k	8	7	among	among	IN
cord-015922-5wwy0m2k	8	8	allogeneic	allogeneic	NN
cord-015922-5wwy0m2k	8	9	recipients	recipient	NNS
cord-015922-5wwy0m2k	8	10	.	.	.
cord-015922-5wwy0m2k	9	1	T	T	NNP
cord-015922-5wwy0m2k	9	2	cell	cell	NN
cord-015922-5wwy0m2k	9	3	depletion	depletion	NN
cord-015922-5wwy0m2k	9	4	and	and	CC
cord-015922-5wwy0m2k	9	5	other	other	JJ
cord-015922-5wwy0m2k	9	6	T	T	NNP
cord-015922-5wwy0m2k	9	7	cell	cell	NN
cord-015922-5wwy0m2k	9	8	manipulation	manipulation	NN
cord-015922-5wwy0m2k	9	9	procedures	procedure	NNS
cord-015922-5wwy0m2k	9	10	lead	lead	VBP
cord-015922-5wwy0m2k	9	11	to	to	IN
cord-015922-5wwy0m2k	9	12	delayed	delay	VBN
cord-015922-5wwy0m2k	9	13	recovery	recovery	NN
cord-015922-5wwy0m2k	9	14	of	of	IN
cord-015922-5wwy0m2k	9	15	lymphocyte	lymphocyte	NN
cord-015922-5wwy0m2k	9	16	function	function	NN
cord-015922-5wwy0m2k	9	17	and	and	CC
cord-015922-5wwy0m2k	9	18	provide	provide	VB
cord-015922-5wwy0m2k	9	19	a	a	DT
cord-015922-5wwy0m2k	9	20	specific	specific	JJ
cord-015922-5wwy0m2k	9	21	immune	immune	JJ
cord-015922-5wwy0m2k	9	22	deficiency	deficiency	NN
cord-015922-5wwy0m2k	9	23	profile	profile	NN
cord-015922-5wwy0m2k	9	24	.	.	.
cord-015922-5wwy0m2k	10	1	c.	c.	NNP
cord-015922-5wwy0m2k	11	1	The	the	DT
cord-015922-5wwy0m2k	11	2	occurrence	occurrence	NN
cord-015922-5wwy0m2k	11	3	and	and	CC
cord-015922-5wwy0m2k	11	4	severity	severity	NN
cord-015922-5wwy0m2k	11	5	of	of	IN
cord-015922-5wwy0m2k	11	6	acute	acute	JJ
cord-015922-5wwy0m2k	11	7	and	and	CC
cord-015922-5wwy0m2k	11	8	chronic	chronic	JJ
cord-015922-5wwy0m2k	11	9	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	11	10	and	and	CC
cord-015922-5wwy0m2k	11	11	its	-PRON-	PRP$
cord-015922-5wwy0m2k	11	12	treatment	treatment	NN
cord-015922-5wwy0m2k	11	13	[	[	-LRB-
cord-015922-5wwy0m2k	11	14	1	1	CD
cord-015922-5wwy0m2k	11	15	,	,	,
cord-015922-5wwy0m2k	11	16	7	7	CD
cord-015922-5wwy0m2k	11	17	]	]	-RRB-
cord-015922-5wwy0m2k	11	18	.	.	.
cord-015922-5wwy0m2k	12	1	The	the	DT
cord-015922-5wwy0m2k	12	2	temporal	temporal	JJ
cord-015922-5wwy0m2k	12	3	course	course	NN
cord-015922-5wwy0m2k	12	4	of	of	IN
cord-015922-5wwy0m2k	12	5	infection	infection	NN
cord-015922-5wwy0m2k	12	6	following	follow	VBG
cord-015922-5wwy0m2k	12	7	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	12	8	can	can	MD
cord-015922-5wwy0m2k	12	9	be	be	VB
cord-015922-5wwy0m2k	12	10	divided	divide	VBN
cord-015922-5wwy0m2k	12	11	into	into	IN
cord-015922-5wwy0m2k	12	12	three	three	CD
cord-015922-5wwy0m2k	12	13	time	time	NN
cord-015922-5wwy0m2k	12	14	periods	period	NNS
cord-015922-5wwy0m2k	12	15	(	(	-LRB-
cord-015922-5wwy0m2k	12	16	Fig	Fig	NNP
cord-015922-5wwy0m2k	12	17	.	.	.
cord-015922-5wwy0m2k	12	18	19	19	CD
cord-015922-5wwy0m2k	12	19	-	-	SYM
cord-015922-5wwy0m2k	12	20	1	1	CD
cord-015922-5wwy0m2k	12	21	)	)	-RRB-
cord-015922-5wwy0m2k	12	22	[	[	-LRB-
cord-015922-5wwy0m2k	12	23	1	1	CD
cord-015922-5wwy0m2k	12	24	,	,	,
cord-015922-5wwy0m2k	12	25	3	3	CD
cord-015922-5wwy0m2k	12	26	,	,	,
cord-015922-5wwy0m2k	12	27	4	4	CD
cord-015922-5wwy0m2k	12	28	,	,	,
cord-015922-5wwy0m2k	12	29	7	7	CD
cord-015922-5wwy0m2k	12	30	]	]	-RRB-
cord-015922-5wwy0m2k	12	31	:	:	:
cord-015922-5wwy0m2k	12	32	1	1	LS
cord-015922-5wwy0m2k	12	33	.	.	.
cord-015922-5wwy0m2k	13	1	Conditioning	conditioning	NN
cord-015922-5wwy0m2k	13	2	to	to	IN
cord-015922-5wwy0m2k	13	3	Engraftment	Engraftment	NNP
cord-015922-5wwy0m2k	14	1	The	the	DT
cord-015922-5wwy0m2k	14	2	duration	duration	NN
cord-015922-5wwy0m2k	14	3	of	of	IN
cord-015922-5wwy0m2k	14	4	this	this	DT
cord-015922-5wwy0m2k	14	5	period	period	NN
cord-015922-5wwy0m2k	14	6	has	have	VBZ
cord-015922-5wwy0m2k	14	7	become	become	VBN
cord-015922-5wwy0m2k	14	8	dynamic	dynamic	JJ
cord-015922-5wwy0m2k	14	9	and	and	CC
cord-015922-5wwy0m2k	14	10	depends	depend	VBZ
cord-015922-5wwy0m2k	14	11	on	on	IN
cord-015922-5wwy0m2k	14	12	the	the	DT
cord-015922-5wwy0m2k	14	13	conditioning	conditioning	NN
cord-015922-5wwy0m2k	14	14	regimen	regimen	NN
cord-015922-5wwy0m2k	14	15	itself	-PRON-	PRP
cord-015922-5wwy0m2k	14	16	,	,	,
cord-015922-5wwy0m2k	14	17	the	the	DT
cord-015922-5wwy0m2k	14	18	source	source	NN
cord-015922-5wwy0m2k	14	19	and	and	CC
cord-015922-5wwy0m2k	14	20	dose	dose	NN
cord-015922-5wwy0m2k	14	21	of	of	IN
cord-015922-5wwy0m2k	14	22	stem	stem	NN
cord-015922-5wwy0m2k	14	23	cells	cell	NNS
cord-015922-5wwy0m2k	14	24	infused	infuse	VBN
cord-015922-5wwy0m2k	14	25	and	and	CC
cord-015922-5wwy0m2k	14	26	whether	whether	IN
cord-015922-5wwy0m2k	14	27	growth	growth	NN
cord-015922-5wwy0m2k	14	28	factors	factor	NNS
cord-015922-5wwy0m2k	14	29	are	be	VBP
cord-015922-5wwy0m2k	14	30	used	use	VBN
cord-015922-5wwy0m2k	14	31	.	.	.
cord-015922-5wwy0m2k	15	1	It	-PRON-	PRP
cord-015922-5wwy0m2k	15	2	usually	usually	RB
cord-015922-5wwy0m2k	15	3	ranges	range	VBZ
cord-015922-5wwy0m2k	15	4	from	from	IN
cord-015922-5wwy0m2k	15	5	five	five	CD
cord-015922-5wwy0m2k	15	6	(	(	-LRB-
cord-015922-5wwy0m2k	15	7	with	with	IN
cord-015922-5wwy0m2k	15	8	nonmyeloablative	nonmyeloablative	JJ
cord-015922-5wwy0m2k	15	9	transplants	transplant	NNS
cord-015922-5wwy0m2k	15	10	)	)	-RRB-
cord-015922-5wwy0m2k	15	11	to	to	IN
cord-015922-5wwy0m2k	15	12	30	30	CD
cord-015922-5wwy0m2k	15	13	days	day	NNS
cord-015922-5wwy0m2k	15	14	(	(	-LRB-
cord-015922-5wwy0m2k	15	15	with	with	IN
cord-015922-5wwy0m2k	15	16	bone	bone	NN
cord-015922-5wwy0m2k	15	17	marrow	marrow	NN
cord-015922-5wwy0m2k	15	18	or	or	CC
cord-015922-5wwy0m2k	15	19	umbilical	umbilical	JJ
cord-015922-5wwy0m2k	15	20	cord	cord	NN
cord-015922-5wwy0m2k	15	21	blood	blood	NN
cord-015922-5wwy0m2k	15	22	transplants	transplant	NNS
cord-015922-5wwy0m2k	15	23	)	)	-RRB-
cord-015922-5wwy0m2k	15	24	.	.	.
cord-015922-5wwy0m2k	16	1	The	the	DT
cord-015922-5wwy0m2k	16	2	combination	combination	NN
cord-015922-5wwy0m2k	16	3	of	of	IN
cord-015922-5wwy0m2k	16	4	profound	profound	JJ
cord-015922-5wwy0m2k	16	5	granulocytopenia	granulocytopenia	NNP
cord-015922-5wwy0m2k	16	6	and	and	CC
cord-015922-5wwy0m2k	16	7	mucositis	mucositis	NNP
cord-015922-5wwy0m2k	16	8	with	with	IN
cord-015922-5wwy0m2k	16	9	myeloablative	myeloablative	NNP
cord-015922-5wwy0m2k	16	10	conditioning	conditioning	NN
cord-015922-5wwy0m2k	16	11	makes	make	VBZ
cord-015922-5wwy0m2k	16	12	the	the	DT
cord-015922-5wwy0m2k	16	13	patient	patient	NN
cord-015922-5wwy0m2k	16	14	particularly	particularly	RB
cord-015922-5wwy0m2k	16	15	vulnerable	vulnerable	JJ
cord-015922-5wwy0m2k	16	16	to	to	IN
cord-015922-5wwy0m2k	16	17	bacterial	bacterial	JJ
cord-015922-5wwy0m2k	16	18	and	and	CC
cord-015922-5wwy0m2k	16	19	candidal	candidal	JJ
cord-015922-5wwy0m2k	16	20	infections	infection	NNS
cord-015922-5wwy0m2k	16	21	.	.	.
cord-015922-5wwy0m2k	17	1	In	in	IN
cord-015922-5wwy0m2k	17	2	addition	addition	NN
cord-015922-5wwy0m2k	17	3	,	,	,
cord-015922-5wwy0m2k	17	4	infection	infection	NN
cord-015922-5wwy0m2k	17	5	present	present	JJ
cord-015922-5wwy0m2k	17	6	in	in	IN
cord-015922-5wwy0m2k	17	7	the	the	DT
cord-015922-5wwy0m2k	17	8	transplant	transplant	NN
cord-015922-5wwy0m2k	17	9	recipient	recipient	NN
cord-015922-5wwy0m2k	17	10	pre	pre	JJ
cord-015922-5wwy0m2k	17	11	-	-	NN
cord-015922-5wwy0m2k	17	12	transplant	transplant	NN
cord-015922-5wwy0m2k	17	13	may	may	MD
cord-015922-5wwy0m2k	17	14	be	be	VB
cord-015922-5wwy0m2k	17	15	amplified	amplify	VBN
cord-015922-5wwy0m2k	17	16	by	by	IN
cord-015922-5wwy0m2k	17	17	the	the	DT
cord-015922-5wwy0m2k	17	18	granulocytopenic	granulocytopenic	NNP
cord-015922-5wwy0m2k	17	19	state	state	NN
cord-015922-5wwy0m2k	17	20	and	and	CC
cord-015922-5wwy0m2k	17	21	deficiencies	deficiency	NNS
cord-015922-5wwy0m2k	17	22	of	of	IN
cord-015922-5wwy0m2k	17	23	T	T	NNP
cord-015922-5wwy0m2k	17	24	and	and	CC
cord-015922-5wwy0m2k	17	25	B	b	NN
cord-015922-5wwy0m2k	17	26	-	-	HYPH
cord-015922-5wwy0m2k	17	27	cell	cell	NN
cord-015922-5wwy0m2k	17	28	numbers	number	NNS
cord-015922-5wwy0m2k	17	29	and	and	CC
cord-015922-5wwy0m2k	17	30	function	function	NN
cord-015922-5wwy0m2k	17	31	.	.	.
cord-015922-5wwy0m2k	18	1	Thus	thus	RB
cord-015922-5wwy0m2k	18	2	,	,	,
cord-015922-5wwy0m2k	18	3	control	control	NN
cord-015922-5wwy0m2k	18	4	of	of	IN
cord-015922-5wwy0m2k	18	5	pre	pre	JJ
cord-015922-5wwy0m2k	18	6	-	-	JJ
cord-015922-5wwy0m2k	18	7	transplant	transplant	JJ
cord-015922-5wwy0m2k	18	8	infection	infection	NN
cord-015922-5wwy0m2k	18	9	is	be	VBZ
cord-015922-5wwy0m2k	18	10	needed	need	VBN
cord-015922-5wwy0m2k	18	11	before	before	IN
cord-015922-5wwy0m2k	18	12	initiating	initiate	VBG
cord-015922-5wwy0m2k	18	13	the	the	DT
cord-015922-5wwy0m2k	18	14	conditioning	conditioning	NN
cord-015922-5wwy0m2k	18	15	regimen	regimen	NN
cord-015922-5wwy0m2k	18	16	.	.	.
cord-015922-5wwy0m2k	19	1	Prior	prior	RB
cord-015922-5wwy0m2k	19	2	to	to	IN
cord-015922-5wwy0m2k	19	3	engraftment	engraftment	NN
cord-015922-5wwy0m2k	19	4	(	(	-LRB-
cord-015922-5wwy0m2k	19	5	both	both	DT
cord-015922-5wwy0m2k	19	6	with	with	IN
cord-015922-5wwy0m2k	19	7	autologous	autologous	JJ
cord-015922-5wwy0m2k	19	8	and	and	CC
cord-015922-5wwy0m2k	19	9	allogeneic	allogeneic	JJ
cord-015922-5wwy0m2k	19	10	transplants	transplant	NNS
cord-015922-5wwy0m2k	19	11	)	)	-RRB-
cord-015922-5wwy0m2k	19	12	,	,	,
cord-015922-5wwy0m2k	19	13	approximately	approximately	RB
cord-015922-5wwy0m2k	19	14	50	50	CD
cord-015922-5wwy0m2k	19	15	percent	percent	NN
cord-015922-5wwy0m2k	19	16	of	of	IN
cord-015922-5wwy0m2k	19	17	patients	patient	NNS
cord-015922-5wwy0m2k	19	18	will	will	MD
cord-015922-5wwy0m2k	19	19	have	have	VB
cord-015922-5wwy0m2k	19	20	fever	fever	NN
cord-015922-5wwy0m2k	19	21	of	of	IN
cord-015922-5wwy0m2k	19	22	unknown	unknown	JJ
cord-015922-5wwy0m2k	19	23	origin	origin	NN
cord-015922-5wwy0m2k	19	24	,	,	,
cord-015922-5wwy0m2k	19	25	with	with	IN
cord-015922-5wwy0m2k	19	26	bloodstream	bloodstream	NN
cord-015922-5wwy0m2k	19	27	infection	infection	NN
cord-015922-5wwy0m2k	19	28	in	in	IN
cord-015922-5wwy0m2k	19	29	~12.5	~12.5	CD
cord-015922-5wwy0m2k	19	30	percent	percent	NN
cord-015922-5wwy0m2k	19	31	and	and	CC
cord-015922-5wwy0m2k	19	32	pneumonia	pneumonia	NN
cord-015922-5wwy0m2k	19	33	in	in	IN
cord-015922-5wwy0m2k	19	34	∼10	∼10	NNP
cord-015922-5wwy0m2k	19	35	percent	percent	NN
cord-015922-5wwy0m2k	19	36	.	.	.
cord-015922-5wwy0m2k	20	1	The	the	DT
cord-015922-5wwy0m2k	20	2	risk	risk	NN
cord-015922-5wwy0m2k	20	3	of	of	IN
cord-015922-5wwy0m2k	20	4	an	an	DT
cord-015922-5wwy0m2k	20	5	invasive	invasive	JJ
cord-015922-5wwy0m2k	20	6	mold	mold	NN
cord-015922-5wwy0m2k	20	7	infection	infection	NN
cord-015922-5wwy0m2k	20	8	is	be	VBZ
cord-015922-5wwy0m2k	20	9	related	relate	VBN
cord-015922-5wwy0m2k	20	10	to	to	IN
cord-015922-5wwy0m2k	20	11	the	the	DT
cord-015922-5wwy0m2k	20	12	duration	duration	NN
cord-015922-5wwy0m2k	20	13	of	of	IN
cord-015922-5wwy0m2k	20	14	neutropenia	neutropenia	NN
cord-015922-5wwy0m2k	20	15	and	and	CC
cord-015922-5wwy0m2k	20	16	the	the	DT
cord-015922-5wwy0m2k	20	17	environmental	environmental	JJ
cord-015922-5wwy0m2k	20	18	strategy	strategy	NN
cord-015922-5wwy0m2k	20	19	used	use	VBN
cord-015922-5wwy0m2k	20	20	in	in	IN
cord-015922-5wwy0m2k	20	21	a	a	DT
cord-015922-5wwy0m2k	20	22	transplant	transplant	NN
cord-015922-5wwy0m2k	20	23	center	center	NN
cord-015922-5wwy0m2k	20	24	.	.	.
cord-015922-5wwy0m2k	21	1	2	2	LS
cord-015922-5wwy0m2k	21	2	.	.	.
cord-015922-5wwy0m2k	22	1	Engraftment	Engraftment	NNP
cord-015922-5wwy0m2k	22	2	to	to	IN
cord-015922-5wwy0m2k	22	3	Post	Post	NNP
cord-015922-5wwy0m2k	22	4	-	-	NNP
cord-015922-5wwy0m2k	22	5	Transplant	Transplant	NNP
cord-015922-5wwy0m2k	22	6	Day	Day	NNP
cord-015922-5wwy0m2k	22	7	100	100	CD
cord-015922-5wwy0m2k	22	8	During	during	IN
cord-015922-5wwy0m2k	22	9	this	this	DT
cord-015922-5wwy0m2k	22	10	time	time	NN
cord-015922-5wwy0m2k	22	11	period	period	NN
cord-015922-5wwy0m2k	22	12	viral	viral	JJ
cord-015922-5wwy0m2k	22	13	infections	infection	NNS
cord-015922-5wwy0m2k	22	14	,	,	,
cord-015922-5wwy0m2k	22	15	particularly	particularly	RB
cord-015922-5wwy0m2k	22	16	cytomegalovirus	cytomegalovirus	NNP
cord-015922-5wwy0m2k	22	17	(	(	-LRB-
cord-015922-5wwy0m2k	22	18	CMV	CMV	NNP
cord-015922-5wwy0m2k	22	19	)	)	-RRB-
cord-015922-5wwy0m2k	22	20	and	and	CC
cord-015922-5wwy0m2k	22	21	the	the	DT
cord-015922-5wwy0m2k	22	22	other	other	JJ
cord-015922-5wwy0m2k	22	23	herpes	herpes	NN
cord-015922-5wwy0m2k	22	24	group	group	NN
cord-015922-5wwy0m2k	22	25	viruses	virus	NNS
cord-015922-5wwy0m2k	22	26	,	,	,
cord-015922-5wwy0m2k	22	27	are	be	VBP
cord-015922-5wwy0m2k	22	28	the	the	DT
cord-015922-5wwy0m2k	22	29	major	major	JJ
cord-015922-5wwy0m2k	22	30	concerns	concern	NNS
cord-015922-5wwy0m2k	22	31	.	.	.
cord-015922-5wwy0m2k	23	1	The	the	DT
cord-015922-5wwy0m2k	23	2	occurrence	occurrence	NN
cord-015922-5wwy0m2k	23	3	,	,	,
cord-015922-5wwy0m2k	23	4	severity	severity	NN
cord-015922-5wwy0m2k	23	5	and	and	CC
cord-015922-5wwy0m2k	23	6	treatment	treatment	NN
cord-015922-5wwy0m2k	23	7	modalities	modality	NNS
cord-015922-5wwy0m2k	23	8	selected	select	VBN
cord-015922-5wwy0m2k	23	9	for	for	IN
cord-015922-5wwy0m2k	23	10	acute	acute	JJ
cord-015922-5wwy0m2k	23	11	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	23	12	further	further	RB
cord-015922-5wwy0m2k	23	13	modulates	modulate	VBZ
cord-015922-5wwy0m2k	23	14	and	and	CC
cord-015922-5wwy0m2k	23	15	increases	increase	VBZ
cord-015922-5wwy0m2k	23	16	the	the	DT
cord-015922-5wwy0m2k	23	17	risk	risk	NN
cord-015922-5wwy0m2k	23	18	of	of	IN
cord-015922-5wwy0m2k	23	19	herpesvirus	herpesvirus	NN
cord-015922-5wwy0m2k	23	20	infections	infection	NNS
cord-015922-5wwy0m2k	23	21	,	,	,
cord-015922-5wwy0m2k	23	22	especially	especially	RB
cord-015922-5wwy0m2k	23	23	CMV	CMV	NNP
cord-015922-5wwy0m2k	23	24	and	and	CC
cord-015922-5wwy0m2k	23	25	Epstein	Epstein	NNP
cord-015922-5wwy0m2k	23	26	-	-	HYPH
cord-015922-5wwy0m2k	23	27	Barr	Barr	NNP
cord-015922-5wwy0m2k	23	28	virus	virus	NN
cord-015922-5wwy0m2k	23	29	(	(	-LRB-
cord-015922-5wwy0m2k	23	30	EBV	EBV	NNP
cord-015922-5wwy0m2k	23	31	)	)	-RRB-
cord-015922-5wwy0m2k	23	32	,	,	,
cord-015922-5wwy0m2k	23	33	and	and	CC
cord-015922-5wwy0m2k	23	34	invasive	invasive	JJ
cord-015922-5wwy0m2k	23	35	mold	mold	NN
cord-015922-5wwy0m2k	23	36	infections	infection	NNS
cord-015922-5wwy0m2k	23	37	[	[	-LRB-
cord-015922-5wwy0m2k	23	38	8	8	CD
cord-015922-5wwy0m2k	23	39	]	]	-RRB-
cord-015922-5wwy0m2k	24	1	[	[	-LRB-
cord-015922-5wwy0m2k	24	2	9	9	CD
cord-015922-5wwy0m2k	24	3	]	]	-RRB-
cord-015922-5wwy0m2k	24	4	[	[	-LRB-
cord-015922-5wwy0m2k	24	5	10	10	CD
cord-015922-5wwy0m2k	24	6	]	]	-RRB-
cord-015922-5wwy0m2k	24	7	[	[	-LRB-
cord-015922-5wwy0m2k	24	8	11	11	CD
cord-015922-5wwy0m2k	24	9	]	]	-RRB-
cord-015922-5wwy0m2k	24	10	.	.	.
cord-015922-5wwy0m2k	25	1	3	3	LS
cord-015922-5wwy0m2k	25	2	.	.	.
cord-015922-5wwy0m2k	26	1	More	More	JJR
cord-015922-5wwy0m2k	26	2	than	than	IN
cord-015922-5wwy0m2k	26	3	100	100	CD
cord-015922-5wwy0m2k	26	4	Days	day	NNS
cord-015922-5wwy0m2k	26	5	Post	Post	NNP
cord-015922-5wwy0m2k	26	6	-	-	NN
cord-015922-5wwy0m2k	26	7	Transplant	transplant	NN
cord-015922-5wwy0m2k	27	1	In	in	IN
cord-015922-5wwy0m2k	27	2	the	the	DT
cord-015922-5wwy0m2k	27	3	absence	absence	NN
cord-015922-5wwy0m2k	27	4	of	of	IN
cord-015922-5wwy0m2k	27	5	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	27	6	,	,	,
cord-015922-5wwy0m2k	27	7	the	the	DT
cord-015922-5wwy0m2k	27	8	incidence	incidence	NN
cord-015922-5wwy0m2k	27	9	of	of	IN
cord-015922-5wwy0m2k	27	10	infection	infection	NN
cord-015922-5wwy0m2k	27	11	decreases	decrease	VBZ
cord-015922-5wwy0m2k	27	12	significantly	significantly	RB
cord-015922-5wwy0m2k	27	13	,	,	,
cord-015922-5wwy0m2k	27	14	with	with	IN
cord-015922-5wwy0m2k	27	15	varicella	varicella	NN
cord-015922-5wwy0m2k	27	16	zoster	zoster	NNP
cord-015922-5wwy0m2k	27	17	virus	virus	NN
cord-015922-5wwy0m2k	27	18	(	(	-LRB-
cord-015922-5wwy0m2k	27	19	VZV	VZV	NNP
cord-015922-5wwy0m2k	27	20	)	)	-RRB-
cord-015922-5wwy0m2k	27	21	,	,	,
cord-015922-5wwy0m2k	27	22	Pneumocystis	Pneumocystis	NNP
cord-015922-5wwy0m2k	27	23	jiroveci	jiroveci	NNP
cord-015922-5wwy0m2k	27	24	(	(	-LRB-
cord-015922-5wwy0m2k	27	25	formerly	formerly	RB
cord-015922-5wwy0m2k	27	26	carinii	carinii	FW
cord-015922-5wwy0m2k	27	27	)	)	-RRB-
cord-015922-5wwy0m2k	27	28	pneumonia	pneumonia	NN
cord-015922-5wwy0m2k	27	29	(	(	-LRB-
cord-015922-5wwy0m2k	27	30	PCP	PCP	NNP
cord-015922-5wwy0m2k	27	31	)	)	-RRB-
cord-015922-5wwy0m2k	27	32	and	and	CC
cord-015922-5wwy0m2k	27	33	pneumococcal	pneumococcal	JJ
cord-015922-5wwy0m2k	27	34	infection	infection	NN
cord-015922-5wwy0m2k	27	35	being	be	VBG
cord-015922-5wwy0m2k	27	36	the	the	DT
cord-015922-5wwy0m2k	27	37	primary	primary	JJ
cord-015922-5wwy0m2k	27	38	problems	problem	NNS
cord-015922-5wwy0m2k	27	39	of	of	IN
cord-015922-5wwy0m2k	27	40	this	this	DT
cord-015922-5wwy0m2k	27	41	time	time	NN
cord-015922-5wwy0m2k	27	42	period	period	NN
cord-015922-5wwy0m2k	27	43	.	.	.
cord-015922-5wwy0m2k	28	1	Routine	routine	JJ
cord-015922-5wwy0m2k	28	2	use	use	NN
cord-015922-5wwy0m2k	28	3	of	of	IN
cord-015922-5wwy0m2k	28	4	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	28	5	,	,	,
cord-015922-5wwy0m2k	28	6	such	such	JJ
cord-015922-5wwy0m2k	28	7	as	as	IN
cord-015922-5wwy0m2k	28	8	with	with	IN
cord-015922-5wwy0m2k	28	9	trimethoprim	trimethoprim	NNP
cord-015922-5wwy0m2k	28	10	/	/	SYM
cord-015922-5wwy0m2k	28	11	sulfamethoxazole	sulfamethoxazole	NNP
cord-015922-5wwy0m2k	28	12	and	and	CC
cord-015922-5wwy0m2k	28	13	acyclovir	acyclovir	NNP
cord-015922-5wwy0m2k	28	14	,	,	,
cord-015922-5wwy0m2k	28	15	significantly	significantly	RB
cord-015922-5wwy0m2k	28	16	decreases	decrease	VBZ
cord-015922-5wwy0m2k	28	17	the	the	DT
cord-015922-5wwy0m2k	28	18	occurrence	occurrence	NN
cord-015922-5wwy0m2k	28	19	of	of	IN
cord-015922-5wwy0m2k	28	20	PCP	PCP	NNP
cord-015922-5wwy0m2k	28	21	and	and	CC
cord-015922-5wwy0m2k	28	22	herpesvirus	herpesvirus	NN
cord-015922-5wwy0m2k	28	23	infections	infection	NNS
cord-015922-5wwy0m2k	28	24	,	,	,
cord-015922-5wwy0m2k	28	25	respectively	respectively	RB
cord-015922-5wwy0m2k	28	26	.	.	.
cord-015922-5wwy0m2k	29	1	In	in	IN
cord-015922-5wwy0m2k	29	2	addition	addition	NN
cord-015922-5wwy0m2k	29	3	,	,	,
cord-015922-5wwy0m2k	29	4	late	late	JJ
cord-015922-5wwy0m2k	29	5	or	or	CC
cord-015922-5wwy0m2k	29	6	relapsing	relapse	VBG
cord-015922-5wwy0m2k	29	7	CMV	CMV	NNP
cord-015922-5wwy0m2k	29	8	infection	infection	NN
cord-015922-5wwy0m2k	29	9	may	may	MD
cord-015922-5wwy0m2k	29	10	manifest	manifest	VB
cord-015922-5wwy0m2k	29	11	during	during	IN
cord-015922-5wwy0m2k	29	12	this	this	DT
cord-015922-5wwy0m2k	29	13	time	time	NN
cord-015922-5wwy0m2k	29	14	.	.	.
cord-015922-5wwy0m2k	30	1	If	if	IN
cord-015922-5wwy0m2k	30	2	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	30	3	is	be	VBZ
cord-015922-5wwy0m2k	30	4	present	present	JJ
cord-015922-5wwy0m2k	30	5	,	,	,
cord-015922-5wwy0m2k	30	6	it	-PRON-	PRP
cord-015922-5wwy0m2k	30	7	is	be	VBZ
cord-015922-5wwy0m2k	30	8	typically	typically	RB
cord-015922-5wwy0m2k	30	9	treated	treat	VBN
cord-015922-5wwy0m2k	30	10	with	with	IN
cord-015922-5wwy0m2k	30	11	significant	significant	JJ
cord-015922-5wwy0m2k	30	12	augmentation	augmentation	NN
cord-015922-5wwy0m2k	30	13	of	of	IN
cord-015922-5wwy0m2k	30	14	immunosuppressive	immunosuppressive	JJ
cord-015922-5wwy0m2k	30	15	therapy	therapy	NN
cord-015922-5wwy0m2k	30	16	such	such	JJ
cord-015922-5wwy0m2k	30	17	as	as	IN
cord-015922-5wwy0m2k	30	18	with	with	IN
cord-015922-5wwy0m2k	30	19	high	high	JJ
cord-015922-5wwy0m2k	30	20	-	-	HYPH
cord-015922-5wwy0m2k	30	21	dose	dose	NN
cord-015922-5wwy0m2k	30	22	corticosteroids	corticosteroid	NNS
cord-015922-5wwy0m2k	30	23	and	and	CC
cord-015922-5wwy0m2k	30	24	monoclonal	monoclonal	JJ
cord-015922-5wwy0m2k	30	25	antibodies	antibody	NNS
cord-015922-5wwy0m2k	30	26	.	.	.
cord-015922-5wwy0m2k	31	1	Patients	patient	NNS
cord-015922-5wwy0m2k	31	2	in	in	IN
cord-015922-5wwy0m2k	31	3	this	this	DT
cord-015922-5wwy0m2k	31	4	last	last	JJ
cord-015922-5wwy0m2k	31	5	category	category	NN
cord-015922-5wwy0m2k	31	6	(	(	-LRB-
cord-015922-5wwy0m2k	31	7	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	31	8	under	under	IN
cord-015922-5wwy0m2k	31	9	treatment	treatment	NN
cord-015922-5wwy0m2k	31	10	)	)	-RRB-
cord-015922-5wwy0m2k	31	11	are	be	VBP
cord-015922-5wwy0m2k	31	12	at	at	IN
cord-015922-5wwy0m2k	31	13	particular	particular	JJ
cord-015922-5wwy0m2k	31	14	risk	risk	NN
cord-015922-5wwy0m2k	31	15	for	for	IN
cord-015922-5wwy0m2k	31	16	invasive	invasive	JJ
cord-015922-5wwy0m2k	31	17	mold	mold	NN
cord-015922-5wwy0m2k	31	18	infection	infection	NN
cord-015922-5wwy0m2k	31	19	,	,	,
cord-015922-5wwy0m2k	31	20	CMV	CMV	NNP
cord-015922-5wwy0m2k	31	21	reactivation	reactivation	NN
cord-015922-5wwy0m2k	31	22	,	,	,
cord-015922-5wwy0m2k	31	23	PCP	PCP	NNP
cord-015922-5wwy0m2k	31	24	and	and	CC
cord-015922-5wwy0m2k	31	25	other	other	JJ
cord-015922-5wwy0m2k	31	26	common	common	JJ
cord-015922-5wwy0m2k	31	27	and	and	CC
cord-015922-5wwy0m2k	31	28	opportunistic	opportunistic	JJ
cord-015922-5wwy0m2k	31	29	pathogens	pathogen	NNS
cord-015922-5wwy0m2k	31	30	.	.	.
cord-015922-5wwy0m2k	32	1	There	there	EX
cord-015922-5wwy0m2k	32	2	are	be	VBP
cord-015922-5wwy0m2k	32	3	four	four	CD
cord-015922-5wwy0m2k	32	4	modes	mode	NNS
cord-015922-5wwy0m2k	32	5	in	in	IN
cord-015922-5wwy0m2k	32	6	which	which	WDT
cord-015922-5wwy0m2k	32	7	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	32	8	therapy	therapy	NN
cord-015922-5wwy0m2k	32	9	can	can	MD
cord-015922-5wwy0m2k	32	10	be	be	VB
cord-015922-5wwy0m2k	32	11	administered	administer	VBN
cord-015922-5wwy0m2k	32	12	to	to	IN
cord-015922-5wwy0m2k	32	13	the	the	DT
cord-015922-5wwy0m2k	32	14	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	32	15	patient	patient	NN
cord-015922-5wwy0m2k	32	16	[	[	-LRB-
cord-015922-5wwy0m2k	32	17	4	4	CD
cord-015922-5wwy0m2k	32	18	]	]	-RRB-
cord-015922-5wwy0m2k	32	19	:	:	:
cord-015922-5wwy0m2k	33	1	1	1	LS
cord-015922-5wwy0m2k	33	2	.	.	.
cord-015922-5wwy0m2k	34	1	A	a	DT
cord-015922-5wwy0m2k	34	2	therapeutic	therapeutic	JJ
cord-015922-5wwy0m2k	34	3	mode	mode	NN
cord-015922-5wwy0m2k	34	4	,	,	,
cord-015922-5wwy0m2k	34	5	in	in	IN
cord-015922-5wwy0m2k	34	6	which	which	WDT
cord-015922-5wwy0m2k	34	7	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	34	8	therapy	therapy	NN
cord-015922-5wwy0m2k	34	9	is	be	VBZ
cord-015922-5wwy0m2k	34	10	prescribed	prescribe	VBN
cord-015922-5wwy0m2k	34	11	for	for	IN
cord-015922-5wwy0m2k	34	12	the	the	DT
cord-015922-5wwy0m2k	34	13	treatment	treatment	NN
cord-015922-5wwy0m2k	34	14	and	and	CC
cord-015922-5wwy0m2k	34	15	eradication	eradication	NN
cord-015922-5wwy0m2k	34	16	of	of	IN
cord-015922-5wwy0m2k	34	17	identified	identify	VBN
cord-015922-5wwy0m2k	34	18	microbes	microbe	NNS
cord-015922-5wwy0m2k	34	19	causing	cause	VBG
cord-015922-5wwy0m2k	34	20	clinical	clinical	JJ
cord-015922-5wwy0m2k	34	21	illness	illness	NN
cord-015922-5wwy0m2k	34	22	.	.	.
cord-015922-5wwy0m2k	35	1	2	2	LS
cord-015922-5wwy0m2k	35	2	.	.	.
cord-015922-5wwy0m2k	36	1	A	a	DT
cord-015922-5wwy0m2k	36	2	prophylactic	prophylactic	JJ
cord-015922-5wwy0m2k	36	3	mode	mode	NN
cord-015922-5wwy0m2k	36	4	,	,	,
cord-015922-5wwy0m2k	36	5	in	in	IN
cord-015922-5wwy0m2k	36	6	which	which	WDT
cord-015922-5wwy0m2k	36	7	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	36	8	therapy	therapy	NN
cord-015922-5wwy0m2k	36	9	is	be	VBZ
cord-015922-5wwy0m2k	36	10	prescribed	prescribe	VBN
cord-015922-5wwy0m2k	36	11	to	to	IN
cord-015922-5wwy0m2k	36	12	an	an	DT
cord-015922-5wwy0m2k	36	13	entire	entire	JJ
cord-015922-5wwy0m2k	36	14	population	population	NN
cord-015922-5wwy0m2k	36	15	before	before	IN
cord-015922-5wwy0m2k	36	16	an	an	DT
cord-015922-5wwy0m2k	36	17	event	event	NN
cord-015922-5wwy0m2k	36	18	to	to	TO
cord-015922-5wwy0m2k	36	19	prevent	prevent	VB
cord-015922-5wwy0m2k	36	20	clinically	clinically	RB
cord-015922-5wwy0m2k	36	21	important	important	JJ
cord-015922-5wwy0m2k	36	22	infection	infection	NN
cord-015922-5wwy0m2k	36	23	.	.	.
cord-015922-5wwy0m2k	37	1	For	for	IN
cord-015922-5wwy0m2k	37	2	such	such	PDT
cord-015922-5wwy0m2k	37	3	a	a	DT
cord-015922-5wwy0m2k	37	4	strategy	strategy	NN
cord-015922-5wwy0m2k	37	5	to	to	TO
cord-015922-5wwy0m2k	37	6	be	be	VB
cord-015922-5wwy0m2k	37	7	successful	successful	JJ
cord-015922-5wwy0m2k	37	8	,	,	,
cord-015922-5wwy0m2k	37	9	the	the	DT
cord-015922-5wwy0m2k	37	10	infection(s	infection(s	NNP
cord-015922-5wwy0m2k	37	11	)	)	-RRB-
cord-015922-5wwy0m2k	37	12	being	be	VBG
cord-015922-5wwy0m2k	37	13	targeted	target	VBN
cord-015922-5wwy0m2k	37	14	must	must	MD
cord-015922-5wwy0m2k	37	15	be	be	VB
cord-015922-5wwy0m2k	37	16	important	important	JJ
cord-015922-5wwy0m2k	37	17	enough	enough	RB
cord-015922-5wwy0m2k	37	18	to	to	TO
cord-015922-5wwy0m2k	37	19	justify	justify	VB
cord-015922-5wwy0m2k	37	20	the	the	DT
cord-015922-5wwy0m2k	37	21	intervention	intervention	NN
cord-015922-5wwy0m2k	37	22	,	,	,
cord-015922-5wwy0m2k	37	23	and	and	CC
cord-015922-5wwy0m2k	37	24	the	the	DT
cord-015922-5wwy0m2k	37	25	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	37	26	therapy	therapy	NN
cord-015922-5wwy0m2k	37	27	prescribed	prescribe	VBN
cord-015922-5wwy0m2k	37	28	must	must	MD
cord-015922-5wwy0m2k	37	29	be	be	VB
cord-015922-5wwy0m2k	37	30	nontoxic	nontoxic	JJ
cord-015922-5wwy0m2k	37	31	and	and	CC
cord-015922-5wwy0m2k	37	32	inexpensive	inexpensive	JJ
cord-015922-5wwy0m2k	37	33	enough	enough	RB
cord-015922-5wwy0m2k	37	34	to	to	TO
cord-015922-5wwy0m2k	37	35	justify	justify	VB
cord-015922-5wwy0m2k	37	36	the	the	DT
cord-015922-5wwy0m2k	37	37	intervention	intervention	NN
cord-015922-5wwy0m2k	37	38	.	.	.
cord-015922-5wwy0m2k	38	1	By	by	IN
cord-015922-5wwy0m2k	38	2	far	far	RB
cord-015922-5wwy0m2k	38	3	the	the	DT
cord-015922-5wwy0m2k	38	4	most	most	RBS
cord-015922-5wwy0m2k	38	5	effective	effective	JJ
cord-015922-5wwy0m2k	38	6	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	38	7	prophylactic	prophylactic	JJ
cord-015922-5wwy0m2k	38	8	strategy	strategy	NN
cord-015922-5wwy0m2k	38	9	is	be	VBZ
cord-015922-5wwy0m2k	38	10	low	low	JJ
cord-015922-5wwy0m2k	38	11	-	-	HYPH
cord-015922-5wwy0m2k	38	12	dose	dose	NN
cord-015922-5wwy0m2k	38	13	trimethoprim	trimethoprim	NNP
cord-015922-5wwy0m2k	38	14	-	-	HYPH
cord-015922-5wwy0m2k	38	15	sulfamethoxazole	sulfamethoxazole	NNP
cord-015922-5wwy0m2k	38	16	,	,	,
cord-015922-5wwy0m2k	38	17	which	which	WDT
cord-015922-5wwy0m2k	38	18	has	have	VBZ
cord-015922-5wwy0m2k	38	19	virtually	virtually	RB
cord-015922-5wwy0m2k	38	20	eliminated	eliminate	VBN
cord-015922-5wwy0m2k	38	21	the	the	DT
cord-015922-5wwy0m2k	38	22	occurrence	occurrence	NN
cord-015922-5wwy0m2k	38	23	of	of	IN
cord-015922-5wwy0m2k	38	24	Pneumocystis	Pneumocystis	NNP
cord-015922-5wwy0m2k	38	25	jiroveci	jiroveci	NNP
cord-015922-5wwy0m2k	38	26	,	,	,
cord-015922-5wwy0m2k	38	27	Listeria	Listeria	NNP
cord-015922-5wwy0m2k	38	28	monocytogenes	monocytogenes	NN
cord-015922-5wwy0m2k	38	29	,	,	,
cord-015922-5wwy0m2k	38	30	Nocardia	Nocardia	NNP
cord-015922-5wwy0m2k	38	31	sp	sp	NN
cord-015922-5wwy0m2k	38	32	,	,	,
cord-015922-5wwy0m2k	38	33	and	and	CC
cord-015922-5wwy0m2k	38	34	Toxoplasma	toxoplasma	NN
cord-015922-5wwy0m2k	38	35	gondii	gondii	NN
cord-015922-5wwy0m2k	38	36	in	in	IN
cord-015922-5wwy0m2k	38	37	patients	patient	NNS
cord-015922-5wwy0m2k	38	38	who	who	WP
cord-015922-5wwy0m2k	38	39	adhere	adhere	VBP
cord-015922-5wwy0m2k	38	40	to	to	IN
cord-015922-5wwy0m2k	38	41	the	the	DT
cord-015922-5wwy0m2k	38	42	regimen	regimen	NN
cord-015922-5wwy0m2k	38	43	.	.	.
cord-015922-5wwy0m2k	39	1	Other	other	JJ
cord-015922-5wwy0m2k	39	2	prophylactic	prophylactic	JJ
cord-015922-5wwy0m2k	39	3	strategies	strategy	NNS
cord-015922-5wwy0m2k	39	4	commonly	commonly	RB
cord-015922-5wwy0m2k	39	5	utilized	utilize	VBN
cord-015922-5wwy0m2k	39	6	in	in	IN
cord-015922-5wwy0m2k	39	7	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	39	8	patients	patient	NNS
cord-015922-5wwy0m2k	39	9	include	include	VBP
cord-015922-5wwy0m2k	39	10	acyclovir	acyclovir	NNP
cord-015922-5wwy0m2k	39	11	to	to	TO
cord-015922-5wwy0m2k	39	12	prevent	prevent	VB
cord-015922-5wwy0m2k	39	13	herpes	herpes	NN
cord-015922-5wwy0m2k	39	14	simplex	simplex	NN
cord-015922-5wwy0m2k	39	15	virus	virus	NN
cord-015922-5wwy0m2k	39	16	(	(	-LRB-
cord-015922-5wwy0m2k	39	17	HSV	HSV	NNP
cord-015922-5wwy0m2k	39	18	)	)	-RRB-
cord-015922-5wwy0m2k	39	19	and	and	CC
cord-015922-5wwy0m2k	39	20	VZV	VZV	NNP
cord-015922-5wwy0m2k	39	21	reactivation	reactivation	NN
cord-015922-5wwy0m2k	39	22	,	,	,
cord-015922-5wwy0m2k	39	23	fluoroquinolones	fluoroquinolone	NNS
cord-015922-5wwy0m2k	39	24	[	[	-LRB-
cord-015922-5wwy0m2k	39	25	5	5	CD
cord-015922-5wwy0m2k	39	26	]	]	-RRB-
cord-015922-5wwy0m2k	39	27	to	to	TO
cord-015922-5wwy0m2k	39	28	prevent	prevent	VB
cord-015922-5wwy0m2k	39	29	gram	gram	NN
cord-015922-5wwy0m2k	39	30	-	-	HYPH
cord-015922-5wwy0m2k	39	31	negative	negative	JJ
cord-015922-5wwy0m2k	39	32	sepsis	sepsis	NN
cord-015922-5wwy0m2k	39	33	and	and	CC
cord-015922-5wwy0m2k	39	34	fluconazole	fluconazole	NN
cord-015922-5wwy0m2k	39	35	to	to	TO
cord-015922-5wwy0m2k	39	36	prevent	prevent	VB
cord-015922-5wwy0m2k	39	37	yeast	yeast	NN
cord-015922-5wwy0m2k	39	38	infection	infection	NN
cord-015922-5wwy0m2k	39	39	.	.	.
cord-015922-5wwy0m2k	40	1	3	3	LS
cord-015922-5wwy0m2k	40	2	.	.	.
cord-015922-5wwy0m2k	41	1	An	an	DT
cord-015922-5wwy0m2k	41	2	empiric	empiric	JJ
cord-015922-5wwy0m2k	41	3	mode	mode	NN
cord-015922-5wwy0m2k	41	4	,	,	,
cord-015922-5wwy0m2k	41	5	in	in	IN
cord-015922-5wwy0m2k	41	6	which	which	WDT
cord-015922-5wwy0m2k	41	7	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	41	8	therapy	therapy	NN
cord-015922-5wwy0m2k	41	9	is	be	VBZ
cord-015922-5wwy0m2k	41	10	administered	administer	VBN
cord-015922-5wwy0m2k	41	11	in	in	IN
cord-015922-5wwy0m2k	41	12	response	response	NN
cord-015922-5wwy0m2k	41	13	to	to	IN
cord-015922-5wwy0m2k	41	14	a	a	DT
cord-015922-5wwy0m2k	41	15	symptom	symptom	NN
cord-015922-5wwy0m2k	41	16	complex	complex	NN
cord-015922-5wwy0m2k	41	17	.	.	.
cord-015922-5wwy0m2k	42	1	In	in	IN
cord-015922-5wwy0m2k	42	2	this	this	DT
cord-015922-5wwy0m2k	42	3	context	context	NN
cord-015922-5wwy0m2k	42	4	,	,	,
cord-015922-5wwy0m2k	42	5	empiric	empiric	JJ
cord-015922-5wwy0m2k	42	6	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	42	7	therapy	therapy	NN
cord-015922-5wwy0m2k	42	8	is	be	VBZ
cord-015922-5wwy0m2k	42	9	initiated	initiate	VBN
cord-015922-5wwy0m2k	42	10	during	during	IN
cord-015922-5wwy0m2k	42	11	the	the	DT
cord-015922-5wwy0m2k	42	12	period	period	NN
cord-015922-5wwy0m2k	42	13	of	of	IN
cord-015922-5wwy0m2k	42	14	profound	profound	JJ
cord-015922-5wwy0m2k	42	15	granulocytopenia	granulocytopenia	NNP
cord-015922-5wwy0m2k	42	16	in	in	IN
cord-015922-5wwy0m2k	42	17	response	response	NN
cord-015922-5wwy0m2k	42	18	to	to	IN
cord-015922-5wwy0m2k	42	19	fever	fever	NN
cord-015922-5wwy0m2k	42	20	+	+	.
cord-015922-5wwy0m2k	43	1	/−	/−	.
cord-015922-5wwy0m2k	43	2	rigors	rigor	NNS
cord-015922-5wwy0m2k	43	3	or	or	CC
cord-015922-5wwy0m2k	43	4	subtle	subtle	JJ
cord-015922-5wwy0m2k	43	5	signs	sign	NNS
cord-015922-5wwy0m2k	43	6	of	of	IN
cord-015922-5wwy0m2k	43	7	sepsis	sepsis	NN
cord-015922-5wwy0m2k	44	1	(	(	-LRB-
cord-015922-5wwy0m2k	44	2	unexplained	unexplained	JJ
cord-015922-5wwy0m2k	44	3	hypotension	hypotension	NN
cord-015922-5wwy0m2k	44	4	,	,	,
cord-015922-5wwy0m2k	44	5	tachypnea	tachypnea	NNP
cord-015922-5wwy0m2k	44	6	,	,	,
cord-015922-5wwy0m2k	44	7	an	an	DT
cord-015922-5wwy0m2k	44	8	ongoing	ongoing	JJ
cord-015922-5wwy0m2k	44	9	volume	volume	NN
cord-015922-5wwy0m2k	44	10	requirement	requirement	NN
cord-015922-5wwy0m2k	44	11	,	,	,
cord-015922-5wwy0m2k	44	12	or	or	CC
cord-015922-5wwy0m2k	44	13	acidosis	acidosis	NN
cord-015922-5wwy0m2k	44	14	)	)	-RRB-
cord-015922-5wwy0m2k	44	15	.	.	.
cord-015922-5wwy0m2k	45	1	In	in	IN
cord-015922-5wwy0m2k	45	2	the	the	DT
cord-015922-5wwy0m2k	45	3	patient	patient	NN
cord-015922-5wwy0m2k	45	4	deemed	deem	VBN
cord-015922-5wwy0m2k	45	5	not	not	RB
cord-015922-5wwy0m2k	45	6	to	to	TO
cord-015922-5wwy0m2k	45	7	be	be	VB
cord-015922-5wwy0m2k	45	8	a	a	DT
cord-015922-5wwy0m2k	45	9	therapeutic	therapeutic	JJ
cord-015922-5wwy0m2k	45	10	emergency	emergency	NN
cord-015922-5wwy0m2k	45	11	,	,	,
cord-015922-5wwy0m2k	45	12	initial	initial	JJ
cord-015922-5wwy0m2k	45	13	therapy	therapy	NN
cord-015922-5wwy0m2k	45	14	is	be	VBZ
cord-015922-5wwy0m2k	45	15	usually	usually	RB
cord-015922-5wwy0m2k	45	16	aimed	aim	VBN
cord-015922-5wwy0m2k	45	17	at	at	IN
cord-015922-5wwy0m2k	45	18	aerobic	aerobic	JJ
cord-015922-5wwy0m2k	45	19	gramnegative	gramnegative	NNP
cord-015922-5wwy0m2k	45	20	bacilli	bacilli	NN
cord-015922-5wwy0m2k	45	21	(	(	-LRB-
cord-015922-5wwy0m2k	45	22	e.g.	e.g.	RB
cord-015922-5wwy0m2k	45	23	,	,	,
cord-015922-5wwy0m2k	45	24	the	the	DT
cord-015922-5wwy0m2k	45	25	Enterobacteriaceae	Enterobacteriaceae	NNP
cord-015922-5wwy0m2k	45	26	and	and	CC
cord-015922-5wwy0m2k	45	27	Pseudomonas	Pseudomonas	NNP
cord-015922-5wwy0m2k	45	28	aeruginosa	aeruginosa	NN
cord-015922-5wwy0m2k	45	29	)	)	-RRB-
cord-015922-5wwy0m2k	45	30	.	.	.
cord-015922-5wwy0m2k	46	1	A	a	DT
cord-015922-5wwy0m2k	46	2	variety	variety	NN
cord-015922-5wwy0m2k	46	3	of	of	IN
cord-015922-5wwy0m2k	46	4	drugs	drug	NNS
cord-015922-5wwy0m2k	46	5	have	have	VBP
cord-015922-5wwy0m2k	46	6	been	be	VBN
cord-015922-5wwy0m2k	46	7	utilized	utilize	VBN
cord-015922-5wwy0m2k	46	8	for	for	IN
cord-015922-5wwy0m2k	46	9	this	this	DT
cord-015922-5wwy0m2k	46	10	purpose	purpose	NN
cord-015922-5wwy0m2k	46	11	,	,	,
cord-015922-5wwy0m2k	46	12	depending	depend	VBG
cord-015922-5wwy0m2k	46	13	in	in	IN
cord-015922-5wwy0m2k	46	14	part	part	NN
cord-015922-5wwy0m2k	46	15	on	on	IN
cord-015922-5wwy0m2k	46	16	the	the	DT
cord-015922-5wwy0m2k	46	17	nature	nature	NN
cord-015922-5wwy0m2k	46	18	of	of	IN
cord-015922-5wwy0m2k	46	19	particular	particular	JJ
cord-015922-5wwy0m2k	46	20	problem	problem	NN
cord-015922-5wwy0m2k	46	21	organisms	organism	NNS
cord-015922-5wwy0m2k	46	22	found	find	VBD
cord-015922-5wwy0m2k	46	23	at	at	IN
cord-015922-5wwy0m2k	46	24	a	a	DT
cord-015922-5wwy0m2k	46	25	given	give	VBN
cord-015922-5wwy0m2k	46	26	medical	medical	JJ
cord-015922-5wwy0m2k	46	27	center	center	NN
cord-015922-5wwy0m2k	46	28	.	.	.
cord-015922-5wwy0m2k	47	1	Advanced	advanced	JJ
cord-015922-5wwy0m2k	47	2	spectrum	spectrum	NN
cord-015922-5wwy0m2k	47	3	beta	beta	NN
cord-015922-5wwy0m2k	47	4	-	-	HYPH
cord-015922-5wwy0m2k	47	5	lactams	lactam	NNS
cord-015922-5wwy0m2k	47	6	(	(	-LRB-
cord-015922-5wwy0m2k	47	7	e.g.	e.g.	RB
cord-015922-5wwy0m2k	47	8	,	,	,
cord-015922-5wwy0m2k	47	9	ceftazidime	ceftazidime	NN
cord-015922-5wwy0m2k	47	10	,	,	,
cord-015922-5wwy0m2k	47	11	piperacillin	piperacillin	NNP
cord-015922-5wwy0m2k	47	12	or	or	CC
cord-015922-5wwy0m2k	47	13	imipenem	imipenem	NNP
cord-015922-5wwy0m2k	47	14	)	)	-RRB-
cord-015922-5wwy0m2k	47	15	,	,	,
cord-015922-5wwy0m2k	48	1	either	either	CC
cord-015922-5wwy0m2k	48	2	alone	alone	RB
cord-015922-5wwy0m2k	48	3	or	or	CC
cord-015922-5wwy0m2k	48	4	together	together	RB
cord-015922-5wwy0m2k	48	5	with	with	IN
cord-015922-5wwy0m2k	48	6	an	an	DT
cord-015922-5wwy0m2k	48	7	aminoglycoside	aminoglycoside	NN
cord-015922-5wwy0m2k	48	8	or	or	CC
cord-015922-5wwy0m2k	48	9	a	a	DT
cord-015922-5wwy0m2k	48	10	fluoroquinolone	fluoroquinolone	NN
cord-015922-5wwy0m2k	48	11	,	,	,
cord-015922-5wwy0m2k	48	12	are	be	VBP
cord-015922-5wwy0m2k	48	13	the	the	DT
cord-015922-5wwy0m2k	48	14	mainstays	mainstay	NNS
cord-015922-5wwy0m2k	48	15	of	of	IN
cord-015922-5wwy0m2k	48	16	this	this	DT
cord-015922-5wwy0m2k	48	17	approach	approach	NN
cord-015922-5wwy0m2k	48	18	.	.	.
cord-015922-5wwy0m2k	49	1	Thus	thus	RB
cord-015922-5wwy0m2k	49	2	,	,	,
cord-015922-5wwy0m2k	49	3	empiric	empiric	JJ
cord-015922-5wwy0m2k	49	4	therapy	therapy	NN
cord-015922-5wwy0m2k	49	5	is	be	VBZ
cord-015922-5wwy0m2k	49	6	based	base	VBN
cord-015922-5wwy0m2k	49	7	on	on	IN
cord-015922-5wwy0m2k	49	8	an	an	DT
cord-015922-5wwy0m2k	49	9	algorithm	algorithm	NN
cord-015922-5wwy0m2k	49	10	rather	rather	RB
cord-015922-5wwy0m2k	49	11	than	than	IN
cord-015922-5wwy0m2k	49	12	on	on	IN
cord-015922-5wwy0m2k	49	13	microbiologic	microbiologic	NNP
cord-015922-5wwy0m2k	49	14	or	or	CC
cord-015922-5wwy0m2k	49	15	other	other	JJ
cord-015922-5wwy0m2k	49	16	studies	study	NNS
cord-015922-5wwy0m2k	49	17	.	.	.
cord-015922-5wwy0m2k	50	1	4	4	LS
cord-015922-5wwy0m2k	50	2	.	.	.
cord-015922-5wwy0m2k	51	1	A	a	DT
cord-015922-5wwy0m2k	51	2	preemptive	preemptive	JJ
cord-015922-5wwy0m2k	51	3	mode	mode	NN
cord-015922-5wwy0m2k	51	4	,	,	,
cord-015922-5wwy0m2k	51	5	in	in	IN
cord-015922-5wwy0m2k	51	6	which	which	WDT
cord-015922-5wwy0m2k	51	7	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	51	8	therapy	therapy	NN
cord-015922-5wwy0m2k	51	9	is	be	VBZ
cord-015922-5wwy0m2k	51	10	prescribed	prescribe	VBN
cord-015922-5wwy0m2k	51	11	to	to	IN
cord-015922-5wwy0m2k	51	12	a	a	DT
cord-015922-5wwy0m2k	51	13	proportion	proportion	NN
cord-015922-5wwy0m2k	51	14	of	of	IN
cord-015922-5wwy0m2k	51	15	patients	patient	NNS
cord-015922-5wwy0m2k	51	16	deemed	deem	VBN
cord-015922-5wwy0m2k	51	17	to	to	TO
cord-015922-5wwy0m2k	51	18	be	be	VB
cord-015922-5wwy0m2k	51	19	at	at	IN
cord-015922-5wwy0m2k	51	20	particularly	particularly	RB
cord-015922-5wwy0m2k	51	21	high	high	JJ
cord-015922-5wwy0m2k	51	22	risk	risk	NN
cord-015922-5wwy0m2k	51	23	because	because	IN
cord-015922-5wwy0m2k	51	24	of	of	IN
cord-015922-5wwy0m2k	51	25	clinical	clinical	JJ
cord-015922-5wwy0m2k	51	26	/	/	SYM
cord-015922-5wwy0m2k	51	27	epidemiologic	epidemiologic	JJ
cord-015922-5wwy0m2k	51	28	information	information	NN
cord-015922-5wwy0m2k	51	29	or	or	CC
cord-015922-5wwy0m2k	51	30	the	the	DT
cord-015922-5wwy0m2k	51	31	isolation	isolation	NN
cord-015922-5wwy0m2k	51	32	of	of	IN
cord-015922-5wwy0m2k	51	33	microbial	microbial	JJ
cord-015922-5wwy0m2k	51	34	pathogens	pathogen	NNS
cord-015922-5wwy0m2k	51	35	.	.	.
cord-015922-5wwy0m2k	52	1	Examples	example	NNS
cord-015922-5wwy0m2k	52	2	of	of	IN
cord-015922-5wwy0m2k	52	3	preemptive	preemptive	JJ
cord-015922-5wwy0m2k	52	4	therapy	therapy	NN
cord-015922-5wwy0m2k	52	5	in	in	IN
cord-015922-5wwy0m2k	52	6	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	52	7	are	be	VBP
cord-015922-5wwy0m2k	52	8	the	the	DT
cord-015922-5wwy0m2k	52	9	molecular	molecular	JJ
cord-015922-5wwy0m2k	52	10	surveillance	surveillance	NN
cord-015922-5wwy0m2k	52	11	of	of	IN
cord-015922-5wwy0m2k	52	12	CMV	CMV	NNP
cord-015922-5wwy0m2k	52	13	linked	link	VBN
cord-015922-5wwy0m2k	52	14	to	to	IN
cord-015922-5wwy0m2k	52	15	deployment	deployment	NN
cord-015922-5wwy0m2k	52	16	of	of	IN
cord-015922-5wwy0m2k	52	17	ganciclovir	ganciclovir	NNP
cord-015922-5wwy0m2k	52	18	or	or	CC
cord-015922-5wwy0m2k	52	19	,	,	,
cord-015922-5wwy0m2k	52	20	more	more	RBR
cord-015922-5wwy0m2k	52	21	recently	recently	RB
cord-015922-5wwy0m2k	52	22	,	,	,
cord-015922-5wwy0m2k	52	23	the	the	DT
cord-015922-5wwy0m2k	52	24	use	use	NN
cord-015922-5wwy0m2k	52	25	of	of	IN
cord-015922-5wwy0m2k	52	26	galactomannan	galactomannan	NNP
cord-015922-5wwy0m2k	52	27	monitoring	monitoring	NN
cord-015922-5wwy0m2k	52	28	for	for	IN
cord-015922-5wwy0m2k	52	29	initiation	initiation	NN
cord-015922-5wwy0m2k	52	30	of	of	IN
cord-015922-5wwy0m2k	52	31	anti	anti	JJ
cord-015922-5wwy0m2k	52	32	-	-	JJ
cord-015922-5wwy0m2k	52	33	Aspergillus	aspergillus	JJ
cord-015922-5wwy0m2k	52	34	antifungal	antifungal	NN
cord-015922-5wwy0m2k	52	35	treatment	treatment	NN
cord-015922-5wwy0m2k	52	36	[	[	-LRB-
cord-015922-5wwy0m2k	52	37	12	12	CD
cord-015922-5wwy0m2k	52	38	]	]	-RRB-
cord-015922-5wwy0m2k	52	39	.	.	.
cord-015922-5wwy0m2k	53	1	Given	give	VBN
cord-015922-5wwy0m2k	53	2	the	the	DT
cord-015922-5wwy0m2k	53	3	nature	nature	NN
cord-015922-5wwy0m2k	53	4	,	,	,
cord-015922-5wwy0m2k	53	5	duration	duration	NN
cord-015922-5wwy0m2k	53	6	and	and	CC
cord-015922-5wwy0m2k	53	7	severity	severity	NN
cord-015922-5wwy0m2k	53	8	of	of	IN
cord-015922-5wwy0m2k	53	9	host	host	NN
cord-015922-5wwy0m2k	53	10	defense	defense	NN
cord-015922-5wwy0m2k	53	11	defects	defect	NNS
cord-015922-5wwy0m2k	53	12	present	present	JJ
cord-015922-5wwy0m2k	53	13	in	in	IN
cord-015922-5wwy0m2k	53	14	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	53	15	patients	patient	NNS
cord-015922-5wwy0m2k	53	16	,	,	,
cord-015922-5wwy0m2k	53	17	it	-PRON-	PRP
cord-015922-5wwy0m2k	53	18	is	be	VBZ
cord-015922-5wwy0m2k	53	19	not	not	RB
cord-015922-5wwy0m2k	53	20	surprising	surprising	JJ
cord-015922-5wwy0m2k	53	21	that	that	IN
cord-015922-5wwy0m2k	53	22	bacterial	bacterial	JJ
cord-015922-5wwy0m2k	53	23	infection	infection	NN
cord-015922-5wwy0m2k	53	24	is	be	VBZ
cord-015922-5wwy0m2k	53	25	a	a	DT
cord-015922-5wwy0m2k	53	26	regular	regular	JJ
cord-015922-5wwy0m2k	53	27	feature	feature	NN
cord-015922-5wwy0m2k	53	28	of	of	IN
cord-015922-5wwy0m2k	53	29	the	the	DT
cord-015922-5wwy0m2k	53	30	post	post	JJ
cord-015922-5wwy0m2k	53	31	-	-	JJ
cord-015922-5wwy0m2k	53	32	transplant	transplant	JJ
cord-015922-5wwy0m2k	53	33	course	course	NN
cord-015922-5wwy0m2k	53	34	.	.	.
cord-015922-5wwy0m2k	54	1	The	the	DT
cord-015922-5wwy0m2k	54	2	most	most	RBS
cord-015922-5wwy0m2k	54	3	common	common	JJ
cord-015922-5wwy0m2k	54	4	involved	involved	JJ
cord-015922-5wwy0m2k	54	5	sites	site	NNS
cord-015922-5wwy0m2k	54	6	include	include	VBP
cord-015922-5wwy0m2k	54	7	blood	blood	NN
cord-015922-5wwy0m2k	54	8	stream	stream	NN
cord-015922-5wwy0m2k	54	9	(	(	-LRB-
cord-015922-5wwy0m2k	54	10	often	often	RB
cord-015922-5wwy0m2k	54	11	catheter	catheter	NN
cord-015922-5wwy0m2k	54	12	-	-	HYPH
cord-015922-5wwy0m2k	54	13	related	relate	VBN
cord-015922-5wwy0m2k	54	14	)	)	-RRB-
cord-015922-5wwy0m2k	54	15	,	,	,
cord-015922-5wwy0m2k	54	16	lung	lung	NN
cord-015922-5wwy0m2k	54	17	,	,	,
cord-015922-5wwy0m2k	54	18	gastrointestinal	gastrointestinal	JJ
cord-015922-5wwy0m2k	54	19	tract	tract	NN
cord-015922-5wwy0m2k	54	20	and	and	CC
cord-015922-5wwy0m2k	54	21	skin	skin	NN
cord-015922-5wwy0m2k	54	22	/	/	SYM
cord-015922-5wwy0m2k	54	23	soft	soft	JJ
cord-015922-5wwy0m2k	54	24	tissue	tissue	NN
cord-015922-5wwy0m2k	54	25	.	.	.
cord-015922-5wwy0m2k	55	1	The	the	DT
cord-015922-5wwy0m2k	55	2	greatest	great	JJS
cord-015922-5wwy0m2k	55	3	rate	rate	NN
cord-015922-5wwy0m2k	55	4	of	of	IN
cord-015922-5wwy0m2k	55	5	bacterial	bacterial	JJ
cord-015922-5wwy0m2k	55	6	infections	infection	NNS
cord-015922-5wwy0m2k	55	7	occur	occur	VBP
cord-015922-5wwy0m2k	55	8	during	during	IN
cord-015922-5wwy0m2k	55	9	the	the	DT
cord-015922-5wwy0m2k	55	10	period	period	NN
cord-015922-5wwy0m2k	55	11	prior	prior	RB
cord-015922-5wwy0m2k	55	12	to	to	IN
cord-015922-5wwy0m2k	55	13	engraftment	engraftment	NN
cord-015922-5wwy0m2k	55	14	;	;	:
cord-015922-5wwy0m2k	55	15	this	this	DT
cord-015922-5wwy0m2k	55	16	rate	rate	NN
cord-015922-5wwy0m2k	55	17	is	be	VBZ
cord-015922-5wwy0m2k	55	18	a	a	DT
cord-015922-5wwy0m2k	55	19	product	product	NN
cord-015922-5wwy0m2k	55	20	of	of	IN
cord-015922-5wwy0m2k	55	21	granulocytopenia	granulocytopenia	NNP
cord-015922-5wwy0m2k	55	22	,	,	,
cord-015922-5wwy0m2k	55	23	mucositis	mucositis	NNP
cord-015922-5wwy0m2k	55	24	that	that	WDT
cord-015922-5wwy0m2k	55	25	permits	permit	VBZ
cord-015922-5wwy0m2k	55	26	the	the	DT
cord-015922-5wwy0m2k	55	27	translocation	translocation	NN
cord-015922-5wwy0m2k	55	28	of	of	IN
cord-015922-5wwy0m2k	55	29	bacteria	bacteria	NNS
cord-015922-5wwy0m2k	55	30	and	and	CC
cord-015922-5wwy0m2k	55	31	yeast	yeast	NN
cord-015922-5wwy0m2k	55	32	from	from	IN
cord-015922-5wwy0m2k	55	33	the	the	DT
cord-015922-5wwy0m2k	55	34	oral	oral	JJ
cord-015922-5wwy0m2k	55	35	cavity	cavity	NN
cord-015922-5wwy0m2k	55	36	and	and	CC
cord-015922-5wwy0m2k	55	37	gut	gut	NN
cord-015922-5wwy0m2k	55	38	into	into	IN
cord-015922-5wwy0m2k	55	39	circulation	circulation	NN
cord-015922-5wwy0m2k	55	40	,	,	,
cord-015922-5wwy0m2k	55	41	and	and	CC
cord-015922-5wwy0m2k	55	42	the	the	DT
cord-015922-5wwy0m2k	55	43	presence	presence	NN
cord-015922-5wwy0m2k	55	44	of	of	IN
cord-015922-5wwy0m2k	55	45	vascular	vascular	JJ
cord-015922-5wwy0m2k	55	46	access	access	NN
cord-015922-5wwy0m2k	55	47	devices	device	NNS
cord-015922-5wwy0m2k	55	48	that	that	WDT
cord-015922-5wwy0m2k	55	49	traverse	traverse	VBP
cord-015922-5wwy0m2k	55	50	the	the	DT
cord-015922-5wwy0m2k	55	51	skin	skin	NN
cord-015922-5wwy0m2k	55	52	and	and	CC
cord-015922-5wwy0m2k	55	53	serve	serve	VB
cord-015922-5wwy0m2k	55	54	as	as	IN
cord-015922-5wwy0m2k	55	55	direct	direct	JJ
cord-015922-5wwy0m2k	55	56	conduits	conduit	NNS
cord-015922-5wwy0m2k	55	57	into	into	IN
cord-015922-5wwy0m2k	55	58	the	the	DT
cord-015922-5wwy0m2k	55	59	systemic	systemic	JJ
cord-015922-5wwy0m2k	55	60	circulation	circulation	NN
cord-015922-5wwy0m2k	55	61	.	.	.
cord-015922-5wwy0m2k	56	1	Thus	thus	RB
cord-015922-5wwy0m2k	56	2	,	,	,
cord-015922-5wwy0m2k	56	3	the	the	DT
cord-015922-5wwy0m2k	56	4	primary	primary	JJ
cord-015922-5wwy0m2k	56	5	mucocutaneous	mucocutaneous	JJ
cord-015922-5wwy0m2k	56	6	barriers	barrier	NNS
cord-015922-5wwy0m2k	56	7	to	to	IN
cord-015922-5wwy0m2k	56	8	infection	infection	NN
cord-015922-5wwy0m2k	56	9	are	be	VBP
cord-015922-5wwy0m2k	56	10	compromised	compromise	VBN
cord-015922-5wwy0m2k	56	11	,	,	,
cord-015922-5wwy0m2k	56	12	and	and	CC
cord-015922-5wwy0m2k	56	13	the	the	DT
cord-015922-5wwy0m2k	56	14	absence	absence	NN
cord-015922-5wwy0m2k	56	15	of	of	IN
cord-015922-5wwy0m2k	56	16	granulocytes	granulocyte	NNS
cord-015922-5wwy0m2k	56	17	only	only	RB
cord-015922-5wwy0m2k	56	18	amplifies	amplify	VBZ
cord-015922-5wwy0m2k	56	19	the	the	DT
cord-015922-5wwy0m2k	56	20	susceptibility	susceptibility	NN
cord-015922-5wwy0m2k	56	21	of	of	IN
cord-015922-5wwy0m2k	56	22	the	the	DT
cord-015922-5wwy0m2k	56	23	patient	patient	NN
cord-015922-5wwy0m2k	56	24	[	[	-LRB-
cord-015922-5wwy0m2k	56	25	1	1	CD
cord-015922-5wwy0m2k	56	26	,	,	,
cord-015922-5wwy0m2k	56	27	4	4	CD
cord-015922-5wwy0m2k	56	28	,	,	,
cord-015922-5wwy0m2k	56	29	7	7	CD
cord-015922-5wwy0m2k	56	30	]	]	-RRB-
cord-015922-5wwy0m2k	56	31	.	.	.
cord-015922-5wwy0m2k	57	1	In	in	IN
cord-015922-5wwy0m2k	57	2	an	an	DT
cord-015922-5wwy0m2k	57	3	attempt	attempt	NN
cord-015922-5wwy0m2k	57	4	to	to	TO
cord-015922-5wwy0m2k	57	5	decrease	decrease	VB
cord-015922-5wwy0m2k	57	6	bacterial	bacterial	JJ
cord-015922-5wwy0m2k	57	7	infections	infection	NNS
cord-015922-5wwy0m2k	57	8	during	during	IN
cord-015922-5wwy0m2k	57	9	the	the	DT
cord-015922-5wwy0m2k	57	10	neutropenic	neutropenic	JJ
cord-015922-5wwy0m2k	57	11	period	period	NN
cord-015922-5wwy0m2k	57	12	,	,	,
cord-015922-5wwy0m2k	57	13	especially	especially	RB
cord-015922-5wwy0m2k	57	14	those	those	DT
cord-015922-5wwy0m2k	57	15	due	due	JJ
cord-015922-5wwy0m2k	57	16	to	to	IN
cord-015922-5wwy0m2k	57	17	gram	gram	NN
cord-015922-5wwy0m2k	57	18	-	-	HYPH
cord-015922-5wwy0m2k	57	19	negative	negative	JJ
cord-015922-5wwy0m2k	57	20	bacilli	bacilli	NN
cord-015922-5wwy0m2k	57	21	,	,	,
cord-015922-5wwy0m2k	57	22	strategies	strategy	NNS
cord-015922-5wwy0m2k	57	23	of	of	IN
cord-015922-5wwy0m2k	57	24	prophylactic	prophylactic	JJ
cord-015922-5wwy0m2k	57	25	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	57	26	use	use	NN
cord-015922-5wwy0m2k	57	27	have	have	VBP
cord-015922-5wwy0m2k	57	28	been	be	VBN
cord-015922-5wwy0m2k	57	29	studied	study	VBN
cord-015922-5wwy0m2k	57	30	,	,	,
cord-015922-5wwy0m2k	57	31	including	include	VBG
cord-015922-5wwy0m2k	57	32	the	the	DT
cord-015922-5wwy0m2k	57	33	use	use	NN
cord-015922-5wwy0m2k	57	34	of	of	IN
cord-015922-5wwy0m2k	57	35	trimethoprimsulfamethoxazole	trimethoprimsulfamethoxazole	NN
cord-015922-5wwy0m2k	57	36	and	and	CC
cord-015922-5wwy0m2k	57	37	fluoroquinolones	fluoroquinolone	NNS
cord-015922-5wwy0m2k	57	38	.	.	.
cord-015922-5wwy0m2k	58	1	Some	some	DT
cord-015922-5wwy0m2k	58	2	studies	study	NNS
cord-015922-5wwy0m2k	58	3	,	,	,
cord-015922-5wwy0m2k	58	4	most	most	RBS
cord-015922-5wwy0m2k	58	5	recently	recently	RB
cord-015922-5wwy0m2k	58	6	with	with	IN
cord-015922-5wwy0m2k	58	7	levofloxacin	levofloxacin	NNS
cord-015922-5wwy0m2k	58	8	,	,	,
cord-015922-5wwy0m2k	58	9	have	have	VBP
cord-015922-5wwy0m2k	58	10	demonstrated	demonstrate	VBN
cord-015922-5wwy0m2k	58	11	benefit	benefit	NN
cord-015922-5wwy0m2k	58	12	in	in	IN
cord-015922-5wwy0m2k	58	13	decreasing	decrease	VBG
cord-015922-5wwy0m2k	58	14	the	the	DT
cord-015922-5wwy0m2k	58	15	occurrence	occurrence	NN
cord-015922-5wwy0m2k	58	16	of	of	IN
cord-015922-5wwy0m2k	58	17	fever	fever	NN
cord-015922-5wwy0m2k	58	18	and	and	CC
cord-015922-5wwy0m2k	58	19	microbiologically	microbiologically	RB
cord-015922-5wwy0m2k	58	20	-	-	HYPH
cord-015922-5wwy0m2k	58	21	confirmed	confirm	VBN
cord-015922-5wwy0m2k	58	22	bacterial	bacterial	JJ
cord-015922-5wwy0m2k	58	23	infections	infection	NNS
cord-015922-5wwy0m2k	58	24	[	[	-LRB-
cord-015922-5wwy0m2k	58	25	13	13	CD
cord-015922-5wwy0m2k	58	26	]	]	-RRB-
cord-015922-5wwy0m2k	58	27	[	[	-LRB-
cord-015922-5wwy0m2k	58	28	14	14	CD
cord-015922-5wwy0m2k	58	29	]	]	-RRB-
cord-015922-5wwy0m2k	58	30	[	[	-LRB-
cord-015922-5wwy0m2k	58	31	15	15	CD
cord-015922-5wwy0m2k	58	32	]	]	-RRB-
cord-015922-5wwy0m2k	58	33	.	.	.
cord-015922-5wwy0m2k	59	1	However	however	RB
cord-015922-5wwy0m2k	59	2	,	,	,
cord-015922-5wwy0m2k	59	3	significant	significant	JJ
cord-015922-5wwy0m2k	59	4	concerns	concern	NNS
cord-015922-5wwy0m2k	59	5	regarding	regard	VBG
cord-015922-5wwy0m2k	59	6	this	this	DT
cord-015922-5wwy0m2k	59	7	approach	approach	NN
cord-015922-5wwy0m2k	59	8	have	have	VBP
cord-015922-5wwy0m2k	59	9	been	be	VBN
cord-015922-5wwy0m2k	59	10	raised	raise	VBN
cord-015922-5wwy0m2k	59	11	given	give	VBN
cord-015922-5wwy0m2k	59	12	that	that	IN
cord-015922-5wwy0m2k	59	13	no	no	DT
cord-015922-5wwy0m2k	59	14	mortality	mortality	NN
cord-015922-5wwy0m2k	59	15	benefit	benefit	NN
cord-015922-5wwy0m2k	59	16	has	have	VBZ
cord-015922-5wwy0m2k	59	17	been	be	VBN
cord-015922-5wwy0m2k	59	18	demonstrated	demonstrate	VBN
cord-015922-5wwy0m2k	59	19	,	,	,
cord-015922-5wwy0m2k	59	20	the	the	DT
cord-015922-5wwy0m2k	59	21	emergence	emergence	NN
cord-015922-5wwy0m2k	59	22	of	of	IN
cord-015922-5wwy0m2k	59	23	resistant	resistant	JJ
cord-015922-5wwy0m2k	59	24	organisms	organism	NNS
cord-015922-5wwy0m2k	59	25	,	,	,
cord-015922-5wwy0m2k	59	26	and	and	CC
cord-015922-5wwy0m2k	59	27	the	the	DT
cord-015922-5wwy0m2k	59	28	impairment	impairment	NN
cord-015922-5wwy0m2k	59	29	this	this	DT
cord-015922-5wwy0m2k	59	30	widespread	widespread	JJ
cord-015922-5wwy0m2k	59	31	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	59	32	approach	approach	NN
cord-015922-5wwy0m2k	59	33	has	have	VBZ
cord-015922-5wwy0m2k	59	34	on	on	IN
cord-015922-5wwy0m2k	59	35	the	the	DT
cord-015922-5wwy0m2k	59	36	use	use	NN
cord-015922-5wwy0m2k	59	37	of	of	IN
cord-015922-5wwy0m2k	59	38	quinolones	quinolone	NNS
cord-015922-5wwy0m2k	59	39	in	in	IN
cord-015922-5wwy0m2k	59	40	future	future	JJ
cord-015922-5wwy0m2k	59	41	oral	oral	JJ
cord-015922-5wwy0m2k	59	42	outpatient	outpatient	NN
cord-015922-5wwy0m2k	59	43	management	management	NN
cord-015922-5wwy0m2k	59	44	.	.	.
cord-015922-5wwy0m2k	60	1	Thus	thus	RB
cord-015922-5wwy0m2k	60	2	,	,	,
cord-015922-5wwy0m2k	60	3	in	in	IN
cord-015922-5wwy0m2k	60	4	many	many	JJ
cord-015922-5wwy0m2k	60	5	transplant	transplant	NN
cord-015922-5wwy0m2k	60	6	centers	center	NNS
cord-015922-5wwy0m2k	60	7	,	,	,
cord-015922-5wwy0m2k	60	8	an	an	DT
cord-015922-5wwy0m2k	60	9	empiric	empiric	JJ
cord-015922-5wwy0m2k	60	10	antibacterial	antibacterial	JJ
cord-015922-5wwy0m2k	60	11	regimen	regimen	NN
cord-015922-5wwy0m2k	60	12	targeting	target	VBG
cord-015922-5wwy0m2k	60	13	Pseudomonas	Pseudomonas	NNP
cord-015922-5wwy0m2k	60	14	and	and	CC
cord-015922-5wwy0m2k	60	15	other	other	JJ
cord-015922-5wwy0m2k	60	16	Enterobacteriaceae	Enterobacteriaceae	NNP
cord-015922-5wwy0m2k	60	17	in	in	IN
cord-015922-5wwy0m2k	60	18	response	response	NN
cord-015922-5wwy0m2k	60	19	to	to	IN
cord-015922-5wwy0m2k	60	20	fever	fever	NN
cord-015922-5wwy0m2k	60	21	or	or	CC
cord-015922-5wwy0m2k	60	22	other	other	JJ
cord-015922-5wwy0m2k	60	23	infectious	infectious	JJ
cord-015922-5wwy0m2k	60	24	syndromes	syndrome	NNS
cord-015922-5wwy0m2k	60	25	remains	remain	VBZ
cord-015922-5wwy0m2k	60	26	a	a	DT
cord-015922-5wwy0m2k	60	27	preferred	preferred	JJ
cord-015922-5wwy0m2k	60	28	approach	approach	NN
cord-015922-5wwy0m2k	60	29	.	.	.
cord-015922-5wwy0m2k	61	1	Whereas	whereas	IN
cord-015922-5wwy0m2k	61	2	gram	gram	NN
cord-015922-5wwy0m2k	61	3	-	-	HYPH
cord-015922-5wwy0m2k	61	4	negative	negative	JJ
cord-015922-5wwy0m2k	61	5	bacteremia	bacteremia	NN
cord-015922-5wwy0m2k	61	6	was	be	VBD
cord-015922-5wwy0m2k	61	7	the	the	DT
cord-015922-5wwy0m2k	61	8	major	major	JJ
cord-015922-5wwy0m2k	61	9	cause	cause	NN
cord-015922-5wwy0m2k	61	10	of	of	IN
cord-015922-5wwy0m2k	61	11	blood	blood	NN
cord-015922-5wwy0m2k	61	12	stream	stream	NN
cord-015922-5wwy0m2k	61	13	infection	infection	NN
cord-015922-5wwy0m2k	61	14	15	15	CD
cord-015922-5wwy0m2k	61	15	to	to	TO
cord-015922-5wwy0m2k	61	16	30	30	CD
cord-015922-5wwy0m2k	61	17	years	year	NNS
cord-015922-5wwy0m2k	61	18	ago	ago	RB
cord-015922-5wwy0m2k	61	19	,	,	,
cord-015922-5wwy0m2k	61	20	today	today	NN
cord-015922-5wwy0m2k	61	21	gram	gram	NN
cord-015922-5wwy0m2k	61	22	-	-	HYPH
cord-015922-5wwy0m2k	61	23	positive	positive	JJ
cord-015922-5wwy0m2k	61	24	organisms	organism	NNS
cord-015922-5wwy0m2k	61	25	are	be	VBP
cord-015922-5wwy0m2k	61	26	the	the	DT
cord-015922-5wwy0m2k	61	27	most	most	RBS
cord-015922-5wwy0m2k	61	28	frequent	frequent	JJ
cord-015922-5wwy0m2k	61	29	cause	cause	NN
cord-015922-5wwy0m2k	61	30	of	of	IN
cord-015922-5wwy0m2k	61	31	positive	positive	JJ
cord-015922-5wwy0m2k	61	32	blood	blood	NN
cord-015922-5wwy0m2k	61	33	cultures	culture	NNS
cord-015922-5wwy0m2k	61	34	.	.	.
cord-015922-5wwy0m2k	62	1	The	the	DT
cord-015922-5wwy0m2k	62	2	possible	possible	JJ
cord-015922-5wwy0m2k	62	3	reasons	reason	NNS
cord-015922-5wwy0m2k	62	4	for	for	IN
cord-015922-5wwy0m2k	62	5	this	this	DT
cord-015922-5wwy0m2k	62	6	shift	shift	NN
cord-015922-5wwy0m2k	62	7	are	be	VBP
cord-015922-5wwy0m2k	62	8	many	many	JJ
cord-015922-5wwy0m2k	62	9	:	:	:
cord-015922-5wwy0m2k	62	10	the	the	DT
cord-015922-5wwy0m2k	62	11	widespread	widespread	JJ
cord-015922-5wwy0m2k	62	12	use	use	NN
cord-015922-5wwy0m2k	62	13	of	of	IN
cord-015922-5wwy0m2k	62	14	fluoroquinolones	fluoroquinolone	NNS
cord-015922-5wwy0m2k	62	15	,	,	,
cord-015922-5wwy0m2k	62	16	with	with	IN
cord-015922-5wwy0m2k	62	17	their	-PRON-	PRP$
cord-015922-5wwy0m2k	62	18	potent	potent	JJ
cord-015922-5wwy0m2k	62	19	activity	activity	NN
cord-015922-5wwy0m2k	62	20	against	against	IN
cord-015922-5wwy0m2k	62	21	gram	gram	NN
cord-015922-5wwy0m2k	62	22	-	-	HYPH
cord-015922-5wwy0m2k	62	23	negative	negative	JJ
cord-015922-5wwy0m2k	62	24	bacteria	bacteria	NNS
cord-015922-5wwy0m2k	62	25	,	,	,
cord-015922-5wwy0m2k	62	26	as	as	IN
cord-015922-5wwy0m2k	62	27	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	62	28	during	during	IN
cord-015922-5wwy0m2k	62	29	this	this	DT
cord-015922-5wwy0m2k	62	30	period	period	NN
cord-015922-5wwy0m2k	62	31	;	;	:
cord-015922-5wwy0m2k	62	32	the	the	DT
cord-015922-5wwy0m2k	62	33	presence	presence	NN
cord-015922-5wwy0m2k	62	34	of	of	IN
cord-015922-5wwy0m2k	62	35	indwelling	indwell	VBG
cord-015922-5wwy0m2k	62	36	central	central	JJ
cord-015922-5wwy0m2k	62	37	venous	venous	JJ
cord-015922-5wwy0m2k	62	38	catheters	catheter	NNS
cord-015922-5wwy0m2k	62	39	for	for	IN
cord-015922-5wwy0m2k	62	40	prolonged	prolonged	JJ
cord-015922-5wwy0m2k	62	41	periods	period	NNS
cord-015922-5wwy0m2k	62	42	;	;	:
cord-015922-5wwy0m2k	62	43	and	and	CC
cord-015922-5wwy0m2k	62	44	the	the	DT
cord-015922-5wwy0m2k	62	45	widespread	widespread	JJ
cord-015922-5wwy0m2k	62	46	use	use	NN
cord-015922-5wwy0m2k	62	47	of	of	IN
cord-015922-5wwy0m2k	62	48	systemic	systemic	JJ
cord-015922-5wwy0m2k	62	49	anti	anti	JJ
cord-015922-5wwy0m2k	62	50	-	-	JJ
cord-015922-5wwy0m2k	62	51	gram	gram	JJ
cord-015922-5wwy0m2k	62	52	-	-	HYPH
cord-015922-5wwy0m2k	62	53	negative	negative	JJ
cord-015922-5wwy0m2k	62	54	therapy	therapy	NN
cord-015922-5wwy0m2k	62	55	all	all	DT
cord-015922-5wwy0m2k	62	56	contribute	contribute	VBP
cord-015922-5wwy0m2k	62	57	to	to	IN
cord-015922-5wwy0m2k	62	58	the	the	DT
cord-015922-5wwy0m2k	62	59	gram	gram	NN
cord-015922-5wwy0m2k	62	60	-	-	HYPH
cord-015922-5wwy0m2k	62	61	positive	positive	JJ
cord-015922-5wwy0m2k	62	62	predominance	predominance	NN
cord-015922-5wwy0m2k	62	63	.	.	.
cord-015922-5wwy0m2k	63	1	The	the	DT
cord-015922-5wwy0m2k	63	2	bacteria	bacteria	NNS
cord-015922-5wwy0m2k	63	3	isolated	isolate	VBN
cord-015922-5wwy0m2k	63	4	during	during	IN
cord-015922-5wwy0m2k	63	5	the	the	DT
cord-015922-5wwy0m2k	63	6	preengraftment	preengraftment	JJ
cord-015922-5wwy0m2k	63	7	period	period	NN
cord-015922-5wwy0m2k	63	8	,	,	,
cord-015922-5wwy0m2k	63	9	then	then	RB
cord-015922-5wwy0m2k	63	10	,	,	,
cord-015922-5wwy0m2k	63	11	include	include	VBP
cord-015922-5wwy0m2k	63	12	staphylococci	staphylococcus	NNS
cord-015922-5wwy0m2k	63	13	(	(	-LRB-
cord-015922-5wwy0m2k	63	14	especially	especially	RB
cord-015922-5wwy0m2k	63	15	coagulase	coagulase	NN
cord-015922-5wwy0m2k	63	16	-	-	HYPH
cord-015922-5wwy0m2k	63	17	negative	negative	JJ
cord-015922-5wwy0m2k	63	18	Staphylococcus	Staphylococcus	NNP
cord-015922-5wwy0m2k	63	19	)	)	-RRB-
cord-015922-5wwy0m2k	63	20	,	,	,
cord-015922-5wwy0m2k	63	21	viridans	viridans	NNP
cord-015922-5wwy0m2k	63	22	streptococci	streptococcus	NNS
cord-015922-5wwy0m2k	63	23	,	,	,
cord-015922-5wwy0m2k	63	24	enterococci	enterococci	NNP
cord-015922-5wwy0m2k	63	25	and	and	CC
cord-015922-5wwy0m2k	63	26	corynebacteria	corynebacteria	NNP
cord-015922-5wwy0m2k	63	27	,	,	,
cord-015922-5wwy0m2k	63	28	with	with	IN
cord-015922-5wwy0m2k	63	29	fewer	few	JJR
cord-015922-5wwy0m2k	63	30	isolates	isolate	NNS
cord-015922-5wwy0m2k	63	31	of	of	IN
cord-015922-5wwy0m2k	63	32	Enterobacteriaceae	Enterobacteriaceae	NNP
cord-015922-5wwy0m2k	63	33	or	or	CC
cord-015922-5wwy0m2k	63	34	Pseudomonas	Pseudomonas	NNP
cord-015922-5wwy0m2k	63	35	aeruginosa	aeruginosa	NN
cord-015922-5wwy0m2k	63	36	being	be	VBG
cord-015922-5wwy0m2k	63	37	identified	identify	VBN
cord-015922-5wwy0m2k	63	38	.	.	.
cord-015922-5wwy0m2k	64	1	An	an	DT
cord-015922-5wwy0m2k	64	2	increasing	increase	VBG
cord-015922-5wwy0m2k	64	3	problem	problem	NN
cord-015922-5wwy0m2k	64	4	in	in	IN
cord-015922-5wwy0m2k	64	5	the	the	DT
cord-015922-5wwy0m2k	64	6	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	64	7	population	population	NN
cord-015922-5wwy0m2k	64	8	is	be	VBZ
cord-015922-5wwy0m2k	64	9	antibiotic	antibiotic	JJ
cord-015922-5wwy0m2k	64	10	resistant	resistant	JJ
cord-015922-5wwy0m2k	64	11	organisms	organism	NNS
cord-015922-5wwy0m2k	64	12	,	,	,
cord-015922-5wwy0m2k	64	13	particularly	particularly	RB
cord-015922-5wwy0m2k	64	14	vancomycin	vancomycin	NN
cord-015922-5wwy0m2k	64	15	-	-	HYPH
cord-015922-5wwy0m2k	64	16	resistant	resistant	JJ
cord-015922-5wwy0m2k	64	17	enterococci	enterococci	NNS
cord-015922-5wwy0m2k	64	18	,	,	,
cord-015922-5wwy0m2k	64	19	methicillin	methicillin	NN
cord-015922-5wwy0m2k	64	20	-	-	HYPH
cord-015922-5wwy0m2k	64	21	resistant	resistant	JJ
cord-015922-5wwy0m2k	64	22	Staphylococcus	Staphylococcus	NNP
cord-015922-5wwy0m2k	64	23	aureus	aureus	NN
cord-015922-5wwy0m2k	64	24	,	,	,
cord-015922-5wwy0m2k	64	25	and	and	CC
cord-015922-5wwy0m2k	64	26	resistant	resistant	JJ
cord-015922-5wwy0m2k	64	27	gram	gram	NN
cord-015922-5wwy0m2k	64	28	-	-	HYPH
cord-015922-5wwy0m2k	64	29	negative	negative	JJ
cord-015922-5wwy0m2k	64	30	bacilli	bacilli	NN
cord-015922-5wwy0m2k	64	31	(	(	-LRB-
cord-015922-5wwy0m2k	64	32	such	such	JJ
cord-015922-5wwy0m2k	64	33	as	as	IN
cord-015922-5wwy0m2k	64	34	extended	extended	JJ
cord-015922-5wwy0m2k	64	35	spectrum	spectrum	NN
cord-015922-5wwy0m2k	64	36	β	β	NN
cord-015922-5wwy0m2k	64	37	-	-	HYPH
cord-015922-5wwy0m2k	64	38	lactamase	lactamase	NN
cord-015922-5wwy0m2k	64	39	producing	produce	VBG
cord-015922-5wwy0m2k	64	40	Klebsiella	Klebsiella	NNP
cord-015922-5wwy0m2k	64	41	and	and	CC
cord-015922-5wwy0m2k	64	42	chromosomal	chromosomal	JJ
cord-015922-5wwy0m2k	64	43	inducible	inducible	JJ
cord-015922-5wwy0m2k	64	44	βlactamase	βlactamase	NN
cord-015922-5wwy0m2k	64	45	producing	produce	VBG
cord-015922-5wwy0m2k	64	46	Enterobacter	Enterobacter	NNP
cord-015922-5wwy0m2k	64	47	species	specie	NNS
cord-015922-5wwy0m2k	64	48	)	)	-RRB-
cord-015922-5wwy0m2k	64	49	[	[	-LRB-
cord-015922-5wwy0m2k	64	50	1	1	CD
cord-015922-5wwy0m2k	64	51	,	,	,
cord-015922-5wwy0m2k	64	52	4	4	CD
cord-015922-5wwy0m2k	64	53	,	,	,
cord-015922-5wwy0m2k	64	54	6	6	CD
cord-015922-5wwy0m2k	64	55	,	,	,
cord-015922-5wwy0m2k	64	56	7	7	CD
cord-015922-5wwy0m2k	64	57	,	,	,
cord-015922-5wwy0m2k	64	58	[	[	-LRB-
cord-015922-5wwy0m2k	64	59	16	16	CD
cord-015922-5wwy0m2k	64	60	]	]	-RRB-
cord-015922-5wwy0m2k	64	61	[	[	-LRB-
cord-015922-5wwy0m2k	64	62	17	17	CD
cord-015922-5wwy0m2k	64	63	]	]	-RRB-
cord-015922-5wwy0m2k	64	64	[	[	-LRB-
cord-015922-5wwy0m2k	64	65	18	18	CD
cord-015922-5wwy0m2k	64	66	]	]	-RRB-
cord-015922-5wwy0m2k	64	67	[	[	-LRB-
cord-015922-5wwy0m2k	64	68	19	19	CD
cord-015922-5wwy0m2k	64	69	]	]	-RRB-
cord-015922-5wwy0m2k	64	70	[	[	-LRB-
cord-015922-5wwy0m2k	64	71	20	20	CD
cord-015922-5wwy0m2k	64	72	]	]	-RRB-
cord-015922-5wwy0m2k	64	73	.	.	.
cord-015922-5wwy0m2k	65	1	The	the	DT
cord-015922-5wwy0m2k	65	2	typical	typical	JJ
cord-015922-5wwy0m2k	65	3	approach	approach	NN
cord-015922-5wwy0m2k	65	4	for	for	IN
cord-015922-5wwy0m2k	65	5	the	the	DT
cord-015922-5wwy0m2k	65	6	severely	severely	RB
cord-015922-5wwy0m2k	65	7	granulocytopenic	granulocytopenic	JJ
cord-015922-5wwy0m2k	65	8	patient	patient	NN
cord-015922-5wwy0m2k	65	9	at	at	IN
cord-015922-5wwy0m2k	65	10	present	present	NN
cord-015922-5wwy0m2k	65	11	is	be	VBZ
cord-015922-5wwy0m2k	65	12	the	the	DT
cord-015922-5wwy0m2k	65	13	initiation	initiation	NN
cord-015922-5wwy0m2k	65	14	of	of	IN
cord-015922-5wwy0m2k	65	15	empiric	empiric	JJ
cord-015922-5wwy0m2k	65	16	antibacterial	antibacterial	JJ
cord-015922-5wwy0m2k	65	17	therapy	therapy	NN
cord-015922-5wwy0m2k	65	18	in	in	IN
cord-015922-5wwy0m2k	65	19	response	response	NN
cord-015922-5wwy0m2k	65	20	to	to	IN
cord-015922-5wwy0m2k	65	21	an	an	DT
cord-015922-5wwy0m2k	65	22	unexplained	unexplained	JJ
cord-015922-5wwy0m2k	65	23	fever	fever	NN
cord-015922-5wwy0m2k	65	24	or	or	CC
cord-015922-5wwy0m2k	65	25	other	other	JJ
cord-015922-5wwy0m2k	65	26	signs	sign	NNS
cord-015922-5wwy0m2k	65	27	of	of	IN
cord-015922-5wwy0m2k	65	28	sepsis	sepsis	NN
cord-015922-5wwy0m2k	65	29	.	.	.
cord-015922-5wwy0m2k	66	1	What	what	WP
cord-015922-5wwy0m2k	66	2	remains	remain	VBZ
cord-015922-5wwy0m2k	66	3	controversial	controversial	JJ
cord-015922-5wwy0m2k	66	4	is	be	VBZ
cord-015922-5wwy0m2k	66	5	what	what	WP
cord-015922-5wwy0m2k	66	6	the	the	DT
cord-015922-5wwy0m2k	66	7	regimen	regimen	NN
cord-015922-5wwy0m2k	66	8	should	should	MD
cord-015922-5wwy0m2k	66	9	be	be	VB
cord-015922-5wwy0m2k	66	10	.	.	.
cord-015922-5wwy0m2k	67	1	Since	since	IN
cord-015922-5wwy0m2k	67	2	clinical	clinical	JJ
cord-015922-5wwy0m2k	67	3	deterioration	deterioration	NN
cord-015922-5wwy0m2k	67	4	can	can	MD
cord-015922-5wwy0m2k	67	5	occur	occur	VB
cord-015922-5wwy0m2k	67	6	rapidly	rapidly	RB
cord-015922-5wwy0m2k	67	7	with	with	IN
cord-015922-5wwy0m2k	67	8	untreated	untreated	JJ
cord-015922-5wwy0m2k	67	9	gram	gram	NN
cord-015922-5wwy0m2k	67	10	-	-	HYPH
cord-015922-5wwy0m2k	67	11	negative	negative	JJ
cord-015922-5wwy0m2k	67	12	sepsis	sepsis	NN
cord-015922-5wwy0m2k	67	13	in	in	IN
cord-015922-5wwy0m2k	67	14	the	the	DT
cord-015922-5wwy0m2k	67	15	granulocytopenic	granulocytopenic	NNP
cord-015922-5wwy0m2k	67	16	patient	patient	NN
cord-015922-5wwy0m2k	67	17	,	,	,
cord-015922-5wwy0m2k	67	18	anti	anti	JJ
cord-015922-5wwy0m2k	67	19	-	-	JJ
cord-015922-5wwy0m2k	67	20	gramnegative	gramnegative	JJ
cord-015922-5wwy0m2k	67	21	therapy	therapy	NN
cord-015922-5wwy0m2k	67	22	is	be	VBZ
cord-015922-5wwy0m2k	67	23	always	always	RB
cord-015922-5wwy0m2k	67	24	employed	employ	VBN
cord-015922-5wwy0m2k	67	25	.	.	.
cord-015922-5wwy0m2k	68	1	The	the	DT
cord-015922-5wwy0m2k	68	2	traditional	traditional	JJ
cord-015922-5wwy0m2k	68	3	approach	approach	NN
cord-015922-5wwy0m2k	68	4	of	of	IN
cord-015922-5wwy0m2k	68	5	a	a	DT
cord-015922-5wwy0m2k	68	6	β	β	NN
cord-015922-5wwy0m2k	68	7	-	-	HYPH
cord-015922-5wwy0m2k	68	8	lactam	lactam	NNP
cord-015922-5wwy0m2k	68	9	(	(	-LRB-
cord-015922-5wwy0m2k	68	10	e.g.	e.g.	RB
cord-015922-5wwy0m2k	68	11	,	,	,
cord-015922-5wwy0m2k	68	12	piperacillin	piperacillin	NNP
cord-015922-5wwy0m2k	68	13	)	)	-RRB-
cord-015922-5wwy0m2k	68	14	plus	plus	CC
cord-015922-5wwy0m2k	68	15	an	an	DT
cord-015922-5wwy0m2k	68	16	aminoglycoside	aminoglycoside	NN
cord-015922-5wwy0m2k	68	17	is	be	VBZ
cord-015922-5wwy0m2k	68	18	still	still	RB
cord-015922-5wwy0m2k	68	19	favored	favor	VBN
cord-015922-5wwy0m2k	68	20	by	by	IN
cord-015922-5wwy0m2k	68	21	some	some	DT
cord-015922-5wwy0m2k	68	22	experts	expert	NNS
cord-015922-5wwy0m2k	68	23	,	,	,
cord-015922-5wwy0m2k	68	24	although	although	IN
cord-015922-5wwy0m2k	68	25	nephrotoxicity	nephrotoxicity	NN
cord-015922-5wwy0m2k	68	26	from	from	IN
cord-015922-5wwy0m2k	68	27	the	the	DT
cord-015922-5wwy0m2k	68	28	aminoglycoside	aminoglycoside	NNP
cord-015922-5wwy0m2k	68	29	has	have	VBZ
cord-015922-5wwy0m2k	68	30	led	lead	VBN
cord-015922-5wwy0m2k	68	31	to	to	IN
cord-015922-5wwy0m2k	68	32	the	the	DT
cord-015922-5wwy0m2k	68	33	trial	trial	NN
cord-015922-5wwy0m2k	68	34	of	of	IN
cord-015922-5wwy0m2k	68	35	other	other	JJ
cord-015922-5wwy0m2k	68	36	approaches	approach	NNS
cord-015922-5wwy0m2k	68	37	,	,	,
cord-015922-5wwy0m2k	68	38	including	include	VBG
cord-015922-5wwy0m2k	68	39	the	the	DT
cord-015922-5wwy0m2k	68	40	substitution	substitution	NN
cord-015922-5wwy0m2k	68	41	of	of	IN
cord-015922-5wwy0m2k	68	42	a	a	DT
cord-015922-5wwy0m2k	68	43	fluoroquinolone	fluoroquinolone	NN
cord-015922-5wwy0m2k	68	44	for	for	IN
cord-015922-5wwy0m2k	68	45	the	the	DT
cord-015922-5wwy0m2k	68	46	aminoglycoside	aminoglycoside	NN
cord-015922-5wwy0m2k	68	47	,	,	,
cord-015922-5wwy0m2k	68	48	or	or	CC
cord-015922-5wwy0m2k	68	49	the	the	DT
cord-015922-5wwy0m2k	68	50	prescription	prescription	NN
cord-015922-5wwy0m2k	68	51	of	of	IN
cord-015922-5wwy0m2k	68	52	a	a	DT
cord-015922-5wwy0m2k	68	53	single	single	JJ
cord-015922-5wwy0m2k	68	54	advanced	advanced	JJ
cord-015922-5wwy0m2k	68	55	spectrum	spectrum	NN
cord-015922-5wwy0m2k	68	56	drug	drug	NN
cord-015922-5wwy0m2k	68	57	such	such	JJ
cord-015922-5wwy0m2k	68	58	as	as	IN
cord-015922-5wwy0m2k	68	59	ceftazidime	ceftazidime	NNP
cord-015922-5wwy0m2k	68	60	,	,	,
cord-015922-5wwy0m2k	68	61	cefepime	cefepime	NNP
cord-015922-5wwy0m2k	68	62	,	,	,
cord-015922-5wwy0m2k	68	63	imipenem	imipenem	NNP
cord-015922-5wwy0m2k	68	64	or	or	CC
cord-015922-5wwy0m2k	68	65	meropenem	meropenem	NNP
cord-015922-5wwy0m2k	68	66	.	.	.
cord-015922-5wwy0m2k	69	1	If	if	IN
cord-015922-5wwy0m2k	69	2	fluoroquinolone	fluoroquinolone	NN
cord-015922-5wwy0m2k	69	3	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	69	4	has	have	VBZ
cord-015922-5wwy0m2k	69	5	been	be	VBN
cord-015922-5wwy0m2k	69	6	utilized	utilize	VBN
cord-015922-5wwy0m2k	69	7	,	,	,
cord-015922-5wwy0m2k	69	8	then	then	RB
cord-015922-5wwy0m2k	69	9	its	-PRON-	PRP$
cord-015922-5wwy0m2k	69	10	use	use	NN
cord-015922-5wwy0m2k	69	11	as	as	IN
cord-015922-5wwy0m2k	69	12	a	a	DT
cord-015922-5wwy0m2k	69	13	therapeutic	therapeutic	JJ
cord-015922-5wwy0m2k	69	14	agent	agent	NN
cord-015922-5wwy0m2k	69	15	may	may	MD
cord-015922-5wwy0m2k	69	16	be	be	VB
cord-015922-5wwy0m2k	69	17	diminished	diminish	VBN
cord-015922-5wwy0m2k	69	18	.	.	.
cord-015922-5wwy0m2k	70	1	Empiric	empiric	NN
cord-015922-5wwy0m2k	70	2	fluoroquinolone	fluoroquinolone	NN
cord-015922-5wwy0m2k	70	3	monotherapy	monotherapy	NN
cord-015922-5wwy0m2k	70	4	is	be	VBZ
cord-015922-5wwy0m2k	70	5	inferior	inferior	JJ
cord-015922-5wwy0m2k	70	6	to	to	IN
cord-015922-5wwy0m2k	70	7	other	other	JJ
cord-015922-5wwy0m2k	70	8	regimens	regimen	NNS
cord-015922-5wwy0m2k	70	9	,	,	,
cord-015922-5wwy0m2k	70	10	and	and	CC
cord-015922-5wwy0m2k	70	11	if	if	IN
cord-015922-5wwy0m2k	70	12	pure	pure	JJ
cord-015922-5wwy0m2k	70	13	aerobic	aerobic	JJ
cord-015922-5wwy0m2k	70	14	gram	gram	NN
cord-015922-5wwy0m2k	70	15	-	-	HYPH
cord-015922-5wwy0m2k	70	16	negative	negative	JJ
cord-015922-5wwy0m2k	70	17	agents	agent	NNS
cord-015922-5wwy0m2k	70	18	are	be	VBP
cord-015922-5wwy0m2k	70	19	utilized	utilize	VBN
cord-015922-5wwy0m2k	70	20	,	,	,
cord-015922-5wwy0m2k	70	21	(	(	-LRB-
cord-015922-5wwy0m2k	70	22	e.g.	e.g.	RB
cord-015922-5wwy0m2k	70	23	,	,	,
cord-015922-5wwy0m2k	70	24	aztreonam	aztreonam	NN
cord-015922-5wwy0m2k	70	25	,	,	,
cord-015922-5wwy0m2k	70	26	aminoglycosides	aminoglycoside	NNS
cord-015922-5wwy0m2k	70	27	)	)	-RRB-
cord-015922-5wwy0m2k	70	28	due	due	JJ
cord-015922-5wwy0m2k	70	29	to	to	IN
cord-015922-5wwy0m2k	70	30	confirmed	confirm	VBN
cord-015922-5wwy0m2k	70	31	severe	severe	JJ
cord-015922-5wwy0m2k	70	32	beta	beta	NN
cord-015922-5wwy0m2k	70	33	-	-	HYPH
cord-015922-5wwy0m2k	70	34	lactam	lactam	NN
cord-015922-5wwy0m2k	70	35	hypersensitivity	hypersensitivity	NN
cord-015922-5wwy0m2k	70	36	,	,	,
cord-015922-5wwy0m2k	70	37	then	then	RB
cord-015922-5wwy0m2k	70	38	the	the	DT
cord-015922-5wwy0m2k	70	39	addition	addition	NN
cord-015922-5wwy0m2k	70	40	of	of	IN
cord-015922-5wwy0m2k	70	41	empiric	empiric	JJ
cord-015922-5wwy0m2k	70	42	gram	gram	NN
cord-015922-5wwy0m2k	70	43	-	-	HYPH
cord-015922-5wwy0m2k	70	44	positive	positive	JJ
cord-015922-5wwy0m2k	70	45	coverage	coverage	NN
cord-015922-5wwy0m2k	70	46	that	that	WDT
cord-015922-5wwy0m2k	70	47	targets	target	VBZ
cord-015922-5wwy0m2k	70	48	aerobic	aerobic	JJ
cord-015922-5wwy0m2k	70	49	and	and	CC
cord-015922-5wwy0m2k	70	50	anaerobic	anaerobic	JJ
cord-015922-5wwy0m2k	70	51	streptococci	streptococcus	NNS
cord-015922-5wwy0m2k	70	52	of	of	IN
cord-015922-5wwy0m2k	70	53	the	the	DT
cord-015922-5wwy0m2k	70	54	gastrointestinal	gastrointestinal	JJ
cord-015922-5wwy0m2k	70	55	tract	tract	NN
cord-015922-5wwy0m2k	70	56	should	should	MD
cord-015922-5wwy0m2k	70	57	be	be	VB
cord-015922-5wwy0m2k	70	58	considered	consider	VBN
cord-015922-5wwy0m2k	70	59	.	.	.
cord-015922-5wwy0m2k	71	1	Use	use	NN
cord-015922-5wwy0m2k	71	2	of	of	IN
cord-015922-5wwy0m2k	71	3	extended	extended	JJ
cord-015922-5wwy0m2k	71	4	interval	interval	NN
cord-015922-5wwy0m2k	71	5	(	(	-LRB-
cord-015922-5wwy0m2k	71	6	once	once	RB
cord-015922-5wwy0m2k	71	7	-	-	HYPH
cord-015922-5wwy0m2k	71	8	daily	daily	NN
cord-015922-5wwy0m2k	71	9	dosing	dosing	NN
cord-015922-5wwy0m2k	71	10	)	)	-RRB-
cord-015922-5wwy0m2k	72	1	aminoglycoside	aminoglycoside	NNP
cord-015922-5wwy0m2k	72	2	administration	administration	NN
cord-015922-5wwy0m2k	72	3	may	may	MD
cord-015922-5wwy0m2k	72	4	be	be	VB
cord-015922-5wwy0m2k	72	5	safer	safe	JJR
cord-015922-5wwy0m2k	72	6	and	and	CC
cord-015922-5wwy0m2k	72	7	as	as	IN
cord-015922-5wwy0m2k	72	8	effective	effective	JJ
cord-015922-5wwy0m2k	72	9	.	.	.
cord-015922-5wwy0m2k	73	1	The	the	DT
cord-015922-5wwy0m2k	73	2	second	second	JJ
cord-015922-5wwy0m2k	73	3	area	area	NN
cord-015922-5wwy0m2k	73	4	of	of	IN
cord-015922-5wwy0m2k	73	5	controversy	controversy	NN
cord-015922-5wwy0m2k	73	6	is	be	VBZ
cord-015922-5wwy0m2k	73	7	whether	whether	IN
cord-015922-5wwy0m2k	73	8	empiric	empiric	JJ
cord-015922-5wwy0m2k	73	9	gram	gram	NN
cord-015922-5wwy0m2k	73	10	-	-	HYPH
cord-015922-5wwy0m2k	73	11	positive	positive	JJ
cord-015922-5wwy0m2k	73	12	treatment	treatment	NN
cord-015922-5wwy0m2k	73	13	should	should	MD
cord-015922-5wwy0m2k	73	14	be	be	VB
cord-015922-5wwy0m2k	73	15	initiated	initiate	VBN
cord-015922-5wwy0m2k	73	16	at	at	IN
cord-015922-5wwy0m2k	73	17	the	the	DT
cord-015922-5wwy0m2k	73	18	same	same	JJ
cord-015922-5wwy0m2k	73	19	time	time	NN
cord-015922-5wwy0m2k	73	20	,	,	,
cord-015922-5wwy0m2k	73	21	given	give	VBN
cord-015922-5wwy0m2k	73	22	the	the	DT
cord-015922-5wwy0m2k	73	23	preponderance	preponderance	NN
cord-015922-5wwy0m2k	73	24	of	of	IN
cord-015922-5wwy0m2k	73	25	grampositive	grampositive	JJ
cord-015922-5wwy0m2k	73	26	infection	infection	NN
cord-015922-5wwy0m2k	73	27	.	.	.
cord-015922-5wwy0m2k	74	1	As	as	IN
cord-015922-5wwy0m2k	74	2	there	there	EX
cord-015922-5wwy0m2k	74	3	is	be	VBZ
cord-015922-5wwy0m2k	74	4	typically	typically	RB
cord-015922-5wwy0m2k	74	5	time	time	NN
cord-015922-5wwy0m2k	74	6	to	to	TO
cord-015922-5wwy0m2k	74	7	evaluate	evaluate	VB
cord-015922-5wwy0m2k	74	8	culture	culture	NN
cord-015922-5wwy0m2k	74	9	data	datum	NNS
cord-015922-5wwy0m2k	74	10	and	and	CC
cord-015922-5wwy0m2k	74	11	deploy	deploy	VB
cord-015922-5wwy0m2k	74	12	targeted	target	VBN
cord-015922-5wwy0m2k	74	13	gram	gram	NN
cord-015922-5wwy0m2k	74	14	-	-	HYPH
cord-015922-5wwy0m2k	74	15	positive	positive	JJ
cord-015922-5wwy0m2k	74	16	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	74	17	therapy	therapy	NN
cord-015922-5wwy0m2k	74	18	rather	rather	RB
cord-015922-5wwy0m2k	74	19	than	than	IN
cord-015922-5wwy0m2k	74	20	empiricism	empiricism	NN
cord-015922-5wwy0m2k	74	21	,	,	,
cord-015922-5wwy0m2k	74	22	vancomycin	vancomycin	NN
cord-015922-5wwy0m2k	74	23	should	should	MD
cord-015922-5wwy0m2k	74	24	rarely	rarely	RB
cord-015922-5wwy0m2k	74	25	be	be	VB
cord-015922-5wwy0m2k	74	26	required	require	VBN
cord-015922-5wwy0m2k	74	27	empirically	empirically	RB
cord-015922-5wwy0m2k	74	28	.	.	.
cord-015922-5wwy0m2k	75	1	Furthermore	furthermore	RB
cord-015922-5wwy0m2k	75	2	,	,	,
cord-015922-5wwy0m2k	75	3	empiric	empiric	JJ
cord-015922-5wwy0m2k	75	4	gram	gram	NN
cord-015922-5wwy0m2k	75	5	-	-	HYPH
cord-015922-5wwy0m2k	75	6	positive	positive	JJ
cord-015922-5wwy0m2k	75	7	coverage	coverage	NN
cord-015922-5wwy0m2k	75	8	is	be	VBZ
cord-015922-5wwy0m2k	75	9	not	not	RB
cord-015922-5wwy0m2k	75	10	associated	associate	VBN
cord-015922-5wwy0m2k	75	11	with	with	IN
cord-015922-5wwy0m2k	75	12	better	well	JJR
cord-015922-5wwy0m2k	75	13	outcomes	outcome	NNS
cord-015922-5wwy0m2k	75	14	[	[	-LRB-
cord-015922-5wwy0m2k	75	15	21	21	CD
cord-015922-5wwy0m2k	75	16	]	]	-RRB-
cord-015922-5wwy0m2k	75	17	.	.	.
cord-015922-5wwy0m2k	76	1	Indications	indication	NNS
cord-015922-5wwy0m2k	76	2	for	for	IN
cord-015922-5wwy0m2k	76	3	the	the	DT
cord-015922-5wwy0m2k	76	4	immediate	immediate	JJ
cord-015922-5wwy0m2k	76	5	initiation	initiation	NN
cord-015922-5wwy0m2k	76	6	of	of	IN
cord-015922-5wwy0m2k	76	7	vancomycin	vancomycin	NN
cord-015922-5wwy0m2k	76	8	as	as	IN
cord-015922-5wwy0m2k	76	9	part	part	NN
cord-015922-5wwy0m2k	76	10	of	of	IN
cord-015922-5wwy0m2k	76	11	the	the	DT
cord-015922-5wwy0m2k	76	12	empiric	empiric	JJ
cord-015922-5wwy0m2k	76	13	therapy	therapy	NN
cord-015922-5wwy0m2k	76	14	regimen	regimen	NN
cord-015922-5wwy0m2k	76	15	include	include	VBP
cord-015922-5wwy0m2k	76	16	the	the	DT
cord-015922-5wwy0m2k	76	17	following	follow	VBG
cord-015922-5wwy0m2k	76	18	[	[	-LRB-
cord-015922-5wwy0m2k	76	19	6	6	CD
cord-015922-5wwy0m2k	76	20	,	,	,
cord-015922-5wwy0m2k	76	21	16	16	CD
cord-015922-5wwy0m2k	76	22	,	,	,
cord-015922-5wwy0m2k	76	23	[	[	-LRB-
cord-015922-5wwy0m2k	76	24	18	18	CD
cord-015922-5wwy0m2k	76	25	]	]	-RRB-
cord-015922-5wwy0m2k	76	26	[	[	-LRB-
cord-015922-5wwy0m2k	76	27	19	19	CD
cord-015922-5wwy0m2k	76	28	]	]	-RRB-
cord-015922-5wwy0m2k	76	29	[	[	-LRB-
cord-015922-5wwy0m2k	76	30	20	20	CD
cord-015922-5wwy0m2k	76	31	]	]	-RRB-
cord-015922-5wwy0m2k	76	32	[	[	-LRB-
cord-015922-5wwy0m2k	76	33	21	21	CD
cord-015922-5wwy0m2k	76	34	]	]	-RRB-
cord-015922-5wwy0m2k	76	35	:	:	:
cord-015922-5wwy0m2k	76	36	catheter	catheter	NN
cord-015922-5wwy0m2k	76	37	-	-	HYPH
cord-015922-5wwy0m2k	76	38	related	relate	VBN
cord-015922-5wwy0m2k	76	39	sepsis	sepsis	NN
cord-015922-5wwy0m2k	76	40	is	be	VBZ
cord-015922-5wwy0m2k	76	41	likely	likely	JJ
cord-015922-5wwy0m2k	76	42	because	because	IN
cord-015922-5wwy0m2k	76	43	of	of	IN
cord-015922-5wwy0m2k	76	44	evidence	evidence	NN
cord-015922-5wwy0m2k	76	45	of	of	IN
cord-015922-5wwy0m2k	76	46	infection	infection	NN
cord-015922-5wwy0m2k	76	47	at	at	IN
cord-015922-5wwy0m2k	76	48	the	the	DT
cord-015922-5wwy0m2k	76	49	insertion	insertion	NN
cord-015922-5wwy0m2k	76	50	site	site	NN
cord-015922-5wwy0m2k	76	51	(	(	-LRB-
cord-015922-5wwy0m2k	76	52	or	or	CC
cord-015922-5wwy0m2k	76	53	within	within	IN
cord-015922-5wwy0m2k	76	54	the	the	DT
cord-015922-5wwy0m2k	76	55	tunnel	tunnel	NN
cord-015922-5wwy0m2k	76	56	)	)	-RRB-
cord-015922-5wwy0m2k	76	57	,	,	,
cord-015922-5wwy0m2k	76	58	severe	severe	JJ
cord-015922-5wwy0m2k	76	59	illness	illness	NN
cord-015922-5wwy0m2k	76	60	such	such	JJ
cord-015922-5wwy0m2k	76	61	as	as	IN
cord-015922-5wwy0m2k	76	62	shock	shock	NN
cord-015922-5wwy0m2k	76	63	and/or	and/or	CC
cord-015922-5wwy0m2k	76	64	respiratory	respiratory	JJ
cord-015922-5wwy0m2k	76	65	distress	distress	NN
cord-015922-5wwy0m2k	76	66	are	be	VBP
cord-015922-5wwy0m2k	76	67	present	present	JJ
cord-015922-5wwy0m2k	76	68	,	,	,
cord-015922-5wwy0m2k	76	69	the	the	DT
cord-015922-5wwy0m2k	76	70	patient	patient	NN
cord-015922-5wwy0m2k	76	71	is	be	VBZ
cord-015922-5wwy0m2k	76	72	at	at	IN
cord-015922-5wwy0m2k	76	73	particular	particular	JJ
cord-015922-5wwy0m2k	76	74	risk	risk	NN
cord-015922-5wwy0m2k	76	75	for	for	IN
cord-015922-5wwy0m2k	76	76	seeding	seeding	NN
cord-015922-5wwy0m2k	76	77	of	of	IN
cord-015922-5wwy0m2k	76	78	a	a	DT
cord-015922-5wwy0m2k	76	79	prosthetic	prosthetic	JJ
cord-015922-5wwy0m2k	76	80	device	device	NN
cord-015922-5wwy0m2k	76	81	(	(	-LRB-
cord-015922-5wwy0m2k	76	82	e.g.	e.g.	RB
cord-015922-5wwy0m2k	76	83	,	,	,
cord-015922-5wwy0m2k	76	84	a	a	DT
cord-015922-5wwy0m2k	76	85	prosthetic	prosthetic	JJ
cord-015922-5wwy0m2k	76	86	valve	valve	NN
cord-015922-5wwy0m2k	76	87	,	,	,
cord-015922-5wwy0m2k	76	88	a	a	DT
cord-015922-5wwy0m2k	76	89	hip	hip	NN
cord-015922-5wwy0m2k	76	90	prosthesis	prosthesis	NN
cord-015922-5wwy0m2k	76	91	,	,	,
cord-015922-5wwy0m2k	76	92	etc	etc	FW
cord-015922-5wwy0m2k	76	93	.	.	.
cord-015922-5wwy0m2k	76	94	)	)	-RRB-
cord-015922-5wwy0m2k	76	95	,	,	,
cord-015922-5wwy0m2k	76	96	or	or	CC
cord-015922-5wwy0m2k	76	97	the	the	DT
cord-015922-5wwy0m2k	76	98	empiric	empiric	JJ
cord-015922-5wwy0m2k	76	99	gram	gram	NN
cord-015922-5wwy0m2k	76	100	-	-	HYPH
cord-015922-5wwy0m2k	76	101	negative	negative	JJ
cord-015922-5wwy0m2k	76	102	coverage	coverage	NN
cord-015922-5wwy0m2k	76	103	exclusively	exclusively	RB
cord-015922-5wwy0m2k	76	104	covers	cover	VBZ
cord-015922-5wwy0m2k	76	105	aerobic	aerobic	JJ
cord-015922-5wwy0m2k	76	106	gram	gram	NN
cord-015922-5wwy0m2k	76	107	-	-	HYPH
cord-015922-5wwy0m2k	76	108	negative	negative	JJ
cord-015922-5wwy0m2k	76	109	rods	rod	NNS
cord-015922-5wwy0m2k	76	110	-such	-such	:
cord-015922-5wwy0m2k	76	111	as	as	IN
cord-015922-5wwy0m2k	76	112	the	the	DT
cord-015922-5wwy0m2k	76	113	combination	combination	NN
cord-015922-5wwy0m2k	76	114	of	of	IN
cord-015922-5wwy0m2k	76	115	aztreonam	aztreonam	NN
cord-015922-5wwy0m2k	76	116	and	and	CC
cord-015922-5wwy0m2k	76	117	gentamicin	gentamicin	NNP
cord-015922-5wwy0m2k	76	118	.	.	.
cord-015922-5wwy0m2k	77	1	Vancomycin	Vancomycin	NNP
cord-015922-5wwy0m2k	77	2	or	or	CC
cord-015922-5wwy0m2k	77	3	other	other	JJ
cord-015922-5wwy0m2k	77	4	anti	anti	JJ
cord-015922-5wwy0m2k	77	5	-	-	JJ
cord-015922-5wwy0m2k	77	6	staphylococcal	staphylococcal	JJ
cord-015922-5wwy0m2k	77	7	agents	agent	NNS
cord-015922-5wwy0m2k	77	8	should	should	MD
cord-015922-5wwy0m2k	77	9	be	be	VB
cord-015922-5wwy0m2k	77	10	started	start	VBN
cord-015922-5wwy0m2k	77	11	if	if	IN
cord-015922-5wwy0m2k	77	12	cultures	culture	NNS
cord-015922-5wwy0m2k	77	13	become	become	VBP
cord-015922-5wwy0m2k	77	14	positive	positive	JJ
cord-015922-5wwy0m2k	77	15	for	for	IN
cord-015922-5wwy0m2k	77	16	gram	gram	NN
cord-015922-5wwy0m2k	77	17	-	-	HYPH
cord-015922-5wwy0m2k	77	18	positive	positive	JJ
cord-015922-5wwy0m2k	77	19	cocci	coccus	NNS
cord-015922-5wwy0m2k	77	20	.	.	.
cord-015922-5wwy0m2k	78	1	In	in	IN
cord-015922-5wwy0m2k	78	2	our	-PRON-	PRP$
cord-015922-5wwy0m2k	78	3	experience	experience	NN
cord-015922-5wwy0m2k	78	4	,	,	,
cord-015922-5wwy0m2k	78	5	vancomycin	vancomycin	FW
cord-015922-5wwy0m2k	78	6	can	can	MD
cord-015922-5wwy0m2k	78	7	be	be	VB
cord-015922-5wwy0m2k	78	8	discontinued	discontinue	VBN
cord-015922-5wwy0m2k	78	9	safely	safely	RB
cord-015922-5wwy0m2k	78	10	in	in	IN
cord-015922-5wwy0m2k	78	11	patients	patient	NNS
cord-015922-5wwy0m2k	78	12	in	in	IN
cord-015922-5wwy0m2k	78	13	whom	whom	WP
cord-015922-5wwy0m2k	78	14	vancomycin	vancomycin	NNP
cord-015922-5wwy0m2k	78	15	was	be	VBD
cord-015922-5wwy0m2k	78	16	started	start	VBN
cord-015922-5wwy0m2k	78	17	empirically	empirically	RB
cord-015922-5wwy0m2k	78	18	,	,	,
cord-015922-5wwy0m2k	78	19	but	but	CC
cord-015922-5wwy0m2k	78	20	in	in	IN
cord-015922-5wwy0m2k	78	21	whom	whom	WP
cord-015922-5wwy0m2k	78	22	blood	blood	NN
cord-015922-5wwy0m2k	78	23	cultures	culture	NNS
cord-015922-5wwy0m2k	78	24	remain	remain	VBP
cord-015922-5wwy0m2k	78	25	negative	negative	JJ
cord-015922-5wwy0m2k	78	26	after	after	IN
cord-015922-5wwy0m2k	78	27	48	48	CD
cord-015922-5wwy0m2k	78	28	to	to	TO
cord-015922-5wwy0m2k	78	29	72	72	CD
cord-015922-5wwy0m2k	78	30	hours	hour	NNS
cord-015922-5wwy0m2k	78	31	and	and	CC
cord-015922-5wwy0m2k	78	32	there	there	EX
cord-015922-5wwy0m2k	78	33	is	be	VBZ
cord-015922-5wwy0m2k	78	34	no	no	DT
cord-015922-5wwy0m2k	78	35	specific	specific	JJ
cord-015922-5wwy0m2k	78	36	syndrome	syndrome	NN
cord-015922-5wwy0m2k	78	37	,	,	,
cord-015922-5wwy0m2k	78	38	such	such	JJ
cord-015922-5wwy0m2k	78	39	as	as	IN
cord-015922-5wwy0m2k	78	40	cellulitis	cellulitis	NN
cord-015922-5wwy0m2k	78	41	,	,	,
cord-015922-5wwy0m2k	78	42	that	that	WDT
cord-015922-5wwy0m2k	78	43	requires	require	VBZ
cord-015922-5wwy0m2k	78	44	treatment	treatment	NN
cord-015922-5wwy0m2k	78	45	with	with	IN
cord-015922-5wwy0m2k	78	46	vancomycin	vancomycin	NNS
cord-015922-5wwy0m2k	78	47	.	.	.
cord-015922-5wwy0m2k	79	1	On	on	IN
cord-015922-5wwy0m2k	79	2	the	the	DT
cord-015922-5wwy0m2k	79	3	other	other	JJ
cord-015922-5wwy0m2k	79	4	hand	hand	NN
cord-015922-5wwy0m2k	79	5	,	,	,
cord-015922-5wwy0m2k	79	6	empirical	empirical	JJ
cord-015922-5wwy0m2k	79	7	treatment	treatment	NN
cord-015922-5wwy0m2k	79	8	against	against	IN
cord-015922-5wwy0m2k	79	9	gram	gram	NN
cord-015922-5wwy0m2k	79	10	-	-	HYPH
cord-015922-5wwy0m2k	79	11	negative	negative	JJ
cord-015922-5wwy0m2k	79	12	organisms	organism	NNS
cord-015922-5wwy0m2k	79	13	should	should	MD
cord-015922-5wwy0m2k	79	14	be	be	VB
cord-015922-5wwy0m2k	79	15	continued	continue	VBN
cord-015922-5wwy0m2k	79	16	until	until	IN
cord-015922-5wwy0m2k	79	17	resolution	resolution	NN
cord-015922-5wwy0m2k	79	18	of	of	IN
cord-015922-5wwy0m2k	79	19	neutropenia	neutropenia	NN
cord-015922-5wwy0m2k	79	20	,	,	,
cord-015922-5wwy0m2k	79	21	whether	whether	IN
cord-015922-5wwy0m2k	79	22	fevers	fever	NNS
cord-015922-5wwy0m2k	79	23	resolve	resolve	VBP
cord-015922-5wwy0m2k	79	24	or	or	CC
cord-015922-5wwy0m2k	79	25	not	not	RB
cord-015922-5wwy0m2k	79	26	[	[	-LRB-
cord-015922-5wwy0m2k	79	27	22	22	CD
cord-015922-5wwy0m2k	79	28	]	]	-RRB-
cord-015922-5wwy0m2k	79	29	.	.	.
cord-015922-5wwy0m2k	80	1	The	the	DT
cord-015922-5wwy0m2k	80	2	emergence	emergence	NN
cord-015922-5wwy0m2k	80	3	and	and	CC
cord-015922-5wwy0m2k	80	4	persistence	persistence	NN
cord-015922-5wwy0m2k	80	5	of	of	IN
cord-015922-5wwy0m2k	80	6	multidrug	multidrug	NN
cord-015922-5wwy0m2k	80	7	-	-	HYPH
cord-015922-5wwy0m2k	80	8	resistant	resistant	JJ
cord-015922-5wwy0m2k	80	9	organisms	organism	NNS
cord-015922-5wwy0m2k	80	10	should	should	MD
cord-015922-5wwy0m2k	80	11	guide	guide	VB
cord-015922-5wwy0m2k	80	12	local	local	JJ
cord-015922-5wwy0m2k	80	13	practice	practice	NN
cord-015922-5wwy0m2k	80	14	in	in	IN
cord-015922-5wwy0m2k	80	15	a	a	DT
cord-015922-5wwy0m2k	80	16	dynamic	dynamic	JJ
cord-015922-5wwy0m2k	80	17	fashion	fashion	NN
cord-015922-5wwy0m2k	80	18	.	.	.
cord-015922-5wwy0m2k	81	1	Indwelling	indwell	VBG
cord-015922-5wwy0m2k	81	2	long	long	JJ
cord-015922-5wwy0m2k	81	3	-	-	HYPH
cord-015922-5wwy0m2k	81	4	term	term	NN
cord-015922-5wwy0m2k	81	5	catheters	catheter	NNS
cord-015922-5wwy0m2k	81	6	remain	remain	VBP
cord-015922-5wwy0m2k	81	7	a	a	DT
cord-015922-5wwy0m2k	81	8	feature	feature	NN
cord-015922-5wwy0m2k	81	9	of	of	IN
cord-015922-5wwy0m2k	81	10	the	the	DT
cord-015922-5wwy0m2k	81	11	early	early	JJ
cord-015922-5wwy0m2k	81	12	post	post	JJ
cord-015922-5wwy0m2k	81	13	-	-	JJ
cord-015922-5wwy0m2k	81	14	transplant	transplant	JJ
cord-015922-5wwy0m2k	81	15	period	period	NN
cord-015922-5wwy0m2k	81	16	to	to	TO
cord-015922-5wwy0m2k	81	17	provide	provide	VB
cord-015922-5wwy0m2k	81	18	chemotherapy	chemotherapy	NN
cord-015922-5wwy0m2k	81	19	,	,	,
cord-015922-5wwy0m2k	81	20	nutritional	nutritional	JJ
cord-015922-5wwy0m2k	81	21	and	and	CC
cord-015922-5wwy0m2k	81	22	blood	blood	NN
cord-015922-5wwy0m2k	81	23	product	product	NN
cord-015922-5wwy0m2k	81	24	support	support	NN
cord-015922-5wwy0m2k	81	25	until	until	IN
cord-015922-5wwy0m2k	81	26	stable	stable	JJ
cord-015922-5wwy0m2k	81	27	engraftment	engraftment	NN
cord-015922-5wwy0m2k	81	28	.	.	.
cord-015922-5wwy0m2k	82	1	Routine	routine	JJ
cord-015922-5wwy0m2k	82	2	anti	anti	JJ
cord-015922-5wwy0m2k	82	3	-	-	JJ
cord-015922-5wwy0m2k	82	4	gram	gram	JJ
cord-015922-5wwy0m2k	82	5	-	-	HYPH
cord-015922-5wwy0m2k	82	6	positive	positive	JJ
cord-015922-5wwy0m2k	82	7	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	82	8	therapy	therapy	NN
cord-015922-5wwy0m2k	82	9	is	be	VBZ
cord-015922-5wwy0m2k	82	10	not	not	RB
cord-015922-5wwy0m2k	82	11	required	require	VBN
cord-015922-5wwy0m2k	82	12	just	just	RB
cord-015922-5wwy0m2k	82	13	because	because	IN
cord-015922-5wwy0m2k	82	14	a	a	DT
cord-015922-5wwy0m2k	82	15	central	central	JJ
cord-015922-5wwy0m2k	82	16	catheter	catheter	NN
cord-015922-5wwy0m2k	82	17	is	be	VBZ
cord-015922-5wwy0m2k	82	18	in	in	IN
cord-015922-5wwy0m2k	82	19	place	place	NN
cord-015922-5wwy0m2k	82	20	for	for	IN
cord-015922-5wwy0m2k	82	21	the	the	DT
cord-015922-5wwy0m2k	82	22	prevention	prevention	NN
cord-015922-5wwy0m2k	82	23	and	and	CC
cord-015922-5wwy0m2k	82	24	management	management	NN
cord-015922-5wwy0m2k	82	25	of	of	IN
cord-015922-5wwy0m2k	82	26	catheter	catheter	NN
cord-015922-5wwy0m2k	82	27	-	-	HYPH
cord-015922-5wwy0m2k	82	28	related	relate	VBN
cord-015922-5wwy0m2k	82	29	infections	infection	NNS
cord-015922-5wwy0m2k	82	30	[	[	-LRB-
cord-015922-5wwy0m2k	82	31	21	21	CD
cord-015922-5wwy0m2k	82	32	,	,	,
cord-015922-5wwy0m2k	82	33	23	23	CD
cord-015922-5wwy0m2k	82	34	]	]	-RRB-
cord-015922-5wwy0m2k	82	35	.	.	.
cord-015922-5wwy0m2k	83	1	The	the	DT
cord-015922-5wwy0m2k	83	2	use	use	NN
cord-015922-5wwy0m2k	83	3	of	of	IN
cord-015922-5wwy0m2k	83	4	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	83	5	-	-	HYPH
cord-015922-5wwy0m2k	83	6	coated	coated	JJ
cord-015922-5wwy0m2k	83	7	catheters	catheter	NNS
cord-015922-5wwy0m2k	83	8	should	should	MD
cord-015922-5wwy0m2k	83	9	be	be	VB
cord-015922-5wwy0m2k	83	10	studied	study	VBN
cord-015922-5wwy0m2k	83	11	in	in	IN
cord-015922-5wwy0m2k	83	12	this	this	DT
cord-015922-5wwy0m2k	83	13	population	population	NN
cord-015922-5wwy0m2k	83	14	,	,	,
cord-015922-5wwy0m2k	83	15	especially	especially	RB
cord-015922-5wwy0m2k	83	16	when	when	WRB
cord-015922-5wwy0m2k	83	17	non	non	JJ
cord-015922-5wwy0m2k	83	18	-	-	JJ
cord-015922-5wwy0m2k	83	19	tunneled	tunnel	VBN
cord-015922-5wwy0m2k	83	20	catheters	catheter	NNS
cord-015922-5wwy0m2k	83	21	need	need	VBP
cord-015922-5wwy0m2k	83	22	to	to	TO
cord-015922-5wwy0m2k	83	23	be	be	VB
cord-015922-5wwy0m2k	83	24	used	use	VBN
cord-015922-5wwy0m2k	83	25	.	.	.
cord-015922-5wwy0m2k	84	1	Nonantimicrobial	Nonantimicrobial	NNP
cord-015922-5wwy0m2k	84	2	-	-	HYPH
cord-015922-5wwy0m2k	84	3	based	base	VBN
cord-015922-5wwy0m2k	84	4	strategies	strategy	NNS
cord-015922-5wwy0m2k	84	5	to	to	TO
cord-015922-5wwy0m2k	84	6	prevent	prevent	VB
cord-015922-5wwy0m2k	84	7	bacterial	bacterial	JJ
cord-015922-5wwy0m2k	84	8	infections	infection	NNS
cord-015922-5wwy0m2k	84	9	during	during	IN
cord-015922-5wwy0m2k	84	10	the	the	DT
cord-015922-5wwy0m2k	84	11	neutropenic	neutropenic	JJ
cord-015922-5wwy0m2k	84	12	period	period	NN
cord-015922-5wwy0m2k	84	13	include	include	VBP
cord-015922-5wwy0m2k	84	14	the	the	DT
cord-015922-5wwy0m2k	84	15	systematic	systematic	JJ
cord-015922-5wwy0m2k	84	16	use	use	NN
cord-015922-5wwy0m2k	84	17	of	of	IN
cord-015922-5wwy0m2k	84	18	hand	hand	NN
cord-015922-5wwy0m2k	84	19	hygiene	hygiene	NN
cord-015922-5wwy0m2k	84	20	and	and	CC
cord-015922-5wwy0m2k	84	21	the	the	DT
cord-015922-5wwy0m2k	84	22	use	use	NN
cord-015922-5wwy0m2k	84	23	of	of	IN
cord-015922-5wwy0m2k	84	24	mask	mask	NN
cord-015922-5wwy0m2k	84	25	and	and	CC
cord-015922-5wwy0m2k	84	26	gloves	glove	NNS
cord-015922-5wwy0m2k	84	27	by	by	IN
cord-015922-5wwy0m2k	84	28	health	health	NN
cord-015922-5wwy0m2k	84	29	care	care	NN
cord-015922-5wwy0m2k	84	30	personnel	personnel	NNS
cord-015922-5wwy0m2k	84	31	and	and	CC
cord-015922-5wwy0m2k	84	32	family	family	NN
cord-015922-5wwy0m2k	84	33	members	member	NNS
cord-015922-5wwy0m2k	84	34	.	.	.
cord-015922-5wwy0m2k	85	1	Other	other	JJ
cord-015922-5wwy0m2k	85	2	nonantimicrobial	nonantimicrobial	JJ
cord-015922-5wwy0m2k	85	3	strategies	strategy	NNS
cord-015922-5wwy0m2k	85	4	which	which	WDT
cord-015922-5wwy0m2k	85	5	may	may	MD
cord-015922-5wwy0m2k	85	6	be	be	VB
cord-015922-5wwy0m2k	85	7	beneficial	beneficial	JJ
cord-015922-5wwy0m2k	85	8	in	in	IN
cord-015922-5wwy0m2k	85	9	preventing	prevent	VBG
cord-015922-5wwy0m2k	85	10	infections	infection	NNS
cord-015922-5wwy0m2k	85	11	,	,	,
cord-015922-5wwy0m2k	85	12	but	but	CC
cord-015922-5wwy0m2k	85	13	have	have	VBP
cord-015922-5wwy0m2k	85	14	not	not	RB
cord-015922-5wwy0m2k	85	15	been	be	VBN
cord-015922-5wwy0m2k	85	16	tested	test	VBN
cord-015922-5wwy0m2k	85	17	in	in	IN
cord-015922-5wwy0m2k	85	18	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	85	19	,	,	,
cord-015922-5wwy0m2k	85	20	include	include	VBP
cord-015922-5wwy0m2k	85	21	the	the	DT
cord-015922-5wwy0m2k	85	22	use	use	NN
cord-015922-5wwy0m2k	85	23	of	of	IN
cord-015922-5wwy0m2k	85	24	palifermin	palifermin	NNP
cord-015922-5wwy0m2k	85	25	to	to	TO
cord-015922-5wwy0m2k	85	26	prevent	prevent	VB
cord-015922-5wwy0m2k	85	27	mucositis	mucositis	NNP
cord-015922-5wwy0m2k	85	28	[	[	-LRB-
cord-015922-5wwy0m2k	85	29	24	24	CD
cord-015922-5wwy0m2k	85	30	]	]	-RRB-
cord-015922-5wwy0m2k	85	31	in	in	IN
cord-015922-5wwy0m2k	85	32	patients	patient	NNS
cord-015922-5wwy0m2k	85	33	undergoing	undergo	VBG
cord-015922-5wwy0m2k	85	34	myeloablative	myeloablative	JJ
cord-015922-5wwy0m2k	85	35	conditioning	conditioning	NN
cord-015922-5wwy0m2k	85	36	.	.	.
cord-015922-5wwy0m2k	86	1	After	after	IN
cord-015922-5wwy0m2k	86	2	engraftment	engraftment	NN
cord-015922-5wwy0m2k	86	3	,	,	,
cord-015922-5wwy0m2k	86	4	the	the	DT
cord-015922-5wwy0m2k	86	5	risk	risk	NN
cord-015922-5wwy0m2k	86	6	of	of	IN
cord-015922-5wwy0m2k	86	7	bacterial	bacterial	JJ
cord-015922-5wwy0m2k	86	8	infections	infection	NNS
cord-015922-5wwy0m2k	86	9	depend	depend	VBP
cord-015922-5wwy0m2k	86	10	on	on	IN
cord-015922-5wwy0m2k	86	11	the	the	DT
cord-015922-5wwy0m2k	86	12	community	community	NN
cord-015922-5wwy0m2k	86	13	exposures	exposure	NNS
cord-015922-5wwy0m2k	86	14	to	to	IN
cord-015922-5wwy0m2k	86	15	common	common	JJ
cord-015922-5wwy0m2k	86	16	and	and	CC
cord-015922-5wwy0m2k	86	17	opportunistic	opportunistic	JJ
cord-015922-5wwy0m2k	86	18	bacteria	bacteria	NNS
cord-015922-5wwy0m2k	86	19	(	(	-LRB-
cord-015922-5wwy0m2k	86	20	e.g.	e.g.	RB
cord-015922-5wwy0m2k	86	21	,	,	,
cord-015922-5wwy0m2k	86	22	Nocardia	Nocardia	NNP
cord-015922-5wwy0m2k	86	23	,	,	,
cord-015922-5wwy0m2k	86	24	Rhodococcus	Rhodococcus	NNP
cord-015922-5wwy0m2k	86	25	,	,	,
cord-015922-5wwy0m2k	86	26	Listeria	Listeria	NNP
cord-015922-5wwy0m2k	86	27	)	)	-RRB-
cord-015922-5wwy0m2k	86	28	,	,	,
cord-015922-5wwy0m2k	86	29	the	the	DT
cord-015922-5wwy0m2k	86	30	presence	presence	NN
cord-015922-5wwy0m2k	86	31	of	of	IN
cord-015922-5wwy0m2k	86	32	acute	acute	JJ
cord-015922-5wwy0m2k	86	33	and	and	CC
cord-015922-5wwy0m2k	86	34	chronic	chronic	JJ
cord-015922-5wwy0m2k	86	35	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	86	36	,	,	,
cord-015922-5wwy0m2k	86	37	the	the	DT
cord-015922-5wwy0m2k	86	38	degree	degree	NN
cord-015922-5wwy0m2k	86	39	of	of	IN
cord-015922-5wwy0m2k	86	40	B	b	NN
cord-015922-5wwy0m2k	86	41	-	-	HYPH
cord-015922-5wwy0m2k	86	42	cell	cell	NN
cord-015922-5wwy0m2k	86	43	reconstitution	reconstitution	NN
cord-015922-5wwy0m2k	86	44	and	and	CC
cord-015922-5wwy0m2k	86	45	the	the	DT
cord-015922-5wwy0m2k	86	46	use	use	NN
cord-015922-5wwy0m2k	86	47	of	of	IN
cord-015922-5wwy0m2k	86	48	trimethoprim	trimethoprim	NNP
cord-015922-5wwy0m2k	86	49	-	-	HYPH
cord-015922-5wwy0m2k	86	50	sulfamethoxazole	sulfamethoxazole	NNP
cord-015922-5wwy0m2k	86	51	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	86	52	.	.	.
cord-015922-5wwy0m2k	87	1	Patients	patient	NNS
cord-015922-5wwy0m2k	87	2	with	with	IN
cord-015922-5wwy0m2k	87	3	chronic	chronic	JJ
cord-015922-5wwy0m2k	87	4	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	87	5	are	be	VBP
cord-015922-5wwy0m2k	87	6	at	at	IN
cord-015922-5wwy0m2k	87	7	risk	risk	NN
cord-015922-5wwy0m2k	87	8	for	for	IN
cord-015922-5wwy0m2k	87	9	invasive	invasive	JJ
cord-015922-5wwy0m2k	87	10	infection	infection	NN
cord-015922-5wwy0m2k	87	11	from	from	IN
cord-015922-5wwy0m2k	87	12	encapsulated	encapsulate	VBN
cord-015922-5wwy0m2k	87	13	organisms	organism	NNS
cord-015922-5wwy0m2k	87	14	,	,	,
cord-015922-5wwy0m2k	87	15	particularly	particularly	RB
cord-015922-5wwy0m2k	87	16	Streptococcus	streptococcus	NN
cord-015922-5wwy0m2k	87	17	pneumoniae	pneumoniae	NN
cord-015922-5wwy0m2k	87	18	,	,	,
cord-015922-5wwy0m2k	87	19	Haemophilus	haemophilus	JJ
cord-015922-5wwy0m2k	87	20	influenzae	influenzae	NN
cord-015922-5wwy0m2k	87	21	and	and	CC
cord-015922-5wwy0m2k	87	22	Neisseria	Neisseria	NNP
cord-015922-5wwy0m2k	87	23	meningitidis	meningitidis	NN
cord-015922-5wwy0m2k	87	24	.	.	.
cord-015922-5wwy0m2k	88	1	It	-PRON-	PRP
cord-015922-5wwy0m2k	88	2	is	be	VBZ
cord-015922-5wwy0m2k	88	3	postulated	postulate	VBN
cord-015922-5wwy0m2k	88	4	that	that	IN
cord-015922-5wwy0m2k	88	5	the	the	DT
cord-015922-5wwy0m2k	88	6	combination	combination	NN
cord-015922-5wwy0m2k	88	7	of	of	IN
cord-015922-5wwy0m2k	88	8	B	b	NN
cord-015922-5wwy0m2k	88	9	lymphocyte	lymphocyte	NN
cord-015922-5wwy0m2k	88	10	dysfunction	dysfunction	NN
cord-015922-5wwy0m2k	88	11	secondary	secondary	JJ
cord-015922-5wwy0m2k	88	12	to	to	IN
cord-015922-5wwy0m2k	88	13	the	the	DT
cord-015922-5wwy0m2k	88	14	conditioning	conditioning	NN
cord-015922-5wwy0m2k	88	15	regimen	regimen	NN
cord-015922-5wwy0m2k	88	16	and	and	CC
cord-015922-5wwy0m2k	88	17	the	the	DT
cord-015922-5wwy0m2k	88	18	effects	effect	NNS
cord-015922-5wwy0m2k	88	19	of	of	IN
cord-015922-5wwy0m2k	88	20	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	88	21	and	and	CC
cord-015922-5wwy0m2k	88	22	its	-PRON-	PRP$
cord-015922-5wwy0m2k	88	23	treatment	treatment	NN
cord-015922-5wwy0m2k	88	24	have	have	VBP
cord-015922-5wwy0m2k	88	25	resulted	result	VBN
cord-015922-5wwy0m2k	88	26	in	in	IN
cord-015922-5wwy0m2k	88	27	the	the	DT
cord-015922-5wwy0m2k	88	28	loss	loss	NN
cord-015922-5wwy0m2k	88	29	and	and	CC
cord-015922-5wwy0m2k	88	30	failure	failure	NN
cord-015922-5wwy0m2k	88	31	to	to	TO
cord-015922-5wwy0m2k	88	32	develop	develop	VB
cord-015922-5wwy0m2k	88	33	an	an	DT
cord-015922-5wwy0m2k	88	34	opsonizing	opsonize	VBG
cord-015922-5wwy0m2k	88	35	antibody	antibody	NN
cord-015922-5wwy0m2k	88	36	to	to	IN
cord-015922-5wwy0m2k	88	37	these	these	DT
cord-015922-5wwy0m2k	88	38	organisms	organism	NNS
cord-015922-5wwy0m2k	88	39	,	,	,
cord-015922-5wwy0m2k	88	40	particularly	particularly	RB
cord-015922-5wwy0m2k	88	41	Streptococcus	streptococcus	NN
cord-015922-5wwy0m2k	88	42	pneumoniae	pneumoniae	NN
cord-015922-5wwy0m2k	88	43	.	.	.
cord-015922-5wwy0m2k	89	1	In	in	IN
cord-015922-5wwy0m2k	89	2	addition	addition	NN
cord-015922-5wwy0m2k	89	3	,	,	,
cord-015922-5wwy0m2k	89	4	for	for	IN
cord-015922-5wwy0m2k	89	5	at	at	RB
cord-015922-5wwy0m2k	89	6	least	least	RBS
cord-015922-5wwy0m2k	89	7	one	one	CD
cord-015922-5wwy0m2k	89	8	to	to	TO
cord-015922-5wwy0m2k	89	9	two	two	CD
cord-015922-5wwy0m2k	89	10	years	year	NNS
cord-015922-5wwy0m2k	89	11	post	post	NN
cord-015922-5wwy0m2k	89	12	-	-	NN
cord-015922-5wwy0m2k	89	13	transplant	transplant	NN
cord-015922-5wwy0m2k	89	14	,	,	,
cord-015922-5wwy0m2k	89	15	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	89	16	patients	patient	NNS
cord-015922-5wwy0m2k	89	17	have	have	VBP
cord-015922-5wwy0m2k	89	18	an	an	DT
cord-015922-5wwy0m2k	89	19	inadequate	inadequate	JJ
cord-015922-5wwy0m2k	89	20	response	response	NN
cord-015922-5wwy0m2k	89	21	to	to	IN
cord-015922-5wwy0m2k	89	22	pneumococcal	pneumococcal	JJ
cord-015922-5wwy0m2k	89	23	vaccine	vaccine	NN
cord-015922-5wwy0m2k	89	24	.	.	.
cord-015922-5wwy0m2k	90	1	As	as	IN
cord-015922-5wwy0m2k	90	2	IgG	igg	NN
cord-015922-5wwy0m2k	90	3	levels	level	NNS
cord-015922-5wwy0m2k	90	4	are	be	VBP
cord-015922-5wwy0m2k	90	5	often	often	RB
cord-015922-5wwy0m2k	90	6	low	low	JJ
cord-015922-5wwy0m2k	90	7	for	for	IN
cord-015922-5wwy0m2k	90	8	some	some	DT
cord-015922-5wwy0m2k	90	9	time	time	NN
cord-015922-5wwy0m2k	90	10	after	after	IN
cord-015922-5wwy0m2k	90	11	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	90	12	,	,	,
cord-015922-5wwy0m2k	90	13	they	-PRON-	PRP
cord-015922-5wwy0m2k	90	14	should	should	MD
cord-015922-5wwy0m2k	90	15	be	be	VB
cord-015922-5wwy0m2k	90	16	routinely	routinely	RB
cord-015922-5wwy0m2k	90	17	monitored	monitor	VBN
cord-015922-5wwy0m2k	90	18	,	,	,
cord-015922-5wwy0m2k	90	19	with	with	IN
cord-015922-5wwy0m2k	90	20	replacement	replacement	NN
cord-015922-5wwy0m2k	90	21	being	be	VBG
cord-015922-5wwy0m2k	90	22	considered	consider	VBN
cord-015922-5wwy0m2k	90	23	when	when	WRB
cord-015922-5wwy0m2k	90	24	the	the	DT
cord-015922-5wwy0m2k	90	25	IgG	igg	NN
cord-015922-5wwy0m2k	90	26	level	level	NN
cord-015922-5wwy0m2k	90	27	falls	fall	VBZ
cord-015922-5wwy0m2k	90	28	below	below	IN
cord-015922-5wwy0m2k	90	29	500	500	CD
cord-015922-5wwy0m2k	90	30	mg	mg	NNP
cord-015922-5wwy0m2k	90	31	/	/	SYM
cord-015922-5wwy0m2k	90	32	ml	ml	NNP
cord-015922-5wwy0m2k	90	33	[	[	-LRB-
cord-015922-5wwy0m2k	90	34	25	25	CD
cord-015922-5wwy0m2k	90	35	,	,	,
cord-015922-5wwy0m2k	90	36	26	26	CD
cord-015922-5wwy0m2k	90	37	]	]	-RRB-
cord-015922-5wwy0m2k	90	38	.	.	.
cord-015922-5wwy0m2k	91	1	In	in	IN
cord-015922-5wwy0m2k	91	2	addition	addition	NN
cord-015922-5wwy0m2k	91	3	,	,	,
cord-015922-5wwy0m2k	91	4	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	91	5	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	91	6	,	,	,
cord-015922-5wwy0m2k	91	7	such	such	JJ
cord-015922-5wwy0m2k	91	8	as	as	IN
cord-015922-5wwy0m2k	91	9	with	with	IN
cord-015922-5wwy0m2k	91	10	low	low	JJ
cord-015922-5wwy0m2k	91	11	-	-	HYPH
cord-015922-5wwy0m2k	91	12	dose	dose	NN
cord-015922-5wwy0m2k	91	13	trimethoprimsulfamethoxazole	trimethoprimsulfamethoxazole	NN
cord-015922-5wwy0m2k	91	14	(	(	-LRB-
cord-015922-5wwy0m2k	91	15	one	one	CD
cord-015922-5wwy0m2k	91	16	single	single	JJ
cord-015922-5wwy0m2k	91	17	strength	strength	NN
cord-015922-5wwy0m2k	91	18	tablet	tablet	NN
cord-015922-5wwy0m2k	91	19	daily	daily	RB
cord-015922-5wwy0m2k	91	20	for	for	IN
cord-015922-5wwy0m2k	91	21	PCP	PCP	NNP
cord-015922-5wwy0m2k	91	22	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	91	23	)	)	-RRB-
cord-015922-5wwy0m2k	91	24	,	,	,
cord-015922-5wwy0m2k	91	25	may	may	MD
cord-015922-5wwy0m2k	91	26	afford	afford	VB
cord-015922-5wwy0m2k	91	27	further	further	JJ
cord-015922-5wwy0m2k	91	28	protection	protection	NN
cord-015922-5wwy0m2k	91	29	against	against	IN
cord-015922-5wwy0m2k	91	30	this	this	DT
cord-015922-5wwy0m2k	91	31	problem	problem	NN
cord-015922-5wwy0m2k	91	32	[	[	-LRB-
cord-015922-5wwy0m2k	91	33	1	1	CD
cord-015922-5wwy0m2k	91	34	,	,	,
cord-015922-5wwy0m2k	91	35	3	3	CD
cord-015922-5wwy0m2k	91	36	]	]	-RRB-
cord-015922-5wwy0m2k	91	37	.	.	.
cord-015922-5wwy0m2k	92	1	There	there	EX
cord-015922-5wwy0m2k	92	2	are	be	VBP
cord-015922-5wwy0m2k	92	3	several	several	JJ
cord-015922-5wwy0m2k	92	4	classes	class	NNS
cord-015922-5wwy0m2k	92	5	of	of	IN
cord-015922-5wwy0m2k	92	6	viral	viral	JJ
cord-015922-5wwy0m2k	92	7	infection	infection	NN
cord-015922-5wwy0m2k	92	8	of	of	IN
cord-015922-5wwy0m2k	92	9	particular	particular	JJ
cord-015922-5wwy0m2k	92	10	importance	importance	NN
cord-015922-5wwy0m2k	92	11	in	in	IN
cord-015922-5wwy0m2k	92	12	the	the	DT
cord-015922-5wwy0m2k	92	13	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	92	14	recipient	recipient	NN
cord-015922-5wwy0m2k	92	15	:	:	:
cord-015922-5wwy0m2k	92	16	those	those	DT
cord-015922-5wwy0m2k	92	17	due	due	JJ
cord-015922-5wwy0m2k	92	18	to	to	IN
cord-015922-5wwy0m2k	92	19	herpesviruses	herpesviruses	NNP
cord-015922-5wwy0m2k	92	20	(	(	-LRB-
cord-015922-5wwy0m2k	92	21	CMV	CMV	NNP
cord-015922-5wwy0m2k	92	22	,	,	,
cord-015922-5wwy0m2k	92	23	EBV	EBV	NNP
cord-015922-5wwy0m2k	92	24	,	,	,
cord-015922-5wwy0m2k	92	25	HSV	HSV	NNP
cord-015922-5wwy0m2k	92	26	,	,	,
cord-015922-5wwy0m2k	92	27	VZV	VZV	NNP
cord-015922-5wwy0m2k	92	28	and	and	CC
cord-015922-5wwy0m2k	92	29	human	human	JJ
cord-015922-5wwy0m2k	92	30	herpesvirus-6	herpesvirus-6	NNP
cord-015922-5wwy0m2k	92	31	[	[	-LRB-
cord-015922-5wwy0m2k	92	32	HHV-6	HHV-6	NNP
cord-015922-5wwy0m2k	92	33	]	]	-RRB-
cord-015922-5wwy0m2k	92	34	)	)	-RRB-
cord-015922-5wwy0m2k	92	35	;	;	:
cord-015922-5wwy0m2k	92	36	those	those	DT
cord-015922-5wwy0m2k	92	37	due	due	JJ
cord-015922-5wwy0m2k	92	38	to	to	IN
cord-015922-5wwy0m2k	92	39	hepatitis	hepatitis	NN
cord-015922-5wwy0m2k	92	40	viruses	virus	NNS
cord-015922-5wwy0m2k	92	41	(	(	-LRB-
cord-015922-5wwy0m2k	92	42	e.g.	e.g.	RB
cord-015922-5wwy0m2k	92	43	,	,	,
cord-015922-5wwy0m2k	92	44	hepatitis	hepatitis	NN
cord-015922-5wwy0m2k	92	45	B	B	NNP
cord-015922-5wwy0m2k	92	46	[	[	-LRB-
cord-015922-5wwy0m2k	92	47	HBV	HBV	NNP
cord-015922-5wwy0m2k	92	48	]	]	-RRB-
cord-015922-5wwy0m2k	92	49	)	)	-RRB-
cord-015922-5wwy0m2k	92	50	;	;	:
cord-015922-5wwy0m2k	92	51	those	those	DT
cord-015922-5wwy0m2k	92	52	due	due	JJ
cord-015922-5wwy0m2k	92	53	to	to	IN
cord-015922-5wwy0m2k	92	54	respiratory	respiratory	JJ
cord-015922-5wwy0m2k	92	55	viruses	virus	NNS
cord-015922-5wwy0m2k	92	56	(	(	-LRB-
cord-015922-5wwy0m2k	92	57	e.g.	e.g.	RB
cord-015922-5wwy0m2k	92	58	,	,	,
cord-015922-5wwy0m2k	92	59	influenza	influenza	NN
cord-015922-5wwy0m2k	92	60	,	,	,
cord-015922-5wwy0m2k	92	61	RSV	RSV	NNP
cord-015922-5wwy0m2k	92	62	,	,	,
cord-015922-5wwy0m2k	92	63	parainfluenza	parainfluenza	NNP
cord-015922-5wwy0m2k	92	64	,	,	,
cord-015922-5wwy0m2k	92	65	adenoviruses	adenovirus	NNS
cord-015922-5wwy0m2k	92	66	,	,	,
cord-015922-5wwy0m2k	92	67	and	and	CC
cord-015922-5wwy0m2k	92	68	others	other	NNS
cord-015922-5wwy0m2k	92	69	)	)	-RRB-
cord-015922-5wwy0m2k	92	70	,	,	,
cord-015922-5wwy0m2k	92	71	and	and	CC
cord-015922-5wwy0m2k	92	72	those	those	DT
cord-015922-5wwy0m2k	92	73	due	due	JJ
cord-015922-5wwy0m2k	92	74	to	to	IN
cord-015922-5wwy0m2k	92	75	polyoma	polyoma	NN
cord-015922-5wwy0m2k	92	76	viruses	virus	NNS
cord-015922-5wwy0m2k	92	77	.	.	.
cord-015922-5wwy0m2k	93	1	The	the	DT
cord-015922-5wwy0m2k	93	2	human	human	JJ
cord-015922-5wwy0m2k	93	3	herpesviruses	herpesviruse	NNS
cord-015922-5wwy0m2k	93	4	share	share	VBP
cord-015922-5wwy0m2k	93	5	a	a	DT
cord-015922-5wwy0m2k	93	6	number	number	NN
cord-015922-5wwy0m2k	93	7	of	of	IN
cord-015922-5wwy0m2k	93	8	characteristics	characteristic	NNS
cord-015922-5wwy0m2k	93	9	that	that	WDT
cord-015922-5wwy0m2k	93	10	make	make	VBP
cord-015922-5wwy0m2k	93	11	them	-PRON-	PRP
cord-015922-5wwy0m2k	93	12	particularly	particularly	RB
cord-015922-5wwy0m2k	93	13	successful	successful	JJ
cord-015922-5wwy0m2k	93	14	pathogens	pathogen	NNS
cord-015922-5wwy0m2k	93	15	in	in	IN
cord-015922-5wwy0m2k	93	16	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	93	17	recipients	recipient	NNS
cord-015922-5wwy0m2k	93	18	[	[	-LRB-
cord-015922-5wwy0m2k	93	19	1	1	CD
cord-015922-5wwy0m2k	93	20	,	,	,
cord-015922-5wwy0m2k	93	21	4	4	CD
cord-015922-5wwy0m2k	93	22	,	,	,
cord-015922-5wwy0m2k	93	23	27	27	CD
cord-015922-5wwy0m2k	93	24	]	]	-RRB-
cord-015922-5wwy0m2k	93	25	:	:	:
cord-015922-5wwy0m2k	94	1	1	1	LS
cord-015922-5wwy0m2k	94	2	.	.	.
cord-015922-5wwy0m2k	95	1	Latency	Latency	NNP
cord-015922-5wwy0m2k	96	1	Once	once	IN
cord-015922-5wwy0m2k	96	2	infected	infect	VBN
cord-015922-5wwy0m2k	96	3	with	with	IN
cord-015922-5wwy0m2k	96	4	a	a	DT
cord-015922-5wwy0m2k	96	5	herpesvirus	herpesvirus	NN
cord-015922-5wwy0m2k	96	6	,	,	,
cord-015922-5wwy0m2k	96	7	one	one	CD
cord-015922-5wwy0m2k	96	8	is	be	VBZ
cord-015922-5wwy0m2k	96	9	infected	infect	VBN
cord-015922-5wwy0m2k	96	10	for	for	IN
cord-015922-5wwy0m2k	96	11	life	life	NN
cord-015922-5wwy0m2k	96	12	,	,	,
cord-015922-5wwy0m2k	96	13	with	with	IN
cord-015922-5wwy0m2k	96	14	a	a	DT
cord-015922-5wwy0m2k	96	15	circulating	circulate	VBG
cord-015922-5wwy0m2k	96	16	antibody	antibody	NN
cord-015922-5wwy0m2k	96	17	(	(	-LRB-
cord-015922-5wwy0m2k	96	18	seropositivity	seropositivity	NN
cord-015922-5wwy0m2k	96	19	)	)	-RRB-
cord-015922-5wwy0m2k	96	20	in	in	IN
cord-015922-5wwy0m2k	96	21	the	the	DT
cord-015922-5wwy0m2k	96	22	absence	absence	NN
cord-015922-5wwy0m2k	96	23	of	of	IN
cord-015922-5wwy0m2k	96	24	active	active	JJ
cord-015922-5wwy0m2k	96	25	viral	viral	JJ
cord-015922-5wwy0m2k	96	26	replication	replication	NN
cord-015922-5wwy0m2k	96	27	being	be	VBG
cord-015922-5wwy0m2k	96	28	the	the	DT
cord-015922-5wwy0m2k	96	29	classic	classic	JJ
cord-015922-5wwy0m2k	96	30	marker	marker	NN
cord-015922-5wwy0m2k	96	31	for	for	IN
cord-015922-5wwy0m2k	96	32	latent	latent	JJ
cord-015922-5wwy0m2k	96	33	infection	infection	NN
cord-015922-5wwy0m2k	96	34	.	.	.
cord-015922-5wwy0m2k	97	1	Reactivation	reactivation	NN
cord-015922-5wwy0m2k	97	2	from	from	IN
cord-015922-5wwy0m2k	97	3	latency	latency	NN
cord-015922-5wwy0m2k	97	4	may	may	MD
cord-015922-5wwy0m2k	97	5	be	be	VB
cord-015922-5wwy0m2k	97	6	triggered	trigger	VBN
cord-015922-5wwy0m2k	97	7	by	by	IN
cord-015922-5wwy0m2k	97	8	tumor	tumor	NN
cord-015922-5wwy0m2k	97	9	necrosis	necrosis	NN
cord-015922-5wwy0m2k	97	10	factor	factor	NN
cord-015922-5wwy0m2k	97	11	(	(	-LRB-
cord-015922-5wwy0m2k	97	12	TNF	TNF	NNP
cord-015922-5wwy0m2k	97	13	)	)	-RRB-
cord-015922-5wwy0m2k	97	14	,	,	,
cord-015922-5wwy0m2k	97	15	with	with	IN
cord-015922-5wwy0m2k	97	16	the	the	DT
cord-015922-5wwy0m2k	97	17	catecholamines	catecholamine	NNS
cord-015922-5wwy0m2k	97	18	epinephrine	epinephrine	NN
cord-015922-5wwy0m2k	97	19	and	and	CC
cord-015922-5wwy0m2k	97	20	norepinephrine	norepinephrine	NN
cord-015922-5wwy0m2k	97	21	and	and	CC
cord-015922-5wwy0m2k	97	22	proinflammatory	proinflammatory	JJ
cord-015922-5wwy0m2k	97	23	prostaglandins	prostaglandin	NNS
cord-015922-5wwy0m2k	97	24	also	also	RB
cord-015922-5wwy0m2k	97	25	playing	play	VBG
cord-015922-5wwy0m2k	97	26	a	a	DT
cord-015922-5wwy0m2k	97	27	role	role	NN
cord-015922-5wwy0m2k	97	28	.	.	.
cord-015922-5wwy0m2k	98	1	Thus	thus	RB
cord-015922-5wwy0m2k	98	2	,	,	,
cord-015922-5wwy0m2k	98	3	the	the	DT
cord-015922-5wwy0m2k	98	4	virus	virus	NN
cord-015922-5wwy0m2k	98	5	may	may	MD
cord-015922-5wwy0m2k	98	6	be	be	VB
cord-015922-5wwy0m2k	98	7	reactivated	reactivate	VBN
cord-015922-5wwy0m2k	98	8	by	by	IN
cord-015922-5wwy0m2k	98	9	such	such	JJ
cord-015922-5wwy0m2k	98	10	processes	process	NNS
cord-015922-5wwy0m2k	98	11	as	as	IN
cord-015922-5wwy0m2k	98	12	sepsis	sepsis	NN
cord-015922-5wwy0m2k	98	13	,	,	,
cord-015922-5wwy0m2k	98	14	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	98	15	,	,	,
cord-015922-5wwy0m2k	98	16	allogeneic	allogeneic	NN
cord-015922-5wwy0m2k	98	17	reactions	reaction	NNS
cord-015922-5wwy0m2k	98	18	,	,	,
cord-015922-5wwy0m2k	98	19	OKT3	OKT3	NNP
cord-015922-5wwy0m2k	98	20	and	and	CC
cord-015922-5wwy0m2k	98	21	antilymphocyte	antilymphocyte	NNP
cord-015922-5wwy0m2k	98	22	globulin	globulin	NNP
cord-015922-5wwy0m2k	98	23	.	.	.
cord-015922-5wwy0m2k	99	1	Once	once	IN
cord-015922-5wwy0m2k	99	2	a	a	DT
cord-015922-5wwy0m2k	99	3	replicating	replicate	VBG
cord-015922-5wwy0m2k	99	4	virus	virus	NN
cord-015922-5wwy0m2k	99	5	is	be	VBZ
cord-015922-5wwy0m2k	99	6	present	present	JJ
cord-015922-5wwy0m2k	99	7	,	,	,
cord-015922-5wwy0m2k	99	8	medications	medication	NNS
cord-015922-5wwy0m2k	99	9	such	such	JJ
cord-015922-5wwy0m2k	99	10	as	as	IN
cord-015922-5wwy0m2k	99	11	cyclosporine	cyclosporine	NN
cord-015922-5wwy0m2k	99	12	,	,	,
cord-015922-5wwy0m2k	99	13	tacrolimus	tacrolimus	NN
cord-015922-5wwy0m2k	99	14	and	and	CC
cord-015922-5wwy0m2k	99	15	prednisone	prednisone	NNP
cord-015922-5wwy0m2k	99	16	may	may	MD
cord-015922-5wwy0m2k	99	17	significantly	significantly	RB
cord-015922-5wwy0m2k	99	18	amplify	amplify	VB
cord-015922-5wwy0m2k	99	19	the	the	DT
cord-015922-5wwy0m2k	99	20	viral	viral	JJ
cord-015922-5wwy0m2k	99	21	replication	replication	NN
cord-015922-5wwy0m2k	99	22	.	.	.
cord-015922-5wwy0m2k	100	1	2	2	LS
cord-015922-5wwy0m2k	100	2	.	.	.
cord-015922-5wwy0m2k	101	1	Cell	Cell	NNP
cord-015922-5wwy0m2k	101	2	Association	Association	NNP
cord-015922-5wwy0m2k	102	1	These	these	DT
cord-015922-5wwy0m2k	102	2	viruses	virus	NNS
cord-015922-5wwy0m2k	102	3	are	be	VBP
cord-015922-5wwy0m2k	102	4	highly	highly	RB
cord-015922-5wwy0m2k	102	5	cell	cell	NN
cord-015922-5wwy0m2k	102	6	-	-	HYPH
cord-015922-5wwy0m2k	102	7	associated	associate	VBN
cord-015922-5wwy0m2k	102	8	,	,	,
cord-015922-5wwy0m2k	102	9	meaning	mean	VBG
cord-015922-5wwy0m2k	102	10	that	that	IN
cord-015922-5wwy0m2k	102	11	transmission	transmission	NN
cord-015922-5wwy0m2k	102	12	occurs	occur	VBZ
cord-015922-5wwy0m2k	102	13	through	through	IN
cord-015922-5wwy0m2k	102	14	intimate	intimate	JJ
cord-015922-5wwy0m2k	102	15	person	person	NN
cord-015922-5wwy0m2k	102	16	-	-	HYPH
cord-015922-5wwy0m2k	102	17	to	to	IN
cord-015922-5wwy0m2k	102	18	-	-	HYPH
cord-015922-5wwy0m2k	102	19	person	person	NN
cord-015922-5wwy0m2k	102	20	contact	contact	NN
cord-015922-5wwy0m2k	102	21	,	,	,
cord-015922-5wwy0m2k	102	22	or	or	CC
cord-015922-5wwy0m2k	102	23	transfusion	transfusion	NN
cord-015922-5wwy0m2k	102	24	or	or	CC
cord-015922-5wwy0m2k	102	25	transplantation	transplantation	NN
cord-015922-5wwy0m2k	102	26	of	of	IN
cord-015922-5wwy0m2k	102	27	latently	latently	RB
cord-015922-5wwy0m2k	102	28	or	or	CC
cord-015922-5wwy0m2k	102	29	actively	actively	RB
cord-015922-5wwy0m2k	102	30	replicating	replicate	VBG
cord-015922-5wwy0m2k	102	31	cells	cell	NNS
cord-015922-5wwy0m2k	102	32	from	from	IN
cord-015922-5wwy0m2k	102	33	a	a	DT
cord-015922-5wwy0m2k	102	34	seropositive	seropositive	JJ
cord-015922-5wwy0m2k	102	35	donor	donor	NN
cord-015922-5wwy0m2k	102	36	.	.	.
cord-015922-5wwy0m2k	103	1	Humoral	humoral	JJ
cord-015922-5wwy0m2k	103	2	immunity	immunity	NN
cord-015922-5wwy0m2k	103	3	is	be	VBZ
cord-015922-5wwy0m2k	103	4	,	,	,
cord-015922-5wwy0m2k	103	5	hence	hence	RB
cord-015922-5wwy0m2k	103	6	,	,	,
cord-015922-5wwy0m2k	103	7	less	less	RBR
cord-015922-5wwy0m2k	103	8	important	important	JJ
cord-015922-5wwy0m2k	103	9	than	than	IN
cord-015922-5wwy0m2k	103	10	cell	cell	NN
cord-015922-5wwy0m2k	103	11	-	-	HYPH
cord-015922-5wwy0m2k	103	12	mediated	mediate	VBN
cord-015922-5wwy0m2k	103	13	immunity	immunity	NN
cord-015922-5wwy0m2k	103	14	.	.	.
cord-015922-5wwy0m2k	104	1	Indeed	indeed	RB
cord-015922-5wwy0m2k	104	2	,	,	,
cord-015922-5wwy0m2k	104	3	the	the	DT
cord-015922-5wwy0m2k	104	4	key	key	JJ
cord-015922-5wwy0m2k	104	5	host	host	NN
cord-015922-5wwy0m2k	104	6	defense	defense	NN
cord-015922-5wwy0m2k	104	7	is	be	VBZ
cord-015922-5wwy0m2k	104	8	accomplished	accomplish	VBN
cord-015922-5wwy0m2k	104	9	by	by	IN
cord-015922-5wwy0m2k	104	10	major	major	JJ
cord-015922-5wwy0m2k	104	11	histocompatibility	histocompatibility	NN
cord-015922-5wwy0m2k	104	12	complex	complex	NN
cord-015922-5wwy0m2k	104	13	(	(	-LRB-
cord-015922-5wwy0m2k	104	14	MHC)-restricted	mhc)-restricte	VBN
cord-015922-5wwy0m2k	104	15	,	,	,
cord-015922-5wwy0m2k	104	16	virus	virus	NN
cord-015922-5wwy0m2k	104	17	-	-	HYPH
cord-015922-5wwy0m2k	104	18	specific	specific	JJ
cord-015922-5wwy0m2k	104	19	,	,	,
cord-015922-5wwy0m2k	104	20	cytotoxic	cytotoxic	JJ
cord-015922-5wwy0m2k	104	21	T	t	NN
cord-015922-5wwy0m2k	104	22	cells	cell	NNS
cord-015922-5wwy0m2k	104	23	,	,	,
cord-015922-5wwy0m2k	104	24	just	just	RB
cord-015922-5wwy0m2k	104	25	that	that	DT
cord-015922-5wwy0m2k	104	26	component	component	NN
cord-015922-5wwy0m2k	104	27	of	of	IN
cord-015922-5wwy0m2k	104	28	host	host	NN
cord-015922-5wwy0m2k	104	29	defense	defense	NN
cord-015922-5wwy0m2k	104	30	most	most	RBS
cord-015922-5wwy0m2k	104	31	affected	affect	VBN
cord-015922-5wwy0m2k	104	32	by	by	IN
cord-015922-5wwy0m2k	104	33	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	104	34	and	and	CC
cord-015922-5wwy0m2k	104	35	its	-PRON-	PRP$
cord-015922-5wwy0m2k	104	36	treatment	treatment	NN
cord-015922-5wwy0m2k	104	37	.	.	.
cord-015922-5wwy0m2k	105	1	3	3	LS
cord-015922-5wwy0m2k	105	2	.	.	.
cord-015922-5wwy0m2k	106	1	Oncogenesis	Oncogenesis	NNP
cord-015922-5wwy0m2k	106	2	Herpesviruses	Herpesviruses	NNP
cord-015922-5wwy0m2k	106	3	,	,	,
cord-015922-5wwy0m2k	106	4	such	such	JJ
cord-015922-5wwy0m2k	106	5	as	as	IN
cord-015922-5wwy0m2k	106	6	EBV	EBV	NNP
cord-015922-5wwy0m2k	106	7	and	and	CC
cord-015922-5wwy0m2k	106	8	HHV-8	HHV-8	NNP
cord-015922-5wwy0m2k	106	9	,	,	,
cord-015922-5wwy0m2k	106	10	play	play	VB
cord-015922-5wwy0m2k	106	11	a	a	DT
cord-015922-5wwy0m2k	106	12	direct	direct	JJ
cord-015922-5wwy0m2k	106	13	role	role	NN
cord-015922-5wwy0m2k	106	14	in	in	IN
cord-015922-5wwy0m2k	106	15	oncogenesis	oncogenesis	NN
cord-015922-5wwy0m2k	106	16	-	-	HYPH
cord-015922-5wwy0m2k	106	17	causing	cause	VBG
cord-015922-5wwy0m2k	106	18	post	post	JJ
cord-015922-5wwy0m2k	106	19	-	-	JJ
cord-015922-5wwy0m2k	106	20	transplant	transplant	JJ
cord-015922-5wwy0m2k	106	21	lymphoproliferative	lymphoproliferative	JJ
cord-015922-5wwy0m2k	106	22	disease	disease	NN
cord-015922-5wwy0m2k	106	23	(	(	-LRB-
cord-015922-5wwy0m2k	106	24	PTLD	PTLD	NNP
cord-015922-5wwy0m2k	106	25	)	)	-RRB-
cord-015922-5wwy0m2k	106	26	and	and	CC
cord-015922-5wwy0m2k	106	27	Kaposi	Kaposi	NNP
cord-015922-5wwy0m2k	106	28	's	's	POS
cord-015922-5wwy0m2k	106	29	sarcoma	sarcoma	NN
cord-015922-5wwy0m2k	106	30	,	,	,
cord-015922-5wwy0m2k	106	31	respectively	respectively	RB
cord-015922-5wwy0m2k	106	32	.	.	.
cord-015922-5wwy0m2k	107	1	Herpesviruses	Herpesviruses	NNP
cord-015922-5wwy0m2k	107	2	may	may	MD
cord-015922-5wwy0m2k	107	3	also	also	RB
cord-015922-5wwy0m2k	107	4	play	play	VB
cord-015922-5wwy0m2k	107	5	an	an	DT
cord-015922-5wwy0m2k	107	6	indirect	indirect	JJ
cord-015922-5wwy0m2k	107	7	role	role	NN
cord-015922-5wwy0m2k	107	8	in	in	IN
cord-015922-5wwy0m2k	107	9	oncogenesis	oncogenesis	NN
cord-015922-5wwy0m2k	107	10	with	with	IN
cord-015922-5wwy0m2k	107	11	symptomatic	symptomatic	JJ
cord-015922-5wwy0m2k	107	12	CMV	CMV	NNP
cord-015922-5wwy0m2k	107	13	disease	disease	NN
cord-015922-5wwy0m2k	107	14	,	,	,
cord-015922-5wwy0m2k	107	15	increasing	increase	VBG
cord-015922-5wwy0m2k	107	16	the	the	DT
cord-015922-5wwy0m2k	107	17	incidence	incidence	NN
cord-015922-5wwy0m2k	107	18	of	of	IN
cord-015922-5wwy0m2k	107	19	EBV	EBV	NNP
cord-015922-5wwy0m2k	107	20	-	-	HYPH
cord-015922-5wwy0m2k	107	21	associated	associate	VBN
cord-015922-5wwy0m2k	107	22	PTLD	PTLD	NNP
cord-015922-5wwy0m2k	107	23	severalfold	severalfold	RB
cord-015922-5wwy0m2k	107	24	.	.	.
cord-015922-5wwy0m2k	108	1	4	4	LS
cord-015922-5wwy0m2k	108	2	.	.	.
cord-015922-5wwy0m2k	109	1	Indirect	indirect	JJ
cord-015922-5wwy0m2k	109	2	Effects	effect	NNS
cord-015922-5wwy0m2k	110	1	In	in	IN
cord-015922-5wwy0m2k	110	2	addition	addition	NN
cord-015922-5wwy0m2k	110	3	to	to	IN
cord-015922-5wwy0m2k	110	4	the	the	DT
cord-015922-5wwy0m2k	110	5	direct	direct	JJ
cord-015922-5wwy0m2k	110	6	causation	causation	NN
cord-015922-5wwy0m2k	110	7	of	of	IN
cord-015922-5wwy0m2k	110	8	infectious	infectious	JJ
cord-015922-5wwy0m2k	110	9	disease	disease	NN
cord-015922-5wwy0m2k	110	10	syndromes	syndrome	NNS
cord-015922-5wwy0m2k	110	11	,	,	,
cord-015922-5wwy0m2k	110	12	human	human	JJ
cord-015922-5wwy0m2k	110	13	herpesviruses	herpesviruse	NNS
cord-015922-5wwy0m2k	110	14	,	,	,
cord-015922-5wwy0m2k	110	15	particularly	particularly	RB
cord-015922-5wwy0m2k	110	16	CMV	CMV	NNP
cord-015922-5wwy0m2k	110	17	,	,	,
cord-015922-5wwy0m2k	110	18	have	have	VBP
cord-015922-5wwy0m2k	110	19	indirect	indirect	JJ
cord-015922-5wwy0m2k	110	20	effects	effect	NNS
cord-015922-5wwy0m2k	110	21	that	that	WDT
cord-015922-5wwy0m2k	110	22	are	be	VBP
cord-015922-5wwy0m2k	110	23	clinically	clinically	RB
cord-015922-5wwy0m2k	110	24	important	important	JJ
cord-015922-5wwy0m2k	110	25	.	.	.
cord-015922-5wwy0m2k	111	1	It	-PRON-	PRP
cord-015922-5wwy0m2k	111	2	is	be	VBZ
cord-015922-5wwy0m2k	111	3	believed	believe	VBN
cord-015922-5wwy0m2k	111	4	that	that	IN
cord-015922-5wwy0m2k	111	5	cytokines	cytokine	NNS
cord-015922-5wwy0m2k	111	6	,	,	,
cord-015922-5wwy0m2k	111	7	chemokines	chemokine	NNS
cord-015922-5wwy0m2k	111	8	and	and	CC
cord-015922-5wwy0m2k	111	9	growth	growth	NN
cord-015922-5wwy0m2k	111	10	factors	factor	NNS
cord-015922-5wwy0m2k	111	11	produced	produce	VBN
cord-015922-5wwy0m2k	111	12	in	in	IN
cord-015922-5wwy0m2k	111	13	response	response	NN
cord-015922-5wwy0m2k	111	14	to	to	IN
cord-015922-5wwy0m2k	111	15	viral	viral	JJ
cord-015922-5wwy0m2k	111	16	replication	replication	NN
cord-015922-5wwy0m2k	111	17	may	may	MD
cord-015922-5wwy0m2k	111	18	be	be	VB
cord-015922-5wwy0m2k	111	19	responsible	responsible	JJ
cord-015922-5wwy0m2k	111	20	for	for	IN
cord-015922-5wwy0m2k	111	21	these	these	DT
cord-015922-5wwy0m2k	111	22	effects	effect	NNS
cord-015922-5wwy0m2k	111	23	.	.	.
cord-015922-5wwy0m2k	112	1	They	-PRON-	PRP
cord-015922-5wwy0m2k	112	2	include	include	VBP
cord-015922-5wwy0m2k	112	3	,	,	,
cord-015922-5wwy0m2k	112	4	in	in	IN
cord-015922-5wwy0m2k	112	5	addition	addition	NN
cord-015922-5wwy0m2k	112	6	to	to	IN
cord-015922-5wwy0m2k	112	7	the	the	DT
cord-015922-5wwy0m2k	112	8	modulation	modulation	NN
cord-015922-5wwy0m2k	112	9	of	of	IN
cord-015922-5wwy0m2k	112	10	oncogenesis	oncogenesis	NN
cord-015922-5wwy0m2k	112	11	,	,	,
cord-015922-5wwy0m2k	112	12	increasing	increase	VBG
cord-015922-5wwy0m2k	112	13	the	the	DT
cord-015922-5wwy0m2k	112	14	net	net	JJ
cord-015922-5wwy0m2k	112	15	state	state	NN
cord-015922-5wwy0m2k	112	16	of	of	IN
cord-015922-5wwy0m2k	112	17	immunosuppression	immunosuppression	NN
cord-015922-5wwy0m2k	112	18	so	so	IN
cord-015922-5wwy0m2k	112	19	that	that	IN
cord-015922-5wwy0m2k	112	20	the	the	DT
cord-015922-5wwy0m2k	112	21	risk	risk	NN
cord-015922-5wwy0m2k	112	22	of	of	IN
cord-015922-5wwy0m2k	112	23	opportunistic	opportunistic	JJ
cord-015922-5wwy0m2k	112	24	infection	infection	NN
cord-015922-5wwy0m2k	112	25	is	be	VBZ
cord-015922-5wwy0m2k	112	26	increased	increase	VBN
cord-015922-5wwy0m2k	112	27	.	.	.
cord-015922-5wwy0m2k	113	1	This	this	DT
cord-015922-5wwy0m2k	113	2	last	last	JJ
cord-015922-5wwy0m2k	113	3	point	point	NN
cord-015922-5wwy0m2k	113	4	is	be	VBZ
cord-015922-5wwy0m2k	113	5	particularly	particularly	RB
cord-015922-5wwy0m2k	113	6	important	important	JJ
cord-015922-5wwy0m2k	113	7	,	,	,
cord-015922-5wwy0m2k	113	8	as	as	IN
cord-015922-5wwy0m2k	113	9	a	a	DT
cord-015922-5wwy0m2k	113	10	variety	variety	NN
cord-015922-5wwy0m2k	113	11	of	of	IN
cord-015922-5wwy0m2k	113	12	experiments	experiment	NNS
cord-015922-5wwy0m2k	113	13	have	have	VBP
cord-015922-5wwy0m2k	113	14	shown	show	VBN
cord-015922-5wwy0m2k	113	15	that	that	IN
cord-015922-5wwy0m2k	113	16	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	113	17	and	and	CC
cord-015922-5wwy0m2k	113	18	infection	infection	NN
cord-015922-5wwy0m2k	113	19	are	be	VBP
cord-015922-5wwy0m2k	113	20	closely	closely	RB
cord-015922-5wwy0m2k	113	21	linked	link	VBN
cord-015922-5wwy0m2k	113	22	by	by	IN
cord-015922-5wwy0m2k	113	23	the	the	DT
cord-015922-5wwy0m2k	113	24	production	production	NN
cord-015922-5wwy0m2k	113	25	of	of	IN
cord-015922-5wwy0m2k	113	26	these	these	DT
cord-015922-5wwy0m2k	113	27	mediators	mediator	NNS
cord-015922-5wwy0m2k	113	28	.	.	.
cord-015922-5wwy0m2k	114	1	That	that	RB
cord-015922-5wwy0m2k	114	2	is	is	RB
cord-015922-5wwy0m2k	114	3	,	,	,
cord-015922-5wwy0m2k	114	4	there	there	EX
cord-015922-5wwy0m2k	114	5	is	be	VBZ
cord-015922-5wwy0m2k	114	6	a	a	DT
cord-015922-5wwy0m2k	114	7	bidirectional	bidirectional	JJ
cord-015922-5wwy0m2k	114	8	trafficking	trafficking	NN
cord-015922-5wwy0m2k	114	9	of	of	IN
cord-015922-5wwy0m2k	114	10	mediators	mediator	NNS
cord-015922-5wwy0m2k	114	11	between	between	IN
cord-015922-5wwy0m2k	114	12	these	these	DT
cord-015922-5wwy0m2k	114	13	two	two	CD
cord-015922-5wwy0m2k	114	14	processes	process	NNS
cord-015922-5wwy0m2k	114	15	.	.	.
cord-015922-5wwy0m2k	115	1	The	the	DT
cord-015922-5wwy0m2k	115	2	clinically	clinically	RB
cord-015922-5wwy0m2k	115	3	most	most	RBS
cord-015922-5wwy0m2k	115	4	important	important	JJ
cord-015922-5wwy0m2k	115	5	direct	direct	JJ
cord-015922-5wwy0m2k	115	6	effects	effect	NNS
cord-015922-5wwy0m2k	115	7	of	of	IN
cord-015922-5wwy0m2k	115	8	CMV	CMV	NNP
cord-015922-5wwy0m2k	115	9	in	in	IN
cord-015922-5wwy0m2k	115	10	the	the	DT
cord-015922-5wwy0m2k	115	11	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	115	12	recipient	recipient	NN
cord-015922-5wwy0m2k	115	13	are	be	VBP
cord-015922-5wwy0m2k	115	14	pneumonia	pneumonia	NN
cord-015922-5wwy0m2k	115	15	and	and	CC
cord-015922-5wwy0m2k	115	16	gastrointestinal	gastrointestinal	JJ
cord-015922-5wwy0m2k	115	17	disease	disease	NN
cord-015922-5wwy0m2k	115	18	.	.	.
cord-015922-5wwy0m2k	116	1	Before	before	IN
cord-015922-5wwy0m2k	116	2	effective	effective	JJ
cord-015922-5wwy0m2k	116	3	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	116	4	treatment	treatment	NN
cord-015922-5wwy0m2k	116	5	became	become	VBD
cord-015922-5wwy0m2k	116	6	available	available	JJ
cord-015922-5wwy0m2k	116	7	,	,	,
cord-015922-5wwy0m2k	116	8	CMV	CMV	NNP
cord-015922-5wwy0m2k	116	9	pneumonia	pneumonia	NN
cord-015922-5wwy0m2k	116	10	occurred	occur	VBD
cord-015922-5wwy0m2k	116	11	in	in	IN
cord-015922-5wwy0m2k	116	12	20	20	CD
cord-015922-5wwy0m2k	116	13	to	to	TO
cord-015922-5wwy0m2k	116	14	30	30	CD
cord-015922-5wwy0m2k	116	15	percent	percent	NN
cord-015922-5wwy0m2k	116	16	of	of	IN
cord-015922-5wwy0m2k	116	17	seropositive	seropositive	JJ
cord-015922-5wwy0m2k	116	18	recipients	recipient	NNS
cord-015922-5wwy0m2k	116	19	and	and	CC
cord-015922-5wwy0m2k	116	20	had	have	VBD
cord-015922-5wwy0m2k	116	21	an	an	DT
cord-015922-5wwy0m2k	116	22	associated	associate	VBN
cord-015922-5wwy0m2k	116	23	mortality	mortality	NN
cord-015922-5wwy0m2k	116	24	around	around	IN
cord-015922-5wwy0m2k	116	25	80	80	CD
cord-015922-5wwy0m2k	116	26	percent	percent	NN
cord-015922-5wwy0m2k	116	27	[	[	-LRB-
cord-015922-5wwy0m2k	116	28	28	28	CD
cord-015922-5wwy0m2k	116	29	]	]	-RRB-
cord-015922-5wwy0m2k	116	30	.	.	.
cord-015922-5wwy0m2k	117	1	CMV	CMV	NNP
cord-015922-5wwy0m2k	117	2	commonly	commonly	RB
cord-015922-5wwy0m2k	117	3	causes	cause	VBZ
cord-015922-5wwy0m2k	117	4	fever	fever	NN
cord-015922-5wwy0m2k	117	5	in	in	IN
cord-015922-5wwy0m2k	117	6	the	the	DT
cord-015922-5wwy0m2k	117	7	absence	absence	NN
cord-015922-5wwy0m2k	117	8	of	of	IN
cord-015922-5wwy0m2k	117	9	preemptive	preemptive	JJ
cord-015922-5wwy0m2k	117	10	treatment	treatment	NN
cord-015922-5wwy0m2k	117	11	,	,	,
cord-015922-5wwy0m2k	117	12	and	and	CC
cord-015922-5wwy0m2k	117	13	end	end	NN
cord-015922-5wwy0m2k	117	14	-	-	HYPH
cord-015922-5wwy0m2k	117	15	organ	organ	NN
cord-015922-5wwy0m2k	117	16	disease	disease	NN
cord-015922-5wwy0m2k	117	17	(	(	-LRB-
cord-015922-5wwy0m2k	117	18	hepatitis	hepatitis	NN
cord-015922-5wwy0m2k	117	19	,	,	,
cord-015922-5wwy0m2k	117	20	bone	bone	NN
cord-015922-5wwy0m2k	117	21	marrow	marrow	NN
cord-015922-5wwy0m2k	117	22	dysfunction	dysfunction	NN
cord-015922-5wwy0m2k	117	23	,	,	,
cord-015922-5wwy0m2k	117	24	retinitis	retinitis	NN
cord-015922-5wwy0m2k	117	25	,	,	,
cord-015922-5wwy0m2k	117	26	and	and	CC
cord-015922-5wwy0m2k	117	27	encephalitis	encephalitis	NN
cord-015922-5wwy0m2k	117	28	)	)	-RRB-
cord-015922-5wwy0m2k	117	29	may	may	MD
cord-015922-5wwy0m2k	117	30	occur	occur	VB
cord-015922-5wwy0m2k	117	31	.	.	.
cord-015922-5wwy0m2k	118	1	Among	among	IN
cord-015922-5wwy0m2k	118	2	allogeneic	allogeneic	JJ
cord-015922-5wwy0m2k	118	3	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	118	4	recipients	recipient	NNS
cord-015922-5wwy0m2k	118	5	,	,	,
cord-015922-5wwy0m2k	118	6	the	the	DT
cord-015922-5wwy0m2k	118	7	risk	risk	NN
cord-015922-5wwy0m2k	118	8	of	of	IN
cord-015922-5wwy0m2k	118	9	CMV	CMV	NNP
cord-015922-5wwy0m2k	118	10	reactivation	reactivation	NN
cord-015922-5wwy0m2k	118	11	(	(	-LRB-
cord-015922-5wwy0m2k	118	12	60	60	CD
cord-015922-5wwy0m2k	118	13	-	-	SYM
cord-015922-5wwy0m2k	118	14	80	80	CD
cord-015922-5wwy0m2k	118	15	%	%	NN
cord-015922-5wwy0m2k	118	16	)	)	-RRB-
cord-015922-5wwy0m2k	118	17	and	and	CC
cord-015922-5wwy0m2k	118	18	end	end	NN
cord-015922-5wwy0m2k	118	19	-	-	HYPH
cord-015922-5wwy0m2k	118	20	organ	organ	NN
cord-015922-5wwy0m2k	118	21	disease	disease	NN
cord-015922-5wwy0m2k	118	22	is	be	VBZ
cord-015922-5wwy0m2k	118	23	greatest	great	JJS
cord-015922-5wwy0m2k	118	24	in	in	IN
cord-015922-5wwy0m2k	118	25	the	the	DT
cord-015922-5wwy0m2k	118	26	seropositive	seropositive	JJ
cord-015922-5wwy0m2k	118	27	recipient	recipient	NN
cord-015922-5wwy0m2k	118	28	who	who	WP
cord-015922-5wwy0m2k	118	29	receives	receive	VBZ
cord-015922-5wwy0m2k	118	30	a	a	DT
cord-015922-5wwy0m2k	118	31	graft	graft	NN
cord-015922-5wwy0m2k	118	32	from	from	IN
cord-015922-5wwy0m2k	118	33	a	a	DT
cord-015922-5wwy0m2k	118	34	CMV	CMV	NNP
cord-015922-5wwy0m2k	118	35	seronegative	seronegative	JJ
cord-015922-5wwy0m2k	118	36	donor	donor	NN
cord-015922-5wwy0m2k	118	37	(	(	-LRB-
cord-015922-5wwy0m2k	118	38	CMV	CMV	NNP
cord-015922-5wwy0m2k	118	39	D−/R+	D−/R+	NNP
cord-015922-5wwy0m2k	118	40	)	)	-RRB-
cord-015922-5wwy0m2k	118	41	,	,	,
cord-015922-5wwy0m2k	118	42	likely	likely	RB
cord-015922-5wwy0m2k	118	43	due	due	IN
cord-015922-5wwy0m2k	118	44	to	to	IN
cord-015922-5wwy0m2k	118	45	the	the	DT
cord-015922-5wwy0m2k	118	46	loss	loss	NN
cord-015922-5wwy0m2k	118	47	of	of	IN
cord-015922-5wwy0m2k	118	48	native	native	JJ
cord-015922-5wwy0m2k	118	49	immunity	immunity	NN
cord-015922-5wwy0m2k	118	50	during	during	IN
cord-015922-5wwy0m2k	118	51	the	the	DT
cord-015922-5wwy0m2k	118	52	transplant	transplant	NN
cord-015922-5wwy0m2k	118	53	process	process	NN
cord-015922-5wwy0m2k	118	54	and	and	CC
cord-015922-5wwy0m2k	118	55	immune	immune	JJ
cord-015922-5wwy0m2k	118	56	reconstitution	reconstitution	NN
cord-015922-5wwy0m2k	118	57	with	with	IN
cord-015922-5wwy0m2k	118	58	a	a	DT
cord-015922-5wwy0m2k	118	59	CMV	CMV	NNP
cord-015922-5wwy0m2k	118	60	naïve	naïve	JJ
cord-015922-5wwy0m2k	118	61	allograft	allograft	NN
cord-015922-5wwy0m2k	118	62	[	[	-LRB-
cord-015922-5wwy0m2k	118	63	29	29	CD
cord-015922-5wwy0m2k	118	64	,	,	,
cord-015922-5wwy0m2k	118	65	30	30	CD
cord-015922-5wwy0m2k	118	66	]	]	-RRB-
cord-015922-5wwy0m2k	118	67	.	.	.
cord-015922-5wwy0m2k	119	1	Patients	patient	NNS
cord-015922-5wwy0m2k	119	2	who	who	WP
cord-015922-5wwy0m2k	119	3	are	be	VBP
cord-015922-5wwy0m2k	119	4	CMV	CMV	NNP
cord-015922-5wwy0m2k	119	5	D+/R+	D+/R+	NNP
cord-015922-5wwy0m2k	119	6	have	have	VBP
cord-015922-5wwy0m2k	119	7	CMV	CMV	NNP
cord-015922-5wwy0m2k	119	8	reactivation	reactivation	NN
cord-015922-5wwy0m2k	119	9	(	(	-LRB-
cord-015922-5wwy0m2k	119	10	50	50	CD
cord-015922-5wwy0m2k	119	11	-	-	SYM
cord-015922-5wwy0m2k	119	12	60	60	CD
cord-015922-5wwy0m2k	119	13	%	%	NN
cord-015922-5wwy0m2k	119	14	)	)	-RRB-
cord-015922-5wwy0m2k	119	15	and	and	CC
cord-015922-5wwy0m2k	119	16	disease	disease	NN
cord-015922-5wwy0m2k	119	17	risk	risk	NN
cord-015922-5wwy0m2k	119	18	that	that	WDT
cord-015922-5wwy0m2k	119	19	is	be	VBZ
cord-015922-5wwy0m2k	119	20	similar	similar	JJ
cord-015922-5wwy0m2k	119	21	to	to	IN
cord-015922-5wwy0m2k	119	22	or	or	CC
cord-015922-5wwy0m2k	119	23	slightly	slightly	RB
cord-015922-5wwy0m2k	119	24	lower	low	JJR
cord-015922-5wwy0m2k	119	25	than	than	IN
cord-015922-5wwy0m2k	119	26	that	that	DT
cord-015922-5wwy0m2k	119	27	of	of	IN
cord-015922-5wwy0m2k	119	28	the	the	DT
cord-015922-5wwy0m2k	119	29	CMV	CMV	NNP
cord-015922-5wwy0m2k	119	30	D−/R+	D−/R+	NNP
cord-015922-5wwy0m2k	119	31	patient	patient	NN
cord-015922-5wwy0m2k	119	32	.	.	.
cord-015922-5wwy0m2k	120	1	Patients	patient	NNS
cord-015922-5wwy0m2k	120	2	who	who	WP
cord-015922-5wwy0m2k	120	3	are	be	VBP
cord-015922-5wwy0m2k	120	4	CMV	CMV	NNP
cord-015922-5wwy0m2k	120	5	D+/	D+/	NNP
cord-015922-5wwy0m2k	120	6	R−	R−	NNP
cord-015922-5wwy0m2k	120	7	have	have	VBP
cord-015922-5wwy0m2k	120	8	a	a	DT
cord-015922-5wwy0m2k	120	9	lower	low	JJR
cord-015922-5wwy0m2k	120	10	risk	risk	NN
cord-015922-5wwy0m2k	120	11	of	of	IN
cord-015922-5wwy0m2k	120	12	CMV	CMV	NNP
cord-015922-5wwy0m2k	120	13	infection	infection	NN
cord-015922-5wwy0m2k	120	14	(	(	-LRB-
cord-015922-5wwy0m2k	120	15	10	10	CD
cord-015922-5wwy0m2k	120	16	-	-	SYM
cord-015922-5wwy0m2k	120	17	30	30	CD
cord-015922-5wwy0m2k	120	18	%	%	NN
cord-015922-5wwy0m2k	120	19	)	)	-RRB-
cord-015922-5wwy0m2k	120	20	and	and	CC
cord-015922-5wwy0m2k	120	21	disease	disease	NN
cord-015922-5wwy0m2k	120	22	,	,	,
cord-015922-5wwy0m2k	120	23	but	but	CC
cord-015922-5wwy0m2k	120	24	higher	high	JJR
cord-015922-5wwy0m2k	120	25	than	than	IN
cord-015922-5wwy0m2k	120	26	CMV	CMV	NNP
cord-015922-5wwy0m2k	120	27	D−/R−	D−/R−	NNP
cord-015922-5wwy0m2k	120	28	patients	patient	NNS
cord-015922-5wwy0m2k	120	29	(	(	-LRB-
cord-015922-5wwy0m2k	120	30	<	<	XX
cord-015922-5wwy0m2k	120	31	5	5	CD
cord-015922-5wwy0m2k	120	32	%	%	NN
cord-015922-5wwy0m2k	120	33	)	)	-RRB-
cord-015922-5wwy0m2k	120	34	.	.	.
cord-015922-5wwy0m2k	121	1	The	the	DT
cord-015922-5wwy0m2k	121	2	risk	risk	NN
cord-015922-5wwy0m2k	121	3	of	of	IN
cord-015922-5wwy0m2k	121	4	CMV	CMV	NNP
cord-015922-5wwy0m2k	121	5	infection	infection	NN
cord-015922-5wwy0m2k	121	6	in	in	IN
cord-015922-5wwy0m2k	121	7	this	this	DT
cord-015922-5wwy0m2k	121	8	latter	latter	JJ
cord-015922-5wwy0m2k	121	9	group	group	NN
cord-015922-5wwy0m2k	121	10	has	have	VBZ
cord-015922-5wwy0m2k	121	11	been	be	VBN
cord-015922-5wwy0m2k	121	12	greatly	greatly	RB
cord-015922-5wwy0m2k	121	13	decreased	decrease	VBN
cord-015922-5wwy0m2k	121	14	by	by	IN
cord-015922-5wwy0m2k	121	15	use	use	NN
cord-015922-5wwy0m2k	121	16	of	of	IN
cord-015922-5wwy0m2k	121	17	leukoreduced	leukoreduced	JJ
cord-015922-5wwy0m2k	121	18	blood	blood	NN
cord-015922-5wwy0m2k	121	19	products	product	NNS
cord-015922-5wwy0m2k	121	20	or	or	CC
cord-015922-5wwy0m2k	121	21	by	by	IN
cord-015922-5wwy0m2k	121	22	exclusive	exclusive	JJ
cord-015922-5wwy0m2k	121	23	use	use	NN
cord-015922-5wwy0m2k	121	24	of	of	IN
cord-015922-5wwy0m2k	121	25	CMV	CMV	NNP
cord-015922-5wwy0m2k	121	26	negative	negative	JJ
cord-015922-5wwy0m2k	121	27	products	product	NNS
cord-015922-5wwy0m2k	121	28	when	when	WRB
cord-015922-5wwy0m2k	121	29	available	available	JJ
cord-015922-5wwy0m2k	121	30	[	[	-LRB-
cord-015922-5wwy0m2k	121	31	31	31	CD
cord-015922-5wwy0m2k	121	32	]	]	-RRB-
cord-015922-5wwy0m2k	121	33	.	.	.
cord-015922-5wwy0m2k	122	1	The	the	DT
cord-015922-5wwy0m2k	122	2	risks	risk	NNS
cord-015922-5wwy0m2k	122	3	of	of	IN
cord-015922-5wwy0m2k	122	4	CMV	CMV	NNP
cord-015922-5wwy0m2k	122	5	reactivation	reactivation	NN
cord-015922-5wwy0m2k	122	6	and	and	CC
cord-015922-5wwy0m2k	122	7	disease	disease	NN
cord-015922-5wwy0m2k	122	8	among	among	IN
cord-015922-5wwy0m2k	122	9	autologous	autologous	JJ
cord-015922-5wwy0m2k	122	10	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	122	11	recipients	recipient	NNS
cord-015922-5wwy0m2k	122	12	is	be	VBZ
cord-015922-5wwy0m2k	122	13	minimal	minimal	JJ
cord-015922-5wwy0m2k	122	14	(	(	-LRB-
cord-015922-5wwy0m2k	122	15	<	<	NNP
cord-015922-5wwy0m2k	122	16	1	1	CD
cord-015922-5wwy0m2k	122	17	%	%	NN
cord-015922-5wwy0m2k	122	18	)	)	-RRB-
cord-015922-5wwy0m2k	122	19	[	[	-LRB-
cord-015922-5wwy0m2k	122	20	1	1	CD
cord-015922-5wwy0m2k	122	21	,	,	,
cord-015922-5wwy0m2k	122	22	4	4	CD
cord-015922-5wwy0m2k	122	23	]	]	-RRB-
cord-015922-5wwy0m2k	122	24	.	.	.
cord-015922-5wwy0m2k	123	1	Another	another	DT
cord-015922-5wwy0m2k	123	2	major	major	JJ
cord-015922-5wwy0m2k	123	3	risk	risk	NN
cord-015922-5wwy0m2k	123	4	factor	factor	NN
cord-015922-5wwy0m2k	123	5	for	for	IN
cord-015922-5wwy0m2k	123	6	the	the	DT
cord-015922-5wwy0m2k	123	7	development	development	NN
cord-015922-5wwy0m2k	123	8	of	of	IN
cord-015922-5wwy0m2k	123	9	CMV	CMV	NNP
cord-015922-5wwy0m2k	123	10	reactivation	reactivation	NN
cord-015922-5wwy0m2k	123	11	and	and	CC
cord-015922-5wwy0m2k	123	12	disease	disease	NN
cord-015922-5wwy0m2k	123	13	is	be	VBZ
cord-015922-5wwy0m2k	123	14	the	the	DT
cord-015922-5wwy0m2k	123	15	occurrence	occurrence	NN
cord-015922-5wwy0m2k	123	16	,	,	,
cord-015922-5wwy0m2k	123	17	severity	severity	NN
cord-015922-5wwy0m2k	123	18	and	and	CC
cord-015922-5wwy0m2k	123	19	treatment	treatment	NN
cord-015922-5wwy0m2k	123	20	of	of	IN
cord-015922-5wwy0m2k	123	21	acute	acute	JJ
cord-015922-5wwy0m2k	123	22	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	123	23	[	[	-LRB-
cord-015922-5wwy0m2k	123	24	29	29	CD
cord-015922-5wwy0m2k	123	25	,	,	,
cord-015922-5wwy0m2k	123	26	30	30	CD
cord-015922-5wwy0m2k	123	27	]	]	-RRB-
cord-015922-5wwy0m2k	123	28	.	.	.
cord-015922-5wwy0m2k	124	1	Other	other	JJ
cord-015922-5wwy0m2k	124	2	potential	potential	JJ
cord-015922-5wwy0m2k	124	3	factors	factor	NNS
cord-015922-5wwy0m2k	124	4	associated	associate	VBN
cord-015922-5wwy0m2k	124	5	with	with	IN
cord-015922-5wwy0m2k	124	6	an	an	DT
cord-015922-5wwy0m2k	124	7	increased	increase	VBN
cord-015922-5wwy0m2k	124	8	risk	risk	NN
cord-015922-5wwy0m2k	124	9	of	of	IN
cord-015922-5wwy0m2k	124	10	CMV	CMV	NNP
cord-015922-5wwy0m2k	124	11	reactivation	reactivation	NN
cord-015922-5wwy0m2k	124	12	and	and	CC
cord-015922-5wwy0m2k	124	13	disease	disease	NN
cord-015922-5wwy0m2k	124	14	are	be	VBP
cord-015922-5wwy0m2k	124	15	reception	reception	NN
cord-015922-5wwy0m2k	124	16	of	of	IN
cord-015922-5wwy0m2k	124	17	T	T	NNP
cord-015922-5wwy0m2k	124	18	cell	cell	NN
cord-015922-5wwy0m2k	124	19	-	-	HYPH
cord-015922-5wwy0m2k	124	20	depleted	deplete	VBN
cord-015922-5wwy0m2k	124	21	or	or	CC
cord-015922-5wwy0m2k	124	22	cord	cord	NN
cord-015922-5wwy0m2k	124	23	blood	blood	NN
cord-015922-5wwy0m2k	124	24	allograft	allograft	NN
cord-015922-5wwy0m2k	124	25	,	,	,
cord-015922-5wwy0m2k	124	26	whether	whether	IN
cord-015922-5wwy0m2k	124	27	the	the	DT
cord-015922-5wwy0m2k	124	28	donor	donor	NN
cord-015922-5wwy0m2k	124	29	is	be	VBZ
cord-015922-5wwy0m2k	124	30	unrelated	unrelated	JJ
cord-015922-5wwy0m2k	124	31	or	or	CC
cord-015922-5wwy0m2k	124	32	mismatched	mismatched	JJ
cord-015922-5wwy0m2k	124	33	,	,	,
cord-015922-5wwy0m2k	124	34	or	or	CC
cord-015922-5wwy0m2k	124	35	donated	donate	VBN
cord-015922-5wwy0m2k	124	36	bone	bone	NN
cord-015922-5wwy0m2k	124	37	marrow	marrow	NN
cord-015922-5wwy0m2k	124	38	(	(	-LRB-
cord-015922-5wwy0m2k	124	39	instead	instead	RB
cord-015922-5wwy0m2k	124	40	of	of	IN
cord-015922-5wwy0m2k	124	41	peripheral	peripheral	JJ
cord-015922-5wwy0m2k	124	42	stem	stem	NN
cord-015922-5wwy0m2k	124	43	cells	cell	NNS
cord-015922-5wwy0m2k	124	44	)	)	-RRB-
cord-015922-5wwy0m2k	124	45	,	,	,
cord-015922-5wwy0m2k	124	46	and	and	CC
cord-015922-5wwy0m2k	124	47	whether	whether	IN
cord-015922-5wwy0m2k	124	48	the	the	DT
cord-015922-5wwy0m2k	124	49	conditioning	conditioning	NN
cord-015922-5wwy0m2k	124	50	regimen	regimen	NN
cord-015922-5wwy0m2k	124	51	was	be	VBD
cord-015922-5wwy0m2k	124	52	myeloablative	myeloablative	NNP
cord-015922-5wwy0m2k	124	53	[	[	-LRB-
cord-015922-5wwy0m2k	124	54	29	29	CD
cord-015922-5wwy0m2k	124	55	,	,	,
cord-015922-5wwy0m2k	124	56	32	32	CD
cord-015922-5wwy0m2k	124	57	]	]	-RRB-
cord-015922-5wwy0m2k	124	58	.	.	.
cord-015922-5wwy0m2k	125	1	The	the	DT
cord-015922-5wwy0m2k	125	2	most	most	RBS
cord-015922-5wwy0m2k	125	3	widely	widely	RB
cord-015922-5wwy0m2k	125	4	used	use	VBN
cord-015922-5wwy0m2k	125	5	therapy	therapy	NN
cord-015922-5wwy0m2k	125	6	for	for	IN
cord-015922-5wwy0m2k	125	7	clinical	clinical	JJ
cord-015922-5wwy0m2k	125	8	CMV	CMV	NNP
cord-015922-5wwy0m2k	125	9	disease	disease	NN
cord-015922-5wwy0m2k	125	10	is	be	VBZ
cord-015922-5wwy0m2k	125	11	ganciclovir	ganciclovir	NNP
cord-015922-5wwy0m2k	125	12	,	,	,
cord-015922-5wwy0m2k	125	13	which	which	WDT
cord-015922-5wwy0m2k	125	14	can	can	MD
cord-015922-5wwy0m2k	125	15	be	be	VB
cord-015922-5wwy0m2k	125	16	administered	administer	VBN
cord-015922-5wwy0m2k	125	17	either	either	CC
cord-015922-5wwy0m2k	125	18	intravenously	intravenously	RB
cord-015922-5wwy0m2k	125	19	or	or	CC
cord-015922-5wwy0m2k	125	20	orally	orally	RB
cord-015922-5wwy0m2k	125	21	in	in	IN
cord-015922-5wwy0m2k	125	22	the	the	DT
cord-015922-5wwy0m2k	125	23	form	form	NN
cord-015922-5wwy0m2k	125	24	of	of	IN
cord-015922-5wwy0m2k	125	25	a	a	DT
cord-015922-5wwy0m2k	125	26	prodrug	prodrug	NN
cord-015922-5wwy0m2k	125	27	,	,	,
cord-015922-5wwy0m2k	125	28	valganciclovir	valganciclovir	NNP
cord-015922-5wwy0m2k	125	29	,	,	,
cord-015922-5wwy0m2k	125	30	with	with	IN
cord-015922-5wwy0m2k	125	31	an	an	DT
cord-015922-5wwy0m2k	125	32	acceptable	acceptable	JJ
cord-015922-5wwy0m2k	125	33	bioavailability	bioavailability	NN
cord-015922-5wwy0m2k	125	34	profile	profile	NN
cord-015922-5wwy0m2k	125	35	(	(	-LRB-
cord-015922-5wwy0m2k	125	36	~50	~50	NFP
cord-015922-5wwy0m2k	125	37	-	-	SYM
cord-015922-5wwy0m2k	125	38	60	60	CD
cord-015922-5wwy0m2k	125	39	%	%	NN
cord-015922-5wwy0m2k	125	40	)	)	-RRB-
cord-015922-5wwy0m2k	125	41	.	.	.
cord-015922-5wwy0m2k	126	1	Typically	typically	RB
cord-015922-5wwy0m2k	126	2	,	,	,
cord-015922-5wwy0m2k	126	3	the	the	DT
cord-015922-5wwy0m2k	126	4	parenteral	parenteral	JJ
cord-015922-5wwy0m2k	126	5	form	form	NN
cord-015922-5wwy0m2k	126	6	is	be	VBZ
cord-015922-5wwy0m2k	126	7	administered	administer	VBN
cord-015922-5wwy0m2k	126	8	until	until	IN
cord-015922-5wwy0m2k	126	9	the	the	DT
cord-015922-5wwy0m2k	126	10	patient	patient	NN
cord-015922-5wwy0m2k	126	11	is	be	VBZ
cord-015922-5wwy0m2k	126	12	able	able	JJ
cord-015922-5wwy0m2k	126	13	to	to	TO
cord-015922-5wwy0m2k	126	14	tolerate	tolerate	VB
cord-015922-5wwy0m2k	126	15	oral	oral	JJ
cord-015922-5wwy0m2k	126	16	therapy	therapy	NN
cord-015922-5wwy0m2k	126	17	.	.	.
cord-015922-5wwy0m2k	127	1	Gastrointestinal	gastrointestinal	JJ
cord-015922-5wwy0m2k	127	2	absorption	absorption	NN
cord-015922-5wwy0m2k	127	3	of	of	IN
cord-015922-5wwy0m2k	127	4	valganciclovir	valganciclovir	NNS
cord-015922-5wwy0m2k	127	5	,	,	,
cord-015922-5wwy0m2k	127	6	even	even	RB
cord-015922-5wwy0m2k	127	7	in	in	IN
cord-015922-5wwy0m2k	127	8	the	the	DT
cord-015922-5wwy0m2k	127	9	setting	setting	NN
cord-015922-5wwy0m2k	127	10	of	of	IN
cord-015922-5wwy0m2k	127	11	mild	mild	JJ
cord-015922-5wwy0m2k	127	12	to	to	TO
cord-015922-5wwy0m2k	127	13	moderate	moderate	JJ
cord-015922-5wwy0m2k	127	14	GI	GI	NNP
cord-015922-5wwy0m2k	127	15	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	127	16	,	,	,
cord-015922-5wwy0m2k	127	17	has	have	VBZ
cord-015922-5wwy0m2k	127	18	been	be	VBN
cord-015922-5wwy0m2k	127	19	demonstrated	demonstrate	VBN
cord-015922-5wwy0m2k	127	20	to	to	TO
cord-015922-5wwy0m2k	127	21	be	be	VB
cord-015922-5wwy0m2k	127	22	adequate	adequate	JJ
cord-015922-5wwy0m2k	127	23	[	[	-LRB-
cord-015922-5wwy0m2k	127	24	33	33	CD
cord-015922-5wwy0m2k	127	25	,	,	,
cord-015922-5wwy0m2k	127	26	34	34	CD
cord-015922-5wwy0m2k	127	27	]	]	-RRB-
cord-015922-5wwy0m2k	127	28	.	.	.
cord-015922-5wwy0m2k	128	1	Duration	duration	NN
cord-015922-5wwy0m2k	128	2	of	of	IN
cord-015922-5wwy0m2k	128	3	treatment	treatment	NN
cord-015922-5wwy0m2k	128	4	depends	depend	VBZ
cord-015922-5wwy0m2k	128	5	on	on	IN
cord-015922-5wwy0m2k	128	6	the	the	DT
cord-015922-5wwy0m2k	128	7	clinical	clinical	JJ
cord-015922-5wwy0m2k	128	8	response	response	NN
cord-015922-5wwy0m2k	128	9	and	and	CC
cord-015922-5wwy0m2k	128	10	the	the	DT
cord-015922-5wwy0m2k	128	11	nature	nature	NN
cord-015922-5wwy0m2k	128	12	of	of	IN
cord-015922-5wwy0m2k	128	13	the	the	DT
cord-015922-5wwy0m2k	128	14	recovery	recovery	NN
cord-015922-5wwy0m2k	128	15	of	of	IN
cord-015922-5wwy0m2k	128	16	native	native	JJ
cord-015922-5wwy0m2k	128	17	immune	immune	JJ
cord-015922-5wwy0m2k	128	18	function	function	NN
cord-015922-5wwy0m2k	128	19	.	.	.
cord-015922-5wwy0m2k	129	1	In	in	IN
cord-015922-5wwy0m2k	129	2	the	the	DT
cord-015922-5wwy0m2k	129	3	case	case	NN
cord-015922-5wwy0m2k	129	4	of	of	IN
cord-015922-5wwy0m2k	129	5	serious	serious	JJ
cord-015922-5wwy0m2k	129	6	illness	illness	NN
cord-015922-5wwy0m2k	129	7	,	,	,
cord-015922-5wwy0m2k	129	8	particularly	particularly	RB
cord-015922-5wwy0m2k	129	9	pneumonia	pneumonia	NN
cord-015922-5wwy0m2k	129	10	,	,	,
cord-015922-5wwy0m2k	129	11	anti	anti	JJ
cord-015922-5wwy0m2k	129	12	-	-	JJ
cord-015922-5wwy0m2k	129	13	CMV	cmv	JJ
cord-015922-5wwy0m2k	129	14	hyperimmune	hyperimmune	NN
cord-015922-5wwy0m2k	129	15	globulin	globulin	NN
cord-015922-5wwy0m2k	129	16	can	can	MD
cord-015922-5wwy0m2k	129	17	be	be	VB
cord-015922-5wwy0m2k	129	18	considered	consider	VBN
cord-015922-5wwy0m2k	129	19	as	as	IN
cord-015922-5wwy0m2k	129	20	adjunctive	adjunctive	JJ
cord-015922-5wwy0m2k	129	21	therapy	therapy	NN
cord-015922-5wwy0m2k	129	22	.	.	.
cord-015922-5wwy0m2k	130	1	Despite	despite	IN
cord-015922-5wwy0m2k	130	2	these	these	DT
cord-015922-5wwy0m2k	130	3	efforts	effort	NNS
cord-015922-5wwy0m2k	130	4	,	,	,
cord-015922-5wwy0m2k	130	5	the	the	DT
cord-015922-5wwy0m2k	130	6	mortality	mortality	NN
cord-015922-5wwy0m2k	130	7	from	from	IN
cord-015922-5wwy0m2k	130	8	CMV	CMV	NNP
cord-015922-5wwy0m2k	130	9	pneumonia	pneumonia	NN
cord-015922-5wwy0m2k	130	10	remains	remain	VBZ
cord-015922-5wwy0m2k	130	11	high	high	JJ
cord-015922-5wwy0m2k	130	12	.	.	.
cord-015922-5wwy0m2k	131	1	The	the	DT
cord-015922-5wwy0m2k	131	2	major	major	JJ
cord-015922-5wwy0m2k	131	3	toxicity	toxicity	NN
cord-015922-5wwy0m2k	131	4	of	of	IN
cord-015922-5wwy0m2k	131	5	ganciclovir	ganciclovir	NNP
cord-015922-5wwy0m2k	131	6	is	be	VBZ
cord-015922-5wwy0m2k	131	7	myelosuppression	myelosuppression	NNP
cord-015922-5wwy0m2k	131	8	,	,	,
cord-015922-5wwy0m2k	131	9	so	so	IN
cord-015922-5wwy0m2k	131	10	that	that	DT
cord-015922-5wwy0m2k	131	11	great	great	JJ
cord-015922-5wwy0m2k	131	12	effort	effort	NN
cord-015922-5wwy0m2k	131	13	is	be	VBZ
cord-015922-5wwy0m2k	131	14	placed	place	VBN
cord-015922-5wwy0m2k	131	15	in	in	IN
cord-015922-5wwy0m2k	131	16	monitoring	monitor	VBG
cord-015922-5wwy0m2k	131	17	these	these	DT
cord-015922-5wwy0m2k	131	18	patients	patient	NNS
cord-015922-5wwy0m2k	131	19	closely	closely	RB
cord-015922-5wwy0m2k	131	20	and	and	CC
cord-015922-5wwy0m2k	131	21	adjusting	adjust	VBG
cord-015922-5wwy0m2k	131	22	doses	dose	NNS
cord-015922-5wwy0m2k	131	23	appropriately	appropriately	RB
cord-015922-5wwy0m2k	131	24	[	[	-LRB-
cord-015922-5wwy0m2k	131	25	1	1	CD
cord-015922-5wwy0m2k	131	26	,	,	,
cord-015922-5wwy0m2k	131	27	4	4	CD
cord-015922-5wwy0m2k	131	28	]	]	-RRB-
cord-015922-5wwy0m2k	131	29	.	.	.
cord-015922-5wwy0m2k	132	1	Occasionally	occasionally	RB
cord-015922-5wwy0m2k	132	2	,	,	,
cord-015922-5wwy0m2k	132	3	G	G	NNP
cord-015922-5wwy0m2k	132	4	-	-	HYPH
cord-015922-5wwy0m2k	132	5	CSF	CSF	NNP
cord-015922-5wwy0m2k	132	6	support	support	NN
cord-015922-5wwy0m2k	132	7	may	may	MD
cord-015922-5wwy0m2k	132	8	be	be	VB
cord-015922-5wwy0m2k	132	9	required	require	VBN
cord-015922-5wwy0m2k	132	10	to	to	TO
cord-015922-5wwy0m2k	132	11	preserve	preserve	VB
cord-015922-5wwy0m2k	132	12	an	an	DT
cord-015922-5wwy0m2k	132	13	acceptable	acceptable	JJ
cord-015922-5wwy0m2k	132	14	neutrophil	neutrophil	NN
cord-015922-5wwy0m2k	132	15	count	count	NN
cord-015922-5wwy0m2k	132	16	and	and	CC
cord-015922-5wwy0m2k	132	17	to	to	TO
cord-015922-5wwy0m2k	132	18	allow	allow	VB
cord-015922-5wwy0m2k	132	19	adequate	adequate	JJ
cord-015922-5wwy0m2k	132	20	therapy	therapy	NN
cord-015922-5wwy0m2k	132	21	of	of	IN
cord-015922-5wwy0m2k	132	22	a	a	DT
cord-015922-5wwy0m2k	132	23	serious	serious	JJ
cord-015922-5wwy0m2k	132	24	CMV	CMV	NNP
cord-015922-5wwy0m2k	132	25	infection	infection	NN
cord-015922-5wwy0m2k	132	26	.	.	.
cord-015922-5wwy0m2k	133	1	While	while	IN
cord-015922-5wwy0m2k	133	2	certain	certain	JJ
cord-015922-5wwy0m2k	133	3	medications	medication	NNS
cord-015922-5wwy0m2k	133	4	,	,	,
cord-015922-5wwy0m2k	133	5	such	such	JJ
cord-015922-5wwy0m2k	133	6	as	as	IN
cord-015922-5wwy0m2k	133	7	ATG	ATG	NNP
cord-015922-5wwy0m2k	133	8	and	and	CC
cord-015922-5wwy0m2k	133	9	OKT3	OKT3	NNP
cord-015922-5wwy0m2k	133	10	,	,	,
cord-015922-5wwy0m2k	133	11	are	be	VBP
cord-015922-5wwy0m2k	133	12	likely	likely	JJ
cord-015922-5wwy0m2k	133	13	to	to	TO
cord-015922-5wwy0m2k	133	14	induce	induce	VB
cord-015922-5wwy0m2k	133	15	CMV	CMV	NNP
cord-015922-5wwy0m2k	133	16	reactivation	reactivation	NN
cord-015922-5wwy0m2k	133	17	,	,	,
cord-015922-5wwy0m2k	133	18	others	other	NNS
cord-015922-5wwy0m2k	133	19	like	like	IN
cord-015922-5wwy0m2k	133	20	sirolimus	sirolimus	NNP
cord-015922-5wwy0m2k	133	21	may	may	MD
cord-015922-5wwy0m2k	133	22	inhibit	inhibit	VB
cord-015922-5wwy0m2k	133	23	this	this	DT
cord-015922-5wwy0m2k	133	24	[	[	-LRB-
cord-015922-5wwy0m2k	133	25	29	29	CD
cord-015922-5wwy0m2k	133	26	]	]	-RRB-
cord-015922-5wwy0m2k	133	27	.	.	.
cord-015922-5wwy0m2k	134	1	Current	current	JJ
cord-015922-5wwy0m2k	134	2	strategies	strategy	NNS
cord-015922-5wwy0m2k	134	3	are	be	VBP
cord-015922-5wwy0m2k	134	4	based	base	VBN
cord-015922-5wwy0m2k	134	5	on	on	IN
cord-015922-5wwy0m2k	134	6	preventing	prevent	VBG
cord-015922-5wwy0m2k	134	7	CMV	CMV	NNP
cord-015922-5wwy0m2k	134	8	disease	disease	NN
cord-015922-5wwy0m2k	134	9	through	through	IN
cord-015922-5wwy0m2k	134	10	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	134	11	or	or	CC
cord-015922-5wwy0m2k	134	12	preemption	preemption	NN
cord-015922-5wwy0m2k	134	13	.	.	.
cord-015922-5wwy0m2k	135	1	Prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	135	2	with	with	IN
cord-015922-5wwy0m2k	135	3	ganciclovir	ganciclovir	NNS
cord-015922-5wwy0m2k	135	4	from	from	IN
cord-015922-5wwy0m2k	135	5	the	the	DT
cord-015922-5wwy0m2k	135	6	time	time	NN
cord-015922-5wwy0m2k	135	7	of	of	IN
cord-015922-5wwy0m2k	135	8	engraftment	engraftment	NN
cord-015922-5wwy0m2k	135	9	until	until	IN
cord-015922-5wwy0m2k	135	10	at	at	IN
cord-015922-5wwy0m2k	135	11	least	least	JJS
cord-015922-5wwy0m2k	135	12	day	day	NN
cord-015922-5wwy0m2k	135	13	100	100	CD
cord-015922-5wwy0m2k	135	14	post	post	JJ
cord-015922-5wwy0m2k	135	15	-	-	NN
cord-015922-5wwy0m2k	135	16	transplant	transplant	NN
cord-015922-5wwy0m2k	135	17	has	have	VBZ
cord-015922-5wwy0m2k	135	18	been	be	VBN
cord-015922-5wwy0m2k	135	19	studied	study	VBN
cord-015922-5wwy0m2k	135	20	in	in	IN
cord-015922-5wwy0m2k	135	21	randomized	randomized	JJ
cord-015922-5wwy0m2k	135	22	trials	trial	NNS
cord-015922-5wwy0m2k	135	23	[	[	-LRB-
cord-015922-5wwy0m2k	135	24	35	35	CD
cord-015922-5wwy0m2k	135	25	,	,	,
cord-015922-5wwy0m2k	135	26	36	36	CD
cord-015922-5wwy0m2k	135	27	]	]	-RRB-
cord-015922-5wwy0m2k	135	28	.	.	.
cord-015922-5wwy0m2k	136	1	Although	although	IN
cord-015922-5wwy0m2k	136	2	CMV	CMV	NNP
cord-015922-5wwy0m2k	136	3	viremia	viremia	NN
cord-015922-5wwy0m2k	136	4	and	and	CC
cord-015922-5wwy0m2k	136	5	disease	disease	NN
cord-015922-5wwy0m2k	136	6	were	be	VBD
cord-015922-5wwy0m2k	136	7	prevented	prevent	VBN
cord-015922-5wwy0m2k	136	8	,	,	,
cord-015922-5wwy0m2k	136	9	there	there	EX
cord-015922-5wwy0m2k	136	10	was	be	VBD
cord-015922-5wwy0m2k	136	11	no	no	DT
cord-015922-5wwy0m2k	136	12	overall	overall	JJ
cord-015922-5wwy0m2k	136	13	benefit	benefit	NN
cord-015922-5wwy0m2k	136	14	of	of	IN
cord-015922-5wwy0m2k	136	15	this	this	DT
cord-015922-5wwy0m2k	136	16	strategy	strategy	NN
cord-015922-5wwy0m2k	136	17	due	due	IN
cord-015922-5wwy0m2k	136	18	to	to	IN
cord-015922-5wwy0m2k	136	19	secondary	secondary	JJ
cord-015922-5wwy0m2k	136	20	bacterial	bacterial	NN
cord-015922-5wwy0m2k	136	21	and	and	CC
cord-015922-5wwy0m2k	136	22	fungal	fungal	JJ
cord-015922-5wwy0m2k	136	23	infections	infection	NNS
cord-015922-5wwy0m2k	136	24	related	relate	VBN
cord-015922-5wwy0m2k	136	25	to	to	IN
cord-015922-5wwy0m2k	136	26	ganciclovir	ganciclovir	NN
cord-015922-5wwy0m2k	136	27	-	-	HYPH
cord-015922-5wwy0m2k	136	28	induced	induce	VBN
cord-015922-5wwy0m2k	136	29	neutropenia	neutropenia	NN
cord-015922-5wwy0m2k	136	30	.	.	.
cord-015922-5wwy0m2k	137	1	Alternatively	alternatively	RB
cord-015922-5wwy0m2k	137	2	,	,	,
cord-015922-5wwy0m2k	137	3	a	a	DT
cord-015922-5wwy0m2k	137	4	preemptive	preemptive	JJ
cord-015922-5wwy0m2k	137	5	strategy	strategy	NN
cord-015922-5wwy0m2k	137	6	is	be	VBZ
cord-015922-5wwy0m2k	137	7	employed	employ	VBN
cord-015922-5wwy0m2k	137	8	in	in	IN
cord-015922-5wwy0m2k	137	9	which	which	WDT
cord-015922-5wwy0m2k	137	10	patients	patient	NNS
cord-015922-5wwy0m2k	137	11	are	be	VBP
cord-015922-5wwy0m2k	137	12	monitored	monitor	VBN
cord-015922-5wwy0m2k	137	13	weekly	weekly	RB
cord-015922-5wwy0m2k	137	14	for	for	IN
cord-015922-5wwy0m2k	137	15	viremia	viremia	NN
cord-015922-5wwy0m2k	137	16	through	through	IN
cord-015922-5wwy0m2k	137	17	either	either	CC
cord-015922-5wwy0m2k	137	18	a	a	DT
cord-015922-5wwy0m2k	137	19	PCR	PCR	NNP
cord-015922-5wwy0m2k	137	20	assay	assay	NN
cord-015922-5wwy0m2k	137	21	for	for	IN
cord-015922-5wwy0m2k	137	22	CMV	CMV	NNP
cord-015922-5wwy0m2k	137	23	DNA	DNA	NNP
cord-015922-5wwy0m2k	137	24	or	or	CC
cord-015922-5wwy0m2k	137	25	an	an	DT
cord-015922-5wwy0m2k	137	26	antigenemia	antigenemia	NN
cord-015922-5wwy0m2k	137	27	assay	assay	NN
cord-015922-5wwy0m2k	137	28	.	.	.
cord-015922-5wwy0m2k	138	1	Positive	positive	JJ
cord-015922-5wwy0m2k	138	2	results	result	NNS
cord-015922-5wwy0m2k	138	3	are	be	VBP
cord-015922-5wwy0m2k	138	4	linked	link	VBN
cord-015922-5wwy0m2k	138	5	to	to	IN
cord-015922-5wwy0m2k	138	6	initiating	initiate	VBG
cord-015922-5wwy0m2k	138	7	ganciclovir	ganciclovir	NNS
cord-015922-5wwy0m2k	138	8	or	or	CC
cord-015922-5wwy0m2k	138	9	other	other	JJ
cord-015922-5wwy0m2k	138	10	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	138	11	drugs	drug	NNS
cord-015922-5wwy0m2k	138	12	active	active	JJ
cord-015922-5wwy0m2k	138	13	against	against	IN
cord-015922-5wwy0m2k	138	14	CMV	CMV	NNP
cord-015922-5wwy0m2k	138	15	.	.	.
cord-015922-5wwy0m2k	139	1	Typically	typically	RB
cord-015922-5wwy0m2k	139	2	,	,	,
cord-015922-5wwy0m2k	139	3	these	these	DT
cord-015922-5wwy0m2k	139	4	assays	assay	NNS
cord-015922-5wwy0m2k	139	5	turn	turn	VBP
cord-015922-5wwy0m2k	139	6	positive	positive	JJ
cord-015922-5wwy0m2k	139	7	several	several	JJ
cord-015922-5wwy0m2k	139	8	days	day	NNS
cord-015922-5wwy0m2k	139	9	to	to	IN
cord-015922-5wwy0m2k	139	10	weeks	week	NNS
cord-015922-5wwy0m2k	139	11	prior	prior	RB
cord-015922-5wwy0m2k	139	12	to	to	IN
cord-015922-5wwy0m2k	139	13	the	the	DT
cord-015922-5wwy0m2k	139	14	onset	onset	NN
cord-015922-5wwy0m2k	139	15	of	of	IN
cord-015922-5wwy0m2k	139	16	clinical	clinical	JJ
cord-015922-5wwy0m2k	139	17	disease	disease	NN
cord-015922-5wwy0m2k	139	18	,	,	,
cord-015922-5wwy0m2k	139	19	permitting	permit	VBG
cord-015922-5wwy0m2k	139	20	the	the	DT
cord-015922-5wwy0m2k	139	21	use	use	NN
cord-015922-5wwy0m2k	139	22	of	of	IN
cord-015922-5wwy0m2k	139	23	effective	effective	JJ
cord-015922-5wwy0m2k	139	24	preemptive	preemptive	JJ
cord-015922-5wwy0m2k	139	25	therapy	therapy	NN
cord-015922-5wwy0m2k	139	26	[	[	-LRB-
cord-015922-5wwy0m2k	139	27	1	1	CD
cord-015922-5wwy0m2k	139	28	,	,	,
cord-015922-5wwy0m2k	139	29	4	4	CD
cord-015922-5wwy0m2k	139	30	,	,	,
cord-015922-5wwy0m2k	139	31	29	29	CD
cord-015922-5wwy0m2k	139	32	,	,	,
cord-015922-5wwy0m2k	139	33	33	33	CD
cord-015922-5wwy0m2k	139	34	,	,	,
cord-015922-5wwy0m2k	139	35	[	[	-LRB-
cord-015922-5wwy0m2k	139	36	37	37	CD
cord-015922-5wwy0m2k	139	37	]	]	-RRB-
cord-015922-5wwy0m2k	139	38	[	[	-LRB-
cord-015922-5wwy0m2k	139	39	38	38	CD
cord-015922-5wwy0m2k	139	40	]	]	-RRB-
cord-015922-5wwy0m2k	139	41	[	[	-LRB-
cord-015922-5wwy0m2k	139	42	39	39	CD
cord-015922-5wwy0m2k	139	43	]	]	-RRB-
cord-015922-5wwy0m2k	139	44	[	[	-LRB-
cord-015922-5wwy0m2k	139	45	40	40	CD
cord-015922-5wwy0m2k	139	46	]	]	-RRB-
cord-015922-5wwy0m2k	139	47	[	[	-LRB-
cord-015922-5wwy0m2k	139	48	41	41	CD
cord-015922-5wwy0m2k	139	49	]	]	-RRB-
cord-015922-5wwy0m2k	139	50	.	.	.
cord-015922-5wwy0m2k	140	1	A	a	DT
cord-015922-5wwy0m2k	140	2	preemptive	preemptive	JJ
cord-015922-5wwy0m2k	140	3	approach	approach	NN
cord-015922-5wwy0m2k	140	4	significantly	significantly	RB
cord-015922-5wwy0m2k	140	5	decreases	decrease	VBZ
cord-015922-5wwy0m2k	140	6	the	the	DT
cord-015922-5wwy0m2k	140	7	amount	amount	NN
cord-015922-5wwy0m2k	140	8	of	of	IN
cord-015922-5wwy0m2k	140	9	prophylactic	prophylactic	JJ
cord-015922-5wwy0m2k	140	10	medication	medication	NN
cord-015922-5wwy0m2k	140	11	used	use	VBN
cord-015922-5wwy0m2k	140	12	,	,	,
cord-015922-5wwy0m2k	140	13	thus	thus	RB
cord-015922-5wwy0m2k	140	14	minimizing	minimize	VBG
cord-015922-5wwy0m2k	140	15	medication	medication	NN
cord-015922-5wwy0m2k	140	16	-	-	HYPH
cord-015922-5wwy0m2k	140	17	associated	associate	VBN
cord-015922-5wwy0m2k	140	18	toxicity	toxicity	NN
cord-015922-5wwy0m2k	140	19	.	.	.
cord-015922-5wwy0m2k	141	1	In	in	IN
cord-015922-5wwy0m2k	141	2	the	the	DT
cord-015922-5wwy0m2k	141	3	pre	pre	JJ
cord-015922-5wwy0m2k	141	4	-	-	JJ
cord-015922-5wwy0m2k	141	5	ganciclovir	ganciclovir	JJ
cord-015922-5wwy0m2k	141	6	era	era	NN
cord-015922-5wwy0m2k	141	7	,	,	,
cord-015922-5wwy0m2k	141	8	CMV	CMV	NNP
cord-015922-5wwy0m2k	141	9	disease	disease	NN
cord-015922-5wwy0m2k	141	10	typically	typically	RB
cord-015922-5wwy0m2k	141	11	occurred	occur	VBD
cord-015922-5wwy0m2k	141	12	during	during	IN
cord-015922-5wwy0m2k	141	13	the	the	DT
cord-015922-5wwy0m2k	141	14	first	first	JJ
cord-015922-5wwy0m2k	141	15	three	three	CD
cord-015922-5wwy0m2k	141	16	months	month	NNS
cord-015922-5wwy0m2k	141	17	post	post	NN
cord-015922-5wwy0m2k	141	18	-	-	NN
cord-015922-5wwy0m2k	141	19	transplant	transplant	NN
cord-015922-5wwy0m2k	141	20	.	.	.
cord-015922-5wwy0m2k	142	1	Increasingly	increasingly	RB
cord-015922-5wwy0m2k	142	2	,	,	,
cord-015922-5wwy0m2k	142	3	with	with	IN
cord-015922-5wwy0m2k	142	4	the	the	DT
cord-015922-5wwy0m2k	142	5	widespread	widespread	JJ
cord-015922-5wwy0m2k	142	6	use	use	NN
cord-015922-5wwy0m2k	142	7	of	of	IN
cord-015922-5wwy0m2k	142	8	a	a	DT
cord-015922-5wwy0m2k	142	9	prophylactic	prophylactic	JJ
cord-015922-5wwy0m2k	142	10	or	or	CC
cord-015922-5wwy0m2k	142	11	preemptive	preemptive	JJ
cord-015922-5wwy0m2k	142	12	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	142	13	strategy	strategy	NN
cord-015922-5wwy0m2k	142	14	,	,	,
cord-015922-5wwy0m2k	142	15	breakthrough	breakthrough	NN
cord-015922-5wwy0m2k	142	16	occurs	occur	VBZ
cord-015922-5wwy0m2k	142	17	much	much	RB
cord-015922-5wwy0m2k	142	18	later	later	RB
cord-015922-5wwy0m2k	142	19	,	,	,
cord-015922-5wwy0m2k	142	20	typically	typically	RB
cord-015922-5wwy0m2k	142	21	one	one	CD
cord-015922-5wwy0m2k	142	22	to	to	TO
cord-015922-5wwy0m2k	142	23	three	three	CD
cord-015922-5wwy0m2k	142	24	months	month	NNS
cord-015922-5wwy0m2k	142	25	after	after	IN
cord-015922-5wwy0m2k	142	26	the	the	DT
cord-015922-5wwy0m2k	142	27	cessation	cessation	NN
cord-015922-5wwy0m2k	142	28	of	of	IN
cord-015922-5wwy0m2k	142	29	the	the	DT
cord-015922-5wwy0m2k	142	30	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	142	31	therapy	therapy	NN
cord-015922-5wwy0m2k	142	32	.	.	.
cord-015922-5wwy0m2k	143	1	Risk	risk	NN
cord-015922-5wwy0m2k	143	2	factors	factor	NNS
cord-015922-5wwy0m2k	143	3	for	for	IN
cord-015922-5wwy0m2k	143	4	late	late	JJ
cord-015922-5wwy0m2k	143	5	CMV	CMV	NNP
cord-015922-5wwy0m2k	143	6	disease	disease	NN
cord-015922-5wwy0m2k	143	7	include	include	VBP
cord-015922-5wwy0m2k	143	8	chronic	chronic	JJ
cord-015922-5wwy0m2k	143	9	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	143	10	,	,	,
cord-015922-5wwy0m2k	143	11	low	low	JJ
cord-015922-5wwy0m2k	143	12	CD4-T	CD4-T	NNP
cord-015922-5wwy0m2k	143	13	cell	cell	NN
cord-015922-5wwy0m2k	143	14	counts	count	NNS
cord-015922-5wwy0m2k	143	15	,	,	,
cord-015922-5wwy0m2k	143	16	and	and	CC
cord-015922-5wwy0m2k	143	17	CMV	CMV	NNP
cord-015922-5wwy0m2k	143	18	infection	infection	NN
cord-015922-5wwy0m2k	143	19	before	before	IN
cord-015922-5wwy0m2k	143	20	day	day	NN
cord-015922-5wwy0m2k	143	21	100	100	CD
cord-015922-5wwy0m2k	143	22	.	.	.
cord-015922-5wwy0m2k	144	1	Relapse	relapse	VB
cord-015922-5wwy0m2k	144	2	or	or	CC
cord-015922-5wwy0m2k	144	3	the	the	DT
cord-015922-5wwy0m2k	144	4	emergence	emergence	NN
cord-015922-5wwy0m2k	144	5	of	of	IN
cord-015922-5wwy0m2k	144	6	ganciclovirresistant	ganciclovirresistant	JJ
cord-015922-5wwy0m2k	144	7	virus	virus	NN
cord-015922-5wwy0m2k	144	8	also	also	RB
cord-015922-5wwy0m2k	144	9	can	can	MD
cord-015922-5wwy0m2k	144	10	occur	occur	VB
cord-015922-5wwy0m2k	144	11	,	,	,
cord-015922-5wwy0m2k	144	12	particularly	particularly	RB
cord-015922-5wwy0m2k	144	13	in	in	IN
cord-015922-5wwy0m2k	144	14	the	the	DT
cord-015922-5wwy0m2k	144	15	face	face	NN
cord-015922-5wwy0m2k	144	16	of	of	IN
cord-015922-5wwy0m2k	144	17	high	high	JJ
cord-015922-5wwy0m2k	144	18	viral	viral	JJ
cord-015922-5wwy0m2k	144	19	loads	load	NNS
cord-015922-5wwy0m2k	144	20	and	and	CC
cord-015922-5wwy0m2k	144	21	inadequate	inadequate	JJ
cord-015922-5wwy0m2k	144	22	courses	course	NNS
cord-015922-5wwy0m2k	144	23	or	or	CC
cord-015922-5wwy0m2k	144	24	dosing	dosing	NN
cord-015922-5wwy0m2k	144	25	of	of	IN
cord-015922-5wwy0m2k	144	26	ganciclovir	ganciclovir	NNS
cord-015922-5wwy0m2k	144	27	.	.	.
cord-015922-5wwy0m2k	145	1	Foscarnet	foscarnet	NN
cord-015922-5wwy0m2k	145	2	is	be	VBZ
cord-015922-5wwy0m2k	145	3	the	the	DT
cord-015922-5wwy0m2k	145	4	preferred	preferred	JJ
cord-015922-5wwy0m2k	145	5	drug	drug	NN
cord-015922-5wwy0m2k	145	6	in	in	IN
cord-015922-5wwy0m2k	145	7	this	this	DT
cord-015922-5wwy0m2k	145	8	setting	setting	NN
cord-015922-5wwy0m2k	145	9	or	or	CC
cord-015922-5wwy0m2k	145	10	when	when	WRB
cord-015922-5wwy0m2k	145	11	further	further	JJ
cord-015922-5wwy0m2k	145	12	potential	potential	JJ
cord-015922-5wwy0m2k	145	13	myelosuppression	myelosuppression	NN
cord-015922-5wwy0m2k	145	14	with	with	IN
cord-015922-5wwy0m2k	145	15	ganciclovir	ganciclovir	NNP
cord-015922-5wwy0m2k	145	16	is	be	VBZ
cord-015922-5wwy0m2k	145	17	not	not	RB
cord-015922-5wwy0m2k	145	18	advisable	advisable	JJ
cord-015922-5wwy0m2k	145	19	.	.	.
cord-015922-5wwy0m2k	146	1	The	the	DT
cord-015922-5wwy0m2k	146	2	experience	experience	NN
cord-015922-5wwy0m2k	146	3	with	with	IN
cord-015922-5wwy0m2k	146	4	cidofovir	cidofovir	NNS
cord-015922-5wwy0m2k	146	5	use	use	VBP
cord-015922-5wwy0m2k	146	6	in	in	IN
cord-015922-5wwy0m2k	146	7	the	the	DT
cord-015922-5wwy0m2k	146	8	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	146	9	population	population	NN
cord-015922-5wwy0m2k	146	10	is	be	VBZ
cord-015922-5wwy0m2k	146	11	limited	limited	JJ
cord-015922-5wwy0m2k	146	12	.	.	.
cord-015922-5wwy0m2k	147	1	Both	both	DT
cord-015922-5wwy0m2k	147	2	foscarnet	foscarnet	NN
cord-015922-5wwy0m2k	147	3	and	and	CC
cord-015922-5wwy0m2k	147	4	cidofovir	cidofovir	NNS
cord-015922-5wwy0m2k	147	5	are	be	VBP
cord-015922-5wwy0m2k	147	6	potentially	potentially	RB
cord-015922-5wwy0m2k	147	7	nephrotoxic	nephrotoxic	JJ
cord-015922-5wwy0m2k	147	8	and	and	CC
cord-015922-5wwy0m2k	147	9	should	should	MD
cord-015922-5wwy0m2k	147	10	be	be	VB
cord-015922-5wwy0m2k	147	11	administered	administer	VBN
cord-015922-5wwy0m2k	147	12	with	with	IN
cord-015922-5wwy0m2k	147	13	caution	caution	NN
cord-015922-5wwy0m2k	147	14	[	[	-LRB-
cord-015922-5wwy0m2k	147	15	1	1	CD
cord-015922-5wwy0m2k	147	16	,	,	,
cord-015922-5wwy0m2k	147	17	4	4	CD
cord-015922-5wwy0m2k	147	18	]	]	-RRB-
cord-015922-5wwy0m2k	147	19	.	.	.
cord-015922-5wwy0m2k	148	1	Studies	study	NNS
cord-015922-5wwy0m2k	148	2	are	be	VBP
cord-015922-5wwy0m2k	148	3	examining	examine	VBG
cord-015922-5wwy0m2k	148	4	the	the	DT
cord-015922-5wwy0m2k	148	5	emerging	emerge	VBG
cord-015922-5wwy0m2k	148	6	strategies	strategy	NNS
cord-015922-5wwy0m2k	148	7	for	for	IN
cord-015922-5wwy0m2k	148	8	the	the	DT
cord-015922-5wwy0m2k	148	9	management	management	NN
cord-015922-5wwy0m2k	148	10	of	of	IN
cord-015922-5wwy0m2k	148	11	CMV	CMV	NNP
cord-015922-5wwy0m2k	148	12	infection	infection	NN
cord-015922-5wwy0m2k	148	13	and	and	CC
cord-015922-5wwy0m2k	148	14	the	the	DT
cord-015922-5wwy0m2k	148	15	use	use	NN
cord-015922-5wwy0m2k	148	16	of	of	IN
cord-015922-5wwy0m2k	148	17	CMV	CMV	NNP
cord-015922-5wwy0m2k	148	18	vaccines	vaccine	NNS
cord-015922-5wwy0m2k	148	19	in	in	IN
cord-015922-5wwy0m2k	148	20	donors	donor	NNS
cord-015922-5wwy0m2k	148	21	and	and	CC
cord-015922-5wwy0m2k	148	22	recipients	recipient	NNS
cord-015922-5wwy0m2k	148	23	,	,	,
cord-015922-5wwy0m2k	148	24	adoptive	adoptive	JJ
cord-015922-5wwy0m2k	148	25	immunotherapy	immunotherapy	NN
cord-015922-5wwy0m2k	148	26	for	for	IN
cord-015922-5wwy0m2k	148	27	patients	patient	NNS
cord-015922-5wwy0m2k	148	28	with	with	IN
cord-015922-5wwy0m2k	148	29	refractory	refractory	JJ
cord-015922-5wwy0m2k	148	30	or	or	CC
cord-015922-5wwy0m2k	148	31	relapsing	relapse	VBG
cord-015922-5wwy0m2k	148	32	CMV	CMV	NNP
cord-015922-5wwy0m2k	148	33	infection	infection	NN
cord-015922-5wwy0m2k	148	34	and	and	CC
cord-015922-5wwy0m2k	148	35	the	the	DT
cord-015922-5wwy0m2k	148	36	use	use	NN
cord-015922-5wwy0m2k	148	37	of	of	IN
cord-015922-5wwy0m2k	148	38	maribavir	maribavir	NNP
cord-015922-5wwy0m2k	148	39	for	for	IN
cord-015922-5wwy0m2k	148	40	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	148	41	.	.	.
cord-015922-5wwy0m2k	149	1	The	the	DT
cord-015922-5wwy0m2k	149	2	major	major	JJ
cord-015922-5wwy0m2k	149	3	recognizable	recognizable	JJ
cord-015922-5wwy0m2k	149	4	clinical	clinical	JJ
cord-015922-5wwy0m2k	149	5	effect	effect	NN
cord-015922-5wwy0m2k	149	6	of	of	IN
cord-015922-5wwy0m2k	149	7	EBV	EBV	NNP
cord-015922-5wwy0m2k	149	8	in	in	IN
cord-015922-5wwy0m2k	149	9	the	the	DT
cord-015922-5wwy0m2k	149	10	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	149	11	patient	patient	NN
cord-015922-5wwy0m2k	149	12	is	be	VBZ
cord-015922-5wwy0m2k	149	13	in	in	IN
cord-015922-5wwy0m2k	149	14	the	the	DT
cord-015922-5wwy0m2k	149	15	pathogenesis	pathogenesis	NN
cord-015922-5wwy0m2k	149	16	of	of	IN
cord-015922-5wwy0m2k	149	17	PTLD	PTLD	NNP
cord-015922-5wwy0m2k	149	18	.	.	.
cord-015922-5wwy0m2k	150	1	Following	follow	VBG
cord-015922-5wwy0m2k	150	2	the	the	DT
cord-015922-5wwy0m2k	150	3	recovery	recovery	NN
cord-015922-5wwy0m2k	150	4	from	from	IN
cord-015922-5wwy0m2k	150	5	primary	primary	JJ
cord-015922-5wwy0m2k	150	6	EBV	EBV	NNP
cord-015922-5wwy0m2k	150	7	infection	infection	NN
cord-015922-5wwy0m2k	150	8	(	(	-LRB-
cord-015922-5wwy0m2k	150	9	>	>	NFP
cord-015922-5wwy0m2k	150	10	95	95	CD
cord-015922-5wwy0m2k	150	11	%	%	NN
cord-015922-5wwy0m2k	150	12	of	of	IN
cord-015922-5wwy0m2k	150	13	the	the	DT
cord-015922-5wwy0m2k	150	14	adult	adult	NN
cord-015922-5wwy0m2k	150	15	population	population	NN
cord-015922-5wwy0m2k	150	16	)	)	-RRB-
cord-015922-5wwy0m2k	150	17	,	,	,
cord-015922-5wwy0m2k	150	18	ongoing	ongoing	JJ
cord-015922-5wwy0m2k	150	19	lytic	lytic	JJ
cord-015922-5wwy0m2k	150	20	infection	infection	NN
cord-015922-5wwy0m2k	150	21	of	of	IN
cord-015922-5wwy0m2k	150	22	B	b	NN
cord-015922-5wwy0m2k	150	23	-	-	HYPH
cord-015922-5wwy0m2k	150	24	cells	cell	NNS
cord-015922-5wwy0m2k	150	25	occurs	occur	VBZ
cord-015922-5wwy0m2k	150	26	in	in	IN
cord-015922-5wwy0m2k	150	27	the	the	DT
cord-015922-5wwy0m2k	150	28	oropharynx	oropharynx	NN
cord-015922-5wwy0m2k	150	29	,	,	,
cord-015922-5wwy0m2k	150	30	with	with	IN
cord-015922-5wwy0m2k	150	31	latent	latent	JJ
cord-015922-5wwy0m2k	150	32	infection	infection	NN
cord-015922-5wwy0m2k	150	33	of	of	IN
cord-015922-5wwy0m2k	150	34	B	b	NN
cord-015922-5wwy0m2k	150	35	-	-	HYPH
cord-015922-5wwy0m2k	150	36	cells	cell	NNS
cord-015922-5wwy0m2k	150	37	in	in	IN
cord-015922-5wwy0m2k	150	38	the	the	DT
cord-015922-5wwy0m2k	150	39	peripheral	peripheral	JJ
cord-015922-5wwy0m2k	150	40	blood	blood	NN
cord-015922-5wwy0m2k	150	41	and	and	CC
cord-015922-5wwy0m2k	150	42	lymphoid	lymphoid	JJ
cord-015922-5wwy0m2k	150	43	tissues	tissue	NNS
cord-015922-5wwy0m2k	150	44	.	.	.
cord-015922-5wwy0m2k	151	1	These	these	DT
cord-015922-5wwy0m2k	151	2	latently	latently	RB
cord-015922-5wwy0m2k	151	3	infected	infected	JJ
cord-015922-5wwy0m2k	151	4	cells	cell	NNS
cord-015922-5wwy0m2k	151	5	can	can	MD
cord-015922-5wwy0m2k	151	6	be	be	VB
cord-015922-5wwy0m2k	151	7	transformed	transform	VBN
cord-015922-5wwy0m2k	151	8	and	and	CC
cord-015922-5wwy0m2k	151	9	immortalized	immortalize	VBN
cord-015922-5wwy0m2k	151	10	,	,	,
cord-015922-5wwy0m2k	151	11	resulting	result	VBG
cord-015922-5wwy0m2k	151	12	in	in	IN
cord-015922-5wwy0m2k	151	13	polyclonal	polyclonal	JJ
cord-015922-5wwy0m2k	151	14	proliferation	proliferation	NN
cord-015922-5wwy0m2k	151	15	.	.	.
cord-015922-5wwy0m2k	152	1	In	in	IN
cord-015922-5wwy0m2k	152	2	the	the	DT
cord-015922-5wwy0m2k	152	3	normal	normal	JJ
cord-015922-5wwy0m2k	152	4	seropositive	seropositive	JJ
cord-015922-5wwy0m2k	152	5	individual	individual	NN
cord-015922-5wwy0m2k	152	6	,	,	,
cord-015922-5wwy0m2k	152	7	these	these	DT
cord-015922-5wwy0m2k	152	8	cells	cell	NNS
cord-015922-5wwy0m2k	152	9	are	be	VBP
cord-015922-5wwy0m2k	152	10	kept	keep	VBN
cord-015922-5wwy0m2k	152	11	in	in	IN
cord-015922-5wwy0m2k	152	12	check	check	NN
cord-015922-5wwy0m2k	152	13	by	by	IN
cord-015922-5wwy0m2k	152	14	a	a	DT
cord-015922-5wwy0m2k	152	15	specific	specific	JJ
cord-015922-5wwy0m2k	152	16	cytotoxic	cytotoxic	JJ
cord-015922-5wwy0m2k	152	17	T	t	NN
cord-015922-5wwy0m2k	152	18	cell	cell	NN
cord-015922-5wwy0m2k	152	19	response	response	NN
cord-015922-5wwy0m2k	152	20	.	.	.
cord-015922-5wwy0m2k	153	1	In	in	IN
cord-015922-5wwy0m2k	153	2	the	the	DT
cord-015922-5wwy0m2k	153	3	presence	presence	NN
cord-015922-5wwy0m2k	153	4	of	of	IN
cord-015922-5wwy0m2k	153	5	immunosuppressive	immunosuppressive	JJ
cord-015922-5wwy0m2k	153	6	therapy	therapy	NN
cord-015922-5wwy0m2k	153	7	,	,	,
cord-015922-5wwy0m2k	153	8	this	this	DT
cord-015922-5wwy0m2k	153	9	surveillance	surveillance	NN
cord-015922-5wwy0m2k	153	10	system	system	NN
cord-015922-5wwy0m2k	153	11	is	be	VBZ
cord-015922-5wwy0m2k	153	12	inhibited	inhibit	VBN
cord-015922-5wwy0m2k	153	13	in	in	IN
cord-015922-5wwy0m2k	153	14	a	a	DT
cord-015922-5wwy0m2k	153	15	dose	dose	RB
cord-015922-5wwy0m2k	153	16	-	-	HYPH
cord-015922-5wwy0m2k	153	17	related	relate	VBN
cord-015922-5wwy0m2k	153	18	fashion	fashion	NN
cord-015922-5wwy0m2k	153	19	,	,	,
cord-015922-5wwy0m2k	153	20	thus	thus	RB
cord-015922-5wwy0m2k	153	21	permitting	permit	VBG
cord-015922-5wwy0m2k	153	22	continued	continue	VBN
cord-015922-5wwy0m2k	153	23	B	b	NN
cord-015922-5wwy0m2k	153	24	-	-	HYPH
cord-015922-5wwy0m2k	153	25	cell	cell	NN
cord-015922-5wwy0m2k	153	26	proliferation	proliferation	NN
cord-015922-5wwy0m2k	153	27	.	.	.
cord-015922-5wwy0m2k	154	1	Such	such	JJ
cord-015922-5wwy0m2k	154	2	ongoing	ongoing	JJ
cord-015922-5wwy0m2k	154	3	proliferation	proliferation	NN
cord-015922-5wwy0m2k	154	4	results	result	NNS
cord-015922-5wwy0m2k	154	5	in	in	IN
cord-015922-5wwy0m2k	154	6	particular	particular	JJ
cord-015922-5wwy0m2k	154	7	clones	clone	NNS
cord-015922-5wwy0m2k	154	8	being	be	VBG
cord-015922-5wwy0m2k	154	9	favored	favor	VBN
cord-015922-5wwy0m2k	154	10	and	and	CC
cord-015922-5wwy0m2k	154	11	the	the	DT
cord-015922-5wwy0m2k	154	12	potential	potential	NN
cord-015922-5wwy0m2k	154	13	for	for	IN
cord-015922-5wwy0m2k	154	14	developing	develop	VBG
cord-015922-5wwy0m2k	154	15	cytogenetic	cytogenetic	JJ
cord-015922-5wwy0m2k	154	16	abnormalities	abnormality	NNS
cord-015922-5wwy0m2k	154	17	,	,	,
cord-015922-5wwy0m2k	154	18	which	which	WDT
cord-015922-5wwy0m2k	154	19	leads	lead	VBZ
cord-015922-5wwy0m2k	154	20	to	to	IN
cord-015922-5wwy0m2k	154	21	the	the	DT
cord-015922-5wwy0m2k	154	22	development	development	NN
cord-015922-5wwy0m2k	154	23	of	of	IN
cord-015922-5wwy0m2k	154	24	a	a	DT
cord-015922-5wwy0m2k	154	25	truly	truly	RB
cord-015922-5wwy0m2k	154	26	malignant	malignant	JJ
cord-015922-5wwy0m2k	154	27	process	process	NN
cord-015922-5wwy0m2k	154	28	-	-	:
cord-015922-5wwy0m2k	154	29	PTLD	PTLD	NNP
cord-015922-5wwy0m2k	154	30	[	[	-LRB-
cord-015922-5wwy0m2k	154	31	1	1	CD
cord-015922-5wwy0m2k	154	32	,	,	,
cord-015922-5wwy0m2k	154	33	4	4	CD
cord-015922-5wwy0m2k	154	34	,	,	,
cord-015922-5wwy0m2k	154	35	27	27	CD
cord-015922-5wwy0m2k	154	36	,	,	,
cord-015922-5wwy0m2k	154	37	42	42	CD
cord-015922-5wwy0m2k	154	38	]	]	-RRB-
cord-015922-5wwy0m2k	154	39	.	.	.
cord-015922-5wwy0m2k	155	1	The	the	DT
cord-015922-5wwy0m2k	155	2	spectrum	spectrum	NN
cord-015922-5wwy0m2k	155	3	of	of	IN
cord-015922-5wwy0m2k	155	4	clinical	clinical	JJ
cord-015922-5wwy0m2k	155	5	disease	disease	NN
cord-015922-5wwy0m2k	155	6	seen	see	VBN
cord-015922-5wwy0m2k	155	7	with	with	IN
cord-015922-5wwy0m2k	155	8	PTLD	PTLD	NNP
cord-015922-5wwy0m2k	155	9	is	be	VBZ
cord-015922-5wwy0m2k	155	10	quite	quite	RB
cord-015922-5wwy0m2k	155	11	broad	broad	JJ
cord-015922-5wwy0m2k	155	12	,	,	,
cord-015922-5wwy0m2k	155	13	ranging	range	VBG
cord-015922-5wwy0m2k	155	14	from	from	IN
cord-015922-5wwy0m2k	155	15	a	a	DT
cord-015922-5wwy0m2k	155	16	mononucleosis	mononucleosis	NN
cord-015922-5wwy0m2k	155	17	-	-	HYPH
cord-015922-5wwy0m2k	155	18	like	like	JJ
cord-015922-5wwy0m2k	155	19	process	process	NN
cord-015922-5wwy0m2k	155	20	or	or	CC
cord-015922-5wwy0m2k	155	21	a	a	DT
cord-015922-5wwy0m2k	155	22	polyclonal	polyclonal	JJ
cord-015922-5wwy0m2k	155	23	proliferation	proliferation	NN
cord-015922-5wwy0m2k	155	24	of	of	IN
cord-015922-5wwy0m2k	155	25	lymphocytes	lymphocyte	NNS
cord-015922-5wwy0m2k	155	26	that	that	WDT
cord-015922-5wwy0m2k	155	27	usually	usually	RB
cord-015922-5wwy0m2k	155	28	responds	respond	VBZ
cord-015922-5wwy0m2k	155	29	to	to	IN
cord-015922-5wwy0m2k	155	30	decreasing	decrease	VBG
cord-015922-5wwy0m2k	155	31	immunosuppressive	immunosuppressive	JJ
cord-015922-5wwy0m2k	155	32	therapy	therapy	NN
cord-015922-5wwy0m2k	155	33	,	,	,
cord-015922-5wwy0m2k	155	34	to	to	IN
cord-015922-5wwy0m2k	155	35	a	a	DT
cord-015922-5wwy0m2k	155	36	monoclonal	monoclonal	JJ
cord-015922-5wwy0m2k	155	37	,	,	,
cord-015922-5wwy0m2k	155	38	highly	highly	RB
cord-015922-5wwy0m2k	155	39	malignant	malignant	JJ
cord-015922-5wwy0m2k	155	40	B	b	NN
cord-015922-5wwy0m2k	155	41	-	-	HYPH
cord-015922-5wwy0m2k	155	42	cell	cell	NN
cord-015922-5wwy0m2k	155	43	lymphoma	lymphoma	NN
cord-015922-5wwy0m2k	155	44	.	.	.
cord-015922-5wwy0m2k	156	1	The	the	DT
cord-015922-5wwy0m2k	156	2	mononucleosis	mononucleosis	NN
cord-015922-5wwy0m2k	156	3	-	-	HYPH
cord-015922-5wwy0m2k	156	4	like	like	JJ
cord-015922-5wwy0m2k	156	5	process	process	NN
cord-015922-5wwy0m2k	156	6	is	be	VBZ
cord-015922-5wwy0m2k	156	7	seen	see	VBN
cord-015922-5wwy0m2k	156	8	particularly	particularly	RB
cord-015922-5wwy0m2k	156	9	in	in	IN
cord-015922-5wwy0m2k	156	10	children	child	NNS
cord-015922-5wwy0m2k	156	11	with	with	IN
cord-015922-5wwy0m2k	156	12	primary	primary	JJ
cord-015922-5wwy0m2k	156	13	post	post	JJ
cord-015922-5wwy0m2k	156	14	-	-	JJ
cord-015922-5wwy0m2k	156	15	transplant	transplant	JJ
cord-015922-5wwy0m2k	156	16	EBV	EBV	NNP
cord-015922-5wwy0m2k	156	17	infection	infection	NN
cord-015922-5wwy0m2k	156	18	.	.	.
cord-015922-5wwy0m2k	157	1	The	the	DT
cord-015922-5wwy0m2k	157	2	clinical	clinical	JJ
cord-015922-5wwy0m2k	157	3	presentation	presentation	NN
cord-015922-5wwy0m2k	157	4	is	be	VBZ
cord-015922-5wwy0m2k	157	5	one	one	CD
cord-015922-5wwy0m2k	157	6	of	of	IN
cord-015922-5wwy0m2k	157	7	fever	fever	NN
cord-015922-5wwy0m2k	157	8	,	,	,
cord-015922-5wwy0m2k	157	9	sore	sore	JJ
cord-015922-5wwy0m2k	157	10	throat	throat	NN
cord-015922-5wwy0m2k	157	11	,	,	,
cord-015922-5wwy0m2k	157	12	cervical	cervical	JJ
cord-015922-5wwy0m2k	157	13	adenopathy	adenopathy	NN
cord-015922-5wwy0m2k	157	14	and	and	CC
cord-015922-5wwy0m2k	157	15	tonsillar	tonsillar	JJ
cord-015922-5wwy0m2k	157	16	hypertrophy	hypertrophy	NN
cord-015922-5wwy0m2k	157	17	and	and	CC
cord-015922-5wwy0m2k	157	18	inflammation	inflammation	NN
cord-015922-5wwy0m2k	157	19	.	.	.
cord-015922-5wwy0m2k	158	1	Unlike	unlike	IN
cord-015922-5wwy0m2k	158	2	B	b	NN
cord-015922-5wwy0m2k	158	3	-	-	HYPH
cord-015922-5wwy0m2k	158	4	cell	cell	NN
cord-015922-5wwy0m2k	158	5	lymphoma	lymphoma	NN
cord-015922-5wwy0m2k	158	6	in	in	IN
cord-015922-5wwy0m2k	158	7	the	the	DT
cord-015922-5wwy0m2k	158	8	normal	normal	JJ
cord-015922-5wwy0m2k	158	9	host	host	NN
cord-015922-5wwy0m2k	158	10	,	,	,
cord-015922-5wwy0m2k	158	11	in	in	IN
cord-015922-5wwy0m2k	158	12	the	the	DT
cord-015922-5wwy0m2k	158	13	transplant	transplant	NN
cord-015922-5wwy0m2k	158	14	patient	patient	NN
cord-015922-5wwy0m2k	158	15	,	,	,
cord-015922-5wwy0m2k	158	16	particularly	particularly	RB
cord-015922-5wwy0m2k	158	17	the	the	DT
cord-015922-5wwy0m2k	158	18	adult	adult	NN
cord-015922-5wwy0m2k	158	19	,	,	,
cord-015922-5wwy0m2k	158	20	the	the	DT
cord-015922-5wwy0m2k	158	21	process	process	NN
cord-015922-5wwy0m2k	158	22	can	can	MD
cord-015922-5wwy0m2k	158	23	be	be	VB
cord-015922-5wwy0m2k	158	24	extranodal	extranodal	NNP
cord-015922-5wwy0m2k	158	25	.	.	.
cord-015922-5wwy0m2k	159	1	Thus	thus	RB
cord-015922-5wwy0m2k	159	2	,	,	,
cord-015922-5wwy0m2k	159	3	presentations	presentation	NNS
cord-015922-5wwy0m2k	159	4	may	may	MD
cord-015922-5wwy0m2k	159	5	include	include	VB
cord-015922-5wwy0m2k	159	6	central	central	JJ
cord-015922-5wwy0m2k	159	7	nervous	nervous	JJ
cord-015922-5wwy0m2k	159	8	system	system	NN
cord-015922-5wwy0m2k	159	9	(	(	-LRB-
cord-015922-5wwy0m2k	159	10	CNS	CNS	NNP
cord-015922-5wwy0m2k	159	11	)	)	-RRB-
cord-015922-5wwy0m2k	159	12	invasion	invasion	NN
cord-015922-5wwy0m2k	159	13	(	(	-LRB-
cord-015922-5wwy0m2k	159	14	from	from	IN
cord-015922-5wwy0m2k	159	15	involvement	involvement	NN
cord-015922-5wwy0m2k	159	16	of	of	IN
cord-015922-5wwy0m2k	159	17	the	the	DT
cord-015922-5wwy0m2k	159	18	meninges	meninge	NNS
cord-015922-5wwy0m2k	159	19	to	to	IN
cord-015922-5wwy0m2k	159	20	focal	focal	JJ
cord-015922-5wwy0m2k	159	21	cerebral	cerebral	JJ
cord-015922-5wwy0m2k	159	22	lesions	lesion	NNS
cord-015922-5wwy0m2k	159	23	)	)	-RRB-
cord-015922-5wwy0m2k	159	24	,	,	,
cord-015922-5wwy0m2k	159	25	liver	liver	NN
cord-015922-5wwy0m2k	159	26	,	,	,
cord-015922-5wwy0m2k	159	27	lung	lung	NN
cord-015922-5wwy0m2k	159	28	and	and	CC
cord-015922-5wwy0m2k	159	29	bone	bone	NN
cord-015922-5wwy0m2k	159	30	marrow	marrow	NN
cord-015922-5wwy0m2k	159	31	diseases	disease	NNS
cord-015922-5wwy0m2k	159	32	.	.	.
cord-015922-5wwy0m2k	160	1	Not	not	RB
cord-015922-5wwy0m2k	160	2	uncommonly	uncommonly	RB
cord-015922-5wwy0m2k	160	3	,	,	,
cord-015922-5wwy0m2k	160	4	involvement	involvement	NN
cord-015922-5wwy0m2k	160	5	of	of	IN
cord-015922-5wwy0m2k	160	6	the	the	DT
cord-015922-5wwy0m2k	160	7	gut	gut	NN
cord-015922-5wwy0m2k	160	8	(	(	-LRB-
cord-015922-5wwy0m2k	160	9	particularly	particularly	RB
cord-015922-5wwy0m2k	160	10	the	the	DT
cord-015922-5wwy0m2k	160	11	small	small	JJ
cord-015922-5wwy0m2k	160	12	bowel	bowel	NN
cord-015922-5wwy0m2k	160	13	)	)	-RRB-
cord-015922-5wwy0m2k	160	14	may	may	MD
cord-015922-5wwy0m2k	160	15	lead	lead	VB
cord-015922-5wwy0m2k	160	16	to	to	IN
cord-015922-5wwy0m2k	160	17	recognition	recognition	NN
cord-015922-5wwy0m2k	160	18	of	of	IN
cord-015922-5wwy0m2k	160	19	the	the	DT
cord-015922-5wwy0m2k	160	20	PTLD	PTLD	NNP
cord-015922-5wwy0m2k	160	21	,	,	,
cord-015922-5wwy0m2k	160	22	with	with	IN
cord-015922-5wwy0m2k	160	23	a	a	DT
cord-015922-5wwy0m2k	160	24	clinical	clinical	JJ
cord-015922-5wwy0m2k	160	25	presentation	presentation	NN
cord-015922-5wwy0m2k	160	26	of	of	IN
cord-015922-5wwy0m2k	160	27	small	small	JJ
cord-015922-5wwy0m2k	160	28	bowel	bowel	NN
cord-015922-5wwy0m2k	160	29	obstruction	obstruction	NN
cord-015922-5wwy0m2k	160	30	,	,	,
cord-015922-5wwy0m2k	160	31	perforation	perforation	NN
cord-015922-5wwy0m2k	160	32	,	,	,
cord-015922-5wwy0m2k	160	33	or	or	CC
cord-015922-5wwy0m2k	160	34	occult	occult	JJ
cord-015922-5wwy0m2k	160	35	gastrointestinal	gastrointestinal	JJ
cord-015922-5wwy0m2k	160	36	bleeding	bleeding	NN
cord-015922-5wwy0m2k	160	37	.	.	.
cord-015922-5wwy0m2k	161	1	Disseminated	disseminate	VBN
cord-015922-5wwy0m2k	161	2	,	,	,
cord-015922-5wwy0m2k	161	3	multi	multi	JJ
cord-015922-5wwy0m2k	161	4	-	-	JJ
cord-015922-5wwy0m2k	161	5	organ	organ	JJ
cord-015922-5wwy0m2k	161	6	disease	disease	NN
cord-015922-5wwy0m2k	161	7	is	be	VBZ
cord-015922-5wwy0m2k	161	8	quite	quite	RB
cord-015922-5wwy0m2k	161	9	common	common	JJ
cord-015922-5wwy0m2k	161	10	in	in	IN
cord-015922-5wwy0m2k	161	11	the	the	DT
cord-015922-5wwy0m2k	161	12	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	161	13	patient	patient	NN
cord-015922-5wwy0m2k	161	14	[	[	-LRB-
cord-015922-5wwy0m2k	161	15	1	1	CD
cord-015922-5wwy0m2k	161	16	,	,	,
cord-015922-5wwy0m2k	161	17	4	4	CD
cord-015922-5wwy0m2k	161	18	,	,	,
cord-015922-5wwy0m2k	161	19	41	41	CD
cord-015922-5wwy0m2k	161	20	,	,	,
cord-015922-5wwy0m2k	161	21	42	42	CD
cord-015922-5wwy0m2k	161	22	]	]	-RRB-
cord-015922-5wwy0m2k	161	23	.	.	.
cord-015922-5wwy0m2k	162	1	Risk	risk	NN
cord-015922-5wwy0m2k	162	2	factors	factor	NNS
cord-015922-5wwy0m2k	162	3	for	for	IN
cord-015922-5wwy0m2k	162	4	developing	develop	VBG
cord-015922-5wwy0m2k	162	5	PTLD	PTLD	NNP
cord-015922-5wwy0m2k	162	6	include	include	VBP
cord-015922-5wwy0m2k	162	7	:	:	:
cord-015922-5wwy0m2k	162	8	primary	primary	JJ
cord-015922-5wwy0m2k	162	9	EBV	EBV	NNP
cord-015922-5wwy0m2k	162	10	infection	infection	NN
cord-015922-5wwy0m2k	162	11	in	in	IN
cord-015922-5wwy0m2k	162	12	association	association	NN
cord-015922-5wwy0m2k	162	13	with	with	IN
cord-015922-5wwy0m2k	162	14	high	high	JJ
cord-015922-5wwy0m2k	162	15	-	-	HYPH
cord-015922-5wwy0m2k	162	16	dose	dose	NN
cord-015922-5wwy0m2k	162	17	immunosuppression	immunosuppression	NN
cord-015922-5wwy0m2k	162	18	;	;	:
cord-015922-5wwy0m2k	162	19	interventions	intervention	NNS
cord-015922-5wwy0m2k	162	20	such	such	JJ
cord-015922-5wwy0m2k	162	21	as	as	IN
cord-015922-5wwy0m2k	162	22	T	T	NNP
cord-015922-5wwy0m2k	162	23	cell	cell	NN
cord-015922-5wwy0m2k	162	24	depletion	depletion	NN
cord-015922-5wwy0m2k	162	25	,	,	,
cord-015922-5wwy0m2k	162	26	umbilical	umbilical	JJ
cord-015922-5wwy0m2k	162	27	cord	cord	NN
cord-015922-5wwy0m2k	162	28	blood	blood	NN
cord-015922-5wwy0m2k	162	29	transplant	transplant	NN
cord-015922-5wwy0m2k	162	30	and	and	CC
cord-015922-5wwy0m2k	162	31	the	the	DT
cord-015922-5wwy0m2k	162	32	systemic	systemic	JJ
cord-015922-5wwy0m2k	162	33	administration	administration	NN
cord-015922-5wwy0m2k	162	34	of	of	IN
cord-015922-5wwy0m2k	162	35	anti	anti	JJ
cord-015922-5wwy0m2k	162	36	-	-	JJ
cord-015922-5wwy0m2k	162	37	thymocyte	thymocyte	JJ
cord-015922-5wwy0m2k	162	38	globulin	globulin	NN
cord-015922-5wwy0m2k	162	39	increase	increase	VBP
cord-015922-5wwy0m2k	162	40	the	the	DT
cord-015922-5wwy0m2k	162	41	risk	risk	NN
cord-015922-5wwy0m2k	162	42	significantly	significantly	RB
cord-015922-5wwy0m2k	162	43	;	;	:
cord-015922-5wwy0m2k	162	44	and	and	CC
cord-015922-5wwy0m2k	162	45	intensive	intensive	JJ
cord-015922-5wwy0m2k	162	46	immunosuppression	immunosuppression	NN
cord-015922-5wwy0m2k	162	47	that	that	WDT
cord-015922-5wwy0m2k	162	48	results	result	VBZ
cord-015922-5wwy0m2k	162	49	in	in	IN
cord-015922-5wwy0m2k	162	50	suppression	suppression	NN
cord-015922-5wwy0m2k	162	51	of	of	IN
cord-015922-5wwy0m2k	162	52	the	the	DT
cord-015922-5wwy0m2k	162	53	key	key	JJ
cord-015922-5wwy0m2k	162	54	host	host	NN
cord-015922-5wwy0m2k	162	55	defense	defense	NN
cord-015922-5wwy0m2k	162	56	against	against	IN
cord-015922-5wwy0m2k	162	57	EBV	EBV	NNP
cord-015922-5wwy0m2k	162	58	-	-	HYPH
cord-015922-5wwy0m2k	162	59	transformed	transform	VBN
cord-015922-5wwy0m2k	162	60	cells	cell	NNS
cord-015922-5wwy0m2k	163	1	(	(	-LRB-
cord-015922-5wwy0m2k	163	2	MHC	MHC	NNP
cord-015922-5wwy0m2k	163	3	-	-	HYPH
cord-015922-5wwy0m2k	163	4	restricted	restrict	VBN
cord-015922-5wwy0m2k	163	5	,	,	,
cord-015922-5wwy0m2k	163	6	EBV	EBV	NNP
cord-015922-5wwy0m2k	163	7	-	-	HYPH
cord-015922-5wwy0m2k	163	8	specific	specific	JJ
cord-015922-5wwy0m2k	163	9	,	,	,
cord-015922-5wwy0m2k	163	10	cytotoxic	cytotoxic	JJ
cord-015922-5wwy0m2k	163	11	T	t	NN
cord-015922-5wwy0m2k	163	12	cells	cell	NNS
cord-015922-5wwy0m2k	163	13	)	)	-RRB-
cord-015922-5wwy0m2k	163	14	significantly	significantly	RB
cord-015922-5wwy0m2k	163	15	increases	increase	VBZ
cord-015922-5wwy0m2k	163	16	the	the	DT
cord-015922-5wwy0m2k	163	17	risk	risk	NN
cord-015922-5wwy0m2k	163	18	of	of	IN
cord-015922-5wwy0m2k	163	19	PTLD	PTLD	NNP
cord-015922-5wwy0m2k	163	20	.	.	.
cord-015922-5wwy0m2k	164	1	In	in	IN
cord-015922-5wwy0m2k	164	2	addition	addition	NN
cord-015922-5wwy0m2k	164	3	to	to	IN
cord-015922-5wwy0m2k	164	4	the	the	DT
cord-015922-5wwy0m2k	164	5	host	host	NN
cord-015922-5wwy0m2k	164	6	characteristics	characteristic	NNS
cord-015922-5wwy0m2k	164	7	mentioned	mention	VBN
cord-015922-5wwy0m2k	164	8	,	,	,
cord-015922-5wwy0m2k	164	9	high	high	JJ
cord-015922-5wwy0m2k	164	10	EBV	EBV	NNP
cord-015922-5wwy0m2k	164	11	viral	viral	JJ
cord-015922-5wwy0m2k	164	12	loads	load	NNS
cord-015922-5wwy0m2k	164	13	correlate	correlate	VBP
cord-015922-5wwy0m2k	164	14	with	with	IN
cord-015922-5wwy0m2k	164	15	an	an	DT
cord-015922-5wwy0m2k	164	16	increased	increase	VBN
cord-015922-5wwy0m2k	164	17	risk	risk	NN
cord-015922-5wwy0m2k	164	18	of	of	IN
cord-015922-5wwy0m2k	164	19	PTLD	PTLD	NNP
cord-015922-5wwy0m2k	164	20	.	.	.
cord-015922-5wwy0m2k	165	1	It	-PRON-	PRP
cord-015922-5wwy0m2k	165	2	has	have	VBZ
cord-015922-5wwy0m2k	165	3	been	be	VBN
cord-015922-5wwy0m2k	165	4	suggested	suggest	VBN
cord-015922-5wwy0m2k	165	5	that	that	IN
cord-015922-5wwy0m2k	165	6	EBV	EBV	NNP
cord-015922-5wwy0m2k	165	7	viral	viral	JJ
cord-015922-5wwy0m2k	165	8	load	load	NN
cord-015922-5wwy0m2k	165	9	surveillance	surveillance	NN
cord-015922-5wwy0m2k	165	10	in	in	IN
cord-015922-5wwy0m2k	165	11	peripheral	peripheral	JJ
cord-015922-5wwy0m2k	165	12	blood	blood	NN
cord-015922-5wwy0m2k	165	13	be	be	VB
cord-015922-5wwy0m2k	165	14	carried	carry	VBN
cord-015922-5wwy0m2k	165	15	out	out	RP
cord-015922-5wwy0m2k	165	16	in	in	IN
cord-015922-5wwy0m2k	165	17	high	high	JJ
cord-015922-5wwy0m2k	165	18	risk	risk	NN
cord-015922-5wwy0m2k	165	19	patients	patient	NNS
cord-015922-5wwy0m2k	165	20	(	(	-LRB-
cord-015922-5wwy0m2k	165	21	those	those	DT
cord-015922-5wwy0m2k	165	22	with	with	IN
cord-015922-5wwy0m2k	165	23	primary	primary	JJ
cord-015922-5wwy0m2k	165	24	EBV	EBV	NNP
cord-015922-5wwy0m2k	165	25	infection	infection	NN
cord-015922-5wwy0m2k	165	26	,	,	,
cord-015922-5wwy0m2k	165	27	anti	anti	JJ
cord-015922-5wwy0m2k	165	28	-	-	JJ
cord-015922-5wwy0m2k	165	29	T	t	JJ
cord-015922-5wwy0m2k	165	30	cell	cell	NN
cord-015922-5wwy0m2k	165	31	antibody	antibody	NN
cord-015922-5wwy0m2k	165	32	therapy	therapy	NN
cord-015922-5wwy0m2k	165	33	for	for	IN
cord-015922-5wwy0m2k	165	34	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	165	35	,	,	,
cord-015922-5wwy0m2k	165	36	HLA	HLA	NNP
cord-015922-5wwy0m2k	165	37	-	-	HYPH
cord-015922-5wwy0m2k	165	38	mismatched	mismatch	VBN
cord-015922-5wwy0m2k	165	39	or	or	CC
cord-015922-5wwy0m2k	165	40	T	t	NN
cord-015922-5wwy0m2k	165	41	cell	cell	NN
cord-015922-5wwy0m2k	165	42	-	-	HYPH
cord-015922-5wwy0m2k	165	43	depleted	deplete	VBN
cord-015922-5wwy0m2k	165	44	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	165	45	recipients	recipient	NNS
cord-015922-5wwy0m2k	165	46	)	)	-RRB-
cord-015922-5wwy0m2k	165	47	,	,	,
cord-015922-5wwy0m2k	165	48	with	with	IN
cord-015922-5wwy0m2k	165	49	decreased	decrease	VBN
cord-015922-5wwy0m2k	165	50	immunosuppression	immunosuppression	NN
cord-015922-5wwy0m2k	165	51	+	+	CC
cord-015922-5wwy0m2k	165	52	/−	/−	.
cord-015922-5wwy0m2k	165	53	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	165	54	therapy	therapy	NN
cord-015922-5wwy0m2k	165	55	(	(	-LRB-
cord-015922-5wwy0m2k	165	56	acyclovir	acyclovir	NNP
cord-015922-5wwy0m2k	165	57	or	or	CC
cord-015922-5wwy0m2k	165	58	ganciclovir	ganciclovir	NNP
cord-015922-5wwy0m2k	165	59	)	)	-RRB-
cord-015922-5wwy0m2k	165	60	carried	carry	VBN
cord-015922-5wwy0m2k	165	61	out	out	RP
cord-015922-5wwy0m2k	165	62	in	in	IN
cord-015922-5wwy0m2k	165	63	the	the	DT
cord-015922-5wwy0m2k	165	64	setting	setting	NN
cord-015922-5wwy0m2k	165	65	of	of	IN
cord-015922-5wwy0m2k	165	66	high	high	JJ
cord-015922-5wwy0m2k	165	67	viral	viral	JJ
cord-015922-5wwy0m2k	165	68	loads	load	NNS
cord-015922-5wwy0m2k	165	69	[	[	-LRB-
cord-015922-5wwy0m2k	165	70	1	1	CD
cord-015922-5wwy0m2k	165	71	,	,	,
cord-015922-5wwy0m2k	165	72	4	4	CD
cord-015922-5wwy0m2k	165	73	,	,	,
cord-015922-5wwy0m2k	165	74	41	41	CD
cord-015922-5wwy0m2k	165	75	,	,	,
cord-015922-5wwy0m2k	165	76	42	42	CD
cord-015922-5wwy0m2k	165	77	]	]	-RRB-
cord-015922-5wwy0m2k	165	78	.	.	.
cord-015922-5wwy0m2k	166	1	Treatment	treatment	NN
cord-015922-5wwy0m2k	166	2	of	of	IN
cord-015922-5wwy0m2k	166	3	PTLD	PTLD	NNP
cord-015922-5wwy0m2k	166	4	remains	remain	VBZ
cord-015922-5wwy0m2k	166	5	controversial	controversial	JJ
cord-015922-5wwy0m2k	166	6	.	.	.
cord-015922-5wwy0m2k	167	1	All	all	DT
cord-015922-5wwy0m2k	167	2	patients	patient	NNS
cord-015922-5wwy0m2k	167	3	with	with	IN
cord-015922-5wwy0m2k	167	4	diagnosed	diagnosed	JJ
cord-015922-5wwy0m2k	167	5	PTLD	PTLD	NNP
cord-015922-5wwy0m2k	167	6	should	should	MD
cord-015922-5wwy0m2k	167	7	have	have	VB
cord-015922-5wwy0m2k	167	8	a	a	DT
cord-015922-5wwy0m2k	167	9	significant	significant	JJ
cord-015922-5wwy0m2k	167	10	decrease	decrease	NN
cord-015922-5wwy0m2k	167	11	in	in	IN
cord-015922-5wwy0m2k	167	12	immunosuppressive	immunosuppressive	JJ
cord-015922-5wwy0m2k	167	13	medications	medication	NNS
cord-015922-5wwy0m2k	167	14	.	.	.
cord-015922-5wwy0m2k	168	1	Many	many	JJ
cord-015922-5wwy0m2k	168	2	centers	center	NNS
cord-015922-5wwy0m2k	168	3	also	also	RB
cord-015922-5wwy0m2k	168	4	prescribe	prescribe	VBP
cord-015922-5wwy0m2k	168	5	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	168	6	therapy	therapy	NN
cord-015922-5wwy0m2k	168	7	.	.	.
cord-015922-5wwy0m2k	169	1	Patients	patient	NNS
cord-015922-5wwy0m2k	169	2	not	not	RB
cord-015922-5wwy0m2k	169	3	responding	respond	VBG
cord-015922-5wwy0m2k	169	4	to	to	IN
cord-015922-5wwy0m2k	169	5	these	these	DT
cord-015922-5wwy0m2k	169	6	measures	measure	NNS
cord-015922-5wwy0m2k	169	7	are	be	VBP
cord-015922-5wwy0m2k	169	8	usually	usually	RB
cord-015922-5wwy0m2k	169	9	treated	treat	VBN
cord-015922-5wwy0m2k	169	10	with	with	IN
cord-015922-5wwy0m2k	169	11	an	an	DT
cord-015922-5wwy0m2k	169	12	anti	anti	JJ
cord-015922-5wwy0m2k	169	13	-	-	JJ
cord-015922-5wwy0m2k	169	14	B	b	NN
cord-015922-5wwy0m2k	169	15	-	-	HYPH
cord-015922-5wwy0m2k	169	16	cell	cell	NN
cord-015922-5wwy0m2k	169	17	monoclonal	monoclonal	JJ
cord-015922-5wwy0m2k	169	18	antibody	antibody	NN
cord-015922-5wwy0m2k	169	19	(	(	-LRB-
cord-015922-5wwy0m2k	169	20	rituximab	rituximab	NNP
cord-015922-5wwy0m2k	169	21	,	,	,
cord-015922-5wwy0m2k	169	22	an	an	DT
cord-015922-5wwy0m2k	169	23	anti	anti	JJ
cord-015922-5wwy0m2k	169	24	-	-	JJ
cord-015922-5wwy0m2k	169	25	CD20	cd20	JJ
cord-015922-5wwy0m2k	169	26	monoclonal	monoclonal	JJ
cord-015922-5wwy0m2k	169	27	antibody	antibody	NN
cord-015922-5wwy0m2k	169	28	)	)	-RRB-
cord-015922-5wwy0m2k	169	29	[	[	-LRB-
cord-015922-5wwy0m2k	169	30	43	43	CD
cord-015922-5wwy0m2k	169	31	,	,	,
cord-015922-5wwy0m2k	169	32	44	44	CD
cord-015922-5wwy0m2k	169	33	]	]	-RRB-
cord-015922-5wwy0m2k	169	34	.	.	.
cord-015922-5wwy0m2k	170	1	After	after	IN
cord-015922-5wwy0m2k	170	2	that	that	DT
cord-015922-5wwy0m2k	170	3	,	,	,
cord-015922-5wwy0m2k	170	4	therapies	therapy	NNS
cord-015922-5wwy0m2k	170	5	have	have	VBP
cord-015922-5wwy0m2k	170	6	ranged	range	VBN
cord-015922-5wwy0m2k	170	7	from	from	IN
cord-015922-5wwy0m2k	170	8	anti	anti	JJ
cord-015922-5wwy0m2k	170	9	-	-	JJ
cord-015922-5wwy0m2k	170	10	lymphoma	lymphoma	JJ
cord-015922-5wwy0m2k	170	11	chemotherapy	chemotherapy	NN
cord-015922-5wwy0m2k	170	12	to	to	IN
cord-015922-5wwy0m2k	170	13	alpha	alpha	NN
cord-015922-5wwy0m2k	170	14	-	-	HYPH
cord-015922-5wwy0m2k	170	15	interferon	interferon	JJ
cord-015922-5wwy0m2k	170	16	and	and	CC
cord-015922-5wwy0m2k	170	17	intravenous	intravenous	JJ
cord-015922-5wwy0m2k	170	18	gamma	gamma	NN
cord-015922-5wwy0m2k	170	19	globulin	globulin	NN
cord-015922-5wwy0m2k	170	20	.	.	.
cord-015922-5wwy0m2k	171	1	HSV	HSV	NNP
cord-015922-5wwy0m2k	171	2	infection	infection	NN
cord-015922-5wwy0m2k	171	3	prior	prior	RB
cord-015922-5wwy0m2k	171	4	to	to	IN
cord-015922-5wwy0m2k	171	5	the	the	DT
cord-015922-5wwy0m2k	171	6	introduction	introduction	NN
cord-015922-5wwy0m2k	171	7	of	of	IN
cord-015922-5wwy0m2k	171	8	acyclovir	acyclovir	NNP
cord-015922-5wwy0m2k	171	9	was	be	VBD
cord-015922-5wwy0m2k	171	10	a	a	DT
cord-015922-5wwy0m2k	171	11	major	major	JJ
cord-015922-5wwy0m2k	171	12	problem	problem	NN
cord-015922-5wwy0m2k	171	13	in	in	IN
cord-015922-5wwy0m2k	171	14	the	the	DT
cord-015922-5wwy0m2k	171	15	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	171	16	recipient	recipient	NN
cord-015922-5wwy0m2k	171	17	.	.	.
cord-015922-5wwy0m2k	172	1	Occurring	occur	VBG
cord-015922-5wwy0m2k	172	2	in	in	IN
cord-015922-5wwy0m2k	172	3	the	the	DT
cord-015922-5wwy0m2k	172	4	preengraftment	preengraftment	JJ
cord-015922-5wwy0m2k	172	5	period	period	NN
cord-015922-5wwy0m2k	172	6	,	,	,
cord-015922-5wwy0m2k	172	7	HSV	HSV	NNP
cord-015922-5wwy0m2k	172	8	infection	infection	NN
cord-015922-5wwy0m2k	172	9	greatly	greatly	RB
cord-015922-5wwy0m2k	172	10	exacerbated	exacerbate	VBD
cord-015922-5wwy0m2k	172	11	the	the	DT
cord-015922-5wwy0m2k	172	12	severity	severity	NN
cord-015922-5wwy0m2k	172	13	of	of	IN
cord-015922-5wwy0m2k	172	14	mucositis	mucositis	NNP
cord-015922-5wwy0m2k	172	15	.	.	.
cord-015922-5wwy0m2k	173	1	Not	not	RB
cord-015922-5wwy0m2k	173	2	only	only	RB
cord-015922-5wwy0m2k	173	3	were	be	VBD
cord-015922-5wwy0m2k	173	4	ulcers	ulcer	NNS
cord-015922-5wwy0m2k	173	5	observed	observe	VBN
cord-015922-5wwy0m2k	173	6	in	in	IN
cord-015922-5wwy0m2k	173	7	the	the	DT
cord-015922-5wwy0m2k	173	8	oral	oral	JJ
cord-015922-5wwy0m2k	173	9	cavity	cavity	NN
cord-015922-5wwy0m2k	173	10	and	and	CC
cord-015922-5wwy0m2k	173	11	anogenital	anogenital	JJ
cord-015922-5wwy0m2k	173	12	areas	area	NNS
cord-015922-5wwy0m2k	173	13	,	,	,
cord-015922-5wwy0m2k	173	14	ulcerations	ulceration	NNS
cord-015922-5wwy0m2k	173	15	of	of	IN
cord-015922-5wwy0m2k	173	16	the	the	DT
cord-015922-5wwy0m2k	173	17	esophagus	esophagus	NN
cord-015922-5wwy0m2k	173	18	,	,	,
cord-015922-5wwy0m2k	173	19	stomach	stomach	NN
cord-015922-5wwy0m2k	173	20	and	and	CC
cord-015922-5wwy0m2k	173	21	intestine	intestine	NN
cord-015922-5wwy0m2k	173	22	were	be	VBD
cord-015922-5wwy0m2k	173	23	also	also	RB
cord-015922-5wwy0m2k	173	24	observed	observe	VBN
cord-015922-5wwy0m2k	173	25	.	.	.
cord-015922-5wwy0m2k	174	1	HSV	HSV	NNP
cord-015922-5wwy0m2k	174	2	pneumonia	pneumonia	NN
cord-015922-5wwy0m2k	174	3	was	be	VBD
cord-015922-5wwy0m2k	174	4	also	also	RB
cord-015922-5wwy0m2k	174	5	noted	note	VBN
cord-015922-5wwy0m2k	174	6	,	,	,
cord-015922-5wwy0m2k	174	7	with	with	IN
cord-015922-5wwy0m2k	174	8	rare	rare	JJ
cord-015922-5wwy0m2k	174	9	cases	case	NNS
cord-015922-5wwy0m2k	174	10	of	of	IN
cord-015922-5wwy0m2k	174	11	cutaneous	cutaneous	JJ
cord-015922-5wwy0m2k	174	12	dissemination	dissemination	NN
cord-015922-5wwy0m2k	174	13	and	and	CC
cord-015922-5wwy0m2k	174	14	encephalitis	encephalitis	NN
cord-015922-5wwy0m2k	174	15	.	.	.
cord-015922-5wwy0m2k	175	1	The	the	DT
cord-015922-5wwy0m2k	175	2	current	current	JJ
cord-015922-5wwy0m2k	175	3	standard	standard	NN
cord-015922-5wwy0m2k	175	4	of	of	IN
cord-015922-5wwy0m2k	175	5	care	care	NN
cord-015922-5wwy0m2k	175	6	is	be	VBZ
cord-015922-5wwy0m2k	175	7	to	to	TO
cord-015922-5wwy0m2k	175	8	test	test	VB
cord-015922-5wwy0m2k	175	9	all	all	DT
cord-015922-5wwy0m2k	175	10	candidates	candidate	NNS
cord-015922-5wwy0m2k	175	11	for	for	IN
cord-015922-5wwy0m2k	175	12	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	175	13	for	for	IN
cord-015922-5wwy0m2k	175	14	an	an	DT
cord-015922-5wwy0m2k	175	15	antibody	antibody	NN
cord-015922-5wwy0m2k	175	16	to	to	IN
cord-015922-5wwy0m2k	175	17	HSV	HSV	NNP
cord-015922-5wwy0m2k	175	18	,	,	,
cord-015922-5wwy0m2k	175	19	with	with	IN
cord-015922-5wwy0m2k	175	20	seropositive	seropositive	JJ
cord-015922-5wwy0m2k	175	21	individuals	individual	NNS
cord-015922-5wwy0m2k	175	22	then	then	RB
cord-015922-5wwy0m2k	175	23	placed	place	VBD
cord-015922-5wwy0m2k	175	24	on	on	IN
cord-015922-5wwy0m2k	175	25	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	175	26	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	175	27	,	,	,
cord-015922-5wwy0m2k	175	28	beginning	begin	VBG
cord-015922-5wwy0m2k	175	29	prior	prior	RB
cord-015922-5wwy0m2k	175	30	to	to	IN
cord-015922-5wwy0m2k	175	31	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	175	32	.	.	.
cord-015922-5wwy0m2k	176	1	Effective	effective	JJ
cord-015922-5wwy0m2k	176	2	agents	agent	NNS
cord-015922-5wwy0m2k	176	3	for	for	IN
cord-015922-5wwy0m2k	176	4	HSV	HSV	NNP
cord-015922-5wwy0m2k	176	5	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	176	6	include	include	VBP
cord-015922-5wwy0m2k	176	7	acyclovir	acyclovir	NNP
cord-015922-5wwy0m2k	176	8	(	(	-LRB-
cord-015922-5wwy0m2k	176	9	intravenous	intravenous	JJ
cord-015922-5wwy0m2k	176	10	or	or	CC
cord-015922-5wwy0m2k	176	11	oral	oral	JJ
cord-015922-5wwy0m2k	176	12	)	)	-RRB-
cord-015922-5wwy0m2k	176	13	,	,	,
cord-015922-5wwy0m2k	176	14	valacyclovir	valacyclovir	NNP
cord-015922-5wwy0m2k	176	15	or	or	CC
cord-015922-5wwy0m2k	176	16	famciclovir	famciclovir	NNP
cord-015922-5wwy0m2k	176	17	.	.	.
cord-015922-5wwy0m2k	177	1	Recurrence	recurrence	NN
cord-015922-5wwy0m2k	177	2	of	of	IN
cord-015922-5wwy0m2k	177	3	HSV	HSV	NNP
cord-015922-5wwy0m2k	177	4	may	may	MD
cord-015922-5wwy0m2k	177	5	occur	occur	VB
cord-015922-5wwy0m2k	177	6	later	later	RB
cord-015922-5wwy0m2k	177	7	in	in	IN
cord-015922-5wwy0m2k	177	8	the	the	DT
cord-015922-5wwy0m2k	177	9	course	course	NN
cord-015922-5wwy0m2k	177	10	,	,	,
cord-015922-5wwy0m2k	177	11	and	and	CC
cord-015922-5wwy0m2k	177	12	should	should	MD
cord-015922-5wwy0m2k	177	13	again	again	RB
cord-015922-5wwy0m2k	177	14	be	be	VB
cord-015922-5wwy0m2k	177	15	treated	treat	VBN
cord-015922-5wwy0m2k	177	16	with	with	IN
cord-015922-5wwy0m2k	177	17	an	an	DT
cord-015922-5wwy0m2k	177	18	acyclovir	acyclovir	NNP
cord-015922-5wwy0m2k	177	19	regimen	regimen	NN
cord-015922-5wwy0m2k	177	20	,	,	,
cord-015922-5wwy0m2k	177	21	with	with	IN
cord-015922-5wwy0m2k	177	22	repeated	repeat	VBN
cord-015922-5wwy0m2k	177	23	episodes	episode	NNS
cord-015922-5wwy0m2k	177	24	justifying	justify	VBG
cord-015922-5wwy0m2k	177	25	long	long	JJ
cord-015922-5wwy0m2k	177	26	-	-	HYPH
cord-015922-5wwy0m2k	177	27	term	term	NN
cord-015922-5wwy0m2k	177	28	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	177	29	.	.	.
cord-015922-5wwy0m2k	178	1	Acyclovir	Acyclovir	NNP
cord-015922-5wwy0m2k	178	2	resistance	resistance	NN
cord-015922-5wwy0m2k	178	3	is	be	VBZ
cord-015922-5wwy0m2k	178	4	uncommon	uncommon	JJ
cord-015922-5wwy0m2k	178	5	in	in	IN
cord-015922-5wwy0m2k	178	6	this	this	DT
cord-015922-5wwy0m2k	178	7	situation	situation	NN
cord-015922-5wwy0m2k	178	8	,	,	,
cord-015922-5wwy0m2k	178	9	but	but	CC
cord-015922-5wwy0m2k	178	10	can	can	MD
cord-015922-5wwy0m2k	178	11	occur	occur	VB
cord-015922-5wwy0m2k	178	12	,	,	,
cord-015922-5wwy0m2k	178	13	and	and	CC
cord-015922-5wwy0m2k	178	14	requires	require	VBZ
cord-015922-5wwy0m2k	178	15	treatment	treatment	NN
cord-015922-5wwy0m2k	178	16	with	with	IN
cord-015922-5wwy0m2k	178	17	foscarnet	foscarnet	NN
cord-015922-5wwy0m2k	178	18	[	[	-LRB-
cord-015922-5wwy0m2k	178	19	1	1	CD
cord-015922-5wwy0m2k	178	20	,	,	,
cord-015922-5wwy0m2k	178	21	4	4	CD
cord-015922-5wwy0m2k	178	22	]	]	-RRB-
cord-015922-5wwy0m2k	178	23	.	.	.
cord-015922-5wwy0m2k	179	1	All	all	DT
cord-015922-5wwy0m2k	179	2	patients	patient	NNS
cord-015922-5wwy0m2k	179	3	and	and	CC
cord-015922-5wwy0m2k	179	4	donors	donor	NNS
cord-015922-5wwy0m2k	179	5	should	should	MD
cord-015922-5wwy0m2k	179	6	have	have	VB
cord-015922-5wwy0m2k	179	7	serologic	serologic	JJ
cord-015922-5wwy0m2k	179	8	testing	testing	NN
cord-015922-5wwy0m2k	179	9	for	for	IN
cord-015922-5wwy0m2k	179	10	VZV	VZV	NNP
cord-015922-5wwy0m2k	179	11	prior	prior	RB
cord-015922-5wwy0m2k	179	12	to	to	IN
cord-015922-5wwy0m2k	179	13	transplant	transplant	NN
cord-015922-5wwy0m2k	179	14	.	.	.
cord-015922-5wwy0m2k	180	1	Seronegative	seronegative	JJ
cord-015922-5wwy0m2k	180	2	individuals	individual	NNS
cord-015922-5wwy0m2k	180	3	post	post	VBP
cord-015922-5wwy0m2k	180	4	-	-	NN
cord-015922-5wwy0m2k	180	5	transplant	transplant	NN
cord-015922-5wwy0m2k	180	6	should	should	MD
cord-015922-5wwy0m2k	180	7	avoid	avoid	VB
cord-015922-5wwy0m2k	180	8	exposures	exposure	NNS
cord-015922-5wwy0m2k	180	9	to	to	IN
cord-015922-5wwy0m2k	180	10	VZV	VZV	NNP
cord-015922-5wwy0m2k	180	11	,	,	,
cord-015922-5wwy0m2k	180	12	but	but	CC
cord-015922-5wwy0m2k	180	13	if	if	IN
cord-015922-5wwy0m2k	180	14	such	such	PDT
cord-015922-5wwy0m2k	180	15	an	an	DT
cord-015922-5wwy0m2k	180	16	exposure	exposure	NN
cord-015922-5wwy0m2k	180	17	occurs	occur	VBZ
cord-015922-5wwy0m2k	180	18	,	,	,
cord-015922-5wwy0m2k	180	19	valacyclovir	valacyclovir	NNP
cord-015922-5wwy0m2k	180	20	or	or	CC
cord-015922-5wwy0m2k	180	21	varicella	varicella	NNP
cord-015922-5wwy0m2k	180	22	hyperimmune	hyperimmune	NNP
cord-015922-5wwy0m2k	180	23	globulin	globulin	NNP
cord-015922-5wwy0m2k	180	24	should	should	MD
cord-015922-5wwy0m2k	180	25	be	be	VB
cord-015922-5wwy0m2k	180	26	promptly	promptly	RB
cord-015922-5wwy0m2k	180	27	initiated	initiate	VBN
cord-015922-5wwy0m2k	180	28	.	.	.
cord-015922-5wwy0m2k	181	1	Before	before	IN
cord-015922-5wwy0m2k	181	2	universal	universal	JJ
cord-015922-5wwy0m2k	181	3	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	181	4	with	with	IN
cord-015922-5wwy0m2k	181	5	acyclovir	acyclovir	NNP
cord-015922-5wwy0m2k	181	6	became	become	VBD
cord-015922-5wwy0m2k	181	7	standard	standard	JJ
cord-015922-5wwy0m2k	181	8	,	,	,
cord-015922-5wwy0m2k	181	9	an	an	DT
cord-015922-5wwy0m2k	181	10	estimated	estimate	VBN
cord-015922-5wwy0m2k	181	11	40	40	CD
cord-015922-5wwy0m2k	181	12	percent	percent	NN
cord-015922-5wwy0m2k	181	13	of	of	IN
cord-015922-5wwy0m2k	181	14	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	181	15	patients	patient	NNS
cord-015922-5wwy0m2k	181	16	developed	develop	VBD
cord-015922-5wwy0m2k	181	17	active	active	JJ
cord-015922-5wwy0m2k	181	18	VZV	VZV	NNP
cord-015922-5wwy0m2k	181	19	,	,	,
cord-015922-5wwy0m2k	181	20	with	with	IN
cord-015922-5wwy0m2k	181	21	a	a	DT
cord-015922-5wwy0m2k	181	22	median	median	JJ
cord-015922-5wwy0m2k	181	23	time	time	NN
cord-015922-5wwy0m2k	181	24	of	of	IN
cord-015922-5wwy0m2k	181	25	onset	onset	NN
cord-015922-5wwy0m2k	181	26	being	be	VBG
cord-015922-5wwy0m2k	181	27	five	five	CD
cord-015922-5wwy0m2k	181	28	months	month	NNS
cord-015922-5wwy0m2k	181	29	post	post	NN
cord-015922-5wwy0m2k	181	30	-	-	NN
cord-015922-5wwy0m2k	181	31	transplant	transplant	NN
cord-015922-5wwy0m2k	181	32	.	.	.
cord-015922-5wwy0m2k	182	1	The	the	DT
cord-015922-5wwy0m2k	182	2	great	great	JJ
cord-015922-5wwy0m2k	182	3	majority	majority	NN
cord-015922-5wwy0m2k	182	4	of	of	IN
cord-015922-5wwy0m2k	182	5	these	these	DT
cord-015922-5wwy0m2k	182	6	patients	patient	NNS
cord-015922-5wwy0m2k	182	7	had	have	VBD
cord-015922-5wwy0m2k	182	8	zoster	zoster	NN
cord-015922-5wwy0m2k	182	9	,	,	,
cord-015922-5wwy0m2k	182	10	but	but	CC
cord-015922-5wwy0m2k	182	11	approximately	approximately	RB
cord-015922-5wwy0m2k	182	12	20	20	CD
cord-015922-5wwy0m2k	182	13	percent	percent	NN
cord-015922-5wwy0m2k	182	14	had	have	VBD
cord-015922-5wwy0m2k	182	15	a	a	DT
cord-015922-5wwy0m2k	182	16	more	more	RBR
cord-015922-5wwy0m2k	182	17	generalized	generalized	JJ
cord-015922-5wwy0m2k	182	18	process	process	NN
cord-015922-5wwy0m2k	182	19	resembling	resemble	VBG
cord-015922-5wwy0m2k	182	20	primary	primary	JJ
cord-015922-5wwy0m2k	182	21	varicella	varicella	NN
cord-015922-5wwy0m2k	182	22	.	.	.
cord-015922-5wwy0m2k	183	1	A	a	DT
cord-015922-5wwy0m2k	183	2	significant	significant	JJ
cord-015922-5wwy0m2k	183	3	concern	concern	NN
cord-015922-5wwy0m2k	183	4	was	be	VBD
cord-015922-5wwy0m2k	183	5	visceral	visceral	JJ
cord-015922-5wwy0m2k	183	6	involvement	involvement	NN
cord-015922-5wwy0m2k	183	7	in	in	IN
cord-015922-5wwy0m2k	183	8	the	the	DT
cord-015922-5wwy0m2k	183	9	setting	setting	NN
cord-015922-5wwy0m2k	183	10	of	of	IN
cord-015922-5wwy0m2k	183	11	disseminated	disseminate	VBN
cord-015922-5wwy0m2k	183	12	disease	disease	NN
cord-015922-5wwy0m2k	183	13	as	as	RB
cord-015922-5wwy0m2k	183	14	well	well	RB
cord-015922-5wwy0m2k	183	15	as	as	IN
cord-015922-5wwy0m2k	183	16	neurologic	neurologic	JJ
cord-015922-5wwy0m2k	183	17	complications	complication	NNS
cord-015922-5wwy0m2k	183	18	such	such	JJ
cord-015922-5wwy0m2k	183	19	as	as	IN
cord-015922-5wwy0m2k	183	20	myelitis	myelitis	NNP
cord-015922-5wwy0m2k	183	21	or	or	CC
cord-015922-5wwy0m2k	183	22	encephalitis	encephalitis	JJ
cord-015922-5wwy0m2k	183	23	[	[	-LRB-
cord-015922-5wwy0m2k	183	24	1	1	CD
cord-015922-5wwy0m2k	183	25	,	,	,
cord-015922-5wwy0m2k	183	26	[	[	-LRB-
cord-015922-5wwy0m2k	183	27	45	45	CD
cord-015922-5wwy0m2k	183	28	]	]	-RRB-
cord-015922-5wwy0m2k	183	29	[	[	-LRB-
cord-015922-5wwy0m2k	183	30	46	46	CD
cord-015922-5wwy0m2k	183	31	]	]	-RRB-
cord-015922-5wwy0m2k	183	32	[	[	-LRB-
cord-015922-5wwy0m2k	183	33	47	47	CD
cord-015922-5wwy0m2k	183	34	]	]	-RRB-
cord-015922-5wwy0m2k	183	35	[	[	-LRB-
cord-015922-5wwy0m2k	183	36	48	48	CD
cord-015922-5wwy0m2k	183	37	]	]	-RRB-
cord-015922-5wwy0m2k	183	38	.	.	.
cord-015922-5wwy0m2k	184	1	Prophylaxis	Prophylaxis	NNP
cord-015922-5wwy0m2k	184	2	with	with	IN
cord-015922-5wwy0m2k	184	3	acyclovir	acyclovir	NNP
cord-015922-5wwy0m2k	184	4	in	in	IN
cord-015922-5wwy0m2k	184	5	the	the	DT
cord-015922-5wwy0m2k	184	6	early	early	JJ
cord-015922-5wwy0m2k	184	7	period	period	NN
cord-015922-5wwy0m2k	184	8	post	post	NN
cord-015922-5wwy0m2k	184	9	-	-	NN
cord-015922-5wwy0m2k	184	10	transplantation	transplantation	NN
cord-015922-5wwy0m2k	184	11	substantially	substantially	RB
cord-015922-5wwy0m2k	184	12	decreases	decrease	VBZ
cord-015922-5wwy0m2k	184	13	the	the	DT
cord-015922-5wwy0m2k	184	14	occurrence	occurrence	NN
cord-015922-5wwy0m2k	184	15	of	of	IN
cord-015922-5wwy0m2k	184	16	herpesvirus	herpesvirus	NN
cord-015922-5wwy0m2k	184	17	infections	infection	NNS
cord-015922-5wwy0m2k	184	18	,	,	,
cord-015922-5wwy0m2k	184	19	including	include	VBG
cord-015922-5wwy0m2k	184	20	VZV	VZV	NNP
cord-015922-5wwy0m2k	184	21	,	,	,
cord-015922-5wwy0m2k	184	22	and	and	CC
cord-015922-5wwy0m2k	184	23	is	be	VBZ
cord-015922-5wwy0m2k	184	24	rarely	rarely	RB
cord-015922-5wwy0m2k	184	25	,	,	,
cord-015922-5wwy0m2k	184	26	if	if	IN
cord-015922-5wwy0m2k	184	27	ever	ever	RB
cord-015922-5wwy0m2k	184	28	,	,	,
cord-015922-5wwy0m2k	184	29	seen	see	VBN
cord-015922-5wwy0m2k	184	30	during	during	IN
cord-015922-5wwy0m2k	184	31	acyclovir	acyclovir	NNP
cord-015922-5wwy0m2k	184	32	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	184	33	.	.	.
cord-015922-5wwy0m2k	185	1	Prophylaxis	Prophylaxis	NNP
cord-015922-5wwy0m2k	185	2	is	be	VBZ
cord-015922-5wwy0m2k	185	3	typically	typically	RB
cord-015922-5wwy0m2k	185	4	given	give	VBN
cord-015922-5wwy0m2k	185	5	for	for	IN
cord-015922-5wwy0m2k	185	6	the	the	DT
cord-015922-5wwy0m2k	185	7	first	first	JJ
cord-015922-5wwy0m2k	185	8	year	year	NN
cord-015922-5wwy0m2k	185	9	post	post	NN
cord-015922-5wwy0m2k	185	10	-	-	JJ
cord-015922-5wwy0m2k	185	11	allogeniec	allogeniec	JJ
cord-015922-5wwy0m2k	185	12	transplantation	transplantation	NN
cord-015922-5wwy0m2k	185	13	.	.	.
cord-015922-5wwy0m2k	186	1	VZV	VZV	NNP
cord-015922-5wwy0m2k	186	2	reactivation	reactivation	NN
cord-015922-5wwy0m2k	186	3	is	be	VBZ
cord-015922-5wwy0m2k	186	4	often	often	RB
cord-015922-5wwy0m2k	186	5	seen	see	VBN
cord-015922-5wwy0m2k	186	6	three	three	CD
cord-015922-5wwy0m2k	186	7	months	month	NNS
cord-015922-5wwy0m2k	186	8	post	post	JJ
cord-015922-5wwy0m2k	186	9	-	-	JJ
cord-015922-5wwy0m2k	186	10	discontinuation	discontinuation	NN
cord-015922-5wwy0m2k	186	11	of	of	IN
cord-015922-5wwy0m2k	186	12	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	186	13	.	.	.
cord-015922-5wwy0m2k	187	1	As	as	IN
cord-015922-5wwy0m2k	187	2	the	the	DT
cord-015922-5wwy0m2k	187	3	VZV	VZV	NNP
cord-015922-5wwy0m2k	187	4	vaccine	vaccine	NN
cord-015922-5wwy0m2k	187	5	is	be	VBZ
cord-015922-5wwy0m2k	187	6	a	a	DT
cord-015922-5wwy0m2k	187	7	live	live	JJ
cord-015922-5wwy0m2k	187	8	attenuated	attenuate	VBN
cord-015922-5wwy0m2k	187	9	viral	viral	JJ
cord-015922-5wwy0m2k	187	10	vaccine	vaccine	NN
cord-015922-5wwy0m2k	187	11	,	,	,
cord-015922-5wwy0m2k	187	12	its	-PRON-	PRP$
cord-015922-5wwy0m2k	187	13	use	use	NN
cord-015922-5wwy0m2k	187	14	is	be	VBZ
cord-015922-5wwy0m2k	187	15	contraindicated	contraindicate	VBN
cord-015922-5wwy0m2k	187	16	for	for	IN
cord-015922-5wwy0m2k	187	17	at	at	RB
cord-015922-5wwy0m2k	187	18	least	least	RBS
cord-015922-5wwy0m2k	187	19	two	two	CD
cord-015922-5wwy0m2k	187	20	years	year	NNS
cord-015922-5wwy0m2k	187	21	posttransplantation	posttransplantation	NN
cord-015922-5wwy0m2k	187	22	,	,	,
cord-015922-5wwy0m2k	187	23	and	and	CC
cord-015922-5wwy0m2k	187	24	unless	unless	IN
cord-015922-5wwy0m2k	187	25	a	a	DT
cord-015922-5wwy0m2k	187	26	research	research	NN
cord-015922-5wwy0m2k	187	27	study	study	NN
cord-015922-5wwy0m2k	187	28	or	or	CC
cord-015922-5wwy0m2k	187	29	close	close	JJ
cord-015922-5wwy0m2k	187	30	follow	follow	NN
cord-015922-5wwy0m2k	187	31	-	-	HYPH
cord-015922-5wwy0m2k	187	32	up	up	NN
cord-015922-5wwy0m2k	187	33	is	be	VBZ
cord-015922-5wwy0m2k	187	34	involved	involve	VBN
cord-015922-5wwy0m2k	187	35	,	,	,
cord-015922-5wwy0m2k	187	36	should	should	MD
cord-015922-5wwy0m2k	187	37	be	be	VB
cord-015922-5wwy0m2k	187	38	omitted	omit	VBN
cord-015922-5wwy0m2k	187	39	.	.	.
cord-015922-5wwy0m2k	188	1	HHV-6	HHV-6	NNP
cord-015922-5wwy0m2k	188	2	is	be	VBZ
cord-015922-5wwy0m2k	188	3	a	a	DT
cord-015922-5wwy0m2k	188	4	β	β	NN
cord-015922-5wwy0m2k	188	5	-	-	HYPH
cord-015922-5wwy0m2k	188	6	herpesvirus	herpesvirus	NN
cord-015922-5wwy0m2k	188	7	(	(	-LRB-
cord-015922-5wwy0m2k	188	8	as	as	IN
cord-015922-5wwy0m2k	188	9	is	be	VBZ
cord-015922-5wwy0m2k	188	10	CMV	CMV	NNP
cord-015922-5wwy0m2k	188	11	)	)	-RRB-
cord-015922-5wwy0m2k	188	12	whose	whose	WP$
cord-015922-5wwy0m2k	188	13	role	role	NN
cord-015922-5wwy0m2k	188	14	in	in	IN
cord-015922-5wwy0m2k	188	15	post	post	JJ
cord-015922-5wwy0m2k	188	16	-	-	JJ
cord-015922-5wwy0m2k	188	17	transplant	transplant	JJ
cord-015922-5wwy0m2k	188	18	complications	complication	NNS
cord-015922-5wwy0m2k	188	19	is	be	VBZ
cord-015922-5wwy0m2k	188	20	being	be	VBG
cord-015922-5wwy0m2k	188	21	defined	define	VBN
cord-015922-5wwy0m2k	188	22	.	.	.
cord-015922-5wwy0m2k	189	1	In	in	IN
cord-015922-5wwy0m2k	189	2	the	the	DT
cord-015922-5wwy0m2k	189	3	great	great	JJ
cord-015922-5wwy0m2k	189	4	majority	majority	NN
cord-015922-5wwy0m2k	189	5	of	of	IN
cord-015922-5wwy0m2k	189	6	instances	instance	NNS
cord-015922-5wwy0m2k	189	7	,	,	,
cord-015922-5wwy0m2k	189	8	HHV-6	HHV-6	NNP
cord-015922-5wwy0m2k	189	9	primary	primary	JJ
cord-015922-5wwy0m2k	189	10	infection	infection	NN
cord-015922-5wwy0m2k	189	11	occurs	occur	VBZ
cord-015922-5wwy0m2k	189	12	by	by	IN
cord-015922-5wwy0m2k	189	13	the	the	DT
cord-015922-5wwy0m2k	189	14	third	third	JJ
cord-015922-5wwy0m2k	189	15	year	year	NN
cord-015922-5wwy0m2k	189	16	of	of	IN
cord-015922-5wwy0m2k	189	17	life	life	NN
cord-015922-5wwy0m2k	189	18	,	,	,
cord-015922-5wwy0m2k	189	19	with	with	IN
cord-015922-5wwy0m2k	189	20	a	a	DT
cord-015922-5wwy0m2k	189	21	seroprevalence	seroprevalence	NN
cord-015922-5wwy0m2k	189	22	rate	rate	NN
cord-015922-5wwy0m2k	189	23	of	of	IN
cord-015922-5wwy0m2k	189	24	90	90	CD
cord-015922-5wwy0m2k	189	25	percent	percent	NN
cord-015922-5wwy0m2k	189	26	at	at	IN
cord-015922-5wwy0m2k	189	27	one	one	CD
cord-015922-5wwy0m2k	189	28	year	year	NN
cord-015922-5wwy0m2k	189	29	,	,	,
cord-015922-5wwy0m2k	189	30	and	and	CC
cord-015922-5wwy0m2k	189	31	close	close	RB
cord-015922-5wwy0m2k	189	32	to	to	TO
cord-015922-5wwy0m2k	189	33	100	100	CD
cord-015922-5wwy0m2k	189	34	percent	percent	NN
cord-015922-5wwy0m2k	189	35	at	at	IN
cord-015922-5wwy0m2k	189	36	three	three	CD
cord-015922-5wwy0m2k	189	37	years	year	NNS
cord-015922-5wwy0m2k	189	38	[	[	-LRB-
cord-015922-5wwy0m2k	189	39	49	49	CD
cord-015922-5wwy0m2k	189	40	,	,	,
cord-015922-5wwy0m2k	189	41	50	50	CD
cord-015922-5wwy0m2k	189	42	]	]	-RRB-
cord-015922-5wwy0m2k	189	43	.	.	.
cord-015922-5wwy0m2k	190	1	The	the	DT
cord-015922-5wwy0m2k	190	2	clinical	clinical	JJ
cord-015922-5wwy0m2k	190	3	effects	effect	NNS
cord-015922-5wwy0m2k	190	4	associated	associate	VBN
cord-015922-5wwy0m2k	190	5	with	with	IN
cord-015922-5wwy0m2k	190	6	primary	primary	JJ
cord-015922-5wwy0m2k	190	7	HHV-6	HHV-6	NNP
cord-015922-5wwy0m2k	190	8	infection	infection	NN
cord-015922-5wwy0m2k	190	9	include	include	VBP
cord-015922-5wwy0m2k	190	10	exanthem	exanthem	NNP
cord-015922-5wwy0m2k	190	11	subitum	subitum	NNP
cord-015922-5wwy0m2k	190	12	(	(	-LRB-
cord-015922-5wwy0m2k	190	13	roseola	roseola	NNP
cord-015922-5wwy0m2k	190	14	)	)	-RRB-
cord-015922-5wwy0m2k	190	15	,	,	,
cord-015922-5wwy0m2k	190	16	and	and	CC
cord-015922-5wwy0m2k	190	17	a	a	DT
cord-015922-5wwy0m2k	190	18	form	form	NN
cord-015922-5wwy0m2k	190	19	of	of	IN
cord-015922-5wwy0m2k	190	20	encephalitis	encephalitis	NN
cord-015922-5wwy0m2k	190	21	.	.	.
cord-015922-5wwy0m2k	191	1	In	in	IN
cord-015922-5wwy0m2k	191	2	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	191	3	patients	patient	NNS
cord-015922-5wwy0m2k	191	4	,	,	,
cord-015922-5wwy0m2k	191	5	bone	bone	NN
cord-015922-5wwy0m2k	191	6	marrow	marrow	NN
cord-015922-5wwy0m2k	191	7	suppression	suppression	NN
cord-015922-5wwy0m2k	191	8	,	,	,
cord-015922-5wwy0m2k	191	9	especially	especially	RB
cord-015922-5wwy0m2k	191	10	delayed	delay	VBN
cord-015922-5wwy0m2k	191	11	platelet	platelet	NN
cord-015922-5wwy0m2k	191	12	engraftment	engraftment	NN
cord-015922-5wwy0m2k	191	13	,	,	,
cord-015922-5wwy0m2k	191	14	and	and	CC
cord-015922-5wwy0m2k	191	15	encephalitis	encephalitis	RB
cord-015922-5wwy0m2k	191	16	have	have	VBP
cord-015922-5wwy0m2k	191	17	been	be	VBN
cord-015922-5wwy0m2k	191	18	associated	associate	VBN
cord-015922-5wwy0m2k	191	19	with	with	IN
cord-015922-5wwy0m2k	191	20	HHV-6	HHV-6	NNP
cord-015922-5wwy0m2k	191	21	type	type	NN
cord-015922-5wwy0m2k	192	1	B.	B.	NNP
cord-015922-5wwy0m2k	193	1	The	the	DT
cord-015922-5wwy0m2k	193	2	encephalitis	encephalitis	RB
cord-015922-5wwy0m2k	193	3	typically	typically	RB
cord-015922-5wwy0m2k	193	4	occurs	occur	VBZ
cord-015922-5wwy0m2k	193	5	one	one	CD
cord-015922-5wwy0m2k	193	6	to	to	TO
cord-015922-5wwy0m2k	193	7	two	two	CD
cord-015922-5wwy0m2k	193	8	months	month	NNS
cord-015922-5wwy0m2k	193	9	after	after	IN
cord-015922-5wwy0m2k	193	10	transplantation	transplantation	NN
cord-015922-5wwy0m2k	193	11	and	and	CC
cord-015922-5wwy0m2k	193	12	is	be	VBZ
cord-015922-5wwy0m2k	193	13	associated	associate	VBN
cord-015922-5wwy0m2k	193	14	with	with	IN
cord-015922-5wwy0m2k	193	15	profound	profound	JJ
cord-015922-5wwy0m2k	193	16	memory	memory	NN
cord-015922-5wwy0m2k	193	17	loss	loss	NN
cord-015922-5wwy0m2k	193	18	,	,	,
cord-015922-5wwy0m2k	193	19	especially	especially	RB
cord-015922-5wwy0m2k	193	20	short	short	JJ
cord-015922-5wwy0m2k	193	21	-	-	HYPH
cord-015922-5wwy0m2k	193	22	term	term	NN
cord-015922-5wwy0m2k	193	23	memory	memory	NN
cord-015922-5wwy0m2k	193	24	,	,	,
cord-015922-5wwy0m2k	193	25	and	and	CC
cord-015922-5wwy0m2k	193	26	MRI	MRI	NNP
cord-015922-5wwy0m2k	193	27	changes	change	NNS
cord-015922-5wwy0m2k	193	28	in	in	IN
cord-015922-5wwy0m2k	193	29	the	the	DT
cord-015922-5wwy0m2k	193	30	mesial	mesial	JJ
cord-015922-5wwy0m2k	193	31	temporal	temporal	JJ
cord-015922-5wwy0m2k	193	32	lobes	lobe	NNS
cord-015922-5wwy0m2k	193	33	(	(	-LRB-
cord-015922-5wwy0m2k	193	34	limbic	limbic	JJ
cord-015922-5wwy0m2k	193	35	encephalitis	encephalitis	RB
cord-015922-5wwy0m2k	193	36	)	)	-RRB-
cord-015922-5wwy0m2k	193	37	[	[	-LRB-
cord-015922-5wwy0m2k	193	38	51	51	CD
cord-015922-5wwy0m2k	193	39	,	,	,
cord-015922-5wwy0m2k	193	40	52	52	CD
cord-015922-5wwy0m2k	193	41	]	]	-RRB-
cord-015922-5wwy0m2k	193	42	.	.	.
cord-015922-5wwy0m2k	194	1	The	the	DT
cord-015922-5wwy0m2k	194	2	highest	high	JJS
cord-015922-5wwy0m2k	194	3	risk	risk	NN
cord-015922-5wwy0m2k	194	4	patients	patient	NNS
cord-015922-5wwy0m2k	194	5	for	for	IN
cord-015922-5wwy0m2k	194	6	this	this	DT
cord-015922-5wwy0m2k	194	7	complication	complication	NN
cord-015922-5wwy0m2k	194	8	are	be	VBP
cord-015922-5wwy0m2k	194	9	male	male	JJ
cord-015922-5wwy0m2k	194	10	,	,	,
cord-015922-5wwy0m2k	194	11	umbilical	umbilical	JJ
cord-015922-5wwy0m2k	194	12	cord	cord	NN
cord-015922-5wwy0m2k	194	13	blood	blood	NN
cord-015922-5wwy0m2k	194	14	recipients	recipient	NNS
cord-015922-5wwy0m2k	194	15	for	for	IN
cord-015922-5wwy0m2k	194	16	whom	whom	WP
cord-015922-5wwy0m2k	194	17	the	the	DT
cord-015922-5wwy0m2k	194	18	attack	attack	NN
cord-015922-5wwy0m2k	194	19	rate	rate	NN
cord-015922-5wwy0m2k	194	20	may	may	MD
cord-015922-5wwy0m2k	194	21	be	be	VB
cord-015922-5wwy0m2k	194	22	as	as	RB
cord-015922-5wwy0m2k	194	23	high	high	JJ
cord-015922-5wwy0m2k	194	24	as	as	IN
cord-015922-5wwy0m2k	194	25	10	10	CD
cord-015922-5wwy0m2k	194	26	to	to	TO
cord-015922-5wwy0m2k	194	27	20	20	CD
cord-015922-5wwy0m2k	194	28	percent	percent	NN
cord-015922-5wwy0m2k	194	29	.	.	.
cord-015922-5wwy0m2k	195	1	Detecting	detect	VBG
cord-015922-5wwy0m2k	195	2	HHV-6	HHV-6	NNP
cord-015922-5wwy0m2k	195	3	DNA	dna	NN
cord-015922-5wwy0m2k	195	4	in	in	IN
cord-015922-5wwy0m2k	195	5	the	the	DT
cord-015922-5wwy0m2k	195	6	blood	blood	NN
cord-015922-5wwy0m2k	195	7	of	of	IN
cord-015922-5wwy0m2k	195	8	allogeneic	allogeneic	VBG
cord-015922-5wwy0m2k	195	9	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	195	10	recipients	recipient	NNS
cord-015922-5wwy0m2k	195	11	is	be	VBZ
cord-015922-5wwy0m2k	195	12	a	a	DT
cord-015922-5wwy0m2k	195	13	common	common	JJ
cord-015922-5wwy0m2k	195	14	phenomenon	phenomenon	NN
cord-015922-5wwy0m2k	195	15	occurring	occur	VBG
cord-015922-5wwy0m2k	195	16	transiently	transiently	RB
cord-015922-5wwy0m2k	195	17	in	in	IN
cord-015922-5wwy0m2k	195	18	40	40	CD
cord-015922-5wwy0m2k	195	19	to	to	TO
cord-015922-5wwy0m2k	195	20	60	60	CD
cord-015922-5wwy0m2k	195	21	percent	percent	NN
cord-015922-5wwy0m2k	195	22	of	of	IN
cord-015922-5wwy0m2k	195	23	patients	patient	NNS
cord-015922-5wwy0m2k	195	24	,	,	,
cord-015922-5wwy0m2k	195	25	yet	yet	CC
cord-015922-5wwy0m2k	195	26	encephalitis	encephalitis	JJ
cord-015922-5wwy0m2k	195	27	is	be	VBZ
cord-015922-5wwy0m2k	195	28	a	a	DT
cord-015922-5wwy0m2k	195	29	rather	rather	RB
cord-015922-5wwy0m2k	195	30	infrequent	infrequent	JJ
cord-015922-5wwy0m2k	195	31	occurrence	occurrence	NN
cord-015922-5wwy0m2k	195	32	(	(	-LRB-
cord-015922-5wwy0m2k	195	33	1	1	CD
cord-015922-5wwy0m2k	195	34	-	-	SYM
cord-015922-5wwy0m2k	195	35	2	2	CD
cord-015922-5wwy0m2k	195	36	%	%	NN
cord-015922-5wwy0m2k	195	37	)	)	-RRB-
cord-015922-5wwy0m2k	195	38	.	.	.
cord-015922-5wwy0m2k	196	1	As	as	IN
cord-015922-5wwy0m2k	196	2	obtaining	obtain	VBG
cord-015922-5wwy0m2k	196	3	brain	brain	NN
cord-015922-5wwy0m2k	196	4	biopsies	biopsy	NNS
cord-015922-5wwy0m2k	196	5	is	be	VBZ
cord-015922-5wwy0m2k	196	6	not	not	RB
cord-015922-5wwy0m2k	196	7	usually	usually	RB
cord-015922-5wwy0m2k	196	8	feasible	feasible	JJ
cord-015922-5wwy0m2k	196	9	early	early	RB
cord-015922-5wwy0m2k	196	10	after	after	IN
cord-015922-5wwy0m2k	196	11	transplantation	transplantation	NN
cord-015922-5wwy0m2k	196	12	,	,	,
cord-015922-5wwy0m2k	196	13	the	the	DT
cord-015922-5wwy0m2k	196	14	diagnosis	diagnosis	NN
cord-015922-5wwy0m2k	196	15	of	of	IN
cord-015922-5wwy0m2k	196	16	HHV-6	HHV-6	NNP
cord-015922-5wwy0m2k	196	17	encephalitis	encephalitis	RB
cord-015922-5wwy0m2k	196	18	is	be	VBZ
cord-015922-5wwy0m2k	196	19	currently	currently	RB
cord-015922-5wwy0m2k	196	20	achieved	achieve	VBN
cord-015922-5wwy0m2k	196	21	by	by	IN
cord-015922-5wwy0m2k	196	22	developing	develop	VBG
cord-015922-5wwy0m2k	196	23	an	an	DT
cord-015922-5wwy0m2k	196	24	acute	acute	JJ
cord-015922-5wwy0m2k	196	25	limbic	limbic	NNP
cord-015922-5wwy0m2k	196	26	encephalitis	encephalitis	NNP
cord-015922-5wwy0m2k	196	27	syndrome	syndrome	NN
cord-015922-5wwy0m2k	196	28	,	,	,
cord-015922-5wwy0m2k	196	29	confirmed	confirm	VBD
cord-015922-5wwy0m2k	196	30	with	with	IN
cord-015922-5wwy0m2k	196	31	MRI	MRI	NNP
cord-015922-5wwy0m2k	196	32	imaging	imaging	NN
cord-015922-5wwy0m2k	196	33	of	of	IN
cord-015922-5wwy0m2k	196	34	the	the	DT
cord-015922-5wwy0m2k	196	35	brain	brain	NN
cord-015922-5wwy0m2k	196	36	and	and	CC
cord-015922-5wwy0m2k	196	37	by	by	IN
cord-015922-5wwy0m2k	196	38	the	the	DT
cord-015922-5wwy0m2k	196	39	detection	detection	NN
cord-015922-5wwy0m2k	196	40	of	of	IN
cord-015922-5wwy0m2k	196	41	HHV-6	HHV-6	NNP
cord-015922-5wwy0m2k	196	42	in	in	IN
cord-015922-5wwy0m2k	196	43	the	the	DT
cord-015922-5wwy0m2k	196	44	CSF	CSF	NNP
cord-015922-5wwy0m2k	196	45	[	[	-LRB-
cord-015922-5wwy0m2k	196	46	52	52	CD
cord-015922-5wwy0m2k	196	47	]	]	-RRB-
cord-015922-5wwy0m2k	196	48	.	.	.
cord-015922-5wwy0m2k	197	1	It	-PRON-	PRP
cord-015922-5wwy0m2k	197	2	remains	remain	VBZ
cord-015922-5wwy0m2k	197	3	unclear	unclear	JJ
cord-015922-5wwy0m2k	197	4	what	what	WP
cord-015922-5wwy0m2k	197	5	the	the	DT
cord-015922-5wwy0m2k	197	6	treatment	treatment	NN
cord-015922-5wwy0m2k	197	7	of	of	IN
cord-015922-5wwy0m2k	197	8	choice	choice	NN
cord-015922-5wwy0m2k	197	9	for	for	IN
cord-015922-5wwy0m2k	197	10	this	this	DT
cord-015922-5wwy0m2k	197	11	virus	virus	NN
cord-015922-5wwy0m2k	197	12	is	be	VBZ
cord-015922-5wwy0m2k	197	13	.	.	.
cord-015922-5wwy0m2k	198	1	One	one	CD
cord-015922-5wwy0m2k	198	2	approach	approach	NN
cord-015922-5wwy0m2k	198	3	that	that	IN
cord-015922-5wwy0m2k	198	4	we	-PRON-	PRP
cord-015922-5wwy0m2k	198	5	currently	currently	RB
cord-015922-5wwy0m2k	198	6	favor	favor	VBP
cord-015922-5wwy0m2k	198	7	is	be	VBZ
cord-015922-5wwy0m2k	198	8	to	to	TO
cord-015922-5wwy0m2k	198	9	use	use	VB
cord-015922-5wwy0m2k	198	10	foscarnet	foscarnet	NN
cord-015922-5wwy0m2k	198	11	.	.	.
cord-015922-5wwy0m2k	199	1	It	-PRON-	PRP
cord-015922-5wwy0m2k	199	2	is	be	VBZ
cord-015922-5wwy0m2k	199	3	possible	possible	JJ
cord-015922-5wwy0m2k	199	4	that	that	IN
cord-015922-5wwy0m2k	199	5	anti	anti	JJ
cord-015922-5wwy0m2k	199	6	-	-	JJ
cord-015922-5wwy0m2k	199	7	CMV	cmv	JJ
cord-015922-5wwy0m2k	199	8	preventative	preventative	JJ
cord-015922-5wwy0m2k	199	9	strategies	strategy	NNS
cord-015922-5wwy0m2k	199	10	with	with	IN
cord-015922-5wwy0m2k	199	11	ganciclovir	ganciclovir	NNS
cord-015922-5wwy0m2k	199	12	may	may	MD
cord-015922-5wwy0m2k	199	13	have	have	VB
cord-015922-5wwy0m2k	199	14	a	a	DT
cord-015922-5wwy0m2k	199	15	beneficial	beneficial	JJ
cord-015922-5wwy0m2k	199	16	effect	effect	NN
cord-015922-5wwy0m2k	199	17	on	on	IN
cord-015922-5wwy0m2k	199	18	this	this	DT
cord-015922-5wwy0m2k	199	19	virus	virus	NN
cord-015922-5wwy0m2k	199	20	as	as	RB
cord-015922-5wwy0m2k	199	21	well	well	RB
cord-015922-5wwy0m2k	199	22	[	[	-LRB-
cord-015922-5wwy0m2k	199	23	1	1	CD
cord-015922-5wwy0m2k	199	24	,	,	,
cord-015922-5wwy0m2k	199	25	53	53	CD
cord-015922-5wwy0m2k	199	26	]	]	-RRB-
cord-015922-5wwy0m2k	199	27	.	.	.
cord-015922-5wwy0m2k	200	1	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	200	2	recipients	recipient	NNS
cord-015922-5wwy0m2k	200	3	are	be	VBP
cord-015922-5wwy0m2k	200	4	at	at	IN
cord-015922-5wwy0m2k	200	5	significant	significant	JJ
cord-015922-5wwy0m2k	200	6	risk	risk	NN
cord-015922-5wwy0m2k	200	7	for	for	IN
cord-015922-5wwy0m2k	200	8	infection	infection	NN
cord-015922-5wwy0m2k	200	9	with	with	IN
cord-015922-5wwy0m2k	200	10	respiratory	respiratory	JJ
cord-015922-5wwy0m2k	200	11	viruses	virus	NNS
cord-015922-5wwy0m2k	200	12	circulating	circulate	VBG
cord-015922-5wwy0m2k	200	13	in	in	IN
cord-015922-5wwy0m2k	200	14	the	the	DT
cord-015922-5wwy0m2k	200	15	community	community	NN
cord-015922-5wwy0m2k	200	16	.	.	.
cord-015922-5wwy0m2k	201	1	These	these	DT
cord-015922-5wwy0m2k	201	2	infections	infection	NNS
cord-015922-5wwy0m2k	201	3	can	can	MD
cord-015922-5wwy0m2k	201	4	occur	occur	VB
cord-015922-5wwy0m2k	201	5	at	at	IN
cord-015922-5wwy0m2k	201	6	any	any	DT
cord-015922-5wwy0m2k	201	7	time	time	NN
cord-015922-5wwy0m2k	201	8	in	in	IN
cord-015922-5wwy0m2k	201	9	the	the	DT
cord-015922-5wwy0m2k	201	10	post	post	JJ
cord-015922-5wwy0m2k	201	11	-	-	JJ
cord-015922-5wwy0m2k	201	12	transplant	transplant	JJ
cord-015922-5wwy0m2k	201	13	course	course	NN
cord-015922-5wwy0m2k	201	14	,	,	,
cord-015922-5wwy0m2k	201	15	and	and	CC
cord-015922-5wwy0m2k	201	16	can	can	MD
cord-015922-5wwy0m2k	201	17	be	be	VB
cord-015922-5wwy0m2k	201	18	acquired	acquire	VBN
cord-015922-5wwy0m2k	201	19	in	in	IN
cord-015922-5wwy0m2k	201	20	the	the	DT
cord-015922-5wwy0m2k	201	21	community	community	NN
cord-015922-5wwy0m2k	201	22	or	or	CC
cord-015922-5wwy0m2k	201	23	during	during	IN
cord-015922-5wwy0m2k	201	24	hospitalization	hospitalization	NN
cord-015922-5wwy0m2k	201	25	from	from	IN
cord-015922-5wwy0m2k	201	26	infected	infected	JJ
cord-015922-5wwy0m2k	201	27	staff	staff	NN
cord-015922-5wwy0m2k	201	28	,	,	,
cord-015922-5wwy0m2k	201	29	family	family	NN
cord-015922-5wwy0m2k	201	30	and	and	CC
cord-015922-5wwy0m2k	201	31	friends	friend	NNS
cord-015922-5wwy0m2k	201	32	.	.	.
cord-015922-5wwy0m2k	202	1	Overall	overall	RB
cord-015922-5wwy0m2k	202	2	,	,	,
cord-015922-5wwy0m2k	202	3	an	an	DT
cord-015922-5wwy0m2k	202	4	estimated	estimate	VBN
cord-015922-5wwy0m2k	202	5	10	10	CD
cord-015922-5wwy0m2k	202	6	to	to	TO
cord-015922-5wwy0m2k	202	7	20	20	CD
cord-015922-5wwy0m2k	202	8	percent	percent	NN
cord-015922-5wwy0m2k	202	9	of	of	IN
cord-015922-5wwy0m2k	202	10	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	202	11	patients	patient	NNS
cord-015922-5wwy0m2k	202	12	will	will	MD
cord-015922-5wwy0m2k	202	13	become	become	VB
cord-015922-5wwy0m2k	202	14	infected	infect	VBN
cord-015922-5wwy0m2k	202	15	in	in	IN
cord-015922-5wwy0m2k	202	16	the	the	DT
cord-015922-5wwy0m2k	202	17	first	first	JJ
cord-015922-5wwy0m2k	202	18	year	year	NN
cord-015922-5wwy0m2k	202	19	posttransplant	posttransplant	NN
cord-015922-5wwy0m2k	202	20	,	,	,
cord-015922-5wwy0m2k	202	21	with	with	IN
cord-015922-5wwy0m2k	202	22	the	the	DT
cord-015922-5wwy0m2k	202	23	potential	potential	NN
cord-015922-5wwy0m2k	202	24	for	for	IN
cord-015922-5wwy0m2k	202	25	this	this	DT
cord-015922-5wwy0m2k	202	26	figure	figure	NN
cord-015922-5wwy0m2k	202	27	to	to	TO
cord-015922-5wwy0m2k	202	28	rise	rise	VB
cord-015922-5wwy0m2k	202	29	significantly	significantly	RB
cord-015922-5wwy0m2k	202	30	in	in	IN
cord-015922-5wwy0m2k	202	31	the	the	DT
cord-015922-5wwy0m2k	202	32	setting	setting	NN
cord-015922-5wwy0m2k	202	33	of	of	IN
cord-015922-5wwy0m2k	202	34	a	a	DT
cord-015922-5wwy0m2k	202	35	community	community	NN
cord-015922-5wwy0m2k	202	36	-	-	HYPH
cord-015922-5wwy0m2k	202	37	wide	wide	JJ
cord-015922-5wwy0m2k	202	38	outbreak	outbreak	NN
cord-015922-5wwy0m2k	202	39	[	[	-LRB-
cord-015922-5wwy0m2k	202	40	54	54	CD
cord-015922-5wwy0m2k	202	41	]	]	-RRB-
cord-015922-5wwy0m2k	202	42	.	.	.
cord-015922-5wwy0m2k	203	1	The	the	DT
cord-015922-5wwy0m2k	203	2	dilemma	dilemma	NN
cord-015922-5wwy0m2k	203	3	for	for	IN
cord-015922-5wwy0m2k	203	4	the	the	DT
cord-015922-5wwy0m2k	203	5	clinician	clinician	NN
cord-015922-5wwy0m2k	203	6	is	be	VBZ
cord-015922-5wwy0m2k	203	7	how	how	WRB
cord-015922-5wwy0m2k	203	8	to	to	TO
cord-015922-5wwy0m2k	203	9	prevent	prevent	VB
cord-015922-5wwy0m2k	203	10	these	these	DT
cord-015922-5wwy0m2k	203	11	infections	infection	NNS
cord-015922-5wwy0m2k	203	12	,	,	,
cord-015922-5wwy0m2k	203	13	as	as	IN
cord-015922-5wwy0m2k	203	14	there	there	EX
cord-015922-5wwy0m2k	203	15	is	be	VBZ
cord-015922-5wwy0m2k	203	16	a	a	DT
cord-015922-5wwy0m2k	203	17	far	far	RB
cord-015922-5wwy0m2k	203	18	higher	high	JJR
cord-015922-5wwy0m2k	203	19	rate	rate	NN
cord-015922-5wwy0m2k	203	20	of	of	IN
cord-015922-5wwy0m2k	203	21	progression	progression	NN
cord-015922-5wwy0m2k	203	22	to	to	IN
cord-015922-5wwy0m2k	203	23	pneumonia	pneumonia	NN
cord-015922-5wwy0m2k	203	24	(	(	-LRB-
cord-015922-5wwy0m2k	203	25	viral	viral	JJ
cord-015922-5wwy0m2k	203	26	and/or	and/or	CC
cord-015922-5wwy0m2k	203	27	bacterial	bacterial	JJ
cord-015922-5wwy0m2k	203	28	or	or	CC
cord-015922-5wwy0m2k	203	29	fungal	fungal	JJ
cord-015922-5wwy0m2k	203	30	superinfection	superinfection	NN
cord-015922-5wwy0m2k	203	31	)	)	-RRB-
cord-015922-5wwy0m2k	203	32	,	,	,
cord-015922-5wwy0m2k	203	33	which	which	WDT
cord-015922-5wwy0m2k	203	34	carries	carry	VBZ
cord-015922-5wwy0m2k	203	35	a	a	DT
cord-015922-5wwy0m2k	203	36	far	far	RB
cord-015922-5wwy0m2k	203	37	higher	high	JJR
cord-015922-5wwy0m2k	203	38	morbidity	morbidity	NN
cord-015922-5wwy0m2k	203	39	and	and	CC
cord-015922-5wwy0m2k	203	40	mortality	mortality	NN
cord-015922-5wwy0m2k	203	41	than	than	IN
cord-015922-5wwy0m2k	203	42	what	what	WP
cord-015922-5wwy0m2k	203	43	is	be	VBZ
cord-015922-5wwy0m2k	203	44	observed	observe	VBN
cord-015922-5wwy0m2k	203	45	in	in	IN
cord-015922-5wwy0m2k	203	46	the	the	DT
cord-015922-5wwy0m2k	203	47	general	general	JJ
cord-015922-5wwy0m2k	203	48	population	population	NN
cord-015922-5wwy0m2k	203	49	.	.	.
cord-015922-5wwy0m2k	204	1	In	in	IN
cord-015922-5wwy0m2k	204	2	addition	addition	NN
cord-015922-5wwy0m2k	204	3	,	,	,
cord-015922-5wwy0m2k	204	4	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	204	5	therapy	therapy	NN
cord-015922-5wwy0m2k	204	6	for	for	IN
cord-015922-5wwy0m2k	204	7	these	these	DT
cord-015922-5wwy0m2k	204	8	agents	agent	NNS
cord-015922-5wwy0m2k	204	9	is	be	VBZ
cord-015922-5wwy0m2k	204	10	in	in	IN
cord-015922-5wwy0m2k	204	11	its	-PRON-	PRP$
cord-015922-5wwy0m2k	204	12	infancy	infancy	NN
cord-015922-5wwy0m2k	204	13	.	.	.
cord-015922-5wwy0m2k	205	1	It	-PRON-	PRP
cord-015922-5wwy0m2k	205	2	is	be	VBZ
cord-015922-5wwy0m2k	205	3	important	important	JJ
cord-015922-5wwy0m2k	205	4	to	to	TO
cord-015922-5wwy0m2k	205	5	attempt	attempt	VB
cord-015922-5wwy0m2k	205	6	to	to	TO
cord-015922-5wwy0m2k	205	7	make	make	VB
cord-015922-5wwy0m2k	205	8	an	an	DT
cord-015922-5wwy0m2k	205	9	etiologic	etiologic	JJ
cord-015922-5wwy0m2k	205	10	diagnosis	diagnosis	NN
cord-015922-5wwy0m2k	205	11	.	.	.
cord-015922-5wwy0m2k	206	1	Avoiding	avoid	VBG
cord-015922-5wwy0m2k	206	2	exposure	exposure	NN
cord-015922-5wwy0m2k	206	3	to	to	IN
cord-015922-5wwy0m2k	206	4	infected	infected	JJ
cord-015922-5wwy0m2k	206	5	individuals	individual	NNS
cord-015922-5wwy0m2k	206	6	by	by	IN
cord-015922-5wwy0m2k	206	7	systematic	systematic	JJ
cord-015922-5wwy0m2k	206	8	infection	infection	NN
cord-015922-5wwy0m2k	206	9	control	control	NN
cord-015922-5wwy0m2k	206	10	measures	measure	NNS
cord-015922-5wwy0m2k	206	11	in	in	IN
cord-015922-5wwy0m2k	206	12	both	both	DT
cord-015922-5wwy0m2k	206	13	family	family	NN
cord-015922-5wwy0m2k	206	14	members	member	NNS
cord-015922-5wwy0m2k	206	15	and	and	CC
cord-015922-5wwy0m2k	206	16	friends	friend	NNS
cord-015922-5wwy0m2k	206	17	,	,	,
cord-015922-5wwy0m2k	206	18	but	but	CC
cord-015922-5wwy0m2k	206	19	most	most	RBS
cord-015922-5wwy0m2k	206	20	importantly	importantly	RB
cord-015922-5wwy0m2k	206	21	in	in	IN
cord-015922-5wwy0m2k	206	22	health	health	NN
cord-015922-5wwy0m2k	206	23	care	care	NN
cord-015922-5wwy0m2k	206	24	workers	worker	NNS
cord-015922-5wwy0m2k	206	25	,	,	,
cord-015922-5wwy0m2k	206	26	is	be	VBZ
cord-015922-5wwy0m2k	206	27	the	the	DT
cord-015922-5wwy0m2k	206	28	best	good	JJS
cord-015922-5wwy0m2k	206	29	preventative	preventative	JJ
cord-015922-5wwy0m2k	206	30	strategy	strategy	NN
cord-015922-5wwy0m2k	206	31	available	available	JJ
cord-015922-5wwy0m2k	206	32	[	[	-LRB-
cord-015922-5wwy0m2k	206	33	55	55	CD
cord-015922-5wwy0m2k	206	34	]	]	-RRB-
cord-015922-5wwy0m2k	206	35	[	[	-LRB-
cord-015922-5wwy0m2k	206	36	56	56	CD
cord-015922-5wwy0m2k	206	37	]	]	-RRB-
cord-015922-5wwy0m2k	206	38	[	[	-LRB-
cord-015922-5wwy0m2k	206	39	57	57	CD
cord-015922-5wwy0m2k	206	40	]	]	-RRB-
cord-015922-5wwy0m2k	206	41	[	[	-LRB-
cord-015922-5wwy0m2k	206	42	58	58	CD
cord-015922-5wwy0m2k	206	43	]	]	-RRB-
cord-015922-5wwy0m2k	206	44	.	.	.
cord-015922-5wwy0m2k	207	1	Although	although	IN
cord-015922-5wwy0m2k	207	2	RSV	RSV	NNP
cord-015922-5wwy0m2k	207	3	can	can	MD
cord-015922-5wwy0m2k	207	4	be	be	VB
cord-015922-5wwy0m2k	207	5	acquired	acquire	VBN
cord-015922-5wwy0m2k	207	6	by	by	IN
cord-015922-5wwy0m2k	207	7	inhaling	inhale	VBG
cord-015922-5wwy0m2k	207	8	an	an	DT
cord-015922-5wwy0m2k	207	9	aerosol	aerosol	NN
cord-015922-5wwy0m2k	207	10	,	,	,
cord-015922-5wwy0m2k	207	11	direct	direct	JJ
cord-015922-5wwy0m2k	207	12	contact	contact	NN
cord-015922-5wwy0m2k	207	13	with	with	IN
cord-015922-5wwy0m2k	207	14	infected	infected	JJ
cord-015922-5wwy0m2k	207	15	secretions	secretion	NNS
cord-015922-5wwy0m2k	207	16	is	be	VBZ
cord-015922-5wwy0m2k	207	17	the	the	DT
cord-015922-5wwy0m2k	207	18	usual	usual	JJ
cord-015922-5wwy0m2k	207	19	mode	mode	NN
cord-015922-5wwy0m2k	207	20	of	of	IN
cord-015922-5wwy0m2k	207	21	spread	spread	NN
cord-015922-5wwy0m2k	207	22	between	between	IN
cord-015922-5wwy0m2k	207	23	individuals	individual	NNS
cord-015922-5wwy0m2k	207	24	.	.	.
cord-015922-5wwy0m2k	208	1	In	in	IN
cord-015922-5wwy0m2k	208	2	the	the	DT
cord-015922-5wwy0m2k	208	3	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	208	4	patient	patient	NN
cord-015922-5wwy0m2k	208	5	,	,	,
cord-015922-5wwy0m2k	208	6	both	both	DT
cord-015922-5wwy0m2k	208	7	adult	adult	NN
cord-015922-5wwy0m2k	208	8	and	and	CC
cord-015922-5wwy0m2k	208	9	pediatric	pediatric	JJ
cord-015922-5wwy0m2k	208	10	,	,	,
cord-015922-5wwy0m2k	208	11	RSV	RSV	NNP
cord-015922-5wwy0m2k	208	12	is	be	VBZ
cord-015922-5wwy0m2k	208	13	a	a	DT
cord-015922-5wwy0m2k	208	14	cause	cause	NN
cord-015922-5wwy0m2k	208	15	of	of	IN
cord-015922-5wwy0m2k	208	16	significant	significant	JJ
cord-015922-5wwy0m2k	208	17	morbidity	morbidity	NN
cord-015922-5wwy0m2k	208	18	and	and	CC
cord-015922-5wwy0m2k	208	19	mortality	mortality	NN
cord-015922-5wwy0m2k	208	20	.	.	.
cord-015922-5wwy0m2k	209	1	The	the	DT
cord-015922-5wwy0m2k	209	2	illness	illness	NN
cord-015922-5wwy0m2k	209	3	begins	begin	VBZ
cord-015922-5wwy0m2k	209	4	with	with	IN
cord-015922-5wwy0m2k	209	5	the	the	DT
cord-015922-5wwy0m2k	209	6	signs	sign	NNS
cord-015922-5wwy0m2k	209	7	and	and	CC
cord-015922-5wwy0m2k	209	8	symptoms	symptom	NNS
cord-015922-5wwy0m2k	209	9	of	of	IN
cord-015922-5wwy0m2k	209	10	a	a	DT
cord-015922-5wwy0m2k	209	11	viral	viral	JJ
cord-015922-5wwy0m2k	209	12	upper	upper	JJ
cord-015922-5wwy0m2k	209	13	respiratory	respiratory	JJ
cord-015922-5wwy0m2k	209	14	tract	tract	NN
cord-015922-5wwy0m2k	209	15	infection	infection	NN
cord-015922-5wwy0m2k	209	16	(	(	-LRB-
cord-015922-5wwy0m2k	209	17	rhinorrhea	rhinorrhea	NNP
cord-015922-5wwy0m2k	209	18	,	,	,
cord-015922-5wwy0m2k	209	19	sinus	sinus	NN
cord-015922-5wwy0m2k	209	20	congestion	congestion	NN
cord-015922-5wwy0m2k	209	21	,	,	,
cord-015922-5wwy0m2k	209	22	sore	sore	JJ
cord-015922-5wwy0m2k	209	23	throat	throat	NN
cord-015922-5wwy0m2k	209	24	and/or	and/or	CC
cord-015922-5wwy0m2k	209	25	otitis	otitis	NN
cord-015922-5wwy0m2k	209	26	media	medium	NNS
cord-015922-5wwy0m2k	209	27	)	)	-RRB-
cord-015922-5wwy0m2k	209	28	,	,	,
cord-015922-5wwy0m2k	209	29	that	that	WDT
cord-015922-5wwy0m2k	209	30	may	may	MD
cord-015922-5wwy0m2k	209	31	progress	progress	VB
cord-015922-5wwy0m2k	209	32	to	to	IN
cord-015922-5wwy0m2k	209	33	pneumonia	pneumonia	NN
cord-015922-5wwy0m2k	209	34	,	,	,
cord-015922-5wwy0m2k	209	35	especially	especially	RB
cord-015922-5wwy0m2k	209	36	if	if	IN
cord-015922-5wwy0m2k	209	37	the	the	DT
cord-015922-5wwy0m2k	209	38	virus	virus	NN
cord-015922-5wwy0m2k	209	39	is	be	VBZ
cord-015922-5wwy0m2k	209	40	acquired	acquire	VBN
cord-015922-5wwy0m2k	209	41	in	in	IN
cord-015922-5wwy0m2k	209	42	the	the	DT
cord-015922-5wwy0m2k	209	43	preengraftment	preengraftment	NN
cord-015922-5wwy0m2k	209	44	phase	phase	NN
cord-015922-5wwy0m2k	209	45	.	.	.
cord-015922-5wwy0m2k	210	1	As	as	IN
cord-015922-5wwy0m2k	210	2	with	with	IN
cord-015922-5wwy0m2k	210	3	influenza	influenza	NN
cord-015922-5wwy0m2k	210	4	,	,	,
cord-015922-5wwy0m2k	210	5	pneumonic	pneumonic	JJ
cord-015922-5wwy0m2k	210	6	syndromes	syndrome	NNS
cord-015922-5wwy0m2k	210	7	can	can	MD
cord-015922-5wwy0m2k	210	8	be	be	VB
cord-015922-5wwy0m2k	210	9	due	due	JJ
cord-015922-5wwy0m2k	210	10	to	to	IN
cord-015922-5wwy0m2k	210	11	RSV	RSV	NNP
cord-015922-5wwy0m2k	210	12	itself	-PRON-	PRP
cord-015922-5wwy0m2k	210	13	,	,	,
cord-015922-5wwy0m2k	210	14	but	but	CC
cord-015922-5wwy0m2k	210	15	in	in	IN
cord-015922-5wwy0m2k	210	16	our	-PRON-	PRP$
cord-015922-5wwy0m2k	210	17	experience	experience	NN
cord-015922-5wwy0m2k	210	18	it	-PRON-	PRP
cord-015922-5wwy0m2k	210	19	is	be	VBZ
cord-015922-5wwy0m2k	210	20	more	more	RBR
cord-015922-5wwy0m2k	210	21	frequently	frequently	RB
cord-015922-5wwy0m2k	210	22	due	due	JJ
cord-015922-5wwy0m2k	210	23	to	to	IN
cord-015922-5wwy0m2k	210	24	secondary	secondary	JJ
cord-015922-5wwy0m2k	210	25	bacterial	bacterial	NN
cord-015922-5wwy0m2k	210	26	and	and	CC
cord-015922-5wwy0m2k	210	27	fungal	fungal	JJ
cord-015922-5wwy0m2k	210	28	infections	infection	NNS
cord-015922-5wwy0m2k	210	29	.	.	.
cord-015922-5wwy0m2k	211	1	The	the	DT
cord-015922-5wwy0m2k	211	2	advent	advent	NN
cord-015922-5wwy0m2k	211	3	of	of	IN
cord-015922-5wwy0m2k	211	4	rapid	rapid	JJ
cord-015922-5wwy0m2k	211	5	RSV	RSV	NNP
cord-015922-5wwy0m2k	211	6	diagnosis	diagnosis	NN
cord-015922-5wwy0m2k	211	7	by	by	IN
cord-015922-5wwy0m2k	211	8	antigen	antigen	NN
cord-015922-5wwy0m2k	211	9	detection	detection	NN
cord-015922-5wwy0m2k	211	10	in	in	IN
cord-015922-5wwy0m2k	211	11	nasopharyngeal	nasopharyngeal	JJ
cord-015922-5wwy0m2k	211	12	swabs	swab	NNS
cord-015922-5wwy0m2k	211	13	has	have	VBZ
cord-015922-5wwy0m2k	211	14	resulted	result	VBN
cord-015922-5wwy0m2k	211	15	in	in	IN
cord-015922-5wwy0m2k	211	16	the	the	DT
cord-015922-5wwy0m2k	211	17	recognition	recognition	NN
cord-015922-5wwy0m2k	211	18	that	that	IN
cord-015922-5wwy0m2k	211	19	RSV	RSV	NNP
cord-015922-5wwy0m2k	211	20	is	be	VBZ
cord-015922-5wwy0m2k	211	21	a	a	DT
cord-015922-5wwy0m2k	211	22	significant	significant	JJ
cord-015922-5wwy0m2k	211	23	pathogen	pathogen	NN
cord-015922-5wwy0m2k	211	24	for	for	IN
cord-015922-5wwy0m2k	211	25	both	both	DT
cord-015922-5wwy0m2k	211	26	adults	adult	NNS
cord-015922-5wwy0m2k	211	27	and	and	CC
cord-015922-5wwy0m2k	211	28	children	child	NNS
cord-015922-5wwy0m2k	211	29	,	,	,
cord-015922-5wwy0m2k	211	30	particularly	particularly	RB
cord-015922-5wwy0m2k	211	31	in	in	IN
cord-015922-5wwy0m2k	211	32	immunosuppressed	immunosuppressed	JJ
cord-015922-5wwy0m2k	211	33	patients	patient	NNS
cord-015922-5wwy0m2k	211	34	.	.	.
cord-015922-5wwy0m2k	212	1	Optimal	optimal	JJ
cord-015922-5wwy0m2k	212	2	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	212	3	management	management	NN
cord-015922-5wwy0m2k	212	4	,	,	,
cord-015922-5wwy0m2k	212	5	however	however	RB
cord-015922-5wwy0m2k	212	6	,	,	,
cord-015922-5wwy0m2k	212	7	remains	remain	VBZ
cord-015922-5wwy0m2k	212	8	unclear	unclear	JJ
cord-015922-5wwy0m2k	212	9	.	.	.
cord-015922-5wwy0m2k	213	1	There	there	EX
cord-015922-5wwy0m2k	213	2	are	be	VBP
cord-015922-5wwy0m2k	213	3	reports	report	NNS
cord-015922-5wwy0m2k	213	4	that	that	IN
cord-015922-5wwy0m2k	213	5	aerosolized	aerosolize	VBN
cord-015922-5wwy0m2k	213	6	ribavirin	ribavirin	RB
cord-015922-5wwy0m2k	213	7	+	+	CC
cord-015922-5wwy0m2k	213	8	/−	/−	.
cord-015922-5wwy0m2k	213	9	anti	anti	JJ
cord-015922-5wwy0m2k	213	10	-	-	JJ
cord-015922-5wwy0m2k	213	11	RSV	rsv	JJ
cord-015922-5wwy0m2k	213	12	polyclonal	polyclonal	JJ
cord-015922-5wwy0m2k	213	13	or	or	CC
cord-015922-5wwy0m2k	213	14	monoclonal	monoclonal	JJ
cord-015922-5wwy0m2k	213	15	antibody	antibody	NN
cord-015922-5wwy0m2k	213	16	may	may	MD
cord-015922-5wwy0m2k	213	17	have	have	VB
cord-015922-5wwy0m2k	213	18	therapeutic	therapeutic	JJ
cord-015922-5wwy0m2k	213	19	benefit	benefit	NN
cord-015922-5wwy0m2k	213	20	,	,	,
cord-015922-5wwy0m2k	213	21	but	but	CC
cord-015922-5wwy0m2k	213	22	this	this	DT
cord-015922-5wwy0m2k	213	23	remains	remain	VBZ
cord-015922-5wwy0m2k	213	24	unproven	unproven	JJ
cord-015922-5wwy0m2k	213	25	.	.	.
cord-015922-5wwy0m2k	214	1	There	there	EX
cord-015922-5wwy0m2k	214	2	is	be	VBZ
cord-015922-5wwy0m2k	214	3	also	also	RB
cord-015922-5wwy0m2k	214	4	interest	interest	NN
cord-015922-5wwy0m2k	214	5	in	in	IN
cord-015922-5wwy0m2k	214	6	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	214	7	with	with	IN
cord-015922-5wwy0m2k	214	8	an	an	DT
cord-015922-5wwy0m2k	214	9	anti	anti	JJ
cord-015922-5wwy0m2k	214	10	-	-	JJ
cord-015922-5wwy0m2k	214	11	RSV	rsv	JJ
cord-015922-5wwy0m2k	214	12	antibody	antibody	NN
cord-015922-5wwy0m2k	214	13	,	,	,
cord-015922-5wwy0m2k	214	14	although	although	IN
cord-015922-5wwy0m2k	214	15	there	there	EX
cord-015922-5wwy0m2k	214	16	have	have	VBP
cord-015922-5wwy0m2k	214	17	been	be	VBN
cord-015922-5wwy0m2k	214	18	no	no	DT
cord-015922-5wwy0m2k	214	19	trials	trial	NNS
cord-015922-5wwy0m2k	214	20	in	in	IN
cord-015922-5wwy0m2k	214	21	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	214	22	patients	patient	NNS
cord-015922-5wwy0m2k	214	23	[	[	-LRB-
cord-015922-5wwy0m2k	214	24	55	55	CD
cord-015922-5wwy0m2k	214	25	]	]	-RRB-
cord-015922-5wwy0m2k	214	26	[	[	-LRB-
cord-015922-5wwy0m2k	214	27	56	56	CD
cord-015922-5wwy0m2k	214	28	]	]	-RRB-
cord-015922-5wwy0m2k	214	29	[	[	-LRB-
cord-015922-5wwy0m2k	214	30	57	57	CD
cord-015922-5wwy0m2k	214	31	]	]	-RRB-
cord-015922-5wwy0m2k	214	32	[	[	-LRB-
cord-015922-5wwy0m2k	214	33	58	58	CD
cord-015922-5wwy0m2k	214	34	]	]	-RRB-
cord-015922-5wwy0m2k	214	35	[	[	-LRB-
cord-015922-5wwy0m2k	214	36	59	59	CD
cord-015922-5wwy0m2k	214	37	]	]	-RRB-
cord-015922-5wwy0m2k	214	38	.	.	.
cord-015922-5wwy0m2k	215	1	As	as	IN
cord-015922-5wwy0m2k	215	2	with	with	IN
cord-015922-5wwy0m2k	215	3	RSV	RSV	NNP
cord-015922-5wwy0m2k	215	4	,	,	,
cord-015922-5wwy0m2k	215	5	the	the	DT
cord-015922-5wwy0m2k	215	6	incidence	incidence	NN
cord-015922-5wwy0m2k	215	7	of	of	IN
cord-015922-5wwy0m2k	215	8	influenza	influenza	NN
cord-015922-5wwy0m2k	215	9	infection	infection	NN
cord-015922-5wwy0m2k	215	10	in	in	IN
cord-015922-5wwy0m2k	215	11	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	215	12	patients	patient	NNS
cord-015922-5wwy0m2k	215	13	reflects	reflect	VBZ
cord-015922-5wwy0m2k	215	14	the	the	DT
cord-015922-5wwy0m2k	215	15	level	level	NN
cord-015922-5wwy0m2k	215	16	of	of	IN
cord-015922-5wwy0m2k	215	17	influenza	influenza	NN
cord-015922-5wwy0m2k	215	18	activity	activity	NN
cord-015922-5wwy0m2k	215	19	in	in	IN
cord-015922-5wwy0m2k	215	20	the	the	DT
cord-015922-5wwy0m2k	215	21	community	community	NN
cord-015922-5wwy0m2k	215	22	.	.	.
cord-015922-5wwy0m2k	216	1	The	the	DT
cord-015922-5wwy0m2k	216	2	impact	impact	NN
cord-015922-5wwy0m2k	216	3	of	of	IN
cord-015922-5wwy0m2k	216	4	this	this	DT
cord-015922-5wwy0m2k	216	5	virus	virus	NN
cord-015922-5wwy0m2k	216	6	on	on	IN
cord-015922-5wwy0m2k	216	7	infected	infected	JJ
cord-015922-5wwy0m2k	216	8	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	216	9	recipients	recipient	NNS
cord-015922-5wwy0m2k	216	10	is	be	VBZ
cord-015922-5wwy0m2k	216	11	demonstrated	demonstrate	VBN
cord-015922-5wwy0m2k	216	12	by	by	IN
cord-015922-5wwy0m2k	216	13	the	the	DT
cord-015922-5wwy0m2k	216	14	following	follow	VBG
cord-015922-5wwy0m2k	216	15	statistics	statistic	NNS
cord-015922-5wwy0m2k	216	16	:	:	:
cord-015922-5wwy0m2k	216	17	~60	~60	CD
cord-015922-5wwy0m2k	216	18	percent	percent	NN
cord-015922-5wwy0m2k	216	19	of	of	IN
cord-015922-5wwy0m2k	216	20	the	the	DT
cord-015922-5wwy0m2k	216	21	patients	patient	NNS
cord-015922-5wwy0m2k	216	22	with	with	IN
cord-015922-5wwy0m2k	216	23	influenza	influenza	NN
cord-015922-5wwy0m2k	216	24	develop	develop	VB
cord-015922-5wwy0m2k	216	25	pneumonia	pneumonia	NN
cord-015922-5wwy0m2k	216	26	and	and	CC
cord-015922-5wwy0m2k	216	27	~25	~25	CD
cord-015922-5wwy0m2k	216	28	percent	percent	NN
cord-015922-5wwy0m2k	216	29	of	of	IN
cord-015922-5wwy0m2k	216	30	patients	patient	NNS
cord-015922-5wwy0m2k	216	31	with	with	IN
cord-015922-5wwy0m2k	216	32	influenza	influenza	NN
cord-015922-5wwy0m2k	216	33	pneumonia	pneumonia	NN
cord-015922-5wwy0m2k	216	34	die	die	NN
cord-015922-5wwy0m2k	216	35	of	of	IN
cord-015922-5wwy0m2k	216	36	progressive	progressive	JJ
cord-015922-5wwy0m2k	216	37	respiratory	respiratory	JJ
cord-015922-5wwy0m2k	216	38	failure	failure	NN
cord-015922-5wwy0m2k	216	39	.	.	.
cord-015922-5wwy0m2k	217	1	When	when	WRB
cord-015922-5wwy0m2k	217	2	influenza	influenza	NN
cord-015922-5wwy0m2k	217	3	is	be	VBZ
cord-015922-5wwy0m2k	217	4	identified	identify	VBN
cord-015922-5wwy0m2k	217	5	as	as	IN
cord-015922-5wwy0m2k	217	6	a	a	DT
cord-015922-5wwy0m2k	217	7	pathogen	pathogen	NN
cord-015922-5wwy0m2k	217	8	,	,	,
cord-015922-5wwy0m2k	217	9	use	use	NN
cord-015922-5wwy0m2k	217	10	of	of	IN
cord-015922-5wwy0m2k	217	11	a	a	DT
cord-015922-5wwy0m2k	217	12	neuraminidase	neuraminidase	NN
cord-015922-5wwy0m2k	217	13	inhibitor	inhibitor	NN
cord-015922-5wwy0m2k	217	14	(	(	-LRB-
cord-015922-5wwy0m2k	217	15	oseltamvir	oseltamvir	NNP
cord-015922-5wwy0m2k	217	16	or	or	CC
cord-015922-5wwy0m2k	217	17	zanamavir	zanamavir	NNP
cord-015922-5wwy0m2k	217	18	)	)	-RRB-
cord-015922-5wwy0m2k	217	19	or	or	CC
cord-015922-5wwy0m2k	217	20	an	an	DT
cord-015922-5wwy0m2k	217	21	amantadate	amantadate	NN
cord-015922-5wwy0m2k	217	22	(	(	-LRB-
cord-015922-5wwy0m2k	217	23	amantadine	amantadine	NNP
cord-015922-5wwy0m2k	217	24	or	or	CC
cord-015922-5wwy0m2k	217	25	rimanatine	rimanatine	NNP
cord-015922-5wwy0m2k	217	26	)	)	-RRB-
cord-015922-5wwy0m2k	217	27	should	should	MD
cord-015922-5wwy0m2k	217	28	be	be	VB
cord-015922-5wwy0m2k	217	29	considered	consider	VBN
cord-015922-5wwy0m2k	217	30	.	.	.
cord-015922-5wwy0m2k	218	1	The	the	DT
cord-015922-5wwy0m2k	218	2	neuraminidase	neuraminidase	NN
cord-015922-5wwy0m2k	218	3	inhibitors	inhibitor	NNS
cord-015922-5wwy0m2k	218	4	are	be	VBP
cord-015922-5wwy0m2k	218	5	attractive	attractive	JJ
cord-015922-5wwy0m2k	218	6	in	in	IN
cord-015922-5wwy0m2k	218	7	this	this	DT
cord-015922-5wwy0m2k	218	8	setting	setting	NN
cord-015922-5wwy0m2k	218	9	as	as	IN
cord-015922-5wwy0m2k	218	10	they	-PRON-	PRP
cord-015922-5wwy0m2k	218	11	are	be	VBP
cord-015922-5wwy0m2k	218	12	effective	effective	JJ
cord-015922-5wwy0m2k	218	13	against	against	IN
cord-015922-5wwy0m2k	218	14	both	both	DT
cord-015922-5wwy0m2k	218	15	influenza	influenza	NN
cord-015922-5wwy0m2k	218	16	A	a	NN
cord-015922-5wwy0m2k	218	17	and	and	CC
cord-015922-5wwy0m2k	218	18	B	b	NN
cord-015922-5wwy0m2k	218	19	and	and	CC
cord-015922-5wwy0m2k	218	20	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	218	21	resistance	resistance	NN
cord-015922-5wwy0m2k	218	22	occurs	occur	VBZ
cord-015922-5wwy0m2k	218	23	more	more	RBR
cord-015922-5wwy0m2k	218	24	slowly	slowly	RB
cord-015922-5wwy0m2k	218	25	compared	compare	VBN
cord-015922-5wwy0m2k	218	26	with	with	IN
cord-015922-5wwy0m2k	218	27	amantadine	amantadine	NNP
cord-015922-5wwy0m2k	218	28	use	use	NN
cord-015922-5wwy0m2k	218	29	.	.	.
cord-015922-5wwy0m2k	219	1	Annual	annual	JJ
cord-015922-5wwy0m2k	219	2	influenza	influenza	NN
cord-015922-5wwy0m2k	219	3	vaccination	vaccination	NN
cord-015922-5wwy0m2k	219	4	should	should	MD
cord-015922-5wwy0m2k	219	5	be	be	VB
cord-015922-5wwy0m2k	219	6	considered	consider	VBN
cord-015922-5wwy0m2k	219	7	,	,	,
cord-015922-5wwy0m2k	219	8	but	but	CC
cord-015922-5wwy0m2k	219	9	its	-PRON-	PRP$
cord-015922-5wwy0m2k	219	10	benefit	benefit	NN
cord-015922-5wwy0m2k	219	11	is	be	VBZ
cord-015922-5wwy0m2k	219	12	attenuated	attenuate	VBN
cord-015922-5wwy0m2k	219	13	;	;	:
cord-015922-5wwy0m2k	219	14	indeed	indeed	RB
cord-015922-5wwy0m2k	219	15	,	,	,
cord-015922-5wwy0m2k	219	16	it	-PRON-	PRP
cord-015922-5wwy0m2k	219	17	is	be	VBZ
cord-015922-5wwy0m2k	219	18	probably	probably	RB
cord-015922-5wwy0m2k	219	19	fair	fair	JJ
cord-015922-5wwy0m2k	219	20	to	to	TO
cord-015922-5wwy0m2k	219	21	say	say	VB
cord-015922-5wwy0m2k	219	22	that	that	IN
cord-015922-5wwy0m2k	219	23	maximal	maximal	JJ
cord-015922-5wwy0m2k	219	24	benefit	benefit	NN
cord-015922-5wwy0m2k	219	25	from	from	IN
cord-015922-5wwy0m2k	219	26	vaccination	vaccination	NN
cord-015922-5wwy0m2k	219	27	occurs	occur	VBZ
cord-015922-5wwy0m2k	219	28	when	when	WRB
cord-015922-5wwy0m2k	219	29	the	the	DT
cord-015922-5wwy0m2k	219	30	vaccine	vaccine	NN
cord-015922-5wwy0m2k	219	31	is	be	VBZ
cord-015922-5wwy0m2k	219	32	administered	administer	VBN
cord-015922-5wwy0m2k	219	33	to	to	IN
cord-015922-5wwy0m2k	219	34	health	health	NN
cord-015922-5wwy0m2k	219	35	care	care	NN
cord-015922-5wwy0m2k	219	36	workers	worker	NNS
cord-015922-5wwy0m2k	219	37	,	,	,
cord-015922-5wwy0m2k	219	38	family	family	NN
cord-015922-5wwy0m2k	219	39	,	,	,
cord-015922-5wwy0m2k	219	40	friends	friend	NNS
cord-015922-5wwy0m2k	219	41	and	and	CC
cord-015922-5wwy0m2k	219	42	other	other	JJ
cord-015922-5wwy0m2k	219	43	contacts	contact	NNS
cord-015922-5wwy0m2k	219	44	of	of	IN
cord-015922-5wwy0m2k	219	45	the	the	DT
cord-015922-5wwy0m2k	219	46	patient	patient	NN
cord-015922-5wwy0m2k	219	47	.	.	.
cord-015922-5wwy0m2k	220	1	When	when	WRB
cord-015922-5wwy0m2k	220	2	an	an	DT
cord-015922-5wwy0m2k	220	3	infection	infection	NN
cord-015922-5wwy0m2k	220	4	is	be	VBZ
cord-015922-5wwy0m2k	220	5	diagnosed	diagnose	VBN
cord-015922-5wwy0m2k	220	6	,	,	,
cord-015922-5wwy0m2k	220	7	early	early	JJ
cord-015922-5wwy0m2k	220	8	treatment	treatment	NN
cord-015922-5wwy0m2k	220	9	should	should	MD
cord-015922-5wwy0m2k	220	10	be	be	VB
cord-015922-5wwy0m2k	220	11	considered	consider	VBN
cord-015922-5wwy0m2k	220	12	[	[	-LRB-
cord-015922-5wwy0m2k	220	13	58	58	CD
cord-015922-5wwy0m2k	220	14	,	,	,
cord-015922-5wwy0m2k	220	15	60	60	CD
cord-015922-5wwy0m2k	220	16	]	]	-RRB-
cord-015922-5wwy0m2k	220	17	.	.	.
cord-015922-5wwy0m2k	221	1	There	there	EX
cord-015922-5wwy0m2k	221	2	are	be	VBP
cord-015922-5wwy0m2k	221	3	more	more	JJR
cord-015922-5wwy0m2k	221	4	than	than	IN
cord-015922-5wwy0m2k	221	5	50	50	CD
cord-015922-5wwy0m2k	221	6	serotypes	serotype	NNS
cord-015922-5wwy0m2k	221	7	of	of	IN
cord-015922-5wwy0m2k	221	8	adenovirus	adenovirus	NN
cord-015922-5wwy0m2k	221	9	and	and	CC
cord-015922-5wwy0m2k	221	10	nearly	nearly	RB
cord-015922-5wwy0m2k	221	11	all	all	DT
cord-015922-5wwy0m2k	221	12	have	have	VBP
cord-015922-5wwy0m2k	221	13	been	be	VBN
cord-015922-5wwy0m2k	221	14	described	describe	VBN
cord-015922-5wwy0m2k	221	15	to	to	TO
cord-015922-5wwy0m2k	221	16	cause	cause	VB
cord-015922-5wwy0m2k	221	17	human	human	JJ
cord-015922-5wwy0m2k	221	18	disease	disease	NN
cord-015922-5wwy0m2k	221	19	.	.	.
cord-015922-5wwy0m2k	222	1	Adenovirus	Adenovirus	NNP
cord-015922-5wwy0m2k	222	2	disease	disease	NN
cord-015922-5wwy0m2k	222	3	post	post	NN
cord-015922-5wwy0m2k	222	4	-	-	NN
cord-015922-5wwy0m2k	222	5	transplantation	transplantation	NN
cord-015922-5wwy0m2k	222	6	is	be	VBZ
cord-015922-5wwy0m2k	222	7	likely	likely	JJ
cord-015922-5wwy0m2k	222	8	due	due	IN
cord-015922-5wwy0m2k	222	9	to	to	IN
cord-015922-5wwy0m2k	222	10	both	both	CC
cord-015922-5wwy0m2k	222	11	a	a	DT
cord-015922-5wwy0m2k	222	12	newly	newly	RB
cord-015922-5wwy0m2k	222	13	acquired	acquire	VBN
cord-015922-5wwy0m2k	222	14	virus	virus	NN
cord-015922-5wwy0m2k	222	15	and	and	CC
cord-015922-5wwy0m2k	222	16	viral	viral	JJ
cord-015922-5wwy0m2k	222	17	reactivation	reactivation	NN
cord-015922-5wwy0m2k	222	18	.	.	.
cord-015922-5wwy0m2k	223	1	The	the	DT
cord-015922-5wwy0m2k	223	2	most	most	RBS
cord-015922-5wwy0m2k	223	3	common	common	JJ
cord-015922-5wwy0m2k	223	4	adenovirus	adenovirus	NN
cord-015922-5wwy0m2k	223	5	-	-	HYPH
cord-015922-5wwy0m2k	223	6	associated	associate	VBN
cord-015922-5wwy0m2k	223	7	illness	illness	NN
cord-015922-5wwy0m2k	223	8	post	post	NN
cord-015922-5wwy0m2k	223	9	-	-	NN
cord-015922-5wwy0m2k	223	10	transplantation	transplantation	NN
cord-015922-5wwy0m2k	223	11	is	be	VBZ
cord-015922-5wwy0m2k	223	12	hemorrhagic	hemorrhagic	JJ
cord-015922-5wwy0m2k	223	13	cystitis	cystitis	NN
cord-015922-5wwy0m2k	223	14	which	which	WDT
cord-015922-5wwy0m2k	223	15	has	have	VBZ
cord-015922-5wwy0m2k	223	16	been	be	VBN
cord-015922-5wwy0m2k	223	17	described	describe	VBN
cord-015922-5wwy0m2k	223	18	in	in	IN
cord-015922-5wwy0m2k	223	19	a	a	DT
cord-015922-5wwy0m2k	223	20	recent	recent	JJ
cord-015922-5wwy0m2k	223	21	report	report	NN
cord-015922-5wwy0m2k	223	22	to	to	TO
cord-015922-5wwy0m2k	223	23	occur	occur	VB
cord-015922-5wwy0m2k	223	24	in	in	IN
cord-015922-5wwy0m2k	223	25	up	up	IN
cord-015922-5wwy0m2k	223	26	to	to	TO
cord-015922-5wwy0m2k	223	27	42	42	CD
cord-015922-5wwy0m2k	223	28	percent	percent	NN
cord-015922-5wwy0m2k	223	29	of	of	IN
cord-015922-5wwy0m2k	223	30	patients	patient	NNS
cord-015922-5wwy0m2k	223	31	in	in	IN
cord-015922-5wwy0m2k	223	32	the	the	DT
cord-015922-5wwy0m2k	223	33	first	first	JJ
cord-015922-5wwy0m2k	223	34	year	year	NN
cord-015922-5wwy0m2k	223	35	post	post	NN
cord-015922-5wwy0m2k	223	36	-	-	NN
cord-015922-5wwy0m2k	223	37	transplantation	transplantation	JJ
cord-015922-5wwy0m2k	223	38	[	[	-LRB-
cord-015922-5wwy0m2k	223	39	61	61	CD
cord-015922-5wwy0m2k	223	40	]	]	-RRB-
cord-015922-5wwy0m2k	223	41	.	.	.
cord-015922-5wwy0m2k	224	1	The	the	DT
cord-015922-5wwy0m2k	224	2	overwhelming	overwhelming	JJ
cord-015922-5wwy0m2k	224	3	majority	majority	NN
cord-015922-5wwy0m2k	224	4	of	of	IN
cord-015922-5wwy0m2k	224	5	cases	case	NNS
cord-015922-5wwy0m2k	224	6	are	be	VBP
cord-015922-5wwy0m2k	224	7	asymptomatic	asymptomatic	JJ
cord-015922-5wwy0m2k	224	8	and	and	CC
cord-015922-5wwy0m2k	224	9	require	require	VBP
cord-015922-5wwy0m2k	224	10	no	no	DT
cord-015922-5wwy0m2k	224	11	intervention	intervention	NN
cord-015922-5wwy0m2k	224	12	[	[	-LRB-
cord-015922-5wwy0m2k	224	13	62	62	CD
cord-015922-5wwy0m2k	224	14	]	]	-RRB-
cord-015922-5wwy0m2k	224	15	.	.	.
cord-015922-5wwy0m2k	225	1	Occasionally	occasionally	RB
cord-015922-5wwy0m2k	225	2	the	the	DT
cord-015922-5wwy0m2k	225	3	severity	severity	NN
cord-015922-5wwy0m2k	225	4	of	of	IN
cord-015922-5wwy0m2k	225	5	hemorrhage	hemorrhage	NN
cord-015922-5wwy0m2k	225	6	or	or	CC
cord-015922-5wwy0m2k	225	7	bladder	bladder	NN
cord-015922-5wwy0m2k	225	8	-	-	HYPH
cord-015922-5wwy0m2k	225	9	associated	associate	VBN
cord-015922-5wwy0m2k	225	10	pain	pain	NN
cord-015922-5wwy0m2k	225	11	is	be	VBZ
cord-015922-5wwy0m2k	225	12	so	so	RB
cord-015922-5wwy0m2k	225	13	great	great	JJ
cord-015922-5wwy0m2k	225	14	that	that	IN
cord-015922-5wwy0m2k	225	15	intervention	intervention	NN
cord-015922-5wwy0m2k	225	16	is	be	VBZ
cord-015922-5wwy0m2k	225	17	required	require	VBN
cord-015922-5wwy0m2k	225	18	.	.	.
cord-015922-5wwy0m2k	226	1	Other	other	JJ
cord-015922-5wwy0m2k	226	2	important	important	JJ
cord-015922-5wwy0m2k	226	3	adenovirus	adenovirus	NN
cord-015922-5wwy0m2k	226	4	-	-	HYPH
cord-015922-5wwy0m2k	226	5	associated	associate	VBN
cord-015922-5wwy0m2k	226	6	syndromes	syndrome	NNS
cord-015922-5wwy0m2k	226	7	include	include	VBP
cord-015922-5wwy0m2k	226	8	hepatitis	hepatitis	NN
cord-015922-5wwy0m2k	226	9	and	and	CC
cord-015922-5wwy0m2k	226	10	pneumonitis	pneumonitis	NN
cord-015922-5wwy0m2k	226	11	which	which	WDT
cord-015922-5wwy0m2k	226	12	may	may	MD
cord-015922-5wwy0m2k	226	13	be	be	VB
cord-015922-5wwy0m2k	226	14	fatal	fatal	JJ
cord-015922-5wwy0m2k	226	15	in	in	IN
cord-015922-5wwy0m2k	226	16	the	the	DT
cord-015922-5wwy0m2k	226	17	early	early	JJ
cord-015922-5wwy0m2k	226	18	post	post	JJ
cord-015922-5wwy0m2k	226	19	-	-	JJ
cord-015922-5wwy0m2k	226	20	transplant	transplant	JJ
cord-015922-5wwy0m2k	226	21	period	period	NN
cord-015922-5wwy0m2k	226	22	.	.	.
cord-015922-5wwy0m2k	227	1	In	in	IN
cord-015922-5wwy0m2k	227	2	the	the	DT
cord-015922-5wwy0m2k	227	3	late	late	JJ
cord-015922-5wwy0m2k	227	4	post	post	JJ
cord-015922-5wwy0m2k	227	5	-	-	JJ
cord-015922-5wwy0m2k	227	6	transplant	transplant	JJ
cord-015922-5wwy0m2k	227	7	period	period	NN
cord-015922-5wwy0m2k	227	8	adenovirus	adenovirus	NN
cord-015922-5wwy0m2k	227	9	gastroenteritis	gastroenteritis	NN
cord-015922-5wwy0m2k	227	10	may	may	MD
cord-015922-5wwy0m2k	227	11	occur	occur	VB
cord-015922-5wwy0m2k	227	12	which	which	WDT
cord-015922-5wwy0m2k	227	13	is	be	VBZ
cord-015922-5wwy0m2k	227	14	often	often	RB
cord-015922-5wwy0m2k	227	15	a	a	DT
cord-015922-5wwy0m2k	227	16	self	self	NN
cord-015922-5wwy0m2k	227	17	-	-	HYPH
cord-015922-5wwy0m2k	227	18	limited	limit	VBN
cord-015922-5wwy0m2k	227	19	illness	illness	NN
cord-015922-5wwy0m2k	227	20	;	;	:
cord-015922-5wwy0m2k	227	21	however	however	RB
cord-015922-5wwy0m2k	227	22	,	,	,
cord-015922-5wwy0m2k	227	23	severe	severe	JJ
cord-015922-5wwy0m2k	227	24	disease	disease	NN
cord-015922-5wwy0m2k	227	25	has	have	VBZ
cord-015922-5wwy0m2k	227	26	been	be	VBN
cord-015922-5wwy0m2k	227	27	described	describe	VBN
cord-015922-5wwy0m2k	227	28	especially	especially	RB
cord-015922-5wwy0m2k	227	29	in	in	IN
cord-015922-5wwy0m2k	227	30	patients	patient	NNS
cord-015922-5wwy0m2k	227	31	requiring	require	VBG
cord-015922-5wwy0m2k	227	32	significant	significant	JJ
cord-015922-5wwy0m2k	227	33	levels	level	NNS
cord-015922-5wwy0m2k	227	34	of	of	IN
cord-015922-5wwy0m2k	227	35	immunosuppression	immunosuppression	NN
cord-015922-5wwy0m2k	227	36	for	for	IN
cord-015922-5wwy0m2k	227	37	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	227	38	.	.	.
cord-015922-5wwy0m2k	228	1	Therapeutic	therapeutic	JJ
cord-015922-5wwy0m2k	228	2	options	option	NNS
cord-015922-5wwy0m2k	228	3	for	for	IN
cord-015922-5wwy0m2k	228	4	adenovirus	adenovirus	NN
cord-015922-5wwy0m2k	228	5	are	be	VBP
cord-015922-5wwy0m2k	228	6	limited	limit	VBN
cord-015922-5wwy0m2k	228	7	.	.	.
cord-015922-5wwy0m2k	229	1	The	the	DT
cord-015922-5wwy0m2k	229	2	role	role	NN
cord-015922-5wwy0m2k	229	3	of	of	IN
cord-015922-5wwy0m2k	229	4	the	the	DT
cord-015922-5wwy0m2k	229	5	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	229	6	cidofovir	cidofovir	NNS
cord-015922-5wwy0m2k	229	7	is	be	VBZ
cord-015922-5wwy0m2k	229	8	controversial	controversial	JJ
cord-015922-5wwy0m2k	229	9	with	with	IN
cord-015922-5wwy0m2k	229	10	mixed	mixed	JJ
cord-015922-5wwy0m2k	229	11	results	result	NNS
cord-015922-5wwy0m2k	229	12	having	have	VBG
cord-015922-5wwy0m2k	229	13	been	be	VBN
cord-015922-5wwy0m2k	229	14	reported	report	VBN
cord-015922-5wwy0m2k	229	15	[	[	-LRB-
cord-015922-5wwy0m2k	229	16	63	63	CD
cord-015922-5wwy0m2k	229	17	]	]	-RRB-
cord-015922-5wwy0m2k	229	18	.	.	.
cord-015922-5wwy0m2k	230	1	Decreasing	decrease	VBG
cord-015922-5wwy0m2k	230	2	immunusuppression	immunusuppression	NN
cord-015922-5wwy0m2k	230	3	and	and	CC
cord-015922-5wwy0m2k	230	4	attempting	attempt	VBG
cord-015922-5wwy0m2k	230	5	reconstitution	reconstitution	NN
cord-015922-5wwy0m2k	230	6	of	of	IN
cord-015922-5wwy0m2k	230	7	the	the	DT
cord-015922-5wwy0m2k	230	8	native	native	JJ
cord-015922-5wwy0m2k	230	9	host	host	NN
cord-015922-5wwy0m2k	230	10	immune	immune	JJ
cord-015922-5wwy0m2k	230	11	response	response	NN
cord-015922-5wwy0m2k	230	12	is	be	VBZ
cord-015922-5wwy0m2k	230	13	critical	critical	JJ
cord-015922-5wwy0m2k	230	14	.	.	.
cord-015922-5wwy0m2k	231	1	The	the	DT
cord-015922-5wwy0m2k	231	2	role	role	NN
cord-015922-5wwy0m2k	231	3	for	for	IN
cord-015922-5wwy0m2k	231	4	other	other	JJ
cord-015922-5wwy0m2k	231	5	adjunctive	adjunctive	JJ
cord-015922-5wwy0m2k	231	6	therapies	therapy	NNS
cord-015922-5wwy0m2k	231	7	,	,	,
cord-015922-5wwy0m2k	231	8	such	such	JJ
cord-015922-5wwy0m2k	231	9	as	as	IN
cord-015922-5wwy0m2k	231	10	IVIg	IVIg	NNP
cord-015922-5wwy0m2k	231	11	,	,	,
cord-015922-5wwy0m2k	231	12	is	be	VBZ
cord-015922-5wwy0m2k	231	13	unproven	unproven	JJ
cord-015922-5wwy0m2k	231	14	,	,	,
cord-015922-5wwy0m2k	231	15	but	but	CC
cord-015922-5wwy0m2k	231	16	can	can	MD
cord-015922-5wwy0m2k	231	17	be	be	VB
cord-015922-5wwy0m2k	231	18	considered	consider	VBN
cord-015922-5wwy0m2k	231	19	in	in	IN
cord-015922-5wwy0m2k	231	20	severe	severe	JJ
cord-015922-5wwy0m2k	231	21	cases	case	NNS
cord-015922-5wwy0m2k	231	22	.	.	.
cord-015922-5wwy0m2k	232	1	Avoiding	avoid	VBG
cord-015922-5wwy0m2k	232	2	exposure	exposure	NN
cord-015922-5wwy0m2k	232	3	to	to	IN
cord-015922-5wwy0m2k	232	4	new	new	JJ
cord-015922-5wwy0m2k	232	5	infection	infection	NN
cord-015922-5wwy0m2k	232	6	,	,	,
cord-015922-5wwy0m2k	232	7	as	as	IN
cord-015922-5wwy0m2k	232	8	with	with	IN
cord-015922-5wwy0m2k	232	9	all	all	DT
cord-015922-5wwy0m2k	232	10	community	community	NN
cord-015922-5wwy0m2k	232	11	-	-	HYPH
cord-015922-5wwy0m2k	232	12	acquired	acquire	VBN
cord-015922-5wwy0m2k	232	13	pathogens	pathogen	NNS
cord-015922-5wwy0m2k	232	14	,	,	,
cord-015922-5wwy0m2k	232	15	is	be	VBZ
cord-015922-5wwy0m2k	232	16	central	central	JJ
cord-015922-5wwy0m2k	232	17	to	to	TO
cord-015922-5wwy0m2k	232	18	optimal	optimal	JJ
cord-015922-5wwy0m2k	232	19	care	care	NN
cord-015922-5wwy0m2k	232	20	.	.	.
cord-015922-5wwy0m2k	233	1	Parainfluenza	Parainfluenza	NNP
cord-015922-5wwy0m2k	233	2	,	,	,
cord-015922-5wwy0m2k	233	3	rhinoviruses	rhinovirus	NNS
cord-015922-5wwy0m2k	233	4	,	,	,
cord-015922-5wwy0m2k	233	5	metapneumovirus	metapneumovirus	NNP
cord-015922-5wwy0m2k	233	6	and	and	CC
cord-015922-5wwy0m2k	233	7	coronaviruses	coronaviruse	NNS
cord-015922-5wwy0m2k	233	8	are	be	VBP
cord-015922-5wwy0m2k	233	9	all	all	DT
cord-015922-5wwy0m2k	233	10	capable	capable	JJ
cord-015922-5wwy0m2k	233	11	of	of	IN
cord-015922-5wwy0m2k	233	12	causing	cause	VBG
cord-015922-5wwy0m2k	233	13	lower	low	JJR
cord-015922-5wwy0m2k	233	14	respiratory	respiratory	JJ
cord-015922-5wwy0m2k	233	15	tract	tract	NN
cord-015922-5wwy0m2k	233	16	infection	infection	NN
cord-015922-5wwy0m2k	233	17	in	in	IN
cord-015922-5wwy0m2k	233	18	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	233	19	recipients	recipient	NNS
cord-015922-5wwy0m2k	233	20	.	.	.
cord-015922-5wwy0m2k	234	1	Of	of	IN
cord-015922-5wwy0m2k	234	2	these	these	DT
cord-015922-5wwy0m2k	234	3	many	many	JJ
cord-015922-5wwy0m2k	234	4	viruses	virus	NNS
cord-015922-5wwy0m2k	234	5	,	,	,
cord-015922-5wwy0m2k	234	6	parainfluenza	parainfluenza	NNP
cord-015922-5wwy0m2k	234	7	virus	virus	NNP
cord-015922-5wwy0m2k	234	8	type	type	NN
cord-015922-5wwy0m2k	234	9	III	III	NNP
cord-015922-5wwy0m2k	234	10	is	be	VBZ
cord-015922-5wwy0m2k	234	11	especially	especially	RB
cord-015922-5wwy0m2k	234	12	associated	associate	VBN
cord-015922-5wwy0m2k	234	13	with	with	IN
cord-015922-5wwy0m2k	234	14	a	a	DT
cord-015922-5wwy0m2k	234	15	high	high	JJ
cord-015922-5wwy0m2k	234	16	mortality	mortality	NN
cord-015922-5wwy0m2k	234	17	[	[	-LRB-
cord-015922-5wwy0m2k	234	18	64	64	CD
cord-015922-5wwy0m2k	234	19	,	,	,
cord-015922-5wwy0m2k	234	20	65	65	CD
cord-015922-5wwy0m2k	234	21	]	]	-RRB-
cord-015922-5wwy0m2k	234	22	.	.	.
cord-015922-5wwy0m2k	235	1	Again	again	RB
cord-015922-5wwy0m2k	235	2	,	,	,
cord-015922-5wwy0m2k	235	3	specific	specific	JJ
cord-015922-5wwy0m2k	235	4	therapy	therapy	NN
cord-015922-5wwy0m2k	235	5	is	be	VBZ
cord-015922-5wwy0m2k	235	6	not	not	RB
cord-015922-5wwy0m2k	235	7	available	available	JJ
cord-015922-5wwy0m2k	235	8	,	,	,
cord-015922-5wwy0m2k	235	9	emphasizing	emphasize	VBG
cord-015922-5wwy0m2k	235	10	infection	infection	NN
cord-015922-5wwy0m2k	235	11	control	control	NN
cord-015922-5wwy0m2k	235	12	strategies	strategy	NNS
cord-015922-5wwy0m2k	235	13	in	in	IN
cord-015922-5wwy0m2k	235	14	the	the	DT
cord-015922-5wwy0m2k	235	15	hospital	hospital	NN
cord-015922-5wwy0m2k	235	16	setting	setting	NN
cord-015922-5wwy0m2k	235	17	and	and	CC
cord-015922-5wwy0m2k	235	18	avoiding	avoid	VBG
cord-015922-5wwy0m2k	235	19	individuals	individual	NNS
cord-015922-5wwy0m2k	235	20	with	with	IN
cord-015922-5wwy0m2k	235	21	respiratory	respiratory	JJ
cord-015922-5wwy0m2k	235	22	tract	tract	NN
cord-015922-5wwy0m2k	235	23	complaints	complaint	NNS
cord-015922-5wwy0m2k	235	24	at	at	IN
cord-015922-5wwy0m2k	235	25	home	home	NN
cord-015922-5wwy0m2k	235	26	.	.	.
cord-015922-5wwy0m2k	236	1	When	when	WRB
cord-015922-5wwy0m2k	236	2	upper	upper	JJ
cord-015922-5wwy0m2k	236	3	respiratory	respiratory	JJ
cord-015922-5wwy0m2k	236	4	tract	tract	NN
cord-015922-5wwy0m2k	236	5	complaints	complaint	NNS
cord-015922-5wwy0m2k	236	6	occur	occur	VBP
cord-015922-5wwy0m2k	236	7	in	in	IN
cord-015922-5wwy0m2k	236	8	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	236	9	patients	patient	NNS
cord-015922-5wwy0m2k	236	10	,	,	,
cord-015922-5wwy0m2k	236	11	a	a	DT
cord-015922-5wwy0m2k	236	12	diagnosis	diagnosis	NN
cord-015922-5wwy0m2k	236	13	should	should	MD
cord-015922-5wwy0m2k	236	14	be	be	VB
cord-015922-5wwy0m2k	236	15	made	make	VBN
cord-015922-5wwy0m2k	236	16	,	,	,
cord-015922-5wwy0m2k	236	17	utilizing	utilize	VBG
cord-015922-5wwy0m2k	236	18	rapid	rapid	JJ
cord-015922-5wwy0m2k	236	19	diagnostic	diagnostic	JJ
cord-015922-5wwy0m2k	236	20	techniques	technique	NNS
cord-015922-5wwy0m2k	236	21	(	(	-LRB-
cord-015922-5wwy0m2k	236	22	e.g.	e.g.	RB
cord-015922-5wwy0m2k	236	23	,	,	,
cord-015922-5wwy0m2k	236	24	antigen	antigen	NN
cord-015922-5wwy0m2k	236	25	detection	detection	NN
cord-015922-5wwy0m2k	236	26	assays	assay	NNS
cord-015922-5wwy0m2k	236	27	or	or	CC
cord-015922-5wwy0m2k	236	28	nucleic	nucleic	JJ
cord-015922-5wwy0m2k	236	29	acid	acid	NN
cord-015922-5wwy0m2k	236	30	testing	testing	NN
cord-015922-5wwy0m2k	236	31	)	)	-RRB-
cord-015922-5wwy0m2k	236	32	.	.	.
cord-015922-5wwy0m2k	237	1	Preemptive	preemptive	JJ
cord-015922-5wwy0m2k	237	2	therapy	therapy	NN
cord-015922-5wwy0m2k	237	3	,	,	,
cord-015922-5wwy0m2k	237	4	when	when	WRB
cord-015922-5wwy0m2k	237	5	available	available	JJ
cord-015922-5wwy0m2k	237	6	,	,	,
cord-015922-5wwy0m2k	237	7	should	should	MD
cord-015922-5wwy0m2k	237	8	be	be	VB
cord-015922-5wwy0m2k	237	9	initiated	initiate	VBN
cord-015922-5wwy0m2k	237	10	,	,	,
cord-015922-5wwy0m2k	237	11	while	while	IN
cord-015922-5wwy0m2k	237	12	immunosuppressive	immunosuppressive	JJ
cord-015922-5wwy0m2k	237	13	therapy	therapy	NN
cord-015922-5wwy0m2k	237	14	diminished	diminish	VBD
cord-015922-5wwy0m2k	237	15	and	and	CC
cord-015922-5wwy0m2k	237	16	isolation	isolation	NN
cord-015922-5wwy0m2k	237	17	from	from	IN
cord-015922-5wwy0m2k	237	18	other	other	JJ
cord-015922-5wwy0m2k	237	19	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	237	20	patients	patient	NNS
cord-015922-5wwy0m2k	237	21	should	should	MD
cord-015922-5wwy0m2k	237	22	be	be	VB
cord-015922-5wwy0m2k	237	23	accomplished	accomplish	VBN
cord-015922-5wwy0m2k	237	24	.	.	.
cord-015922-5wwy0m2k	238	1	BK	BK	NNP
cord-015922-5wwy0m2k	238	2	and	and	CC
cord-015922-5wwy0m2k	238	3	JC	JC	NNP
cord-015922-5wwy0m2k	238	4	viruses	virus	NNS
cord-015922-5wwy0m2k	238	5	are	be	VBP
cord-015922-5wwy0m2k	238	6	the	the	DT
cord-015922-5wwy0m2k	238	7	two	two	CD
cord-015922-5wwy0m2k	238	8	important	important	JJ
cord-015922-5wwy0m2k	238	9	species	specie	NNS
cord-015922-5wwy0m2k	238	10	in	in	IN
cord-015922-5wwy0m2k	238	11	this	this	DT
cord-015922-5wwy0m2k	238	12	family	family	NN
cord-015922-5wwy0m2k	238	13	of	of	IN
cord-015922-5wwy0m2k	238	14	viruses	virus	NNS
cord-015922-5wwy0m2k	238	15	with	with	IN
cord-015922-5wwy0m2k	238	16	a	a	DT
cord-015922-5wwy0m2k	238	17	genitourinary	genitourinary	JJ
cord-015922-5wwy0m2k	238	18	and	and	CC
cord-015922-5wwy0m2k	238	19	CNS	cns	JJ
cord-015922-5wwy0m2k	238	20	predilection	predilection	NN
cord-015922-5wwy0m2k	238	21	,	,	,
cord-015922-5wwy0m2k	238	22	respectively	respectively	RB
cord-015922-5wwy0m2k	238	23	.	.	.
cord-015922-5wwy0m2k	239	1	Approximately	approximately	RB
cord-015922-5wwy0m2k	239	2	60	60	CD
cord-015922-5wwy0m2k	239	3	to	to	TO
cord-015922-5wwy0m2k	239	4	80	80	CD
cord-015922-5wwy0m2k	239	5	percent	percent	NN
cord-015922-5wwy0m2k	239	6	of	of	IN
cord-015922-5wwy0m2k	239	7	adults	adult	NNS
cord-015922-5wwy0m2k	239	8	have	have	VBP
cord-015922-5wwy0m2k	239	9	been	be	VBN
cord-015922-5wwy0m2k	239	10	infected	infect	VBN
cord-015922-5wwy0m2k	239	11	with	with	IN
cord-015922-5wwy0m2k	239	12	one	one	CD
cord-015922-5wwy0m2k	239	13	or	or	CC
cord-015922-5wwy0m2k	239	14	both	both	DT
cord-015922-5wwy0m2k	239	15	of	of	IN
cord-015922-5wwy0m2k	239	16	these	these	DT
cord-015922-5wwy0m2k	239	17	viruses	virus	NNS
cord-015922-5wwy0m2k	239	18	,	,	,
cord-015922-5wwy0m2k	239	19	typically	typically	RB
cord-015922-5wwy0m2k	239	20	in	in	IN
cord-015922-5wwy0m2k	239	21	childhood	childhood	NN
cord-015922-5wwy0m2k	239	22	.	.	.
cord-015922-5wwy0m2k	240	1	With	with	IN
cord-015922-5wwy0m2k	240	2	immunosuppression	immunosuppression	NN
cord-015922-5wwy0m2k	240	3	,	,	,
cord-015922-5wwy0m2k	240	4	reactivation	reactivation	NN
cord-015922-5wwy0m2k	240	5	occurs	occur	VBZ
cord-015922-5wwy0m2k	240	6	which	which	WDT
cord-015922-5wwy0m2k	240	7	may	may	MD
cord-015922-5wwy0m2k	240	8	lead	lead	VB
cord-015922-5wwy0m2k	240	9	to	to	IN
cord-015922-5wwy0m2k	240	10	disease	disease	NN
cord-015922-5wwy0m2k	240	11	.	.	.
cord-015922-5wwy0m2k	241	1	BK	BK	NNP
cord-015922-5wwy0m2k	241	2	virus	virus	NN
cord-015922-5wwy0m2k	241	3	is	be	VBZ
cord-015922-5wwy0m2k	241	4	associated	associate	VBN
cord-015922-5wwy0m2k	241	5	with	with	IN
cord-015922-5wwy0m2k	241	6	hemorrhagic	hemorrhagic	JJ
cord-015922-5wwy0m2k	241	7	cystitis	cystitis	NN
cord-015922-5wwy0m2k	241	8	in	in	IN
cord-015922-5wwy0m2k	241	9	the	the	DT
cord-015922-5wwy0m2k	241	10	early	early	JJ
cord-015922-5wwy0m2k	241	11	post	post	JJ
cord-015922-5wwy0m2k	241	12	-	-	JJ
cord-015922-5wwy0m2k	241	13	transplant	transplant	JJ
cord-015922-5wwy0m2k	241	14	period	period	NN
cord-015922-5wwy0m2k	241	15	.	.	.
cord-015922-5wwy0m2k	242	1	This	this	DT
cord-015922-5wwy0m2k	242	2	virus	virus	NN
cord-015922-5wwy0m2k	242	3	is	be	VBZ
cord-015922-5wwy0m2k	242	4	commonly	commonly	RB
cord-015922-5wwy0m2k	242	5	found	find	VBN
cord-015922-5wwy0m2k	242	6	in	in	IN
cord-015922-5wwy0m2k	242	7	the	the	DT
cord-015922-5wwy0m2k	242	8	urine	urine	NN
cord-015922-5wwy0m2k	242	9	and	and	CC
cord-015922-5wwy0m2k	242	10	rarely	rarely	RB
cord-015922-5wwy0m2k	242	11	requires	require	VBZ
cord-015922-5wwy0m2k	242	12	any	any	DT
cord-015922-5wwy0m2k	242	13	therapeutic	therapeutic	JJ
cord-015922-5wwy0m2k	242	14	intervention	intervention	NN
cord-015922-5wwy0m2k	242	15	.	.	.
cord-015922-5wwy0m2k	243	1	JC	JC	NNP
cord-015922-5wwy0m2k	243	2	virus	virus	NN
cord-015922-5wwy0m2k	243	3	is	be	VBZ
cord-015922-5wwy0m2k	243	4	the	the	DT
cord-015922-5wwy0m2k	243	5	etiologic	etiologic	JJ
cord-015922-5wwy0m2k	243	6	agent	agent	NN
cord-015922-5wwy0m2k	243	7	of	of	IN
cord-015922-5wwy0m2k	243	8	progressive	progressive	JJ
cord-015922-5wwy0m2k	243	9	multifocal	multifocal	JJ
cord-015922-5wwy0m2k	243	10	leukoencephalopathy	leukoencephalopathy	NNS
cord-015922-5wwy0m2k	243	11	(	(	-LRB-
cord-015922-5wwy0m2k	243	12	PML	PML	NNP
cord-015922-5wwy0m2k	243	13	)	)	-RRB-
cord-015922-5wwy0m2k	243	14	which	which	WDT
cord-015922-5wwy0m2k	243	15	is	be	VBZ
cord-015922-5wwy0m2k	243	16	a	a	DT
cord-015922-5wwy0m2k	243	17	rare	rare	JJ
cord-015922-5wwy0m2k	243	18	,	,	,
cord-015922-5wwy0m2k	243	19	but	but	CC
cord-015922-5wwy0m2k	243	20	severe	severe	JJ
cord-015922-5wwy0m2k	243	21	post	post	JJ
cord-015922-5wwy0m2k	243	22	-	-	JJ
cord-015922-5wwy0m2k	243	23	transplant	transplant	JJ
cord-015922-5wwy0m2k	243	24	complication	complication	NN
cord-015922-5wwy0m2k	243	25	.	.	.
cord-015922-5wwy0m2k	244	1	PML	PML	NNP
cord-015922-5wwy0m2k	244	2	involves	involve	VBZ
cord-015922-5wwy0m2k	244	3	the	the	DT
cord-015922-5wwy0m2k	244	4	white	white	JJ
cord-015922-5wwy0m2k	244	5	matter	matter	NN
cord-015922-5wwy0m2k	244	6	and	and	CC
cord-015922-5wwy0m2k	244	7	presents	present	VBZ
cord-015922-5wwy0m2k	244	8	with	with	IN
cord-015922-5wwy0m2k	244	9	focal	focal	JJ
cord-015922-5wwy0m2k	244	10	neurologic	neurologic	JJ
cord-015922-5wwy0m2k	244	11	symptoms	symptom	NNS
cord-015922-5wwy0m2k	244	12	associated	associate	VBN
cord-015922-5wwy0m2k	244	13	with	with	IN
cord-015922-5wwy0m2k	244	14	the	the	DT
cord-015922-5wwy0m2k	244	15	specific	specific	JJ
cord-015922-5wwy0m2k	244	16	area	area	NN
cord-015922-5wwy0m2k	244	17	of	of	IN
cord-015922-5wwy0m2k	244	18	the	the	DT
cord-015922-5wwy0m2k	244	19	CNS	CNS	NNP
cord-015922-5wwy0m2k	244	20	where	where	WRB
cord-015922-5wwy0m2k	244	21	the	the	DT
cord-015922-5wwy0m2k	244	22	lesion(s	lesion(s	NNP
cord-015922-5wwy0m2k	244	23	)	)	-RRB-
cord-015922-5wwy0m2k	244	24	occur	occur	VB
cord-015922-5wwy0m2k	244	25	.	.	.
cord-015922-5wwy0m2k	245	1	Diagnosis	diagnosis	NN
cord-015922-5wwy0m2k	245	2	requires	require	VBZ
cord-015922-5wwy0m2k	245	3	correlating	correlate	VBG
cord-015922-5wwy0m2k	245	4	the	the	DT
cord-015922-5wwy0m2k	245	5	clinical	clinical	JJ
cord-015922-5wwy0m2k	245	6	presentation	presentation	NN
cord-015922-5wwy0m2k	245	7	,	,	,
cord-015922-5wwy0m2k	245	8	radiographic	radiographic	JJ
cord-015922-5wwy0m2k	245	9	findings	finding	NNS
cord-015922-5wwy0m2k	245	10	(	(	-LRB-
cord-015922-5wwy0m2k	245	11	typically	typically	RB
cord-015922-5wwy0m2k	245	12	by	by	IN
cord-015922-5wwy0m2k	245	13	contrast	contrast	NN
cord-015922-5wwy0m2k	245	14	-	-	HYPH
cord-015922-5wwy0m2k	245	15	enhanced	enhance	VBN
cord-015922-5wwy0m2k	245	16	MRI	MRI	NNP
cord-015922-5wwy0m2k	245	17	imaging	imaging	NN
cord-015922-5wwy0m2k	245	18	)	)	-RRB-
cord-015922-5wwy0m2k	245	19	and	and	CC
cord-015922-5wwy0m2k	245	20	CSF	CSF	NNP
cord-015922-5wwy0m2k	245	21	PCR	PCR	NNP
cord-015922-5wwy0m2k	245	22	results	result	NNS
cord-015922-5wwy0m2k	245	23	for	for	IN
cord-015922-5wwy0m2k	245	24	JC	JC	NNP
cord-015922-5wwy0m2k	245	25	virus	virus	NN
cord-015922-5wwy0m2k	245	26	.	.	.
cord-015922-5wwy0m2k	246	1	Control	Control	NNP
cord-015922-5wwy0m2k	246	2	of	of	IN
cord-015922-5wwy0m2k	246	3	JC	JC	NNP
cord-015922-5wwy0m2k	246	4	virus	virus	NN
cord-015922-5wwy0m2k	246	5	is	be	VBZ
cord-015922-5wwy0m2k	246	6	associated	associate	VBN
cord-015922-5wwy0m2k	246	7	with	with	IN
cord-015922-5wwy0m2k	246	8	an	an	DT
cord-015922-5wwy0m2k	246	9	intact	intact	JJ
cord-015922-5wwy0m2k	246	10	cell	cell	NN
cord-015922-5wwy0m2k	246	11	-	-	HYPH
cord-015922-5wwy0m2k	246	12	mediated	mediate	VBN
cord-015922-5wwy0m2k	246	13	immune	immune	JJ
cord-015922-5wwy0m2k	246	14	response	response	NN
cord-015922-5wwy0m2k	246	15	.	.	.
cord-015922-5wwy0m2k	247	1	Therapy	therapy	NN
cord-015922-5wwy0m2k	247	2	for	for	IN
cord-015922-5wwy0m2k	247	3	polyomavirus	polyomavirus	JJ
cord-015922-5wwy0m2k	247	4	infection	infection	NN
cord-015922-5wwy0m2k	247	5	is	be	VBZ
cord-015922-5wwy0m2k	247	6	quite	quite	RB
cord-015922-5wwy0m2k	247	7	limited	limited	JJ
cord-015922-5wwy0m2k	247	8	with	with	IN
cord-015922-5wwy0m2k	247	9	minimizing	minimize	VBG
cord-015922-5wwy0m2k	247	10	immunsuppression	immunsuppression	NN
cord-015922-5wwy0m2k	247	11	,	,	,
cord-015922-5wwy0m2k	247	12	when	when	WRB
cord-015922-5wwy0m2k	247	13	possible	possible	JJ
cord-015922-5wwy0m2k	247	14	,	,	,
cord-015922-5wwy0m2k	247	15	being	be	VBG
cord-015922-5wwy0m2k	247	16	critical	critical	JJ
cord-015922-5wwy0m2k	247	17	.	.	.
cord-015922-5wwy0m2k	248	1	The	the	DT
cord-015922-5wwy0m2k	248	2	role	role	NN
cord-015922-5wwy0m2k	248	3	of	of	IN
cord-015922-5wwy0m2k	248	4	cidofovir	cidofovir	NNP
cord-015922-5wwy0m2k	248	5	is	be	VBZ
cord-015922-5wwy0m2k	248	6	controversial	controversial	JJ
cord-015922-5wwy0m2k	248	7	with	with	IN
cord-015922-5wwy0m2k	248	8	mixed	mixed	JJ
cord-015922-5wwy0m2k	248	9	results	result	NNS
cord-015922-5wwy0m2k	248	10	being	be	VBG
cord-015922-5wwy0m2k	248	11	reported	report	VBN
cord-015922-5wwy0m2k	248	12	.	.	.
cord-015922-5wwy0m2k	249	1	The	the	DT
cord-015922-5wwy0m2k	249	2	use	use	NN
cord-015922-5wwy0m2k	249	3	of	of	IN
cord-015922-5wwy0m2k	249	4	quinolones	quinolone	NNS
cord-015922-5wwy0m2k	249	5	for	for	IN
cord-015922-5wwy0m2k	249	6	BK	BK	NNP
cord-015922-5wwy0m2k	249	7	viruria	viruria	NNP
cord-015922-5wwy0m2k	249	8	is	be	VBZ
cord-015922-5wwy0m2k	249	9	controversial	controversial	JJ
cord-015922-5wwy0m2k	249	10	at	at	IN
cord-015922-5wwy0m2k	249	11	best	good	JJS
cord-015922-5wwy0m2k	249	12	and	and	CC
cord-015922-5wwy0m2k	249	13	we	-PRON-	PRP
cord-015922-5wwy0m2k	249	14	do	do	VBP
cord-015922-5wwy0m2k	249	15	not	not	RB
cord-015922-5wwy0m2k	249	16	recommend	recommend	VB
cord-015922-5wwy0m2k	249	17	this	this	DT
cord-015922-5wwy0m2k	249	18	practice	practice	NN
cord-015922-5wwy0m2k	249	19	[	[	-LRB-
cord-015922-5wwy0m2k	249	20	66	66	CD
cord-015922-5wwy0m2k	249	21	]	]	-RRB-
cord-015922-5wwy0m2k	249	22	.	.	.
cord-015922-5wwy0m2k	250	1	Although	although	IN
cord-015922-5wwy0m2k	250	2	the	the	DT
cord-015922-5wwy0m2k	250	3	use	use	NN
cord-015922-5wwy0m2k	250	4	of	of	IN
cord-015922-5wwy0m2k	250	5	gatifloxacin	gatifloxacin	NNS
cord-015922-5wwy0m2k	250	6	was	be	VBD
cord-015922-5wwy0m2k	250	7	advocated	advocate	VBN
cord-015922-5wwy0m2k	250	8	by	by	IN
cord-015922-5wwy0m2k	250	9	some	some	DT
cord-015922-5wwy0m2k	250	10	authors	author	NNS
cord-015922-5wwy0m2k	250	11	,	,	,
cord-015922-5wwy0m2k	250	12	this	this	DT
cord-015922-5wwy0m2k	250	13	drug	drug	NN
cord-015922-5wwy0m2k	250	14	is	be	VBZ
cord-015922-5wwy0m2k	250	15	no	no	DT
cord-015922-5wwy0m2k	250	16	longer	long	RBR
cord-015922-5wwy0m2k	250	17	available	available	JJ
cord-015922-5wwy0m2k	250	18	.	.	.
cord-015922-5wwy0m2k	251	1	Leflunomide	Leflunomide	NNP
cord-015922-5wwy0m2k	251	2	administration	administration	NN
cord-015922-5wwy0m2k	251	3	has	have	VBZ
cord-015922-5wwy0m2k	251	4	been	be	VBN
cord-015922-5wwy0m2k	251	5	used	use	VBN
cord-015922-5wwy0m2k	251	6	by	by	IN
cord-015922-5wwy0m2k	251	7	some	some	DT
cord-015922-5wwy0m2k	251	8	for	for	IN
cord-015922-5wwy0m2k	251	9	treatment	treatment	NN
cord-015922-5wwy0m2k	251	10	of	of	IN
cord-015922-5wwy0m2k	251	11	BK	BK	NNP
cord-015922-5wwy0m2k	251	12	in	in	IN
cord-015922-5wwy0m2k	251	13	renal	renal	JJ
cord-015922-5wwy0m2k	251	14	transplant	transplant	NN
cord-015922-5wwy0m2k	251	15	patients	patient	NNS
cord-015922-5wwy0m2k	251	16	,	,	,
cord-015922-5wwy0m2k	251	17	but	but	CC
cord-015922-5wwy0m2k	251	18	no	no	DT
cord-015922-5wwy0m2k	251	19	randomized	randomized	JJ
cord-015922-5wwy0m2k	251	20	trial	trial	NN
cord-015922-5wwy0m2k	251	21	data	data	NN
cord-015922-5wwy0m2k	251	22	exists	exist	VBZ
cord-015922-5wwy0m2k	251	23	to	to	TO
cord-015922-5wwy0m2k	251	24	support	support	VB
cord-015922-5wwy0m2k	251	25	or	or	CC
cord-015922-5wwy0m2k	251	26	recommend	recommend	VB
cord-015922-5wwy0m2k	251	27	its	-PRON-	PRP$
cord-015922-5wwy0m2k	251	28	use	use	NN
cord-015922-5wwy0m2k	251	29	in	in	IN
cord-015922-5wwy0m2k	251	30	either	either	CC
cord-015922-5wwy0m2k	251	31	kidney	kidney	NN
cord-015922-5wwy0m2k	251	32	or	or	CC
cord-015922-5wwy0m2k	251	33	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	251	34	recipients	recipient	NNS
cord-015922-5wwy0m2k	251	35	at	at	IN
cord-015922-5wwy0m2k	251	36	this	this	DT
cord-015922-5wwy0m2k	251	37	time	time	NN
cord-015922-5wwy0m2k	251	38	.	.	.
cord-015922-5wwy0m2k	252	1	Hepatitis	Hepatitis	NNP
cord-015922-5wwy0m2k	252	2	B	B	NNP
cord-015922-5wwy0m2k	252	3	and	and	CC
cord-015922-5wwy0m2k	252	4	C	c	NN
cord-015922-5wwy0m2k	252	5	viruses	virus	NNS
cord-015922-5wwy0m2k	252	6	may	may	MD
cord-015922-5wwy0m2k	252	7	cause	cause	VB
cord-015922-5wwy0m2k	252	8	chronic	chronic	JJ
cord-015922-5wwy0m2k	252	9	infection	infection	NN
cord-015922-5wwy0m2k	252	10	which	which	WDT
cord-015922-5wwy0m2k	252	11	often	often	RB
cord-015922-5wwy0m2k	252	12	leads	lead	VBZ
cord-015922-5wwy0m2k	252	13	to	to	IN
cord-015922-5wwy0m2k	252	14	eventual	eventual	JJ
cord-015922-5wwy0m2k	252	15	significant	significant	JJ
cord-015922-5wwy0m2k	252	16	liver	liver	NN
cord-015922-5wwy0m2k	252	17	dysfunction	dysfunction	NN
cord-015922-5wwy0m2k	252	18	.	.	.
cord-015922-5wwy0m2k	253	1	Given	give	VBN
cord-015922-5wwy0m2k	253	2	the	the	DT
cord-015922-5wwy0m2k	253	3	high	high	JJ
cord-015922-5wwy0m2k	253	4	global	global	JJ
cord-015922-5wwy0m2k	253	5	prevalence	prevalence	NN
cord-015922-5wwy0m2k	253	6	of	of	IN
cord-015922-5wwy0m2k	253	7	these	these	DT
cord-015922-5wwy0m2k	253	8	viruses	virus	NNS
cord-015922-5wwy0m2k	253	9	,	,	,
cord-015922-5wwy0m2k	253	10	it	-PRON-	PRP
cord-015922-5wwy0m2k	253	11	is	be	VBZ
cord-015922-5wwy0m2k	253	12	prudent	prudent	JJ
cord-015922-5wwy0m2k	253	13	to	to	TO
cord-015922-5wwy0m2k	253	14	screen	screen	VB
cord-015922-5wwy0m2k	253	15	for	for	IN
cord-015922-5wwy0m2k	253	16	past	past	JJ
cord-015922-5wwy0m2k	253	17	or	or	CC
cord-015922-5wwy0m2k	253	18	current	current	JJ
cord-015922-5wwy0m2k	253	19	infection	infection	NN
cord-015922-5wwy0m2k	253	20	prior	prior	RB
cord-015922-5wwy0m2k	253	21	to	to	IN
cord-015922-5wwy0m2k	253	22	transplantation	transplantation	NN
cord-015922-5wwy0m2k	253	23	.	.	.
cord-015922-5wwy0m2k	254	1	When	when	WRB
cord-015922-5wwy0m2k	254	2	ongoing	ongoing	JJ
cord-015922-5wwy0m2k	254	3	infection	infection	NN
cord-015922-5wwy0m2k	254	4	is	be	VBZ
cord-015922-5wwy0m2k	254	5	found	find	VBN
cord-015922-5wwy0m2k	254	6	,	,	,
cord-015922-5wwy0m2k	254	7	careful	careful	JJ
cord-015922-5wwy0m2k	254	8	assessment	assessment	NN
cord-015922-5wwy0m2k	254	9	of	of	IN
cord-015922-5wwy0m2k	254	10	liver	liver	NN
cord-015922-5wwy0m2k	254	11	function	function	NN
cord-015922-5wwy0m2k	254	12	and	and	CC
cord-015922-5wwy0m2k	254	13	a	a	DT
cord-015922-5wwy0m2k	254	14	pre	pre	JJ
cord-015922-5wwy0m2k	254	15	-	-	JJ
cord-015922-5wwy0m2k	254	16	transplant	transplant	JJ
cord-015922-5wwy0m2k	254	17	liver	liver	NN
cord-015922-5wwy0m2k	254	18	biopsy	biopsy	NN
cord-015922-5wwy0m2k	254	19	should	should	MD
cord-015922-5wwy0m2k	254	20	be	be	VB
cord-015922-5wwy0m2k	254	21	considered	consider	VBN
cord-015922-5wwy0m2k	254	22	to	to	TO
cord-015922-5wwy0m2k	254	23	assess	assess	VB
cord-015922-5wwy0m2k	254	24	for	for	IN
cord-015922-5wwy0m2k	254	25	occult	occult	JJ
cord-015922-5wwy0m2k	254	26	cirrhosis	cirrhosis	NN
cord-015922-5wwy0m2k	254	27	,	,	,
cord-015922-5wwy0m2k	254	28	as	as	IN
cord-015922-5wwy0m2k	254	29	this	this	DT
cord-015922-5wwy0m2k	254	30	may	may	MD
cord-015922-5wwy0m2k	254	31	influence	influence	VB
cord-015922-5wwy0m2k	254	32	peri	peri	NN
cord-015922-5wwy0m2k	254	33	-	-	HYPH
cord-015922-5wwy0m2k	254	34	transplant	transplant	NN
cord-015922-5wwy0m2k	254	35	management	management	NN
cord-015922-5wwy0m2k	254	36	[	[	-LRB-
cord-015922-5wwy0m2k	254	37	67	67	CD
cord-015922-5wwy0m2k	254	38	]	]	-RRB-
cord-015922-5wwy0m2k	254	39	.	.	.
cord-015922-5wwy0m2k	255	1	HBV	HBV	NNP
cord-015922-5wwy0m2k	255	2	infects	infect	VBZ
cord-015922-5wwy0m2k	255	3	approximately	approximately	RB
cord-015922-5wwy0m2k	255	4	350	350	CD
cord-015922-5wwy0m2k	255	5	million	million	CD
cord-015922-5wwy0m2k	255	6	people	people	NNS
cord-015922-5wwy0m2k	255	7	worldwide	worldwide	RB
cord-015922-5wwy0m2k	255	8	chronically	chronically	RB
cord-015922-5wwy0m2k	255	9	,	,	,
cord-015922-5wwy0m2k	255	10	and	and	CC
cord-015922-5wwy0m2k	255	11	substantially	substantially	RB
cord-015922-5wwy0m2k	255	12	more	more	JJR
cord-015922-5wwy0m2k	255	13	have	have	VBP
cord-015922-5wwy0m2k	255	14	had	have	VBN
cord-015922-5wwy0m2k	255	15	prior	prior	RB
cord-015922-5wwy0m2k	255	16	resolved	resolve	VBN
cord-015922-5wwy0m2k	255	17	infection	infection	NN
cord-015922-5wwy0m2k	255	18	.	.	.
cord-015922-5wwy0m2k	256	1	The	the	DT
cord-015922-5wwy0m2k	256	2	use	use	NN
cord-015922-5wwy0m2k	256	3	of	of	IN
cord-015922-5wwy0m2k	256	4	the	the	DT
cord-015922-5wwy0m2k	256	5	HBV	HBV	NNP
cord-015922-5wwy0m2k	256	6	vaccine	vaccine	NN
cord-015922-5wwy0m2k	256	7	as	as	IN
cord-015922-5wwy0m2k	256	8	a	a	DT
cord-015922-5wwy0m2k	256	9	routine	routine	JJ
cord-015922-5wwy0m2k	256	10	childhood	childhood	NN
cord-015922-5wwy0m2k	256	11	immunization	immunization	NN
cord-015922-5wwy0m2k	256	12	will	will	MD
cord-015922-5wwy0m2k	256	13	likely	likely	RB
cord-015922-5wwy0m2k	256	14	decrease	decrease	VB
cord-015922-5wwy0m2k	256	15	the	the	DT
cord-015922-5wwy0m2k	256	16	number	number	NN
cord-015922-5wwy0m2k	256	17	of	of	IN
cord-015922-5wwy0m2k	256	18	chronically	chronically	RB
cord-015922-5wwy0m2k	256	19	infected	infect	VBN
cord-015922-5wwy0m2k	256	20	individuals	individual	NNS
cord-015922-5wwy0m2k	256	21	over	over	IN
cord-015922-5wwy0m2k	256	22	the	the	DT
cord-015922-5wwy0m2k	256	23	next	next	JJ
cord-015922-5wwy0m2k	256	24	several	several	JJ
cord-015922-5wwy0m2k	256	25	decades	decade	NNS
cord-015922-5wwy0m2k	256	26	.	.	.
cord-015922-5wwy0m2k	257	1	The	the	DT
cord-015922-5wwy0m2k	257	2	advent	advent	NN
cord-015922-5wwy0m2k	257	3	of	of	IN
cord-015922-5wwy0m2k	257	4	nucleic	nucleic	JJ
cord-015922-5wwy0m2k	257	5	acid	acid	NN
cord-015922-5wwy0m2k	257	6	detection	detection	NN
cord-015922-5wwy0m2k	257	7	technology	technology	NN
cord-015922-5wwy0m2k	257	8	has	have	VBZ
cord-015922-5wwy0m2k	257	9	allowed	allow	VBN
cord-015922-5wwy0m2k	257	10	a	a	DT
cord-015922-5wwy0m2k	257	11	more	more	RBR
cord-015922-5wwy0m2k	257	12	precise	precise	JJ
cord-015922-5wwy0m2k	257	13	mechanism	mechanism	NN
cord-015922-5wwy0m2k	257	14	to	to	TO
cord-015922-5wwy0m2k	257	15	detect	detect	VB
cord-015922-5wwy0m2k	257	16	active	active	JJ
cord-015922-5wwy0m2k	257	17	HBV	HBV	NNP
cord-015922-5wwy0m2k	257	18	replication	replication	NN
cord-015922-5wwy0m2k	257	19	compared	compare	VBN
cord-015922-5wwy0m2k	257	20	with	with	IN
cord-015922-5wwy0m2k	257	21	antigen-(for	antigen-(for	NNP
cord-015922-5wwy0m2k	257	22	surface	surface	NN
cord-015922-5wwy0m2k	257	23	and	and	CC
cord-015922-5wwy0m2k	257	24	e	e	LS
cord-015922-5wwy0m2k	257	25	)	)	-RRB-
cord-015922-5wwy0m2k	257	26	only	only	JJ
cord-015922-5wwy0m2k	257	27	methods	method	NNS
cord-015922-5wwy0m2k	257	28	.	.	.
cord-015922-5wwy0m2k	258	1	For	for	IN
cord-015922-5wwy0m2k	258	2	patients	patient	NNS
cord-015922-5wwy0m2k	258	3	with	with	IN
cord-015922-5wwy0m2k	258	4	evidence	evidence	NN
cord-015922-5wwy0m2k	258	5	of	of	IN
cord-015922-5wwy0m2k	258	6	prior	prior	JJ
cord-015922-5wwy0m2k	258	7	HBV	HBV	NNP
cord-015922-5wwy0m2k	258	8	exposure	exposure	NN
cord-015922-5wwy0m2k	258	9	(	(	-LRB-
cord-015922-5wwy0m2k	258	10	HBV	HBV	NNP
cord-015922-5wwy0m2k	258	11	core	core	NN
cord-015922-5wwy0m2k	258	12	antibody	antibody	NN
cord-015922-5wwy0m2k	258	13	positive	positive	JJ
cord-015922-5wwy0m2k	258	14	)	)	-RRB-
cord-015922-5wwy0m2k	258	15	,	,	,
cord-015922-5wwy0m2k	258	16	it	-PRON-	PRP
cord-015922-5wwy0m2k	258	17	is	be	VBZ
cord-015922-5wwy0m2k	258	18	important	important	JJ
cord-015922-5wwy0m2k	258	19	to	to	TO
cord-015922-5wwy0m2k	258	20	consider	consider	VB
cord-015922-5wwy0m2k	258	21	HBV	HBV	NNP
cord-015922-5wwy0m2k	258	22	reactivation	reactivation	NN
cord-015922-5wwy0m2k	258	23	in	in	IN
cord-015922-5wwy0m2k	258	24	the	the	DT
cord-015922-5wwy0m2k	258	25	setting	setting	NN
cord-015922-5wwy0m2k	258	26	of	of	IN
cord-015922-5wwy0m2k	258	27	post	post	JJ
cord-015922-5wwy0m2k	258	28	-	-	JJ
cord-015922-5wwy0m2k	258	29	transplant	transplant	JJ
cord-015922-5wwy0m2k	258	30	liver	liver	NN
cord-015922-5wwy0m2k	258	31	dysfunction	dysfunction	NN
cord-015922-5wwy0m2k	258	32	and	and	CC
cord-015922-5wwy0m2k	258	33	to	to	TO
cord-015922-5wwy0m2k	258	34	differentiate	differentiate	VB
cord-015922-5wwy0m2k	258	35	this	this	DT
cord-015922-5wwy0m2k	258	36	from	from	IN
cord-015922-5wwy0m2k	258	37	other	other	JJ
cord-015922-5wwy0m2k	258	38	causes	cause	NNS
cord-015922-5wwy0m2k	258	39	such	such	JJ
cord-015922-5wwy0m2k	258	40	as	as	IN
cord-015922-5wwy0m2k	258	41	hepatic	hepatic	JJ
cord-015922-5wwy0m2k	258	42	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	258	43	or	or	CC
cord-015922-5wwy0m2k	258	44	medication	medication	NN
cord-015922-5wwy0m2k	258	45	toxicity	toxicity	NN
cord-015922-5wwy0m2k	258	46	,	,	,
cord-015922-5wwy0m2k	258	47	although	although	IN
cord-015922-5wwy0m2k	258	48	reactivation	reactivation	NN
cord-015922-5wwy0m2k	258	49	initially	initially	RB
cord-015922-5wwy0m2k	258	50	occurs	occur	VBZ
cord-015922-5wwy0m2k	258	51	in	in	IN
cord-015922-5wwy0m2k	258	52	the	the	DT
cord-015922-5wwy0m2k	258	53	setting	setting	NN
cord-015922-5wwy0m2k	258	54	of	of	IN
cord-015922-5wwy0m2k	258	55	normal	normal	JJ
cord-015922-5wwy0m2k	258	56	liver	liver	NN
cord-015922-5wwy0m2k	258	57	tests	test	NNS
cord-015922-5wwy0m2k	258	58	.	.	.
cord-015922-5wwy0m2k	259	1	The	the	DT
cord-015922-5wwy0m2k	259	2	best	good	JJS
cord-015922-5wwy0m2k	259	3	strategy	strategy	NN
cord-015922-5wwy0m2k	259	4	for	for	IN
cord-015922-5wwy0m2k	259	5	surveillance	surveillance	NN
cord-015922-5wwy0m2k	259	6	post	post	JJ
cord-015922-5wwy0m2k	259	7	-	-	NN
cord-015922-5wwy0m2k	259	8	transplantation	transplantation	NN
cord-015922-5wwy0m2k	259	9	remains	remain	VBZ
cord-015922-5wwy0m2k	259	10	to	to	TO
cord-015922-5wwy0m2k	259	11	be	be	VB
cord-015922-5wwy0m2k	259	12	defined	define	VBN
cord-015922-5wwy0m2k	259	13	.	.	.
cord-015922-5wwy0m2k	260	1	Some	some	DT
cord-015922-5wwy0m2k	260	2	recommend	recommend	VBP
cord-015922-5wwy0m2k	260	3	routine	routine	JJ
cord-015922-5wwy0m2k	260	4	surveillance	surveillance	NN
cord-015922-5wwy0m2k	260	5	for	for	IN
cord-015922-5wwy0m2k	260	6	HBV	HBV	NNP
cord-015922-5wwy0m2k	260	7	reactivation	reactivation	NN
cord-015922-5wwy0m2k	260	8	post	post	NN
cord-015922-5wwy0m2k	260	9	-	-	NN
cord-015922-5wwy0m2k	260	10	transplantation	transplantation	NN
cord-015922-5wwy0m2k	260	11	,	,	,
cord-015922-5wwy0m2k	260	12	whereas	whereas	IN
cord-015922-5wwy0m2k	260	13	others	other	NNS
cord-015922-5wwy0m2k	260	14	would	would	MD
cord-015922-5wwy0m2k	260	15	suggest	suggest	VB
cord-015922-5wwy0m2k	260	16	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	260	17	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	260	18	.	.	.
cord-015922-5wwy0m2k	261	1	It	-PRON-	PRP
cord-015922-5wwy0m2k	261	2	is	be	VBZ
cord-015922-5wwy0m2k	261	3	important	important	JJ
cord-015922-5wwy0m2k	261	4	to	to	TO
cord-015922-5wwy0m2k	261	5	be	be	VB
cord-015922-5wwy0m2k	261	6	aware	aware	JJ
cord-015922-5wwy0m2k	261	7	that	that	IN
cord-015922-5wwy0m2k	261	8	old	old	JJ
cord-015922-5wwy0m2k	261	9	resolved	resolve	VBN
cord-015922-5wwy0m2k	261	10	infections	infection	NNS
cord-015922-5wwy0m2k	261	11	,	,	,
cord-015922-5wwy0m2k	261	12	including	include	VBG
cord-015922-5wwy0m2k	261	13	those	those	DT
cord-015922-5wwy0m2k	261	14	with	with	IN
cord-015922-5wwy0m2k	261	15	hepatitis	hepatitis	NN
cord-015922-5wwy0m2k	261	16	core	core	NN
cord-015922-5wwy0m2k	261	17	and	and	CC
cord-015922-5wwy0m2k	261	18	surface	surface	NN
cord-015922-5wwy0m2k	261	19	antibody	antibody	NN
cord-015922-5wwy0m2k	261	20	,	,	,
cord-015922-5wwy0m2k	261	21	but	but	CC
cord-015922-5wwy0m2k	261	22	without	without	IN
cord-015922-5wwy0m2k	261	23	antigen	antigen	NN
cord-015922-5wwy0m2k	261	24	or	or	CC
cord-015922-5wwy0m2k	261	25	HBV	HBV	NNP
cord-015922-5wwy0m2k	261	26	DNA	DNA	NNP
cord-015922-5wwy0m2k	261	27	detected	detect	VBD
cord-015922-5wwy0m2k	261	28	,	,	,
cord-015922-5wwy0m2k	261	29	are	be	VBP
cord-015922-5wwy0m2k	261	30	at	at	IN
cord-015922-5wwy0m2k	261	31	risk	risk	NN
cord-015922-5wwy0m2k	261	32	for	for	IN
cord-015922-5wwy0m2k	261	33	reactivation	reactivation	NN
cord-015922-5wwy0m2k	261	34	(	(	-LRB-
cord-015922-5wwy0m2k	261	35	seroreversion	seroreversion	NN
cord-015922-5wwy0m2k	261	36	)	)	-RRB-
cord-015922-5wwy0m2k	261	37	post	post	NN
cord-015922-5wwy0m2k	261	38	-	-	NN
cord-015922-5wwy0m2k	261	39	transplantation	transplantation	NN
cord-015922-5wwy0m2k	261	40	,	,	,
cord-015922-5wwy0m2k	261	41	especially	especially	RB
cord-015922-5wwy0m2k	261	42	in	in	IN
cord-015922-5wwy0m2k	261	43	the	the	DT
cord-015922-5wwy0m2k	261	44	setting	setting	NN
cord-015922-5wwy0m2k	261	45	of	of	IN
cord-015922-5wwy0m2k	261	46	high	high	JJ
cord-015922-5wwy0m2k	261	47	levels	level	NNS
cord-015922-5wwy0m2k	261	48	of	of	IN
cord-015922-5wwy0m2k	261	49	immunosuppression	immunosuppression	NN
cord-015922-5wwy0m2k	261	50	[	[	-LRB-
cord-015922-5wwy0m2k	261	51	68	68	CD
cord-015922-5wwy0m2k	261	52	,	,	,
cord-015922-5wwy0m2k	261	53	69	69	CD
cord-015922-5wwy0m2k	261	54	]	]	-RRB-
cord-015922-5wwy0m2k	261	55	.	.	.
cord-015922-5wwy0m2k	262	1	Several	several	JJ
cord-015922-5wwy0m2k	262	2	therapeutic	therapeutic	JJ
cord-015922-5wwy0m2k	262	3	options	option	NNS
cord-015922-5wwy0m2k	262	4	have	have	VBP
cord-015922-5wwy0m2k	262	5	become	become	VBN
cord-015922-5wwy0m2k	262	6	available	available	JJ
cord-015922-5wwy0m2k	262	7	over	over	IN
cord-015922-5wwy0m2k	262	8	the	the	DT
cord-015922-5wwy0m2k	262	9	last	last	JJ
cord-015922-5wwy0m2k	262	10	several	several	JJ
cord-015922-5wwy0m2k	262	11	years	year	NNS
cord-015922-5wwy0m2k	262	12	and	and	CC
cord-015922-5wwy0m2k	262	13	include	include	VBP
cord-015922-5wwy0m2k	262	14	lamivudine	lamivudine	JJ
cord-015922-5wwy0m2k	262	15	[	[	-LRB-
cord-015922-5wwy0m2k	262	16	70	70	CD
cord-015922-5wwy0m2k	262	17	]	]	-RRB-
cord-015922-5wwy0m2k	262	18	[	[	-LRB-
cord-015922-5wwy0m2k	262	19	71	71	CD
cord-015922-5wwy0m2k	262	20	]	]	-RRB-
cord-015922-5wwy0m2k	262	21	[	[	-LRB-
cord-015922-5wwy0m2k	262	22	72	72	CD
cord-015922-5wwy0m2k	262	23	]	]	-RRB-
cord-015922-5wwy0m2k	262	24	,	,	,
cord-015922-5wwy0m2k	262	25	adefovir	adefovir	NNP
cord-015922-5wwy0m2k	262	26	[	[	-LRB-
cord-015922-5wwy0m2k	262	27	73	73	CD
cord-015922-5wwy0m2k	262	28	]	]	-RRB-
cord-015922-5wwy0m2k	262	29	,	,	,
cord-015922-5wwy0m2k	262	30	entecavir	entecavir	NNP
cord-015922-5wwy0m2k	262	31	[	[	-LRB-
cord-015922-5wwy0m2k	262	32	71	71	CD
cord-015922-5wwy0m2k	262	33	,	,	,
cord-015922-5wwy0m2k	262	34	72	72	CD
cord-015922-5wwy0m2k	262	35	]	]	-RRB-
cord-015922-5wwy0m2k	262	36	and	and	CC
cord-015922-5wwy0m2k	262	37	telbivudine	telbivudine	NNP
cord-015922-5wwy0m2k	262	38	.	.	.
cord-015922-5wwy0m2k	263	1	Other	other	JJ
cord-015922-5wwy0m2k	263	2	agents	agent	NNS
cord-015922-5wwy0m2k	263	3	such	such	JJ
cord-015922-5wwy0m2k	263	4	as	as	IN
cord-015922-5wwy0m2k	263	5	tenofovir	tenofovir	NNP
cord-015922-5wwy0m2k	263	6	and	and	CC
cord-015922-5wwy0m2k	263	7	emtricitabine	emtricitabine	NNP
cord-015922-5wwy0m2k	263	8	also	also	RB
cord-015922-5wwy0m2k	263	9	have	have	VBP
cord-015922-5wwy0m2k	263	10	excellent	excellent	JJ
cord-015922-5wwy0m2k	263	11	anti	anti	JJ
cord-015922-5wwy0m2k	263	12	-	-	JJ
cord-015922-5wwy0m2k	263	13	HBV	hbv	JJ
cord-015922-5wwy0m2k	263	14	activity	activity	NN
cord-015922-5wwy0m2k	263	15	.	.	.
cord-015922-5wwy0m2k	264	1	Use	use	NN
cord-015922-5wwy0m2k	264	2	of	of	IN
cord-015922-5wwy0m2k	264	3	these	these	DT
cord-015922-5wwy0m2k	264	4	agents	agent	NNS
cord-015922-5wwy0m2k	264	5	requires	require	VBZ
cord-015922-5wwy0m2k	264	6	careful	careful	JJ
cord-015922-5wwy0m2k	264	7	consideration	consideration	NN
cord-015922-5wwy0m2k	264	8	to	to	TO
cord-015922-5wwy0m2k	264	9	minimize	minimize	VB
cord-015922-5wwy0m2k	264	10	the	the	DT
cord-015922-5wwy0m2k	264	11	risk	risk	NN
cord-015922-5wwy0m2k	264	12	for	for	IN
cord-015922-5wwy0m2k	264	13	the	the	DT
cord-015922-5wwy0m2k	264	14	emergence	emergence	NN
cord-015922-5wwy0m2k	264	15	of	of	IN
cord-015922-5wwy0m2k	264	16	resistant	resistant	JJ
cord-015922-5wwy0m2k	264	17	virus	virus	NN
cord-015922-5wwy0m2k	264	18	,	,	,
cord-015922-5wwy0m2k	264	19	which	which	WDT
cord-015922-5wwy0m2k	264	20	may	may	MD
cord-015922-5wwy0m2k	264	21	be	be	VB
cord-015922-5wwy0m2k	264	22	as	as	RB
cord-015922-5wwy0m2k	264	23	high	high	JJ
cord-015922-5wwy0m2k	264	24	as	as	IN
cord-015922-5wwy0m2k	264	25	10	10	CD
cord-015922-5wwy0m2k	264	26	percent	percent	NN
cord-015922-5wwy0m2k	264	27	per	per	IN
cord-015922-5wwy0m2k	264	28	year	year	NN
cord-015922-5wwy0m2k	264	29	for	for	IN
cord-015922-5wwy0m2k	264	30	lamivudine	lamivudine	NNP
cord-015922-5wwy0m2k	264	31	,	,	,
cord-015922-5wwy0m2k	264	32	but	but	CC
cord-015922-5wwy0m2k	264	33	is	be	VBZ
cord-015922-5wwy0m2k	264	34	less	less	JJR
cord-015922-5wwy0m2k	264	35	than	than	IN
cord-015922-5wwy0m2k	264	36	1	1	CD
cord-015922-5wwy0m2k	264	37	percent	percent	NN
cord-015922-5wwy0m2k	264	38	for	for	IN
cord-015922-5wwy0m2k	264	39	adefovir	adefovir	NNP
cord-015922-5wwy0m2k	264	40	and	and	CC
cord-015922-5wwy0m2k	264	41	entecavir	entecavir	NNP
cord-015922-5wwy0m2k	264	42	.	.	.
cord-015922-5wwy0m2k	265	1	Epidemiologic	epidemiologic	JJ
cord-015922-5wwy0m2k	265	2	studies	study	NNS
cord-015922-5wwy0m2k	265	3	suggest	suggest	VBP
cord-015922-5wwy0m2k	265	4	that	that	IN
cord-015922-5wwy0m2k	265	5	more	more	JJR
cord-015922-5wwy0m2k	265	6	than	than	IN
cord-015922-5wwy0m2k	265	7	170	170	CD
cord-015922-5wwy0m2k	265	8	million	million	CD
cord-015922-5wwy0m2k	265	9	people	people	NNS
cord-015922-5wwy0m2k	265	10	worldwide	worldwide	RB
cord-015922-5wwy0m2k	265	11	have	have	VBP
cord-015922-5wwy0m2k	265	12	been	be	VBN
cord-015922-5wwy0m2k	265	13	infected	infect	VBN
cord-015922-5wwy0m2k	265	14	with	with	IN
cord-015922-5wwy0m2k	265	15	hepatitis	hepatitis	NN
cord-015922-5wwy0m2k	265	16	C	C	NNP
cord-015922-5wwy0m2k	265	17	virus	virus	NN
cord-015922-5wwy0m2k	265	18	(	(	-LRB-
cord-015922-5wwy0m2k	265	19	HCV	HCV	NNP
cord-015922-5wwy0m2k	265	20	)	)	-RRB-
cord-015922-5wwy0m2k	265	21	and	and	CC
cord-015922-5wwy0m2k	265	22	the	the	DT
cord-015922-5wwy0m2k	265	23	majority	majority	NN
cord-015922-5wwy0m2k	265	24	(	(	-LRB-
cord-015922-5wwy0m2k	265	25	approximately	approximately	RB
cord-015922-5wwy0m2k	265	26	85	85	CD
cord-015922-5wwy0m2k	265	27	%	%	NN
cord-015922-5wwy0m2k	265	28	)	)	-RRB-
cord-015922-5wwy0m2k	265	29	are	be	VBP
cord-015922-5wwy0m2k	265	30	chronically	chronically	RB
cord-015922-5wwy0m2k	265	31	infected	infect	VBN
cord-015922-5wwy0m2k	265	32	[	[	-LRB-
cord-015922-5wwy0m2k	265	33	67	67	CD
cord-015922-5wwy0m2k	265	34	]	]	-RRB-
cord-015922-5wwy0m2k	265	35	.	.	.
cord-015922-5wwy0m2k	266	1	Over	over	IN
cord-015922-5wwy0m2k	266	2	several	several	JJ
cord-015922-5wwy0m2k	266	3	decades	decade	NNS
cord-015922-5wwy0m2k	266	4	,	,	,
cord-015922-5wwy0m2k	266	5	chronic	chronic	JJ
cord-015922-5wwy0m2k	266	6	HCV	HCV	NNP
cord-015922-5wwy0m2k	266	7	infection	infection	NN
cord-015922-5wwy0m2k	266	8	is	be	VBZ
cord-015922-5wwy0m2k	266	9	associated	associate	VBN
cord-015922-5wwy0m2k	266	10	with	with	IN
cord-015922-5wwy0m2k	266	11	progressive	progressive	JJ
cord-015922-5wwy0m2k	266	12	hepatic	hepatic	JJ
cord-015922-5wwy0m2k	266	13	fibrosis	fibrosis	NN
cord-015922-5wwy0m2k	266	14	,	,	,
cord-015922-5wwy0m2k	266	15	liver	liver	NN
cord-015922-5wwy0m2k	266	16	failure	failure	NN
cord-015922-5wwy0m2k	266	17	,	,	,
cord-015922-5wwy0m2k	266	18	and	and	CC
cord-015922-5wwy0m2k	266	19	hepatoma	hepatoma	NNP
cord-015922-5wwy0m2k	266	20	.	.	.
cord-015922-5wwy0m2k	267	1	This	this	DT
cord-015922-5wwy0m2k	267	2	process	process	NN
cord-015922-5wwy0m2k	267	3	is	be	VBZ
cord-015922-5wwy0m2k	267	4	accelerated	accelerate	VBN
cord-015922-5wwy0m2k	267	5	in	in	IN
cord-015922-5wwy0m2k	267	6	certain	certain	JJ
cord-015922-5wwy0m2k	267	7	immunocompromised	immunocompromised	JJ
cord-015922-5wwy0m2k	267	8	patients	patient	NNS
cord-015922-5wwy0m2k	267	9	including	include	VBG
cord-015922-5wwy0m2k	267	10	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	267	11	recipients	recipient	NNS
cord-015922-5wwy0m2k	267	12	[	[	-LRB-
cord-015922-5wwy0m2k	267	13	74	74	CD
cord-015922-5wwy0m2k	267	14	,	,	,
cord-015922-5wwy0m2k	267	15	75	75	CD
cord-015922-5wwy0m2k	267	16	]	]	-RRB-
cord-015922-5wwy0m2k	267	17	.	.	.
cord-015922-5wwy0m2k	268	1	It	-PRON-	PRP
cord-015922-5wwy0m2k	268	2	is	be	VBZ
cord-015922-5wwy0m2k	268	3	important	important	JJ
cord-015922-5wwy0m2k	268	4	to	to	TO
cord-015922-5wwy0m2k	268	5	assess	assess	VB
cord-015922-5wwy0m2k	268	6	patients	patient	NNS
cord-015922-5wwy0m2k	268	7	for	for	IN
cord-015922-5wwy0m2k	268	8	seropositivity	seropositivity	NN
cord-015922-5wwy0m2k	268	9	to	to	IN
cord-015922-5wwy0m2k	268	10	HCV	HCV	NNP
cord-015922-5wwy0m2k	268	11	prior	prior	RB
cord-015922-5wwy0m2k	268	12	to	to	IN
cord-015922-5wwy0m2k	268	13	transplantation	transplantation	NN
cord-015922-5wwy0m2k	268	14	and	and	CC
cord-015922-5wwy0m2k	268	15	in	in	IN
cord-015922-5wwy0m2k	268	16	those	those	DT
cord-015922-5wwy0m2k	268	17	who	who	WP
cord-015922-5wwy0m2k	268	18	are	be	VBP
cord-015922-5wwy0m2k	268	19	found	find	VBN
cord-015922-5wwy0m2k	268	20	seropositive	seropositive	JJ
cord-015922-5wwy0m2k	268	21	,	,	,
cord-015922-5wwy0m2k	268	22	to	to	TO
cord-015922-5wwy0m2k	268	23	assess	assess	VB
cord-015922-5wwy0m2k	268	24	the	the	DT
cord-015922-5wwy0m2k	268	25	HCV	HCV	NNP
cord-015922-5wwy0m2k	268	26	viral	viral	JJ
cord-015922-5wwy0m2k	268	27	load	load	NN
cord-015922-5wwy0m2k	268	28	,	,	,
cord-015922-5wwy0m2k	268	29	genotype	genotype	NN
cord-015922-5wwy0m2k	268	30	and	and	CC
cord-015922-5wwy0m2k	268	31	liver	liver	NN
cord-015922-5wwy0m2k	268	32	pathology	pathology	NN
cord-015922-5wwy0m2k	268	33	.	.	.
cord-015922-5wwy0m2k	269	1	The	the	DT
cord-015922-5wwy0m2k	269	2	presence	presence	NN
cord-015922-5wwy0m2k	269	3	of	of	IN
cord-015922-5wwy0m2k	269	4	elevated	elevated	JJ
cord-015922-5wwy0m2k	269	5	liver	liver	NN
cord-015922-5wwy0m2k	269	6	enzymes	enzyme	NNS
cord-015922-5wwy0m2k	269	7	in	in	IN
cord-015922-5wwy0m2k	269	8	the	the	DT
cord-015922-5wwy0m2k	269	9	setting	setting	NN
cord-015922-5wwy0m2k	269	10	of	of	IN
cord-015922-5wwy0m2k	269	11	HCV	HCV	NNP
cord-015922-5wwy0m2k	269	12	before	before	IN
cord-015922-5wwy0m2k	269	13	allogeneic	allogeneic	NN
cord-015922-5wwy0m2k	269	14	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	269	15	has	have	VBZ
cord-015922-5wwy0m2k	269	16	been	be	VBN
cord-015922-5wwy0m2k	269	17	associated	associate	VBN
cord-015922-5wwy0m2k	269	18	with	with	IN
cord-015922-5wwy0m2k	269	19	an	an	DT
cord-015922-5wwy0m2k	269	20	increased	increase	VBN
cord-015922-5wwy0m2k	269	21	incidence	incidence	NN
cord-015922-5wwy0m2k	269	22	of	of	IN
cord-015922-5wwy0m2k	269	23	VOD	VOD	NNP
cord-015922-5wwy0m2k	269	24	[	[	-LRB-
cord-015922-5wwy0m2k	269	25	76	76	CD
cord-015922-5wwy0m2k	269	26	]	]	-RRB-
cord-015922-5wwy0m2k	269	27	.	.	.
cord-015922-5wwy0m2k	270	1	A	a	DT
cord-015922-5wwy0m2k	270	2	more	more	RBR
cord-015922-5wwy0m2k	270	3	precise	precise	JJ
cord-015922-5wwy0m2k	270	4	profiling	profiling	NN
cord-015922-5wwy0m2k	270	5	of	of	IN
cord-015922-5wwy0m2k	270	6	the	the	DT
cord-015922-5wwy0m2k	270	7	HCV	HCV	NNP
cord-015922-5wwy0m2k	270	8	-	-	HYPH
cord-015922-5wwy0m2k	270	9	infected	infect	VBN
cord-015922-5wwy0m2k	270	10	patient	patient	NN
cord-015922-5wwy0m2k	270	11	,	,	,
cord-015922-5wwy0m2k	270	12	including	include	VBG
cord-015922-5wwy0m2k	270	13	liver	liver	NN
cord-015922-5wwy0m2k	270	14	biopsy	biopsy	NN
cord-015922-5wwy0m2k	270	15	,	,	,
cord-015922-5wwy0m2k	270	16	should	should	MD
cord-015922-5wwy0m2k	270	17	be	be	VB
cord-015922-5wwy0m2k	270	18	considered	consider	VBN
cord-015922-5wwy0m2k	270	19	to	to	TO
cord-015922-5wwy0m2k	270	20	better	better	RB
cord-015922-5wwy0m2k	270	21	define	define	VB
cord-015922-5wwy0m2k	270	22	the	the	DT
cord-015922-5wwy0m2k	270	23	extent	extent	NN
cord-015922-5wwy0m2k	270	24	of	of	IN
cord-015922-5wwy0m2k	270	25	the	the	DT
cord-015922-5wwy0m2k	270	26	HCV	HCV	NNP
cord-015922-5wwy0m2k	270	27	-	-	HYPH
cord-015922-5wwy0m2k	270	28	induced	induce	VBN
cord-015922-5wwy0m2k	270	29	liver	liver	NN
cord-015922-5wwy0m2k	270	30	disease	disease	NN
cord-015922-5wwy0m2k	270	31	,	,	,
cord-015922-5wwy0m2k	270	32	and	and	CC
cord-015922-5wwy0m2k	270	33	to	to	TO
cord-015922-5wwy0m2k	270	34	optimize	optimize	VB
cord-015922-5wwy0m2k	270	35	the	the	DT
cord-015922-5wwy0m2k	270	36	conditioning	conditioning	NN
cord-015922-5wwy0m2k	270	37	regimen	regimen	NN
cord-015922-5wwy0m2k	270	38	and	and	CC
cord-015922-5wwy0m2k	270	39	frequency	frequency	NN
cord-015922-5wwy0m2k	270	40	of	of	IN
cord-015922-5wwy0m2k	270	41	surveillance	surveillance	NN
cord-015922-5wwy0m2k	270	42	posttransplantation	posttransplantation	NN
cord-015922-5wwy0m2k	270	43	.	.	.
cord-015922-5wwy0m2k	271	1	Treatment	treatment	NN
cord-015922-5wwy0m2k	271	2	of	of	IN
cord-015922-5wwy0m2k	271	3	HCV	HCV	NNP
cord-015922-5wwy0m2k	271	4	is	be	VBZ
cord-015922-5wwy0m2k	271	5	limited	limit	VBN
cord-015922-5wwy0m2k	271	6	and	and	CC
cord-015922-5wwy0m2k	271	7	typically	typically	RB
cord-015922-5wwy0m2k	271	8	requires	require	VBZ
cord-015922-5wwy0m2k	271	9	use	use	NN
cord-015922-5wwy0m2k	271	10	of	of	IN
cord-015922-5wwy0m2k	271	11	an	an	DT
cord-015922-5wwy0m2k	271	12	interferon	interferon	NN
cord-015922-5wwy0m2k	271	13	and	and	CC
cord-015922-5wwy0m2k	271	14	ribavirin	ribavirin	NN
cord-015922-5wwy0m2k	271	15	which	which	WDT
cord-015922-5wwy0m2k	271	16	are	be	VBP
cord-015922-5wwy0m2k	271	17	likely	likely	JJ
cord-015922-5wwy0m2k	271	18	to	to	TO
cord-015922-5wwy0m2k	271	19	be	be	VB
cord-015922-5wwy0m2k	271	20	poorly	poorly	RB
cord-015922-5wwy0m2k	271	21	tolerated	tolerate	VBN
cord-015922-5wwy0m2k	271	22	in	in	IN
cord-015922-5wwy0m2k	271	23	the	the	DT
cord-015922-5wwy0m2k	271	24	early	early	JJ
cord-015922-5wwy0m2k	271	25	post	post	JJ
cord-015922-5wwy0m2k	271	26	-	-	JJ
cord-015922-5wwy0m2k	271	27	transplant	transplant	JJ
cord-015922-5wwy0m2k	271	28	setting	setting	NN
cord-015922-5wwy0m2k	271	29	.	.	.
cord-015922-5wwy0m2k	272	1	In	in	IN
cord-015922-5wwy0m2k	272	2	patients	patient	NNS
cord-015922-5wwy0m2k	272	3	who	who	WP
cord-015922-5wwy0m2k	272	4	are	be	VBP
cord-015922-5wwy0m2k	272	5	infected	infect	VBN
cord-015922-5wwy0m2k	272	6	,	,	,
cord-015922-5wwy0m2k	272	7	it	-PRON-	PRP
cord-015922-5wwy0m2k	272	8	is	be	VBZ
cord-015922-5wwy0m2k	272	9	prudent	prudent	JJ
cord-015922-5wwy0m2k	272	10	to	to	TO
cord-015922-5wwy0m2k	272	11	counsel	counsel	VB
cord-015922-5wwy0m2k	272	12	them	-PRON-	PRP
cord-015922-5wwy0m2k	272	13	to	to	TO
cord-015922-5wwy0m2k	272	14	avoid	avoid	VB
cord-015922-5wwy0m2k	272	15	hepatotoxins	hepatotoxin	NNS
cord-015922-5wwy0m2k	272	16	,	,	,
cord-015922-5wwy0m2k	272	17	receive	receive	VB
cord-015922-5wwy0m2k	272	18	the	the	DT
cord-015922-5wwy0m2k	272	19	hepatitis	hepatitis	NN
cord-015922-5wwy0m2k	272	20	A	a	NN
cord-015922-5wwy0m2k	272	21	and	and	CC
cord-015922-5wwy0m2k	272	22	B	b	NN
cord-015922-5wwy0m2k	272	23	vaccines	vaccine	NNS
cord-015922-5wwy0m2k	272	24	,	,	,
cord-015922-5wwy0m2k	272	25	and	and	CC
cord-015922-5wwy0m2k	272	26	minimize	minimize	VB
cord-015922-5wwy0m2k	272	27	the	the	DT
cord-015922-5wwy0m2k	272	28	risk	risk	NN
cord-015922-5wwy0m2k	272	29	of	of	IN
cord-015922-5wwy0m2k	272	30	transmission	transmission	NN
cord-015922-5wwy0m2k	272	31	to	to	TO
cord-015922-5wwy0m2k	272	32	close	close	VB
cord-015922-5wwy0m2k	272	33	contacts	contact	NNS
cord-015922-5wwy0m2k	272	34	.	.	.
cord-015922-5wwy0m2k	273	1	There	there	EX
cord-015922-5wwy0m2k	273	2	are	be	VBP
cord-015922-5wwy0m2k	273	3	three	three	CD
cord-015922-5wwy0m2k	273	4	categories	category	NNS
cord-015922-5wwy0m2k	273	5	of	of	IN
cord-015922-5wwy0m2k	273	6	fungal	fungal	JJ
cord-015922-5wwy0m2k	273	7	pathogens	pathogen	NNS
cord-015922-5wwy0m2k	273	8	that	that	WDT
cord-015922-5wwy0m2k	273	9	can	can	MD
cord-015922-5wwy0m2k	273	10	infect	infect	VB
cord-015922-5wwy0m2k	273	11	the	the	DT
cord-015922-5wwy0m2k	273	12	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	273	13	patient	patient	NN
cord-015922-5wwy0m2k	273	14	:	:	:
cord-015922-5wwy0m2k	273	15	a	a	LS
cord-015922-5wwy0m2k	273	16	)	)	-RRB-
cord-015922-5wwy0m2k	273	17	the	the	DT
cord-015922-5wwy0m2k	273	18	classic	classic	JJ
cord-015922-5wwy0m2k	273	19	opportunistic	opportunistic	JJ
cord-015922-5wwy0m2k	273	20	fungi	fungus	NNS
cord-015922-5wwy0m2k	273	21	,	,	,
cord-015922-5wwy0m2k	273	22	which	which	WDT
cord-015922-5wwy0m2k	273	23	cause	cause	VBP
cord-015922-5wwy0m2k	273	24	>	>	XX
cord-015922-5wwy0m2k	273	25	90	90	CD
cord-015922-5wwy0m2k	273	26	percent	percent	NN
cord-015922-5wwy0m2k	273	27	of	of	IN
cord-015922-5wwy0m2k	273	28	the	the	DT
cord-015922-5wwy0m2k	273	29	invasive	invasive	JJ
cord-015922-5wwy0m2k	273	30	fungal	fungal	JJ
cord-015922-5wwy0m2k	273	31	infections	infection	NNS
cord-015922-5wwy0m2k	273	32	that	that	WDT
cord-015922-5wwy0m2k	273	33	occur	occur	VBP
cord-015922-5wwy0m2k	273	34	in	in	IN
cord-015922-5wwy0m2k	273	35	the	the	DT
cord-015922-5wwy0m2k	273	36	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	273	37	patient	patient	NN
cord-015922-5wwy0m2k	274	1	-Candida	-Candida	NNP
cord-015922-5wwy0m2k	274	2	,	,	,
cord-015922-5wwy0m2k	274	3	Aspergillus	Aspergillus	NNP
cord-015922-5wwy0m2k	274	4	and	and	CC
cord-015922-5wwy0m2k	274	5	Cryptococcus	Cryptococcus	NNP
cord-015922-5wwy0m2k	274	6	being	be	VBG
cord-015922-5wwy0m2k	274	7	the	the	DT
cord-015922-5wwy0m2k	274	8	most	most	RBS
cord-015922-5wwy0m2k	274	9	important	important	JJ
cord-015922-5wwy0m2k	274	10	of	of	IN
cord-015922-5wwy0m2k	274	11	these	these	DT
cord-015922-5wwy0m2k	274	12	infections	infection	NNS
cord-015922-5wwy0m2k	274	13	;	;	:
cord-015922-5wwy0m2k	274	14	b	b	LS
cord-015922-5wwy0m2k	274	15	)	)	-RRB-
cord-015922-5wwy0m2k	274	16	the	the	DT
cord-015922-5wwy0m2k	274	17	geographically	geographically	RB
cord-015922-5wwy0m2k	274	18	restricted	restricted	JJ
cord-015922-5wwy0m2k	274	19	systemic	systemic	JJ
cord-015922-5wwy0m2k	274	20	mycoses	mycose	NNS
cord-015922-5wwy0m2k	274	21	caused	cause	VBN
cord-015922-5wwy0m2k	274	22	by	by	IN
cord-015922-5wwy0m2k	274	23	Blastomyces	Blastomyces	NNP
cord-015922-5wwy0m2k	274	24	dermatitidis	dermatitidis	NN
cord-015922-5wwy0m2k	274	25	,	,	,
cord-015922-5wwy0m2k	274	26	Coccidioides	Coccidioides	NNP
cord-015922-5wwy0m2k	274	27	immitis	immitis	NNP
cord-015922-5wwy0m2k	274	28	and	and	CC
cord-015922-5wwy0m2k	274	29	Histoplasma	Histoplasma	NNP
cord-015922-5wwy0m2k	274	30	capsulatum	capsulatum	NN
cord-015922-5wwy0m2k	274	31	;	;	:
cord-015922-5wwy0m2k	274	32	and	and	CC
cord-015922-5wwy0m2k	274	33	c	c	LS
cord-015922-5wwy0m2k	274	34	)	)	-RRB-
cord-015922-5wwy0m2k	274	35	invasive	invasive	JJ
cord-015922-5wwy0m2k	274	36	infection	infection	NN
cord-015922-5wwy0m2k	274	37	due	due	IN
cord-015922-5wwy0m2k	274	38	to	to	IN
cord-015922-5wwy0m2k	274	39	the	the	DT
cord-015922-5wwy0m2k	274	40	so	so	RB
cord-015922-5wwy0m2k	274	41	-	-	HYPH
cord-015922-5wwy0m2k	274	42	called	call	VBN
cord-015922-5wwy0m2k	274	43	"	"	``
cord-015922-5wwy0m2k	274	44	newly	newly	RB
cord-015922-5wwy0m2k	274	45	emerging	emerge	VBG
cord-015922-5wwy0m2k	274	46	fungi	fungus	NNS
cord-015922-5wwy0m2k	274	47	"	"	''
cord-015922-5wwy0m2k	274	48	-Fusarium	-fusarium	NN
cord-015922-5wwy0m2k	274	49	,	,	,
cord-015922-5wwy0m2k	274	50	the	the	DT
cord-015922-5wwy0m2k	274	51	zygomycetes	zygomycetes	NNPS
cord-015922-5wwy0m2k	274	52	and	and	CC
cord-015922-5wwy0m2k	274	53	such	such	JJ
cord-015922-5wwy0m2k	274	54	dematiaceous	dematiaceous	JJ
cord-015922-5wwy0m2k	274	55	fungi	fungus	NNS
cord-015922-5wwy0m2k	274	56	as	as	IN
cord-015922-5wwy0m2k	274	57	Scedosporium	Scedosporium	NNP
cord-015922-5wwy0m2k	274	58	,	,	,
cord-015922-5wwy0m2k	274	59	Scopulariopsis	Scopulariopsis	NNP
cord-015922-5wwy0m2k	274	60	and	and	CC
cord-015922-5wwy0m2k	274	61	Dactylaria	Dactylaria	NNP
cord-015922-5wwy0m2k	274	62	[	[	-LRB-
cord-015922-5wwy0m2k	274	63	4	4	CD
cord-015922-5wwy0m2k	274	64	]	]	-RRB-
cord-015922-5wwy0m2k	274	65	.	.	.
cord-015922-5wwy0m2k	275	1	Candida	Candida	NNP
cord-015922-5wwy0m2k	275	2	is	be	VBZ
cord-015922-5wwy0m2k	275	3	a	a	DT
cord-015922-5wwy0m2k	275	4	major	major	JJ
cord-015922-5wwy0m2k	275	5	cause	cause	NN
cord-015922-5wwy0m2k	275	6	of	of	IN
cord-015922-5wwy0m2k	275	7	fungal	fungal	JJ
cord-015922-5wwy0m2k	275	8	bloodstream	bloodstream	NN
cord-015922-5wwy0m2k	275	9	infection	infection	NN
cord-015922-5wwy0m2k	275	10	during	during	IN
cord-015922-5wwy0m2k	275	11	the	the	DT
cord-015922-5wwy0m2k	275	12	preengraftment	preengraftment	NN
cord-015922-5wwy0m2k	275	13	phase	phase	NN
cord-015922-5wwy0m2k	275	14	of	of	IN
cord-015922-5wwy0m2k	275	15	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	275	16	.	.	.
cord-015922-5wwy0m2k	276	1	Although	although	IN
cord-015922-5wwy0m2k	276	2	there	there	EX
cord-015922-5wwy0m2k	276	3	is	be	VBZ
cord-015922-5wwy0m2k	276	4	the	the	DT
cord-015922-5wwy0m2k	276	5	possibility	possibility	NN
cord-015922-5wwy0m2k	276	6	that	that	IN
cord-015922-5wwy0m2k	276	7	the	the	DT
cord-015922-5wwy0m2k	276	8	portal	portal	NN
cord-015922-5wwy0m2k	276	9	of	of	IN
cord-015922-5wwy0m2k	276	10	entry	entry	NN
cord-015922-5wwy0m2k	276	11	can	can	MD
cord-015922-5wwy0m2k	276	12	be	be	VB
cord-015922-5wwy0m2k	276	13	vascular	vascular	JJ
cord-015922-5wwy0m2k	276	14	access	access	NN
cord-015922-5wwy0m2k	276	15	catheters	catheter	NNS
cord-015922-5wwy0m2k	276	16	,	,	,
cord-015922-5wwy0m2k	276	17	it	-PRON-	PRP
cord-015922-5wwy0m2k	276	18	is	be	VBZ
cord-015922-5wwy0m2k	276	19	believed	believe	VBN
cord-015922-5wwy0m2k	276	20	that	that	IN
cord-015922-5wwy0m2k	276	21	translocation	translocation	NN
cord-015922-5wwy0m2k	276	22	of	of	IN
cord-015922-5wwy0m2k	276	23	Candida	Candida	NNP
cord-015922-5wwy0m2k	276	24	species	specie	NNS
cord-015922-5wwy0m2k	276	25	across	across	IN
cord-015922-5wwy0m2k	276	26	gut	gut	NN
cord-015922-5wwy0m2k	276	27	mucosa	mucosa	NN
cord-015922-5wwy0m2k	276	28	damaged	damage	VBN
cord-015922-5wwy0m2k	276	29	by	by	IN
cord-015922-5wwy0m2k	276	30	the	the	DT
cord-015922-5wwy0m2k	276	31	pre	pre	JJ
cord-015922-5wwy0m2k	276	32	-	-	JJ
cord-015922-5wwy0m2k	276	33	transplant	transplant	JJ
cord-015922-5wwy0m2k	276	34	conditioning	conditioning	NN
cord-015922-5wwy0m2k	276	35	regimen	regimen	NN
cord-015922-5wwy0m2k	276	36	is	be	VBZ
cord-015922-5wwy0m2k	276	37	the	the	DT
cord-015922-5wwy0m2k	276	38	major	major	JJ
cord-015922-5wwy0m2k	276	39	route	route	NN
cord-015922-5wwy0m2k	276	40	of	of	IN
cord-015922-5wwy0m2k	276	41	access	access	NN
cord-015922-5wwy0m2k	276	42	to	to	IN
cord-015922-5wwy0m2k	276	43	the	the	DT
cord-015922-5wwy0m2k	276	44	bloodstream	bloodstream	NN
cord-015922-5wwy0m2k	276	45	in	in	IN
cord-015922-5wwy0m2k	276	46	the	the	DT
cord-015922-5wwy0m2k	276	47	granulocytopenic	granulocytopenic	JJ
cord-015922-5wwy0m2k	276	48	patient	patient	NN
cord-015922-5wwy0m2k	276	49	[	[	-LRB-
cord-015922-5wwy0m2k	276	50	77	77	CD
cord-015922-5wwy0m2k	276	51	,	,	,
cord-015922-5wwy0m2k	276	52	78	78	CD
cord-015922-5wwy0m2k	276	53	]	]	-RRB-
cord-015922-5wwy0m2k	276	54	.	.	.
cord-015922-5wwy0m2k	277	1	In	in	IN
cord-015922-5wwy0m2k	277	2	the	the	DT
cord-015922-5wwy0m2k	277	3	past	past	NN
cord-015922-5wwy0m2k	277	4	,	,	,
cord-015922-5wwy0m2k	277	5	C.	C.	NNP
cord-015922-5wwy0m2k	277	6	albicans	albican	NNS
cord-015922-5wwy0m2k	277	7	and	and	CC
cord-015922-5wwy0m2k	277	8	C.	C.	NNP
cord-015922-5wwy0m2k	277	9	tropicalis	tropicalis	NNP
cord-015922-5wwy0m2k	277	10	accounted	account	VBD
cord-015922-5wwy0m2k	277	11	for	for	IN
cord-015922-5wwy0m2k	277	12	virtually	virtually	RB
cord-015922-5wwy0m2k	277	13	all	all	DT
cord-015922-5wwy0m2k	277	14	of	of	IN
cord-015922-5wwy0m2k	277	15	the	the	DT
cord-015922-5wwy0m2k	277	16	Candida	Candida	NNP
cord-015922-5wwy0m2k	277	17	bloodstream	bloodstream	NN
cord-015922-5wwy0m2k	277	18	infections	infection	NNS
cord-015922-5wwy0m2k	277	19	.	.	.
cord-015922-5wwy0m2k	278	1	The	the	DT
cord-015922-5wwy0m2k	278	2	incidence	incidence	NN
cord-015922-5wwy0m2k	278	3	of	of	IN
cord-015922-5wwy0m2k	278	4	candidemia	candidemia	NN
cord-015922-5wwy0m2k	278	5	was	be	VBD
cord-015922-5wwy0m2k	278	6	∼11	∼11	NN
cord-015922-5wwy0m2k	278	7	to	to	IN
cord-015922-5wwy0m2k	278	8	16	16	CD
cord-015922-5wwy0m2k	278	9	percent	percent	NN
cord-015922-5wwy0m2k	278	10	(	(	-LRB-
cord-015922-5wwy0m2k	278	11	with	with	IN
cord-015922-5wwy0m2k	278	12	a	a	DT
cord-015922-5wwy0m2k	278	13	median	median	JJ
cord-015922-5wwy0m2k	278	14	time	time	NN
cord-015922-5wwy0m2k	278	15	to	to	IN
cord-015922-5wwy0m2k	278	16	onset	onset	NN
cord-015922-5wwy0m2k	278	17	of	of	IN
cord-015922-5wwy0m2k	278	18	two	two	CD
cord-015922-5wwy0m2k	278	19	weeks	week	NNS
cord-015922-5wwy0m2k	278	20	post	post	NN
cord-015922-5wwy0m2k	278	21	-	-	JJ
cord-015922-5wwy0m2k	278	22	transplant	transplant	JJ
cord-015922-5wwy0m2k	278	23	)	)	-RRB-
cord-015922-5wwy0m2k	278	24	,	,	,
cord-015922-5wwy0m2k	278	25	resulting	result	VBG
cord-015922-5wwy0m2k	278	26	in	in	IN
cord-015922-5wwy0m2k	278	27	a	a	DT
cord-015922-5wwy0m2k	278	28	high	high	JJ
cord-015922-5wwy0m2k	278	29	rate	rate	NN
cord-015922-5wwy0m2k	278	30	of	of	IN
cord-015922-5wwy0m2k	278	31	tissue	tissue	NN
cord-015922-5wwy0m2k	278	32	invasion	invasion	NN
cord-015922-5wwy0m2k	278	33	and	and	CC
cord-015922-5wwy0m2k	278	34	an	an	DT
cord-015922-5wwy0m2k	278	35	attributable	attributable	JJ
cord-015922-5wwy0m2k	278	36	mortality	mortality	NN
cord-015922-5wwy0m2k	278	37	of	of	IN
cord-015922-5wwy0m2k	278	38	nearly	nearly	RB
cord-015922-5wwy0m2k	278	39	40	40	CD
cord-015922-5wwy0m2k	278	40	percent	percent	NN
cord-015922-5wwy0m2k	278	41	[	[	-LRB-
cord-015922-5wwy0m2k	278	42	79	79	CD
cord-015922-5wwy0m2k	278	43	,	,	,
cord-015922-5wwy0m2k	278	44	80	80	CD
cord-015922-5wwy0m2k	278	45	]	]	-RRB-
cord-015922-5wwy0m2k	278	46	.	.	.
cord-015922-5wwy0m2k	279	1	With	with	IN
cord-015922-5wwy0m2k	279	2	the	the	DT
cord-015922-5wwy0m2k	279	3	introduction	introduction	NN
cord-015922-5wwy0m2k	279	4	of	of	IN
cord-015922-5wwy0m2k	279	5	empirical	empirical	JJ
cord-015922-5wwy0m2k	279	6	antifungal	antifungal	NN
cord-015922-5wwy0m2k	279	7	therapy	therapy	NN
cord-015922-5wwy0m2k	279	8	or	or	CC
cord-015922-5wwy0m2k	279	9	fluconazole	fluconazole	NN
cord-015922-5wwy0m2k	279	10	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	279	11	(	(	-LRB-
cord-015922-5wwy0m2k	279	12	400	400	CD
cord-015922-5wwy0m2k	279	13	mg	mg	NNP
cord-015922-5wwy0m2k	279	14	/	/	SYM
cord-015922-5wwy0m2k	279	15	day	day	NN
cord-015922-5wwy0m2k	279	16	)	)	-RRB-
cord-015922-5wwy0m2k	279	17	during	during	IN
cord-015922-5wwy0m2k	279	18	the	the	DT
cord-015922-5wwy0m2k	279	19	preengraftment	preengraftment	JJ
cord-015922-5wwy0m2k	279	20	period	period	NN
cord-015922-5wwy0m2k	279	21	,	,	,
cord-015922-5wwy0m2k	279	22	the	the	DT
cord-015922-5wwy0m2k	279	23	incidence	incidence	NN
cord-015922-5wwy0m2k	279	24	of	of	IN
cord-015922-5wwy0m2k	279	25	candidemia	candidemia	NN
cord-015922-5wwy0m2k	279	26	has	have	VBZ
cord-015922-5wwy0m2k	279	27	been	be	VBN
cord-015922-5wwy0m2k	279	28	significantly	significantly	RB
cord-015922-5wwy0m2k	279	29	decreased	decrease	VBN
cord-015922-5wwy0m2k	279	30	,	,	,
cord-015922-5wwy0m2k	279	31	hepatosplenic	hepatosplenic	NNP
cord-015922-5wwy0m2k	279	32	candidiasis	candidiasis	NN
cord-015922-5wwy0m2k	279	33	has	have	VBZ
cord-015922-5wwy0m2k	279	34	become	become	VBN
cord-015922-5wwy0m2k	279	35	quite	quite	RB
cord-015922-5wwy0m2k	279	36	rare	rare	JJ
cord-015922-5wwy0m2k	279	37	,	,	,
cord-015922-5wwy0m2k	279	38	and	and	CC
cord-015922-5wwy0m2k	279	39	the	the	DT
cord-015922-5wwy0m2k	279	40	attributable	attributable	JJ
cord-015922-5wwy0m2k	279	41	mortality	mortality	NN
cord-015922-5wwy0m2k	279	42	has	have	VBZ
cord-015922-5wwy0m2k	279	43	been	be	VBN
cord-015922-5wwy0m2k	279	44	significantly	significantly	RB
cord-015922-5wwy0m2k	279	45	decreased	decrease	VBN
cord-015922-5wwy0m2k	279	46	.	.	.
cord-015922-5wwy0m2k	280	1	Fluconazole	fluconazole	NN
cord-015922-5wwy0m2k	280	2	-	-	HYPH
cord-015922-5wwy0m2k	280	3	resistant	resistant	JJ
cord-015922-5wwy0m2k	280	4	Candida	Candida	NNP
cord-015922-5wwy0m2k	280	5	sp	sp	NN
cord-015922-5wwy0m2k	280	6	,	,	,
cord-015922-5wwy0m2k	280	7	C.	C.	NNP
cord-015922-5wwy0m2k	280	8	krusei	krusei	NNP
cord-015922-5wwy0m2k	280	9	and	and	CC
cord-015922-5wwy0m2k	280	10	C.	C.	NNP
cord-015922-5wwy0m2k	280	11	glabrata	glabrata	NNP
cord-015922-5wwy0m2k	280	12	,	,	,
cord-015922-5wwy0m2k	280	13	have	have	VBP
cord-015922-5wwy0m2k	280	14	emerged	emerge	VBN
cord-015922-5wwy0m2k	280	15	as	as	IN
cord-015922-5wwy0m2k	280	16	not	not	RB
cord-015922-5wwy0m2k	280	17	uncommon	uncommon	JJ
cord-015922-5wwy0m2k	280	18	causes	cause	NNS
cord-015922-5wwy0m2k	280	19	of	of	IN
cord-015922-5wwy0m2k	280	20	candidemia	candidemia	NN
cord-015922-5wwy0m2k	280	21	in	in	IN
cord-015922-5wwy0m2k	280	22	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	280	23	patients	patient	NNS
cord-015922-5wwy0m2k	280	24	,	,	,
cord-015922-5wwy0m2k	280	25	as	as	IN
cord-015922-5wwy0m2k	280	26	have	have	VBP
cord-015922-5wwy0m2k	280	27	the	the	DT
cord-015922-5wwy0m2k	280	28	other	other	JJ
cord-015922-5wwy0m2k	280	29	non	non	NNS
cord-015922-5wwy0m2k	280	30	-	-	JJ
cord-015922-5wwy0m2k	280	31	albicans	albicans	JJ
cord-015922-5wwy0m2k	280	32	Candida	candida	NN
cord-015922-5wwy0m2k	280	33	species	specie	NNS
cord-015922-5wwy0m2k	280	34	[	[	-LRB-
cord-015922-5wwy0m2k	280	35	1	1	CD
cord-015922-5wwy0m2k	280	36	,	,	,
cord-015922-5wwy0m2k	280	37	4	4	CD
cord-015922-5wwy0m2k	280	38	,	,	,
cord-015922-5wwy0m2k	280	39	[	[	-LRB-
cord-015922-5wwy0m2k	280	40	81	81	CD
cord-015922-5wwy0m2k	280	41	]	]	-RRB-
cord-015922-5wwy0m2k	280	42	[	[	-LRB-
cord-015922-5wwy0m2k	280	43	82	82	CD
cord-015922-5wwy0m2k	280	44	]	]	-RRB-
cord-015922-5wwy0m2k	280	45	[	[	-LRB-
cord-015922-5wwy0m2k	280	46	83	83	CD
cord-015922-5wwy0m2k	280	47	]	]	-RRB-
cord-015922-5wwy0m2k	280	48	[	[	-LRB-
cord-015922-5wwy0m2k	280	49	84	84	CD
cord-015922-5wwy0m2k	280	50	]	]	-RRB-
cord-015922-5wwy0m2k	280	51	[	[	-LRB-
cord-015922-5wwy0m2k	280	52	85	85	CD
cord-015922-5wwy0m2k	280	53	]	]	-RRB-
cord-015922-5wwy0m2k	280	54	[	[	-LRB-
cord-015922-5wwy0m2k	280	55	86	86	CD
cord-015922-5wwy0m2k	280	56	]	]	-RRB-
cord-015922-5wwy0m2k	280	57	[	[	-LRB-
cord-015922-5wwy0m2k	280	58	87	87	CD
cord-015922-5wwy0m2k	280	59	]	]	-RRB-
cord-015922-5wwy0m2k	280	60	.	.	.
cord-015922-5wwy0m2k	281	1	It	-PRON-	PRP
cord-015922-5wwy0m2k	281	2	is	be	VBZ
cord-015922-5wwy0m2k	281	3	also	also	RB
cord-015922-5wwy0m2k	281	4	important	important	JJ
cord-015922-5wwy0m2k	281	5	to	to	TO
cord-015922-5wwy0m2k	281	6	recognize	recognize	VB
cord-015922-5wwy0m2k	281	7	that	that	IN
cord-015922-5wwy0m2k	281	8	other	other	JJ
cord-015922-5wwy0m2k	281	9	species	specie	NNS
cord-015922-5wwy0m2k	281	10	of	of	IN
cord-015922-5wwy0m2k	281	11	yeast	yeast	NN
cord-015922-5wwy0m2k	281	12	(	(	-LRB-
cord-015922-5wwy0m2k	281	13	e.g.	e.g.	RB
cord-015922-5wwy0m2k	281	14	,	,	,
cord-015922-5wwy0m2k	281	15	Trichosporon	Trichosporon	NNP
cord-015922-5wwy0m2k	281	16	sp	sp	NNP
cord-015922-5wwy0m2k	281	17	,	,	,
cord-015922-5wwy0m2k	281	18	Blastoschyzomyces	Blastoschyzomyces	NNP
cord-015922-5wwy0m2k	281	19	capitatus	capitatus	NN
cord-015922-5wwy0m2k	281	20	,	,	,
cord-015922-5wwy0m2k	281	21	Saccharomyces	Saccharomyces	NNP
cord-015922-5wwy0m2k	281	22	cereviseae	cereviseae	NN
cord-015922-5wwy0m2k	281	23	and	and	CC
cord-015922-5wwy0m2k	281	24	Rhodotorula	Rhodotorula	NNP
cord-015922-5wwy0m2k	281	25	sp	sp	NN
cord-015922-5wwy0m2k	281	26	.	.	.
cord-015922-5wwy0m2k	281	27	)	)	-RRB-
cord-015922-5wwy0m2k	281	28	can	can	MD
cord-015922-5wwy0m2k	281	29	cause	cause	VB
cord-015922-5wwy0m2k	281	30	clinical	clinical	JJ
cord-015922-5wwy0m2k	281	31	syndromes	syndrome	NNS
cord-015922-5wwy0m2k	281	32	identical	identical	JJ
cord-015922-5wwy0m2k	281	33	to	to	IN
cord-015922-5wwy0m2k	281	34	those	those	DT
cord-015922-5wwy0m2k	281	35	observed	observe	VBN
cord-015922-5wwy0m2k	281	36	with	with	IN
cord-015922-5wwy0m2k	281	37	invasive	invasive	JJ
cord-015922-5wwy0m2k	281	38	candidiasis	candidiasi	NNS
cord-015922-5wwy0m2k	281	39	(	(	-LRB-
cord-015922-5wwy0m2k	281	40	bloodstream	bloodstream	NN
cord-015922-5wwy0m2k	281	41	infection	infection	NN
cord-015922-5wwy0m2k	281	42	,	,	,
cord-015922-5wwy0m2k	281	43	infection	infection	NN
cord-015922-5wwy0m2k	281	44	metastatic	metastatic	JJ
cord-015922-5wwy0m2k	281	45	to	to	IN
cord-015922-5wwy0m2k	281	46	the	the	DT
cord-015922-5wwy0m2k	281	47	skin	skin	NN
cord-015922-5wwy0m2k	281	48	and	and	CC
cord-015922-5wwy0m2k	281	49	subcutaneous	subcutaneous	JJ
cord-015922-5wwy0m2k	281	50	tissues	tissue	NNS
cord-015922-5wwy0m2k	281	51	,	,	,
cord-015922-5wwy0m2k	281	52	as	as	RB
cord-015922-5wwy0m2k	281	53	well	well	RB
cord-015922-5wwy0m2k	281	54	as	as	IN
cord-015922-5wwy0m2k	281	55	other	other	JJ
cord-015922-5wwy0m2k	281	56	sites	site	NNS
cord-015922-5wwy0m2k	281	57	,	,	,
cord-015922-5wwy0m2k	281	58	including	include	VBG
cord-015922-5wwy0m2k	281	59	hepatosplenic	hepatosplenic	NNP
cord-015922-5wwy0m2k	281	60	disease	disease	NN
cord-015922-5wwy0m2k	281	61	identical	identical	JJ
cord-015922-5wwy0m2k	281	62	to	to	IN
cord-015922-5wwy0m2k	281	63	that	that	DT
cord-015922-5wwy0m2k	281	64	caused	cause	VBN
cord-015922-5wwy0m2k	281	65	by	by	IN
cord-015922-5wwy0m2k	281	66	Candida	Candida	NNP
cord-015922-5wwy0m2k	281	67	species	specie	NNS
cord-015922-5wwy0m2k	281	68	)	)	-RRB-
cord-015922-5wwy0m2k	282	1	[	[	-LRB-
cord-015922-5wwy0m2k	282	2	88	88	CD
cord-015922-5wwy0m2k	282	3	]	]	-RRB-
cord-015922-5wwy0m2k	282	4	.	.	.
cord-015922-5wwy0m2k	283	1	In	in	IN
cord-015922-5wwy0m2k	283	2	an	an	DT
cord-015922-5wwy0m2k	283	3	era	era	NN
cord-015922-5wwy0m2k	283	4	of	of	IN
cord-015922-5wwy0m2k	283	5	increased	increase	VBN
cord-015922-5wwy0m2k	283	6	use	use	NN
cord-015922-5wwy0m2k	283	7	of	of	IN
cord-015922-5wwy0m2k	283	8	echinocandins	echinocandin	NNS
cord-015922-5wwy0m2k	283	9	for	for	IN
cord-015922-5wwy0m2k	283	10	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	283	11	[	[	-LRB-
cord-015922-5wwy0m2k	283	12	89	89	CD
cord-015922-5wwy0m2k	283	13	]	]	-RRB-
cord-015922-5wwy0m2k	283	14	and	and	CC
cord-015922-5wwy0m2k	283	15	empirical	empirical	JJ
cord-015922-5wwy0m2k	283	16	antifungal	antifungal	JJ
cord-015922-5wwy0m2k	283	17	treatment	treatment	NN
cord-015922-5wwy0m2k	283	18	[	[	-LRB-
cord-015922-5wwy0m2k	283	19	90	90	CD
cord-015922-5wwy0m2k	283	20	]	]	-RRB-
cord-015922-5wwy0m2k	283	21	,	,	,
cord-015922-5wwy0m2k	283	22	these	these	DT
cord-015922-5wwy0m2k	283	23	organisms	organism	NNS
cord-015922-5wwy0m2k	283	24	[	[	-LRB-
cord-015922-5wwy0m2k	283	25	88	88	CD
cord-015922-5wwy0m2k	283	26	,	,	,
cord-015922-5wwy0m2k	283	27	91	91	CD
cord-015922-5wwy0m2k	283	28	]	]	-RRB-
cord-015922-5wwy0m2k	283	29	and	and	CC
cord-015922-5wwy0m2k	283	30	echinocandin	echinocandin	NN
cord-015922-5wwy0m2k	283	31	-	-	HYPH
cord-015922-5wwy0m2k	283	32	resistant	resistant	JJ
cord-015922-5wwy0m2k	283	33	Candida	Candida	NNP
cord-015922-5wwy0m2k	283	34	sp	sp	NN
cord-015922-5wwy0m2k	283	35	,	,	,
cord-015922-5wwy0m2k	283	36	especially	especially	RB
cord-015922-5wwy0m2k	283	37	C.	C.	NNP
cord-015922-5wwy0m2k	283	38	parapsilopsis	parapsilopsis	NNP
cord-015922-5wwy0m2k	283	39	,	,	,
cord-015922-5wwy0m2k	283	40	have	have	VBP
cord-015922-5wwy0m2k	283	41	become	become	VBN
cord-015922-5wwy0m2k	283	42	emerging	emerge	VBG
cord-015922-5wwy0m2k	283	43	causes	cause	NNS
cord-015922-5wwy0m2k	283	44	of	of	IN
cord-015922-5wwy0m2k	283	45	fungemia	fungemia	NN
cord-015922-5wwy0m2k	283	46	in	in	IN
cord-015922-5wwy0m2k	283	47	the	the	DT
cord-015922-5wwy0m2k	283	48	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	283	49	units	unit	NNS
cord-015922-5wwy0m2k	283	50	[	[	-LRB-
cord-015922-5wwy0m2k	283	51	1	1	CD
cord-015922-5wwy0m2k	283	52	,	,	,
cord-015922-5wwy0m2k	283	53	4	4	CD
cord-015922-5wwy0m2k	283	54	,	,	,
cord-015922-5wwy0m2k	283	55	82	82	CD
cord-015922-5wwy0m2k	283	56	]	]	-RRB-
cord-015922-5wwy0m2k	283	57	.	.	.
cord-015922-5wwy0m2k	284	1	Invasive	invasive	JJ
cord-015922-5wwy0m2k	284	2	fungal	fungal	NN
cord-015922-5wwy0m2k	284	3	disease	disease	NN
cord-015922-5wwy0m2k	284	4	has	have	VBZ
cord-015922-5wwy0m2k	284	5	been	be	VBN
cord-015922-5wwy0m2k	284	6	most	most	RBS
cord-015922-5wwy0m2k	284	7	commonly	commonly	RB
cord-015922-5wwy0m2k	284	8	caused	cause	VBN
cord-015922-5wwy0m2k	284	9	by	by	IN
cord-015922-5wwy0m2k	284	10	Aspergillus	aspergillus	NN
cord-015922-5wwy0m2k	284	11	sp	sp	NN
cord-015922-5wwy0m2k	284	12	,	,	,
cord-015922-5wwy0m2k	284	13	with	with	IN
cord-015922-5wwy0m2k	284	14	A.	a.	NN
cord-015922-5wwy0m2k	284	15	fumigatus	fumigatus	NNP
cord-015922-5wwy0m2k	284	16	,	,	,
cord-015922-5wwy0m2k	284	17	A.	a.	NN
cord-015922-5wwy0m2k	284	18	flavus	flavus	NN
cord-015922-5wwy0m2k	284	19	,	,	,
cord-015922-5wwy0m2k	284	20	A.	A.	NNP
cord-015922-5wwy0m2k	284	21	terreus	terreus	NNP
cord-015922-5wwy0m2k	284	22	,	,	,
cord-015922-5wwy0m2k	284	23	A.	A.	NNP
cord-015922-5wwy0m2k	284	24	niger	niger	NNP
cord-015922-5wwy0m2k	284	25	and	and	CC
cord-015922-5wwy0m2k	284	26	A.	A.	NNP
cord-015922-5wwy0m2k	284	27	nidulans	nidulans	NNP
cord-015922-5wwy0m2k	284	28	being	be	VBG
cord-015922-5wwy0m2k	284	29	the	the	DT
cord-015922-5wwy0m2k	284	30	most	most	RBS
cord-015922-5wwy0m2k	284	31	common	common	JJ
cord-015922-5wwy0m2k	284	32	causes	cause	NNS
cord-015922-5wwy0m2k	284	33	of	of	IN
cord-015922-5wwy0m2k	284	34	invasive	invasive	JJ
cord-015922-5wwy0m2k	284	35	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	284	36	.	.	.
cord-015922-5wwy0m2k	285	1	The	the	DT
cord-015922-5wwy0m2k	285	2	portal	portal	NN
cord-015922-5wwy0m2k	285	3	of	of	IN
cord-015922-5wwy0m2k	285	4	entry	entry	NN
cord-015922-5wwy0m2k	285	5	for	for	IN
cord-015922-5wwy0m2k	285	6	90	90	CD
cord-015922-5wwy0m2k	285	7	percent	percent	NN
cord-015922-5wwy0m2k	285	8	of	of	IN
cord-015922-5wwy0m2k	285	9	cases	case	NNS
cord-015922-5wwy0m2k	285	10	of	of	IN
cord-015922-5wwy0m2k	285	11	invasive	invasive	JJ
cord-015922-5wwy0m2k	285	12	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	285	13	is	be	VBZ
cord-015922-5wwy0m2k	285	14	the	the	DT
cord-015922-5wwy0m2k	285	15	lungs	lung	NNS
cord-015922-5wwy0m2k	285	16	,	,	,
cord-015922-5wwy0m2k	285	17	with	with	IN
cord-015922-5wwy0m2k	285	18	the	the	DT
cord-015922-5wwy0m2k	285	19	nasal	nasal	NN
cord-015922-5wwy0m2k	285	20	sinuses	sinus	NNS
cord-015922-5wwy0m2k	285	21	and	and	CC
cord-015922-5wwy0m2k	285	22	the	the	DT
cord-015922-5wwy0m2k	285	23	skin	skin	NN
cord-015922-5wwy0m2k	285	24	accounting	account	VBG
cord-015922-5wwy0m2k	285	25	for	for	IN
cord-015922-5wwy0m2k	285	26	virtually	virtually	RB
cord-015922-5wwy0m2k	285	27	all	all	DT
cord-015922-5wwy0m2k	285	28	of	of	IN
cord-015922-5wwy0m2k	285	29	the	the	DT
cord-015922-5wwy0m2k	285	30	remaining	remain	VBG
cord-015922-5wwy0m2k	285	31	cases	case	NNS
cord-015922-5wwy0m2k	285	32	.	.	.
cord-015922-5wwy0m2k	286	1	There	there	EX
cord-015922-5wwy0m2k	286	2	are	be	VBP
cord-015922-5wwy0m2k	286	3	two	two	CD
cord-015922-5wwy0m2k	286	4	major	major	JJ
cord-015922-5wwy0m2k	286	5	host	host	NN
cord-015922-5wwy0m2k	286	6	defenses	defense	NNS
cord-015922-5wwy0m2k	286	7	that	that	WDT
cord-015922-5wwy0m2k	286	8	are	be	VBP
cord-015922-5wwy0m2k	286	9	mobilized	mobilize	VBN
cord-015922-5wwy0m2k	286	10	in	in	IN
cord-015922-5wwy0m2k	286	11	response	response	NN
cord-015922-5wwy0m2k	286	12	to	to	IN
cord-015922-5wwy0m2k	286	13	inhalation	inhalation	NN
cord-015922-5wwy0m2k	286	14	of	of	IN
cord-015922-5wwy0m2k	286	15	the	the	DT
cord-015922-5wwy0m2k	286	16	Aspergillus	aspergillus	NN
cord-015922-5wwy0m2k	286	17	spores	spore	NNS
cord-015922-5wwy0m2k	286	18	-granulocytes	-granulocyte	NNS
cord-015922-5wwy0m2k	286	19	and	and	CC
cord-015922-5wwy0m2k	286	20	cell	cell	NN
cord-015922-5wwy0m2k	286	21	-	-	HYPH
cord-015922-5wwy0m2k	286	22	mediated	mediate	VBN
cord-015922-5wwy0m2k	286	23	immunity	immunity	NN
cord-015922-5wwy0m2k	286	24	,	,	,
cord-015922-5wwy0m2k	286	25	specifically	specifically	RB
cord-015922-5wwy0m2k	286	26	cytotoxic	cytotoxic	JJ
cord-015922-5wwy0m2k	286	27	T	t	NN
cord-015922-5wwy0m2k	286	28	cells	cell	NNS
cord-015922-5wwy0m2k	286	29	.	.	.
cord-015922-5wwy0m2k	287	1	The	the	DT
cord-015922-5wwy0m2k	287	2	importance	importance	NN
cord-015922-5wwy0m2k	287	3	of	of	IN
cord-015922-5wwy0m2k	287	4	these	these	DT
cord-015922-5wwy0m2k	287	5	mechanisms	mechanism	NNS
cord-015922-5wwy0m2k	287	6	is	be	VBZ
cord-015922-5wwy0m2k	287	7	demonstrated	demonstrate	VBN
cord-015922-5wwy0m2k	287	8	by	by	IN
cord-015922-5wwy0m2k	287	9	the	the	DT
cord-015922-5wwy0m2k	287	10	clustering	clustering	NN
cord-015922-5wwy0m2k	287	11	of	of	IN
cord-015922-5wwy0m2k	287	12	cases	case	NNS
cord-015922-5wwy0m2k	287	13	of	of	IN
cord-015922-5wwy0m2k	287	14	invasive	invasive	JJ
cord-015922-5wwy0m2k	287	15	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	287	16	at	at	IN
cord-015922-5wwy0m2k	287	17	two	two	CD
cord-015922-5wwy0m2k	287	18	timepoints	timepoint	NNS
cord-015922-5wwy0m2k	287	19	in	in	IN
cord-015922-5wwy0m2k	287	20	the	the	DT
cord-015922-5wwy0m2k	287	21	posttransplant	posttransplant	NNP
cord-015922-5wwy0m2k	287	22	course	course	NN
cord-015922-5wwy0m2k	287	23	:	:	:
cord-015922-5wwy0m2k	287	24	preengraftment	preengraftment	NNP
cord-015922-5wwy0m2k	287	25	when	when	WRB
cord-015922-5wwy0m2k	287	26	profound	profound	JJ
cord-015922-5wwy0m2k	287	27	granulocytopenia	granulocytopenia	NNP
cord-015922-5wwy0m2k	287	28	is	be	VBZ
cord-015922-5wwy0m2k	287	29	present	present	JJ
cord-015922-5wwy0m2k	287	30	,	,	,
cord-015922-5wwy0m2k	287	31	with	with	IN
cord-015922-5wwy0m2k	287	32	the	the	DT
cord-015922-5wwy0m2k	287	33	incidence	incidence	NN
cord-015922-5wwy0m2k	287	34	of	of	IN
cord-015922-5wwy0m2k	287	35	invasive	invasive	JJ
cord-015922-5wwy0m2k	287	36	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	287	37	increasing	increase	VBG
cord-015922-5wwy0m2k	287	38	steadily	steadily	RB
cord-015922-5wwy0m2k	287	39	as	as	IN
cord-015922-5wwy0m2k	287	40	the	the	DT
cord-015922-5wwy0m2k	287	41	period	period	NN
cord-015922-5wwy0m2k	287	42	of	of	IN
cord-015922-5wwy0m2k	287	43	granulocytopenia	granulocytopenia	NNP
cord-015922-5wwy0m2k	287	44	is	be	VBZ
cord-015922-5wwy0m2k	287	45	extended	extend	VBN
cord-015922-5wwy0m2k	287	46	,	,	,
cord-015922-5wwy0m2k	287	47	and	and	CC
cord-015922-5wwy0m2k	287	48	after	after	IN
cord-015922-5wwy0m2k	287	49	the	the	DT
cord-015922-5wwy0m2k	287	50	diagnosis	diagnosis	NN
cord-015922-5wwy0m2k	287	51	of	of	IN
cord-015922-5wwy0m2k	287	52	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	287	53	and	and	CC
cord-015922-5wwy0m2k	287	54	the	the	DT
cord-015922-5wwy0m2k	287	55	treatment	treatment	NN
cord-015922-5wwy0m2k	287	56	of	of	IN
cord-015922-5wwy0m2k	287	57	this	this	DT
cord-015922-5wwy0m2k	287	58	adverse	adverse	JJ
cord-015922-5wwy0m2k	287	59	event	event	NN
cord-015922-5wwy0m2k	287	60	.	.	.
cord-015922-5wwy0m2k	288	1	Indeed	indeed	RB
cord-015922-5wwy0m2k	288	2	,	,	,
cord-015922-5wwy0m2k	288	3	these	these	DT
cord-015922-5wwy0m2k	288	4	late	late	JJ
cord-015922-5wwy0m2k	288	5	cases	case	NNS
cord-015922-5wwy0m2k	288	6	of	of	IN
cord-015922-5wwy0m2k	288	7	invasive	invasive	JJ
cord-015922-5wwy0m2k	288	8	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	288	9	have	have	VBP
cord-015922-5wwy0m2k	288	10	become	become	VBN
cord-015922-5wwy0m2k	288	11	more	more	RBR
cord-015922-5wwy0m2k	288	12	common	common	JJ
cord-015922-5wwy0m2k	288	13	than	than	IN
cord-015922-5wwy0m2k	288	14	the	the	DT
cord-015922-5wwy0m2k	288	15	preengraftment	preengraftment	NN
cord-015922-5wwy0m2k	288	16	cases	case	NNS
cord-015922-5wwy0m2k	288	17	.	.	.
cord-015922-5wwy0m2k	289	1	Mortality	mortality	NN
cord-015922-5wwy0m2k	289	2	rates	rate	NNS
cord-015922-5wwy0m2k	289	3	have	have	VBP
cord-015922-5wwy0m2k	289	4	traditionally	traditionally	RB
cord-015922-5wwy0m2k	289	5	been	be	VBN
cord-015922-5wwy0m2k	289	6	high	high	JJ
cord-015922-5wwy0m2k	289	7	in	in	IN
cord-015922-5wwy0m2k	289	8	patients	patient	NNS
cord-015922-5wwy0m2k	289	9	who	who	WP
cord-015922-5wwy0m2k	289	10	developed	develop	VBD
cord-015922-5wwy0m2k	289	11	invasive	invasive	JJ
cord-015922-5wwy0m2k	289	12	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	289	13	in	in	IN
cord-015922-5wwy0m2k	289	14	either	either	DT
cord-015922-5wwy0m2k	289	15	time	time	NN
cord-015922-5wwy0m2k	289	16	period	period	NN
cord-015922-5wwy0m2k	289	17	[	[	-LRB-
cord-015922-5wwy0m2k	289	18	1	1	CD
cord-015922-5wwy0m2k	289	19	,	,	,
cord-015922-5wwy0m2k	289	20	4	4	CD
cord-015922-5wwy0m2k	289	21	,	,	,
cord-015922-5wwy0m2k	289	22	92	92	CD
cord-015922-5wwy0m2k	289	23	,	,	,
cord-015922-5wwy0m2k	289	24	93	93	CD
cord-015922-5wwy0m2k	289	25	]	]	-RRB-
cord-015922-5wwy0m2k	289	26	.	.	.
cord-015922-5wwy0m2k	290	1	The	the	DT
cord-015922-5wwy0m2k	290	2	clinical	clinical	JJ
cord-015922-5wwy0m2k	290	3	syndromes	syndrome	NNS
cord-015922-5wwy0m2k	290	4	caused	cause	VBN
cord-015922-5wwy0m2k	290	5	by	by	IN
cord-015922-5wwy0m2k	290	6	Aspergillus	aspergillus	NN
cord-015922-5wwy0m2k	290	7	invasion	invasion	NN
cord-015922-5wwy0m2k	290	8	reflect	reflect	VBP
cord-015922-5wwy0m2k	290	9	the	the	DT
cord-015922-5wwy0m2k	290	10	pathologic	pathologic	JJ
cord-015922-5wwy0m2k	290	11	consequences	consequence	NNS
cord-015922-5wwy0m2k	290	12	of	of	IN
cord-015922-5wwy0m2k	290	13	the	the	DT
cord-015922-5wwy0m2k	290	14	vasculotropic	vasculotropic	JJ
cord-015922-5wwy0m2k	290	15	nature	nature	NN
cord-015922-5wwy0m2k	290	16	of	of	IN
cord-015922-5wwy0m2k	290	17	this	this	DT
cord-015922-5wwy0m2k	290	18	mold	mold	NN
cord-015922-5wwy0m2k	290	19	.	.	.
cord-015922-5wwy0m2k	291	1	The	the	DT
cord-015922-5wwy0m2k	291	2	three	three	CD
cord-015922-5wwy0m2k	291	3	major	major	JJ
cord-015922-5wwy0m2k	291	4	consequences	consequence	NNS
cord-015922-5wwy0m2k	291	5	of	of	IN
cord-015922-5wwy0m2k	291	6	the	the	DT
cord-015922-5wwy0m2k	291	7	vascular	vascular	JJ
cord-015922-5wwy0m2k	291	8	invasion	invasion	NN
cord-015922-5wwy0m2k	291	9	that	that	WDT
cord-015922-5wwy0m2k	291	10	characterizes	characterize	VBZ
cord-015922-5wwy0m2k	291	11	Aspergillus	aspergillus	NN
cord-015922-5wwy0m2k	291	12	invasion	invasion	NN
cord-015922-5wwy0m2k	291	13	include	include	VBP
cord-015922-5wwy0m2k	291	14	hemorrhage	hemorrhage	NN
cord-015922-5wwy0m2k	291	15	,	,	,
cord-015922-5wwy0m2k	291	16	infarction	infarction	NN
cord-015922-5wwy0m2k	291	17	and	and	CC
cord-015922-5wwy0m2k	291	18	metastatic	metastatic	JJ
cord-015922-5wwy0m2k	291	19	disease	disease	NN
cord-015922-5wwy0m2k	291	20	.	.	.
cord-015922-5wwy0m2k	292	1	Initial	initial	JJ
cord-015922-5wwy0m2k	292	2	clinical	clinical	JJ
cord-015922-5wwy0m2k	292	3	complaints	complaint	NNS
cord-015922-5wwy0m2k	292	4	include	include	VBP
cord-015922-5wwy0m2k	292	5	persistent	persistent	JJ
cord-015922-5wwy0m2k	292	6	fever	fever	NN
cord-015922-5wwy0m2k	292	7	,	,	,
cord-015922-5wwy0m2k	292	8	chest	chest	NN
cord-015922-5wwy0m2k	292	9	pain	pain	NN
cord-015922-5wwy0m2k	292	10	,	,	,
cord-015922-5wwy0m2k	292	11	tachypnea	tachypnea	NNP
cord-015922-5wwy0m2k	292	12	,	,	,
cord-015922-5wwy0m2k	292	13	hypoxemia	hypoxemia	NN
cord-015922-5wwy0m2k	292	14	and	and	CC
cord-015922-5wwy0m2k	292	15	hemoptysis	hemoptysis	NN
cord-015922-5wwy0m2k	292	16	,	,	,
cord-015922-5wwy0m2k	292	17	as	as	RB
cord-015922-5wwy0m2k	292	18	well	well	RB
cord-015922-5wwy0m2k	292	19	as	as	IN
cord-015922-5wwy0m2k	292	20	symptoms	symptom	NNS
cord-015922-5wwy0m2k	292	21	related	relate	VBN
cord-015922-5wwy0m2k	292	22	to	to	IN
cord-015922-5wwy0m2k	292	23	metastases	metastasis	NNS
cord-015922-5wwy0m2k	292	24	.	.	.
cord-015922-5wwy0m2k	293	1	Before	before	IN
cord-015922-5wwy0m2k	293	2	the	the	DT
cord-015922-5wwy0m2k	293	3	availability	availability	NN
cord-015922-5wwy0m2k	293	4	of	of	IN
cord-015922-5wwy0m2k	293	5	noninvasive	noninvasive	JJ
cord-015922-5wwy0m2k	293	6	fungal	fungal	JJ
cord-015922-5wwy0m2k	293	7	markers	marker	NNS
cord-015922-5wwy0m2k	293	8	(	(	-LRB-
cord-015922-5wwy0m2k	293	9	galactomannan	galactomannan	NNP
cord-015922-5wwy0m2k	293	10	and	and	CC
cord-015922-5wwy0m2k	293	11	β	β	NN
cord-015922-5wwy0m2k	293	12	-	-	HYPH
cord-015922-5wwy0m2k	293	13	glucan	glucan	NNP
cord-015922-5wwy0m2k	293	14	)	)	-RRB-
cord-015922-5wwy0m2k	293	15	and	and	CC
cord-015922-5wwy0m2k	293	16	aggressive	aggressive	JJ
cord-015922-5wwy0m2k	293	17	imaging	imaging	NN
cord-015922-5wwy0m2k	293	18	with	with	IN
cord-015922-5wwy0m2k	293	19	spiral	spiral	JJ
cord-015922-5wwy0m2k	293	20	chest	chest	NN
cord-015922-5wwy0m2k	293	21	computerized	computerized	NN
cord-015922-5wwy0m2k	293	22	tomographic	tomographic	NN
cord-015922-5wwy0m2k	293	23	(	(	-LRB-
cord-015922-5wwy0m2k	293	24	CT	CT	NNP
cord-015922-5wwy0m2k	293	25	)	)	-RRB-
cord-015922-5wwy0m2k	293	26	scanning	scanning	NN
cord-015922-5wwy0m2k	293	27	,	,	,
cord-015922-5wwy0m2k	293	28	50	50	CD
cord-015922-5wwy0m2k	293	29	percent	percent	NN
cord-015922-5wwy0m2k	293	30	or	or	CC
cord-015922-5wwy0m2k	293	31	more	more	JJR
cord-015922-5wwy0m2k	293	32	of	of	IN
cord-015922-5wwy0m2k	293	33	patients	patient	NNS
cord-015922-5wwy0m2k	293	34	experience	experience	NN
cord-015922-5wwy0m2k	293	35	disseminated	disseminate	VBN
cord-015922-5wwy0m2k	293	36	infection	infection	NN
cord-015922-5wwy0m2k	293	37	at	at	IN
cord-015922-5wwy0m2k	293	38	the	the	DT
cord-015922-5wwy0m2k	293	39	time	time	NN
cord-015922-5wwy0m2k	293	40	of	of	IN
cord-015922-5wwy0m2k	293	41	first	first	JJ
cord-015922-5wwy0m2k	293	42	diagnosis	diagnosis	NN
cord-015922-5wwy0m2k	293	43	,	,	,
cord-015922-5wwy0m2k	293	44	accounting	account	VBG
cord-015922-5wwy0m2k	293	45	for	for	IN
cord-015922-5wwy0m2k	293	46	the	the	DT
cord-015922-5wwy0m2k	293	47	high	high	JJ
cord-015922-5wwy0m2k	293	48	mortality	mortality	NN
cord-015922-5wwy0m2k	293	49	observed	observe	VBN
cord-015922-5wwy0m2k	293	50	in	in	IN
cord-015922-5wwy0m2k	293	51	allogeneic	allogeneic	JJ
cord-015922-5wwy0m2k	293	52	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	293	53	recipients	recipient	NNS
cord-015922-5wwy0m2k	293	54	.	.	.
cord-015922-5wwy0m2k	294	1	A	a	DT
cord-015922-5wwy0m2k	294	2	particular	particular	JJ
cord-015922-5wwy0m2k	294	3	problem	problem	NN
cord-015922-5wwy0m2k	294	4	is	be	VBZ
cord-015922-5wwy0m2k	294	5	infection	infection	NN
cord-015922-5wwy0m2k	294	6	in	in	IN
cord-015922-5wwy0m2k	294	7	the	the	DT
cord-015922-5wwy0m2k	294	8	CNS	CNS	NNP
cord-015922-5wwy0m2k	294	9	,	,	,
cord-015922-5wwy0m2k	294	10	where	where	WRB
cord-015922-5wwy0m2k	294	11	mortality	mortality	NN
cord-015922-5wwy0m2k	294	12	historically	historically	RB
cord-015922-5wwy0m2k	294	13	has	have	VBZ
cord-015922-5wwy0m2k	294	14	approached	approach	VBN
cord-015922-5wwy0m2k	294	15	100	100	CD
cord-015922-5wwy0m2k	294	16	percent	percent	NN
cord-015922-5wwy0m2k	294	17	.	.	.
cord-015922-5wwy0m2k	295	1	Metastases	Metastases	NNP
cord-015922-5wwy0m2k	295	2	can	can	MD
cord-015922-5wwy0m2k	295	3	present	present	VB
cord-015922-5wwy0m2k	295	4	any	any	DT
cord-015922-5wwy0m2k	295	5	site	site	NN
cord-015922-5wwy0m2k	295	6	,	,	,
cord-015922-5wwy0m2k	295	7	but	but	CC
cord-015922-5wwy0m2k	295	8	particularly	particularly	RB
cord-015922-5wwy0m2k	295	9	important	important	JJ
cord-015922-5wwy0m2k	295	10	is	be	VBZ
cord-015922-5wwy0m2k	295	11	the	the	DT
cord-015922-5wwy0m2k	295	12	skin	skin	NN
cord-015922-5wwy0m2k	295	13	,	,	,
cord-015922-5wwy0m2k	295	14	as	as	IN
cord-015922-5wwy0m2k	295	15	innocent	innocent	JJ
cord-015922-5wwy0m2k	295	16	appearing	appear	VBG
cord-015922-5wwy0m2k	295	17	skin	skin	NN
cord-015922-5wwy0m2k	295	18	lesions	lesion	NNS
cord-015922-5wwy0m2k	295	19	can	can	MD
cord-015922-5wwy0m2k	295	20	lead	lead	VB
cord-015922-5wwy0m2k	295	21	to	to	IN
cord-015922-5wwy0m2k	295	22	early	early	JJ
cord-015922-5wwy0m2k	295	23	recognition	recognition	NN
cord-015922-5wwy0m2k	295	24	of	of	IN
cord-015922-5wwy0m2k	295	25	the	the	DT
cord-015922-5wwy0m2k	295	26	disease	disease	NN
cord-015922-5wwy0m2k	295	27	,	,	,
cord-015922-5wwy0m2k	295	28	and	and	CC
cord-015922-5wwy0m2k	295	29	should	should	MD
cord-015922-5wwy0m2k	295	30	be	be	VB
cord-015922-5wwy0m2k	295	31	aggressively	aggressively	RB
cord-015922-5wwy0m2k	295	32	biopsied	biopsie	VBN
cord-015922-5wwy0m2k	295	33	[	[	-LRB-
cord-015922-5wwy0m2k	295	34	4	4	CD
cord-015922-5wwy0m2k	295	35	]	]	-RRB-
cord-015922-5wwy0m2k	295	36	.	.	.
cord-015922-5wwy0m2k	296	1	Definitive	definitive	JJ
cord-015922-5wwy0m2k	296	2	diagnosis	diagnosis	NN
cord-015922-5wwy0m2k	296	3	of	of	IN
cord-015922-5wwy0m2k	296	4	invasive	invasive	JJ
cord-015922-5wwy0m2k	296	5	mold	mold	NN
cord-015922-5wwy0m2k	296	6	infections	infection	NNS
cord-015922-5wwy0m2k	296	7	,	,	,
cord-015922-5wwy0m2k	296	8	including	include	VBG
cord-015922-5wwy0m2k	296	9	invasive	invasive	JJ
cord-015922-5wwy0m2k	296	10	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	296	11	,	,	,
cord-015922-5wwy0m2k	296	12	is	be	VBZ
cord-015922-5wwy0m2k	296	13	usually	usually	RB
cord-015922-5wwy0m2k	296	14	accomplished	accomplish	VBN
cord-015922-5wwy0m2k	296	15	by	by	IN
cord-015922-5wwy0m2k	296	16	biopsying	biopsye	VBG
cord-015922-5wwy0m2k	296	17	the	the	DT
cord-015922-5wwy0m2k	296	18	site	site	NN
cord-015922-5wwy0m2k	296	19	of	of	IN
cord-015922-5wwy0m2k	296	20	abnormality	abnormality	NN
cord-015922-5wwy0m2k	296	21	.	.	.
cord-015922-5wwy0m2k	297	1	Early	early	JJ
cord-015922-5wwy0m2k	297	2	diagnosis	diagnosis	NN
cord-015922-5wwy0m2k	297	3	is	be	VBZ
cord-015922-5wwy0m2k	297	4	the	the	DT
cord-015922-5wwy0m2k	297	5	key	key	NN
cord-015922-5wwy0m2k	297	6	to	to	IN
cord-015922-5wwy0m2k	297	7	effective	effective	JJ
cord-015922-5wwy0m2k	297	8	therapy	therapy	NN
cord-015922-5wwy0m2k	297	9	[	[	-LRB-
cord-015922-5wwy0m2k	297	10	94	94	CD
cord-015922-5wwy0m2k	297	11	]	]	-RRB-
cord-015922-5wwy0m2k	297	12	.	.	.
cord-015922-5wwy0m2k	298	1	Sputum	Sputum	NNP
cord-015922-5wwy0m2k	298	2	or	or	CC
cord-015922-5wwy0m2k	298	3	bronchoscopic	bronchoscopic	NN
cord-015922-5wwy0m2k	298	4	samples	sample	NNS
cord-015922-5wwy0m2k	298	5	rarely	rarely	RB
cord-015922-5wwy0m2k	298	6	yield	yield	VBP
cord-015922-5wwy0m2k	298	7	mold	mold	NN
cord-015922-5wwy0m2k	298	8	on	on	IN
cord-015922-5wwy0m2k	298	9	culture	culture	NN
cord-015922-5wwy0m2k	298	10	.	.	.
cord-015922-5wwy0m2k	299	1	In	in	IN
cord-015922-5wwy0m2k	299	2	recent	recent	JJ
cord-015922-5wwy0m2k	299	3	years	year	NNS
cord-015922-5wwy0m2k	299	4	,	,	,
cord-015922-5wwy0m2k	299	5	considerable	considerable	JJ
cord-015922-5wwy0m2k	299	6	effort	effort	NN
cord-015922-5wwy0m2k	299	7	has	have	VBZ
cord-015922-5wwy0m2k	299	8	been	be	VBN
cord-015922-5wwy0m2k	299	9	made	make	VBN
cord-015922-5wwy0m2k	299	10	to	to	TO
cord-015922-5wwy0m2k	299	11	find	find	VB
cord-015922-5wwy0m2k	299	12	other	other	JJ
cord-015922-5wwy0m2k	299	13	technology	technology	NN
cord-015922-5wwy0m2k	299	14	that	that	WDT
cord-015922-5wwy0m2k	299	15	will	will	MD
cord-015922-5wwy0m2k	299	16	lead	lead	VB
cord-015922-5wwy0m2k	299	17	to	to	IN
cord-015922-5wwy0m2k	299	18	an	an	DT
cord-015922-5wwy0m2k	299	19	earlier	early	JJR
cord-015922-5wwy0m2k	299	20	and	and	CC
cord-015922-5wwy0m2k	299	21	timely	timely	JJ
cord-015922-5wwy0m2k	299	22	diagnosis	diagnosis	NN
cord-015922-5wwy0m2k	299	23	.	.	.
cord-015922-5wwy0m2k	300	1	The	the	DT
cord-015922-5wwy0m2k	300	2	ones	one	NNS
cord-015922-5wwy0m2k	300	3	that	that	WDT
cord-015922-5wwy0m2k	300	4	have	have	VBP
cord-015922-5wwy0m2k	300	5	been	be	VBN
cord-015922-5wwy0m2k	300	6	incorporated	incorporate	VBN
cord-015922-5wwy0m2k	300	7	into	into	IN
cord-015922-5wwy0m2k	300	8	practice	practice	NN
cord-015922-5wwy0m2k	300	9	are	be	VBP
cord-015922-5wwy0m2k	300	10	the	the	DT
cord-015922-5wwy0m2k	300	11	systematic	systematic	JJ
cord-015922-5wwy0m2k	300	12	measurement	measurement	NN
cord-015922-5wwy0m2k	300	13	of	of	IN
cord-015922-5wwy0m2k	300	14	Aspergillus	aspergillus	NN
cord-015922-5wwy0m2k	300	15	antigens	antigen	NNS
cord-015922-5wwy0m2k	300	16	and	and	CC
cord-015922-5wwy0m2k	300	17	serial	serial	JJ
cord-015922-5wwy0m2k	300	18	chest	chest	NN
cord-015922-5wwy0m2k	300	19	CT	CT	NNP
cord-015922-5wwy0m2k	300	20	imaging	imaging	NN
cord-015922-5wwy0m2k	300	21	.	.	.
cord-015922-5wwy0m2k	301	1	Monitoring	monitor	VBG
cord-015922-5wwy0m2k	301	2	the	the	DT
cord-015922-5wwy0m2k	301	3	serum	serum	NN
cord-015922-5wwy0m2k	301	4	of	of	IN
cord-015922-5wwy0m2k	301	5	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	301	6	patients	patient	NNS
cord-015922-5wwy0m2k	301	7	for	for	IN
cord-015922-5wwy0m2k	301	8	galactomannan	galactomannan	NNP
cord-015922-5wwy0m2k	301	9	or	or	CC
cord-015922-5wwy0m2k	301	10	β	β	NN
cord-015922-5wwy0m2k	301	11	-	-	HYPH
cord-015922-5wwy0m2k	301	12	glucan	glucan	NN
cord-015922-5wwy0m2k	301	13	is	be	VBZ
cord-015922-5wwy0m2k	301	14	now	now	RB
cord-015922-5wwy0m2k	301	15	commercially	commercially	RB
cord-015922-5wwy0m2k	301	16	available	available	JJ
cord-015922-5wwy0m2k	301	17	and	and	CC
cord-015922-5wwy0m2k	301	18	has	have	VBZ
cord-015922-5wwy0m2k	301	19	been	be	VBN
cord-015922-5wwy0m2k	301	20	incorporated	incorporate	VBN
cord-015922-5wwy0m2k	301	21	into	into	IN
cord-015922-5wwy0m2k	301	22	the	the	DT
cord-015922-5wwy0m2k	301	23	current	current	JJ
cord-015922-5wwy0m2k	301	24	diagnosis	diagnosis	NN
cord-015922-5wwy0m2k	301	25	guidelines	guideline	NNS
cord-015922-5wwy0m2k	301	26	[	[	-LRB-
cord-015922-5wwy0m2k	301	27	95	95	CD
cord-015922-5wwy0m2k	301	28	,	,	,
cord-015922-5wwy0m2k	301	29	96	96	CD
cord-015922-5wwy0m2k	301	30	]	]	-RRB-
cord-015922-5wwy0m2k	301	31	.	.	.
cord-015922-5wwy0m2k	302	1	The	the	DT
cord-015922-5wwy0m2k	302	2	detection	detection	NN
cord-015922-5wwy0m2k	302	3	of	of	IN
cord-015922-5wwy0m2k	302	4	circulating	circulate	VBG
cord-015922-5wwy0m2k	302	5	fungal	fungal	JJ
cord-015922-5wwy0m2k	302	6	DNA	dna	NN
cord-015922-5wwy0m2k	302	7	in	in	IN
cord-015922-5wwy0m2k	302	8	the	the	DT
cord-015922-5wwy0m2k	302	9	blood	blood	NN
cord-015922-5wwy0m2k	302	10	by	by	IN
cord-015922-5wwy0m2k	302	11	PCR	PCR	NNP
cord-015922-5wwy0m2k	302	12	[	[	-LRB-
cord-015922-5wwy0m2k	302	13	97	97	CD
cord-015922-5wwy0m2k	302	14	]	]	-RRB-
cord-015922-5wwy0m2k	302	15	remains	remain	VBZ
cord-015922-5wwy0m2k	302	16	experimental	experimental	JJ
cord-015922-5wwy0m2k	302	17	.	.	.
cord-015922-5wwy0m2k	303	1	Findings	finding	NNS
cord-015922-5wwy0m2k	303	2	on	on	IN
cord-015922-5wwy0m2k	303	3	chest	chest	NN
cord-015922-5wwy0m2k	303	4	CT	CT	NNP
cord-015922-5wwy0m2k	303	5	,	,	,
cord-015922-5wwy0m2k	303	6	in	in	IN
cord-015922-5wwy0m2k	303	7	particular	particular	JJ
cord-015922-5wwy0m2k	303	8	the	the	DT
cord-015922-5wwy0m2k	303	9	halo	halo	NN
cord-015922-5wwy0m2k	303	10	sign	sign	NN
cord-015922-5wwy0m2k	303	11	(	(	-LRB-
cord-015922-5wwy0m2k	303	12	Fig	Fig	NNP
cord-015922-5wwy0m2k	303	13	.	.	.
cord-015922-5wwy0m2k	303	14	 	 	_SP
cord-015922-5wwy0m2k	303	15	19	19	CD
cord-015922-5wwy0m2k	303	16	-	-	SYM
cord-015922-5wwy0m2k	303	17	2	2	CD
cord-015922-5wwy0m2k	303	18	)	)	-RRB-
cord-015922-5wwy0m2k	303	19	,	,	,
cord-015922-5wwy0m2k	303	20	are	be	VBP
cord-015922-5wwy0m2k	303	21	associated	associate	VBN
cord-015922-5wwy0m2k	303	22	in	in	IN
cord-015922-5wwy0m2k	303	23	the	the	DT
cord-015922-5wwy0m2k	303	24	neutropenic	neutropenic	JJ
cord-015922-5wwy0m2k	303	25	patient	patient	JJ
cord-015922-5wwy0m2k	303	26	with	with	IN
cord-015922-5wwy0m2k	303	27	invasive	invasive	JJ
cord-015922-5wwy0m2k	303	28	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	303	29	(	(	-LRB-
cord-015922-5wwy0m2k	303	30	although	although	IN
cord-015922-5wwy0m2k	303	31	other	other	JJ
cord-015922-5wwy0m2k	303	32	pathogens	pathogen	NNS
cord-015922-5wwy0m2k	303	33	can	can	MD
cord-015922-5wwy0m2k	303	34	cause	cause	VB
cord-015922-5wwy0m2k	303	35	the	the	DT
cord-015922-5wwy0m2k	303	36	same	same	JJ
cord-015922-5wwy0m2k	303	37	radiologic	radiologic	JJ
cord-015922-5wwy0m2k	303	38	finding	finding	NN
cord-015922-5wwy0m2k	303	39	:	:	:
cord-015922-5wwy0m2k	303	40	Fusarium	fusarium	NN
cord-015922-5wwy0m2k	303	41	and	and	CC
cord-015922-5wwy0m2k	303	42	other	other	JJ
cord-015922-5wwy0m2k	303	43	vasculotrophic	vasculotrophic	JJ
cord-015922-5wwy0m2k	303	44	molds	mold	NNS
cord-015922-5wwy0m2k	303	45	and	and	CC
cord-015922-5wwy0m2k	303	46	Nocardia	Nocardia	NNP
cord-015922-5wwy0m2k	303	47	asteroides	asteroides	NNP
cord-015922-5wwy0m2k	303	48	being	be	VBG
cord-015922-5wwy0m2k	303	49	examples	example	NNS
cord-015922-5wwy0m2k	303	50	of	of	IN
cord-015922-5wwy0m2k	303	51	this	this	DT
cord-015922-5wwy0m2k	303	52	)	)	-RRB-
cord-015922-5wwy0m2k	303	53	.	.	.
cord-015922-5wwy0m2k	304	1	European	european	JJ
cord-015922-5wwy0m2k	304	2	groups	group	NNS
cord-015922-5wwy0m2k	304	3	have	have	VBP
cord-015922-5wwy0m2k	304	4	been	be	VBN
cord-015922-5wwy0m2k	304	5	advocating	advocate	VBG
cord-015922-5wwy0m2k	304	6	protocol	protocol	NN
cord-015922-5wwy0m2k	304	7	serial	serial	JJ
cord-015922-5wwy0m2k	304	8	chest	chest	NN
cord-015922-5wwy0m2k	304	9	CT	CT	NNP
cord-015922-5wwy0m2k	304	10	scans	scan	NNS
cord-015922-5wwy0m2k	304	11	to	to	TO
cord-015922-5wwy0m2k	304	12	find	find	VB
cord-015922-5wwy0m2k	304	13	such	such	JJ
cord-015922-5wwy0m2k	304	14	pathology	pathology	NN
cord-015922-5wwy0m2k	304	15	as	as	IN
cord-015922-5wwy0m2k	304	16	a	a	DT
cord-015922-5wwy0m2k	304	17	guide	guide	NN
cord-015922-5wwy0m2k	304	18	to	to	IN
cord-015922-5wwy0m2k	304	19	early	early	JJ
cord-015922-5wwy0m2k	304	20	diagnosis	diagnosis	NN
cord-015922-5wwy0m2k	304	21	[	[	-LRB-
cord-015922-5wwy0m2k	304	22	98	98	CD
cord-015922-5wwy0m2k	304	23	]	]	-RRB-
cord-015922-5wwy0m2k	304	24	.	.	.
cord-015922-5wwy0m2k	305	1	If	if	IN
cord-015922-5wwy0m2k	305	2	prevention	prevention	NN
cord-015922-5wwy0m2k	305	3	fails	fail	VBZ
cord-015922-5wwy0m2k	305	4	,	,	,
cord-015922-5wwy0m2k	305	5	then	then	RB
cord-015922-5wwy0m2k	305	6	early	early	JJ
cord-015922-5wwy0m2k	305	7	diagnosis	diagnosis	NN
cord-015922-5wwy0m2k	305	8	is	be	VBZ
cord-015922-5wwy0m2k	305	9	the	the	DT
cord-015922-5wwy0m2k	305	10	key	key	NN
cord-015922-5wwy0m2k	305	11	to	to	IN
cord-015922-5wwy0m2k	305	12	the	the	DT
cord-015922-5wwy0m2k	305	13	patient	patient	NN
cord-015922-5wwy0m2k	305	14	's	's	POS
cord-015922-5wwy0m2k	305	15	survival	survival	NN
cord-015922-5wwy0m2k	305	16	[	[	-LRB-
cord-015922-5wwy0m2k	305	17	4	4	CD
cord-015922-5wwy0m2k	305	18	,	,	,
cord-015922-5wwy0m2k	305	19	92	92	CD
cord-015922-5wwy0m2k	305	20	,	,	,
cord-015922-5wwy0m2k	305	21	93	93	CD
cord-015922-5wwy0m2k	305	22	]	]	-RRB-
cord-015922-5wwy0m2k	305	23	.	.	.
cord-015922-5wwy0m2k	306	1	Given	give	VBN
cord-015922-5wwy0m2k	306	2	the	the	DT
cord-015922-5wwy0m2k	306	3	limitations	limitation	NNS
cord-015922-5wwy0m2k	306	4	of	of	IN
cord-015922-5wwy0m2k	306	5	current	current	JJ
cord-015922-5wwy0m2k	306	6	diagnostic	diagnostic	JJ
cord-015922-5wwy0m2k	306	7	techniques	technique	NNS
cord-015922-5wwy0m2k	306	8	and	and	CC
cord-015922-5wwy0m2k	306	9	the	the	DT
cord-015922-5wwy0m2k	306	10	significant	significant	JJ
cord-015922-5wwy0m2k	306	11	morbidity	morbidity	NN
cord-015922-5wwy0m2k	306	12	associated	associate	VBN
cord-015922-5wwy0m2k	306	13	with	with	IN
cord-015922-5wwy0m2k	306	14	invasive	invasive	JJ
cord-015922-5wwy0m2k	306	15	fungal	fungal	JJ
cord-015922-5wwy0m2k	306	16	infection	infection	NN
cord-015922-5wwy0m2k	306	17	,	,	,
cord-015922-5wwy0m2k	306	18	two	two	CD
cord-015922-5wwy0m2k	306	19	strategies	strategy	NNS
cord-015922-5wwy0m2k	306	20	of	of	IN
cord-015922-5wwy0m2k	306	21	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	306	22	use	use	NN
cord-015922-5wwy0m2k	306	23	are	be	VBP
cord-015922-5wwy0m2k	306	24	commonly	commonly	RB
cord-015922-5wwy0m2k	306	25	deployed	deploy	VBN
cord-015922-5wwy0m2k	306	26	in	in	IN
cord-015922-5wwy0m2k	306	27	the	the	DT
cord-015922-5wwy0m2k	306	28	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	306	29	patient	patient	NN
cord-015922-5wwy0m2k	306	30	.	.	.
cord-015922-5wwy0m2k	307	1	The	the	DT
cord-015922-5wwy0m2k	307	2	first	first	JJ
cord-015922-5wwy0m2k	307	3	is	be	VBZ
cord-015922-5wwy0m2k	307	4	prophylactic	prophylactic	JJ
cord-015922-5wwy0m2k	307	5	fluconazole	fluconazole	NN
cord-015922-5wwy0m2k	307	6	use	use	NN
cord-015922-5wwy0m2k	307	7	during	during	IN
cord-015922-5wwy0m2k	307	8	the	the	DT
cord-015922-5wwy0m2k	307	9	initial	initial	JJ
cord-015922-5wwy0m2k	307	10	transplant	transplant	NN
cord-015922-5wwy0m2k	307	11	period	period	NN
cord-015922-5wwy0m2k	307	12	,	,	,
cord-015922-5wwy0m2k	307	13	which	which	WDT
cord-015922-5wwy0m2k	307	14	has	have	VBZ
cord-015922-5wwy0m2k	307	15	been	be	VBN
cord-015922-5wwy0m2k	307	16	shown	show	VBN
cord-015922-5wwy0m2k	307	17	to	to	TO
cord-015922-5wwy0m2k	307	18	decrease	decrease	VB
cord-015922-5wwy0m2k	307	19	fungal	fungal	JJ
cord-015922-5wwy0m2k	307	20	infections	infection	NNS
cord-015922-5wwy0m2k	307	21	[	[	-LRB-
cord-015922-5wwy0m2k	307	22	80	80	CD
cord-015922-5wwy0m2k	307	23	]	]	-RRB-
cord-015922-5wwy0m2k	307	24	in	in	IN
cord-015922-5wwy0m2k	307	25	one	one	CD
cord-015922-5wwy0m2k	307	26	study	study	NN
cord-015922-5wwy0m2k	307	27	,	,	,
cord-015922-5wwy0m2k	307	28	and	and	CC
cord-015922-5wwy0m2k	307	29	overall	overall	JJ
cord-015922-5wwy0m2k	307	30	mortality	mortality	NN
cord-015922-5wwy0m2k	307	31	Fig	Fig	NNP
cord-015922-5wwy0m2k	307	32	.	.	.
cord-015922-5wwy0m2k	308	1	19	19	CD
cord-015922-5wwy0m2k	308	2	-	-	SYM
cord-015922-5wwy0m2k	308	3	2	2	CD
cord-015922-5wwy0m2k	308	4	.	.	.
cord-015922-5wwy0m2k	309	1	Computerized	computerize	VBN
cord-015922-5wwy0m2k	309	2	tomographic	tomographic	JJ
cord-015922-5wwy0m2k	309	3	scan	scan	NN
cord-015922-5wwy0m2k	309	4	of	of	IN
cord-015922-5wwy0m2k	309	5	the	the	DT
cord-015922-5wwy0m2k	309	6	chest	chest	NN
cord-015922-5wwy0m2k	309	7	in	in	IN
cord-015922-5wwy0m2k	309	8	a	a	DT
cord-015922-5wwy0m2k	309	9	patient	patient	NN
cord-015922-5wwy0m2k	309	10	with	with	IN
cord-015922-5wwy0m2k	309	11	a	a	DT
cord-015922-5wwy0m2k	309	12	"	"	``
cord-015922-5wwy0m2k	309	13	halo	halo	NN
cord-015922-5wwy0m2k	309	14	sign	sign	NN
cord-015922-5wwy0m2k	309	15	"	"	''
cord-015922-5wwy0m2k	309	16	due	due	JJ
cord-015922-5wwy0m2k	309	17	to	to	IN
cord-015922-5wwy0m2k	309	18	invasive	invasive	JJ
cord-015922-5wwy0m2k	309	19	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	309	20	.	.	.
cord-015922-5wwy0m2k	310	1	Note	note	VB
cord-015922-5wwy0m2k	310	2	that	that	IN
cord-015922-5wwy0m2k	310	3	halo	halo	NN
cord-015922-5wwy0m2k	310	4	signs	sign	NNS
cord-015922-5wwy0m2k	310	5	most	most	RBS
cord-015922-5wwy0m2k	310	6	commonly	commonly	RB
cord-015922-5wwy0m2k	310	7	occur	occur	VBP
cord-015922-5wwy0m2k	310	8	in	in	IN
cord-015922-5wwy0m2k	310	9	granulocytopenic	granulocytopenic	NN
cord-015922-5wwy0m2k	310	10	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	310	11	recipients	recipient	NNS
cord-015922-5wwy0m2k	310	12	with	with	IN
cord-015922-5wwy0m2k	310	13	invasive	invasive	JJ
cord-015922-5wwy0m2k	310	14	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	310	15	.	.	.
cord-015922-5wwy0m2k	311	1	However	however	RB
cord-015922-5wwy0m2k	311	2	,	,	,
cord-015922-5wwy0m2k	311	3	it	-PRON-	PRP
cord-015922-5wwy0m2k	311	4	must	must	MD
cord-015922-5wwy0m2k	311	5	be	be	VB
cord-015922-5wwy0m2k	311	6	emphasized	emphasize	VBN
cord-015922-5wwy0m2k	311	7	that	that	IN
cord-015922-5wwy0m2k	311	8	a	a	DT
cord-015922-5wwy0m2k	311	9	halo	halo	NN
cord-015922-5wwy0m2k	311	10	sign	sign	NN
cord-015922-5wwy0m2k	311	11	is	be	VBZ
cord-015922-5wwy0m2k	311	12	occasionally	occasionally	RB
cord-015922-5wwy0m2k	311	13	seen	see	VBN
cord-015922-5wwy0m2k	311	14	in	in	IN
cord-015922-5wwy0m2k	311	15	patients	patient	NNS
cord-015922-5wwy0m2k	311	16	with	with	IN
cord-015922-5wwy0m2k	311	17	Nocardia	Nocardia	NNP
cord-015922-5wwy0m2k	311	18	,	,	,
cord-015922-5wwy0m2k	311	19	Scedosporium	Scedosporium	NNP
cord-015922-5wwy0m2k	311	20	,	,	,
cord-015922-5wwy0m2k	311	21	Fusarium	fusarium	NN
cord-015922-5wwy0m2k	311	22	and	and	CC
cord-015922-5wwy0m2k	311	23	other	other	JJ
cord-015922-5wwy0m2k	311	24	forms	form	NNS
cord-015922-5wwy0m2k	311	25	of	of	IN
cord-015922-5wwy0m2k	311	26	pneumonia	pneumonia	NN
cord-015922-5wwy0m2k	311	27	.	.	.
cord-015922-5wwy0m2k	312	1	The	the	DT
cord-015922-5wwy0m2k	312	2	patient	patient	NN
cord-015922-5wwy0m2k	312	3	was	be	VBD
cord-015922-5wwy0m2k	312	4	treated	treat	VBN
cord-015922-5wwy0m2k	312	5	with	with	IN
cord-015922-5wwy0m2k	312	6	voriconazole	voriconazole	NN
cord-015922-5wwy0m2k	312	7	monotherapy	monotherapy	JJ
cord-015922-5wwy0m2k	312	8	during	during	IN
cord-015922-5wwy0m2k	312	9	neutropenia	neutropenia	NN
cord-015922-5wwy0m2k	312	10	during	during	IN
cord-015922-5wwy0m2k	312	11	consolidation	consolidation	NN
cord-015922-5wwy0m2k	312	12	chemotherapy	chemotherapy	NN
cord-015922-5wwy0m2k	312	13	for	for	IN
cord-015922-5wwy0m2k	312	14	AML	AML	NNP
cord-015922-5wwy0m2k	312	15	and	and	CC
cord-015922-5wwy0m2k	312	16	his	-PRON-	PRP$
cord-015922-5wwy0m2k	312	17	treatment	treatment	NN
cord-015922-5wwy0m2k	312	18	was	be	VBD
cord-015922-5wwy0m2k	312	19	continued	continue	VBN
cord-015922-5wwy0m2k	312	20	through	through	IN
cord-015922-5wwy0m2k	312	21	allogeneic	allogeneic	NN
cord-015922-5wwy0m2k	312	22	transplantation	transplantation	NN
cord-015922-5wwy0m2k	312	23	.	.	.
cord-015922-5wwy0m2k	313	1	[	[	-LRB-
cord-015922-5wwy0m2k	313	2	79	79	CD
cord-015922-5wwy0m2k	313	3	]	]	-RRB-
cord-015922-5wwy0m2k	313	4	in	in	IN
cord-015922-5wwy0m2k	313	5	another	another	DT
cord-015922-5wwy0m2k	313	6	,	,	,
cord-015922-5wwy0m2k	313	7	when	when	WRB
cord-015922-5wwy0m2k	313	8	started	start	VBN
cord-015922-5wwy0m2k	313	9	on	on	IN
cord-015922-5wwy0m2k	313	10	day	day	NN
cord-015922-5wwy0m2k	313	11	0	0	CD
cord-015922-5wwy0m2k	313	12	until	until	IN
cord-015922-5wwy0m2k	313	13	engraftment	engraftment	NN
cord-015922-5wwy0m2k	313	14	[	[	-LRB-
cord-015922-5wwy0m2k	313	15	80	80	CD
cord-015922-5wwy0m2k	313	16	]	]	-RRB-
cord-015922-5wwy0m2k	313	17	or	or	CC
cord-015922-5wwy0m2k	313	18	day	day	NN
cord-015922-5wwy0m2k	313	19	+75	+75	XX
cord-015922-5wwy0m2k	313	20	[	[	-LRB-
cord-015922-5wwy0m2k	313	21	79	79	CD
cord-015922-5wwy0m2k	313	22	]	]	-RRB-
cord-015922-5wwy0m2k	313	23	.	.	.
cord-015922-5wwy0m2k	314	1	It	-PRON-	PRP
cord-015922-5wwy0m2k	314	2	is	be	VBZ
cord-015922-5wwy0m2k	314	3	important	important	JJ
cord-015922-5wwy0m2k	314	4	to	to	TO
cord-015922-5wwy0m2k	314	5	note	note	VB
cord-015922-5wwy0m2k	314	6	that	that	IN
cord-015922-5wwy0m2k	314	7	a	a	DT
cord-015922-5wwy0m2k	314	8	high	high	JJ
cord-015922-5wwy0m2k	314	9	background	background	NN
cord-015922-5wwy0m2k	314	10	rate	rate	NN
cord-015922-5wwy0m2k	314	11	of	of	IN
cord-015922-5wwy0m2k	314	12	Candida	Candida	NNP
cord-015922-5wwy0m2k	314	13	infections	infection	NNS
cord-015922-5wwy0m2k	314	14	was	be	VBD
cord-015922-5wwy0m2k	314	15	noted	note	VBN
cord-015922-5wwy0m2k	314	16	in	in	IN
cord-015922-5wwy0m2k	314	17	both	both	DT
cord-015922-5wwy0m2k	314	18	of	of	IN
cord-015922-5wwy0m2k	314	19	these	these	DT
cord-015922-5wwy0m2k	314	20	reports	report	NNS
cord-015922-5wwy0m2k	314	21	and	and	CC
cord-015922-5wwy0m2k	314	22	may	may	MD
cord-015922-5wwy0m2k	314	23	not	not	RB
cord-015922-5wwy0m2k	314	24	represent	represent	VB
cord-015922-5wwy0m2k	314	25	the	the	DT
cord-015922-5wwy0m2k	314	26	experience	experience	NN
cord-015922-5wwy0m2k	314	27	of	of	IN
cord-015922-5wwy0m2k	314	28	other	other	JJ
cord-015922-5wwy0m2k	314	29	transplant	transplant	NN
cord-015922-5wwy0m2k	314	30	centers	center	NNS
cord-015922-5wwy0m2k	314	31	.	.	.
cord-015922-5wwy0m2k	315	1	Echinocandins	Echinocandins	NNP
cord-015922-5wwy0m2k	315	2	may	may	MD
cord-015922-5wwy0m2k	315	3	be	be	VB
cord-015922-5wwy0m2k	315	4	an	an	DT
cord-015922-5wwy0m2k	315	5	alternative	alternative	NN
cord-015922-5wwy0m2k	315	6	to	to	TO
cord-015922-5wwy0m2k	315	7	fluconazole	fluconazole	VB
cord-015922-5wwy0m2k	315	8	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	315	9	during	during	IN
cord-015922-5wwy0m2k	315	10	this	this	DT
cord-015922-5wwy0m2k	315	11	risk	risk	NN
cord-015922-5wwy0m2k	315	12	period	period	NN
cord-015922-5wwy0m2k	315	13	[	[	-LRB-
cord-015922-5wwy0m2k	315	14	89	89	CD
cord-015922-5wwy0m2k	315	15	]	]	-RRB-
cord-015922-5wwy0m2k	315	16	.	.	.
cord-015922-5wwy0m2k	316	1	The	the	DT
cord-015922-5wwy0m2k	316	2	second	second	JJ
cord-015922-5wwy0m2k	316	3	common	common	JJ
cord-015922-5wwy0m2k	316	4	strategy	strategy	NN
cord-015922-5wwy0m2k	316	5	is	be	VBZ
cord-015922-5wwy0m2k	316	6	empiric	empiric	JJ
cord-015922-5wwy0m2k	316	7	antifungal	antifungal	JJ
cord-015922-5wwy0m2k	316	8	therapy	therapy	NN
cord-015922-5wwy0m2k	316	9	in	in	IN
cord-015922-5wwy0m2k	316	10	neutropenic	neutropenic	JJ
cord-015922-5wwy0m2k	316	11	patients	patient	NNS
cord-015922-5wwy0m2k	316	12	with	with	IN
cord-015922-5wwy0m2k	316	13	persistent	persistent	JJ
cord-015922-5wwy0m2k	316	14	fever	fever	NN
cord-015922-5wwy0m2k	316	15	without	without	IN
cord-015922-5wwy0m2k	316	16	a	a	DT
cord-015922-5wwy0m2k	316	17	source	source	NN
cord-015922-5wwy0m2k	316	18	,	,	,
cord-015922-5wwy0m2k	316	19	despite	despite	IN
cord-015922-5wwy0m2k	316	20	broad	broad	JJ
cord-015922-5wwy0m2k	316	21	-	-	HYPH
cord-015922-5wwy0m2k	316	22	spectrum	spectrum	NN
cord-015922-5wwy0m2k	316	23	antimicrobial	antimicrobial	NN
cord-015922-5wwy0m2k	316	24	therapy	therapy	NN
cord-015922-5wwy0m2k	316	25	for	for	IN
cord-015922-5wwy0m2k	316	26	>	>	$
cord-015922-5wwy0m2k	316	27	96	96	CD
cord-015922-5wwy0m2k	316	28	hours	hour	NNS
cord-015922-5wwy0m2k	316	29	[	[	-LRB-
cord-015922-5wwy0m2k	316	30	99	99	CD
cord-015922-5wwy0m2k	316	31	,	,	,
cord-015922-5wwy0m2k	316	32	100	100	CD
cord-015922-5wwy0m2k	316	33	]	]	-RRB-
cord-015922-5wwy0m2k	316	34	.	.	.
cord-015922-5wwy0m2k	317	1	In	in	IN
cord-015922-5wwy0m2k	317	2	this	this	DT
cord-015922-5wwy0m2k	317	3	setting	set	VBG
cord-015922-5wwy0m2k	317	4	the	the	DT
cord-015922-5wwy0m2k	317	5	primary	primary	JJ
cord-015922-5wwy0m2k	317	6	concern	concern	NN
cord-015922-5wwy0m2k	317	7	is	be	VBZ
cord-015922-5wwy0m2k	317	8	both	both	CC
cord-015922-5wwy0m2k	317	9	Candida	Candida	NNP
cord-015922-5wwy0m2k	317	10	and	and	CC
cord-015922-5wwy0m2k	317	11	invasive	invasive	JJ
cord-015922-5wwy0m2k	317	12	mold	mold	NN
cord-015922-5wwy0m2k	317	13	infection	infection	NN
cord-015922-5wwy0m2k	317	14	,	,	,
cord-015922-5wwy0m2k	317	15	especially	especially	RB
cord-015922-5wwy0m2k	317	16	Aspergillus	aspergillus	NN
cord-015922-5wwy0m2k	317	17	[	[	-LRB-
cord-015922-5wwy0m2k	317	18	2	2	CD
cord-015922-5wwy0m2k	317	19	]	]	-RRB-
cord-015922-5wwy0m2k	317	20	.	.	.
cord-015922-5wwy0m2k	318	1	The	the	DT
cord-015922-5wwy0m2k	318	2	traditional	traditional	JJ
cord-015922-5wwy0m2k	318	3	antifungal	antifungal	NN
cord-015922-5wwy0m2k	318	4	therapy	therapy	NN
cord-015922-5wwy0m2k	318	5	utilized	utilize	VBN
cord-015922-5wwy0m2k	318	6	as	as	IN
cord-015922-5wwy0m2k	318	7	empiric	empiric	JJ
cord-015922-5wwy0m2k	318	8	therapy	therapy	NN
cord-015922-5wwy0m2k	318	9	is	be	VBZ
cord-015922-5wwy0m2k	318	10	an	an	DT
cord-015922-5wwy0m2k	318	11	amphotericin	amphotericin	NN
cord-015922-5wwy0m2k	318	12	product	product	NN
cord-015922-5wwy0m2k	318	13	[	[	-LRB-
cord-015922-5wwy0m2k	318	14	101	101	CD
cord-015922-5wwy0m2k	318	15	,	,	,
cord-015922-5wwy0m2k	318	16	102	102	CD
cord-015922-5wwy0m2k	318	17	]	]	-RRB-
cord-015922-5wwy0m2k	318	18	.	.	.
cord-015922-5wwy0m2k	319	1	Caspofungin	Caspofungin	NNP
cord-015922-5wwy0m2k	319	2	use	use	NN
cord-015922-5wwy0m2k	319	3	in	in	IN
cord-015922-5wwy0m2k	319	4	this	this	DT
cord-015922-5wwy0m2k	319	5	setting	setting	NN
cord-015922-5wwy0m2k	319	6	has	have	VBZ
cord-015922-5wwy0m2k	319	7	become	become	VBN
cord-015922-5wwy0m2k	319	8	common	common	JJ
cord-015922-5wwy0m2k	319	9	because	because	IN
cord-015922-5wwy0m2k	319	10	of	of	IN
cord-015922-5wwy0m2k	319	11	the	the	DT
cord-015922-5wwy0m2k	319	12	favorable	favorable	JJ
cord-015922-5wwy0m2k	319	13	side	side	NN
cord-015922-5wwy0m2k	319	14	effect	effect	NN
cord-015922-5wwy0m2k	319	15	profile	profile	NN
cord-015922-5wwy0m2k	319	16	of	of	IN
cord-015922-5wwy0m2k	319	17	this	this	DT
cord-015922-5wwy0m2k	319	18	class	class	NN
cord-015922-5wwy0m2k	319	19	of	of	IN
cord-015922-5wwy0m2k	319	20	agents	agent	NNS
cord-015922-5wwy0m2k	319	21	,	,	,
cord-015922-5wwy0m2k	319	22	but	but	CC
cord-015922-5wwy0m2k	319	23	at	at	IN
cord-015922-5wwy0m2k	319	24	the	the	DT
cord-015922-5wwy0m2k	319	25	expense	expense	NN
cord-015922-5wwy0m2k	319	26	of	of	IN
cord-015922-5wwy0m2k	319	27	a	a	DT
cord-015922-5wwy0m2k	319	28	more	more	RBR
cord-015922-5wwy0m2k	319	29	limited	limited	JJ
cord-015922-5wwy0m2k	319	30	fungal	fungal	NN
cord-015922-5wwy0m2k	319	31	spectrum	spectrum	NN
cord-015922-5wwy0m2k	319	32	[	[	-LRB-
cord-015922-5wwy0m2k	319	33	90	90	CD
cord-015922-5wwy0m2k	319	34	]	]	-RRB-
cord-015922-5wwy0m2k	319	35	.	.	.
cord-015922-5wwy0m2k	320	1	Other	other	JJ
cord-015922-5wwy0m2k	320	2	echinocandins	echinocandin	NNS
cord-015922-5wwy0m2k	320	3	(	(	-LRB-
cord-015922-5wwy0m2k	320	4	micafungin	micafungin	NNP
cord-015922-5wwy0m2k	320	5	,	,	,
cord-015922-5wwy0m2k	320	6	anidulafungin	anidulafungin	NNP
cord-015922-5wwy0m2k	320	7	)	)	-RRB-
cord-015922-5wwy0m2k	320	8	are	be	VBP
cord-015922-5wwy0m2k	320	9	likely	likely	JJ
cord-015922-5wwy0m2k	320	10	to	to	TO
cord-015922-5wwy0m2k	320	11	be	be	VB
cord-015922-5wwy0m2k	320	12	similarly	similarly	RB
cord-015922-5wwy0m2k	320	13	effective	effective	JJ
cord-015922-5wwy0m2k	320	14	,	,	,
cord-015922-5wwy0m2k	320	15	but	but	CC
cord-015922-5wwy0m2k	320	16	no	no	DT
cord-015922-5wwy0m2k	320	17	randomized	randomized	JJ
cord-015922-5wwy0m2k	320	18	comparisons	comparison	NNS
cord-015922-5wwy0m2k	320	19	with	with	IN
cord-015922-5wwy0m2k	320	20	these	these	DT
cord-015922-5wwy0m2k	320	21	latest	late	JJS
cord-015922-5wwy0m2k	320	22	drugs	drug	NNS
cord-015922-5wwy0m2k	320	23	have	have	VBP
cord-015922-5wwy0m2k	320	24	been	be	VBN
cord-015922-5wwy0m2k	320	25	performed	perform	VBN
cord-015922-5wwy0m2k	320	26	.	.	.
cord-015922-5wwy0m2k	321	1	The	the	DT
cord-015922-5wwy0m2k	321	2	role	role	NN
cord-015922-5wwy0m2k	321	3	of	of	IN
cord-015922-5wwy0m2k	321	4	voriconazole	voriconazole	NN
cord-015922-5wwy0m2k	321	5	in	in	IN
cord-015922-5wwy0m2k	321	6	this	this	DT
cord-015922-5wwy0m2k	321	7	setting	setting	NN
cord-015922-5wwy0m2k	321	8	is	be	VBZ
cord-015922-5wwy0m2k	321	9	controversial	controversial	JJ
cord-015922-5wwy0m2k	321	10	[	[	-LRB-
cord-015922-5wwy0m2k	321	11	102	102	CD
cord-015922-5wwy0m2k	321	12	]	]	-RRB-
cord-015922-5wwy0m2k	321	13	.	.	.
cord-015922-5wwy0m2k	322	1	When	when	WRB
cord-015922-5wwy0m2k	322	2	treating	treat	VBG
cord-015922-5wwy0m2k	322	3	invasive	invasive	JJ
cord-015922-5wwy0m2k	322	4	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	322	5	several	several	JJ
cord-015922-5wwy0m2k	322	6	approaches	approach	NNS
cord-015922-5wwy0m2k	322	7	should	should	MD
cord-015922-5wwy0m2k	322	8	be	be	VB
cord-015922-5wwy0m2k	322	9	considered	consider	VBN
cord-015922-5wwy0m2k	322	10	simultaneously	simultaneously	RB
cord-015922-5wwy0m2k	322	11	:	:	:
cord-015922-5wwy0m2k	322	12	1	1	LS
cord-015922-5wwy0m2k	322	13	)	)	-RRB-
cord-015922-5wwy0m2k	322	14	antifungal	antifungal	NN
cord-015922-5wwy0m2k	322	15	therapy	therapy	NN
cord-015922-5wwy0m2k	322	16	,	,	,
cord-015922-5wwy0m2k	322	17	2	2	LS
cord-015922-5wwy0m2k	322	18	)	)	-RRB-
cord-015922-5wwy0m2k	322	19	reverse	reverse	VBP
cord-015922-5wwy0m2k	322	20	or	or	CC
cord-015922-5wwy0m2k	322	21	minimize	minimize	VB
cord-015922-5wwy0m2k	322	22	the	the	DT
cord-015922-5wwy0m2k	322	23	host	host	NN
cord-015922-5wwy0m2k	322	24	immune	immune	JJ
cord-015922-5wwy0m2k	322	25	defects	defect	NNS
cord-015922-5wwy0m2k	322	26	(	(	-LRB-
cord-015922-5wwy0m2k	322	27	decrease	decrease	NN
cord-015922-5wwy0m2k	322	28	corticosteroids	corticosteroid	NNS
cord-015922-5wwy0m2k	322	29	,	,	,
cord-015922-5wwy0m2k	322	30	increase	increase	VBP
cord-015922-5wwy0m2k	322	31	neutrophils	neutrophil	NNS
cord-015922-5wwy0m2k	322	32	)	)	-RRB-
cord-015922-5wwy0m2k	322	33	,	,	,
cord-015922-5wwy0m2k	322	34	3	3	LS
cord-015922-5wwy0m2k	322	35	)	)	-RRB-
cord-015922-5wwy0m2k	322	36	control	control	VBP
cord-015922-5wwy0m2k	322	37	permissive	permissive	JJ
cord-015922-5wwy0m2k	322	38	viral	viral	JJ
cord-015922-5wwy0m2k	322	39	infections	infection	NNS
cord-015922-5wwy0m2k	323	1	(	(	-LRB-
cord-015922-5wwy0m2k	323	2	e.g.	e.g.	RB
cord-015922-5wwy0m2k	323	3	,	,	,
cord-015922-5wwy0m2k	323	4	CMV	CMV	NNP
cord-015922-5wwy0m2k	323	5	)	)	-RRB-
cord-015922-5wwy0m2k	323	6	and	and	CC
cord-015922-5wwy0m2k	323	7	4	4	LS
cord-015922-5wwy0m2k	323	8	)	)	-RRB-
cord-015922-5wwy0m2k	323	9	consider	consider	VB
cord-015922-5wwy0m2k	323	10	surgical	surgical	JJ
cord-015922-5wwy0m2k	323	11	excision	excision	NN
cord-015922-5wwy0m2k	323	12	,	,	,
cord-015922-5wwy0m2k	323	13	if	if	IN
cord-015922-5wwy0m2k	323	14	possible	possible	JJ
cord-015922-5wwy0m2k	323	15	.	.	.
cord-015922-5wwy0m2k	324	1	Voriconazole	Voriconazole	NNP
cord-015922-5wwy0m2k	324	2	has	have	VBZ
cord-015922-5wwy0m2k	324	3	become	become	VBN
cord-015922-5wwy0m2k	324	4	a	a	DT
cord-015922-5wwy0m2k	324	5	cornerstone	cornerstone	NN
cord-015922-5wwy0m2k	324	6	of	of	IN
cord-015922-5wwy0m2k	324	7	therapy	therapy	NN
cord-015922-5wwy0m2k	324	8	for	for	IN
cord-015922-5wwy0m2k	324	9	invasive	invasive	JJ
cord-015922-5wwy0m2k	324	10	Aspergillus	aspergillus	NN
cord-015922-5wwy0m2k	324	11	infections	infection	NNS
cord-015922-5wwy0m2k	324	12	,	,	,
cord-015922-5wwy0m2k	324	13	though	though	IN
cord-015922-5wwy0m2k	324	14	the	the	DT
cord-015922-5wwy0m2k	324	15	management	management	NN
cord-015922-5wwy0m2k	324	16	of	of	IN
cord-015922-5wwy0m2k	324	17	potential	potential	JJ
cord-015922-5wwy0m2k	324	18	side	side	NN
cord-015922-5wwy0m2k	324	19	effects	effect	NNS
cord-015922-5wwy0m2k	324	20	is	be	VBZ
cord-015922-5wwy0m2k	324	21	substantial	substantial	JJ
cord-015922-5wwy0m2k	324	22	[	[	-LRB-
cord-015922-5wwy0m2k	324	23	103	103	CD
cord-015922-5wwy0m2k	324	24	]	]	-RRB-
cord-015922-5wwy0m2k	324	25	[	[	-LRB-
cord-015922-5wwy0m2k	324	26	104	104	CD
cord-015922-5wwy0m2k	324	27	]	]	-RRB-
cord-015922-5wwy0m2k	324	28	[	[	-LRB-
cord-015922-5wwy0m2k	324	29	105	105	CD
cord-015922-5wwy0m2k	324	30	]	]	-RRB-
cord-015922-5wwy0m2k	324	31	.	.	.
cord-015922-5wwy0m2k	325	1	Whether	whether	IN
cord-015922-5wwy0m2k	325	2	the	the	DT
cord-015922-5wwy0m2k	325	3	combination	combination	NN
cord-015922-5wwy0m2k	325	4	of	of	IN
cord-015922-5wwy0m2k	325	5	therapeutic	therapeutic	JJ
cord-015922-5wwy0m2k	325	6	agents	agent	NNS
cord-015922-5wwy0m2k	325	7	(	(	-LRB-
cord-015922-5wwy0m2k	325	8	polyenes	polyenes	NNPS
cord-015922-5wwy0m2k	325	9	,	,	,
cord-015922-5wwy0m2k	325	10	azoles	azoles	NNP
cord-015922-5wwy0m2k	325	11	and	and	CC
cord-015922-5wwy0m2k	325	12	echinocandins	echinocandins	NNP
cord-015922-5wwy0m2k	325	13	)	)	-RRB-
cord-015922-5wwy0m2k	325	14	increases	increase	VBZ
cord-015922-5wwy0m2k	325	15	the	the	DT
cord-015922-5wwy0m2k	325	16	therapeutic	therapeutic	JJ
cord-015922-5wwy0m2k	325	17	benefit	benefit	NN
cord-015922-5wwy0m2k	325	18	has	have	VBZ
cord-015922-5wwy0m2k	325	19	yet	yet	RB
cord-015922-5wwy0m2k	325	20	to	to	TO
cord-015922-5wwy0m2k	325	21	be	be	VB
cord-015922-5wwy0m2k	325	22	determined	determine	VBN
cord-015922-5wwy0m2k	325	23	[	[	-LRB-
cord-015922-5wwy0m2k	325	24	106	106	CD
cord-015922-5wwy0m2k	325	25	]	]	-RRB-
cord-015922-5wwy0m2k	325	26	.	.	.
cord-015922-5wwy0m2k	326	1	Increasing	increase	VBG
cord-015922-5wwy0m2k	326	2	experience	experience	NN
cord-015922-5wwy0m2k	326	3	suggests	suggest	VBZ
cord-015922-5wwy0m2k	326	4	that	that	IN
cord-015922-5wwy0m2k	326	5	voriconazole	voriconazole	NN
cord-015922-5wwy0m2k	326	6	alone	alone	RB
cord-015922-5wwy0m2k	326	7	is	be	VBZ
cord-015922-5wwy0m2k	326	8	sufficient	sufficient	JJ
cord-015922-5wwy0m2k	326	9	in	in	IN
cord-015922-5wwy0m2k	326	10	most	most	JJS
cord-015922-5wwy0m2k	326	11	cases	case	NNS
cord-015922-5wwy0m2k	326	12	for	for	IN
cord-015922-5wwy0m2k	326	13	a	a	DT
cord-015922-5wwy0m2k	326	14	successful	successful	JJ
cord-015922-5wwy0m2k	326	15	outcome	outcome	NN
cord-015922-5wwy0m2k	326	16	in	in	IN
cord-015922-5wwy0m2k	326	17	invasive	invasive	JJ
cord-015922-5wwy0m2k	326	18	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	326	19	and	and	CC
cord-015922-5wwy0m2k	326	20	has	have	VBZ
cord-015922-5wwy0m2k	326	21	decreased	decrease	VBN
cord-015922-5wwy0m2k	326	22	the	the	DT
cord-015922-5wwy0m2k	326	23	morbidity	morbidity	NN
cord-015922-5wwy0m2k	326	24	and	and	CC
cord-015922-5wwy0m2k	326	25	mortality	mortality	NN
cord-015922-5wwy0m2k	326	26	of	of	IN
cord-015922-5wwy0m2k	326	27	this	this	DT
cord-015922-5wwy0m2k	326	28	infection	infection	NN
cord-015922-5wwy0m2k	326	29	[	[	-LRB-
cord-015922-5wwy0m2k	326	30	11	11	CD
cord-015922-5wwy0m2k	326	31	,	,	,
cord-015922-5wwy0m2k	326	32	106	106	CD
cord-015922-5wwy0m2k	326	33	]	]	-RRB-
cord-015922-5wwy0m2k	326	34	.	.	.
cord-015922-5wwy0m2k	327	1	Another	another	DT
cord-015922-5wwy0m2k	327	2	significant	significant	JJ
cord-015922-5wwy0m2k	327	3	risk	risk	NN
cord-015922-5wwy0m2k	327	4	period	period	NN
cord-015922-5wwy0m2k	327	5	for	for	IN
cord-015922-5wwy0m2k	327	6	invasive	invasive	JJ
cord-015922-5wwy0m2k	327	7	fungal	fungal	JJ
cord-015922-5wwy0m2k	327	8	infections	infection	NNS
cord-015922-5wwy0m2k	327	9	(	(	-LRB-
cord-015922-5wwy0m2k	327	10	IFI	IFI	NNP
cord-015922-5wwy0m2k	327	11	)	)	-RRB-
cord-015922-5wwy0m2k	327	12	is	be	VBZ
cord-015922-5wwy0m2k	327	13	in	in	IN
cord-015922-5wwy0m2k	327	14	the	the	DT
cord-015922-5wwy0m2k	327	15	setting	setting	NN
cord-015922-5wwy0m2k	327	16	of	of	IN
cord-015922-5wwy0m2k	327	17	significant	significant	JJ
cord-015922-5wwy0m2k	327	18	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	327	19	,	,	,
cord-015922-5wwy0m2k	327	20	such	such	JJ
cord-015922-5wwy0m2k	327	21	as	as	IN
cord-015922-5wwy0m2k	327	22	grade	grade	NN
cord-015922-5wwy0m2k	327	23	III	III	NNP
cord-015922-5wwy0m2k	327	24	or	or	CC
cord-015922-5wwy0m2k	327	25	IV	IV	NNP
cord-015922-5wwy0m2k	327	26	,	,	,
cord-015922-5wwy0m2k	327	27	and	and	CC
cord-015922-5wwy0m2k	327	28	its	-PRON-	PRP$
cord-015922-5wwy0m2k	327	29	therapy	therapy	NN
cord-015922-5wwy0m2k	327	30	[	[	-LRB-
cord-015922-5wwy0m2k	327	31	9	9	CD
cord-015922-5wwy0m2k	327	32	]	]	-RRB-
cord-015922-5wwy0m2k	327	33	.	.	.
cord-015922-5wwy0m2k	328	1	In	in	IN
cord-015922-5wwy0m2k	328	2	this	this	DT
cord-015922-5wwy0m2k	328	3	setting	setting	NN
cord-015922-5wwy0m2k	328	4	,	,	,
cord-015922-5wwy0m2k	328	5	posaconazole	posaconazole	NNP
cord-015922-5wwy0m2k	328	6	(	(	-LRB-
cord-015922-5wwy0m2k	328	7	versus	versus	IN
cord-015922-5wwy0m2k	328	8	fluconazole	fluconazole	NNP
cord-015922-5wwy0m2k	328	9	)	)	-RRB-
cord-015922-5wwy0m2k	328	10	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	328	11	has	have	VBZ
cord-015922-5wwy0m2k	328	12	recently	recently	RB
cord-015922-5wwy0m2k	328	13	demonstrated	demonstrate	VBN
cord-015922-5wwy0m2k	328	14	some	some	DT
cord-015922-5wwy0m2k	328	15	benefit	benefit	NN
cord-015922-5wwy0m2k	328	16	in	in	IN
cord-015922-5wwy0m2k	328	17	preventing	prevent	VBG
cord-015922-5wwy0m2k	328	18	IFI	IFI	NNP
cord-015922-5wwy0m2k	328	19	compared	compare	VBN
cord-015922-5wwy0m2k	328	20	to	to	IN
cord-015922-5wwy0m2k	328	21	fluconazole	fluconazole	NN
cord-015922-5wwy0m2k	328	22	(	(	-LRB-
cord-015922-5wwy0m2k	328	23	5.3	5.3	CD
cord-015922-5wwy0m2k	328	24	%	%	NN
cord-015922-5wwy0m2k	328	25	versus	versus	IN
cord-015922-5wwy0m2k	328	26	9.0	9.0	CD
cord-015922-5wwy0m2k	328	27	%	%	NN
cord-015922-5wwy0m2k	328	28	,	,	,
cord-015922-5wwy0m2k	328	29	p	p	NN
cord-015922-5wwy0m2k	328	30	=	=	SYM
cord-015922-5wwy0m2k	328	31	0.07	0.07	CD
cord-015922-5wwy0m2k	328	32	)	)	-RRB-
cord-015922-5wwy0m2k	328	33	and	and	CC
cord-015922-5wwy0m2k	328	34	in	in	IN
cord-015922-5wwy0m2k	328	35	preventing	prevent	VBG
cord-015922-5wwy0m2k	328	36	probable	probable	JJ
cord-015922-5wwy0m2k	328	37	or	or	CC
cord-015922-5wwy0m2k	328	38	proven	prove	VBN
cord-015922-5wwy0m2k	328	39	invasive	invasive	JJ
cord-015922-5wwy0m2k	328	40	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	328	41	(	(	-LRB-
cord-015922-5wwy0m2k	328	42	2.3	2.3	CD
cord-015922-5wwy0m2k	328	43	%	%	NN
cord-015922-5wwy0m2k	328	44	versus	versus	IN
cord-015922-5wwy0m2k	328	45	7.0	7.0	CD
cord-015922-5wwy0m2k	328	46	%	%	NN
cord-015922-5wwy0m2k	328	47	,	,	,
cord-015922-5wwy0m2k	328	48	p	p	NN
cord-015922-5wwy0m2k	328	49	=	=	SYM
cord-015922-5wwy0m2k	328	50	0.006	0.006	CD
cord-015922-5wwy0m2k	328	51	-interestingly	-interestingly	RB
cord-015922-5wwy0m2k	328	52	,	,	,
cord-015922-5wwy0m2k	328	53	these	these	DT
cord-015922-5wwy0m2k	328	54	results	result	NNS
cord-015922-5wwy0m2k	328	55	were	be	VBD
cord-015922-5wwy0m2k	328	56	largely	largely	RB
cord-015922-5wwy0m2k	328	57	driven	drive	VBN
cord-015922-5wwy0m2k	328	58	by	by	IN
cord-015922-5wwy0m2k	328	59	results	result	NNS
cord-015922-5wwy0m2k	328	60	from	from	IN
cord-015922-5wwy0m2k	328	61	galactomannan	galactomannan	NNP
cord-015922-5wwy0m2k	328	62	assay	assay	NNP
cord-015922-5wwy0m2k	328	63	testing	testing	NN
cord-015922-5wwy0m2k	328	64	)	)	-RRB-
cord-015922-5wwy0m2k	329	1	[	[	-LRB-
cord-015922-5wwy0m2k	329	2	107	107	CD
cord-015922-5wwy0m2k	329	3	]	]	-RRB-
cord-015922-5wwy0m2k	330	1	[	[	-LRB-
cord-015922-5wwy0m2k	330	2	108	108	CD
cord-015922-5wwy0m2k	330	3	]	]	-RRB-
cord-015922-5wwy0m2k	330	4	[	[	-LRB-
cord-015922-5wwy0m2k	330	5	109	109	CD
cord-015922-5wwy0m2k	330	6	]	]	-RRB-
cord-015922-5wwy0m2k	330	7	.	.	.
cord-015922-5wwy0m2k	331	1	Posaconazole	Posaconazole	NNP
cord-015922-5wwy0m2k	331	2	has	have	VBZ
cord-015922-5wwy0m2k	331	3	activity	activity	NN
cord-015922-5wwy0m2k	331	4	against	against	IN
cord-015922-5wwy0m2k	331	5	the	the	DT
cord-015922-5wwy0m2k	331	6	Zygomycetes	Zygomycetes	NNPS
cord-015922-5wwy0m2k	331	7	as	as	RB
cord-015922-5wwy0m2k	331	8	well	well	RB
cord-015922-5wwy0m2k	331	9	as	as	IN
cord-015922-5wwy0m2k	331	10	Aspergillus	aspergillus	NN
cord-015922-5wwy0m2k	331	11	sp	sp	NN
cord-015922-5wwy0m2k	331	12	[	[	-LRB-
cord-015922-5wwy0m2k	331	13	110	110	CD
cord-015922-5wwy0m2k	331	14	]	]	-RRB-
cord-015922-5wwy0m2k	331	15	[	[	-LRB-
cord-015922-5wwy0m2k	331	16	111	111	CD
cord-015922-5wwy0m2k	331	17	]	]	-RRB-
cord-015922-5wwy0m2k	331	18	[	[	-LRB-
cord-015922-5wwy0m2k	331	19	112	112	CD
cord-015922-5wwy0m2k	331	20	]	]	-RRB-
cord-015922-5wwy0m2k	331	21	.	.	.
cord-015922-5wwy0m2k	332	1	When	when	WRB
cord-015922-5wwy0m2k	332	2	an	an	DT
cord-015922-5wwy0m2k	332	3	azole	azole	NN
cord-015922-5wwy0m2k	332	4	is	be	VBZ
cord-015922-5wwy0m2k	332	5	used	use	VBN
cord-015922-5wwy0m2k	332	6	in	in	IN
cord-015922-5wwy0m2k	332	7	this	this	DT
cord-015922-5wwy0m2k	332	8	patient	patient	JJ
cord-015922-5wwy0m2k	332	9	population	population	NN
cord-015922-5wwy0m2k	332	10	,	,	,
cord-015922-5wwy0m2k	332	11	careful	careful	JJ
cord-015922-5wwy0m2k	332	12	assessment	assessment	NN
cord-015922-5wwy0m2k	332	13	of	of	IN
cord-015922-5wwy0m2k	332	14	drug	drug	NN
cord-015922-5wwy0m2k	332	15	interactions	interaction	NNS
cord-015922-5wwy0m2k	332	16	,	,	,
cord-015922-5wwy0m2k	332	17	both	both	CC
cord-015922-5wwy0m2k	332	18	with	with	IN
cord-015922-5wwy0m2k	332	19	the	the	DT
cord-015922-5wwy0m2k	332	20	initiation	initiation	NN
cord-015922-5wwy0m2k	332	21	and	and	CC
cord-015922-5wwy0m2k	332	22	cessation	cessation	NN
cord-015922-5wwy0m2k	332	23	of	of	IN
cord-015922-5wwy0m2k	332	24	therapy	therapy	NN
cord-015922-5wwy0m2k	332	25	,	,	,
cord-015922-5wwy0m2k	332	26	is	be	VBZ
cord-015922-5wwy0m2k	332	27	critical	critical	JJ
cord-015922-5wwy0m2k	332	28	.	.	.
cord-015922-5wwy0m2k	333	1	Therapy	therapy	NN
cord-015922-5wwy0m2k	333	2	for	for	IN
cord-015922-5wwy0m2k	333	3	the	the	DT
cord-015922-5wwy0m2k	333	4	emerging	emerge	VBG
cord-015922-5wwy0m2k	333	5	fungi	fungus	NNS
cord-015922-5wwy0m2k	333	6	Fusarium	Fusarium	NNP
cord-015922-5wwy0m2k	333	7	and	and	CC
cord-015922-5wwy0m2k	333	8	Scedosporium	Scedosporium	NNP
cord-015922-5wwy0m2k	333	9	should	should	MD
cord-015922-5wwy0m2k	333	10	be	be	VB
cord-015922-5wwy0m2k	333	11	guided	guide	VBN
cord-015922-5wwy0m2k	333	12	by	by	IN
cord-015922-5wwy0m2k	333	13	in	in	FW
cord-015922-5wwy0m2k	333	14	vitro	vitro	FW
cord-015922-5wwy0m2k	333	15	sensitivity	sensitivity	NN
cord-015922-5wwy0m2k	333	16	testing	testing	NN
cord-015922-5wwy0m2k	333	17	done	do	VBN
cord-015922-5wwy0m2k	333	18	locally	locally	RB
cord-015922-5wwy0m2k	333	19	or	or	CC
cord-015922-5wwy0m2k	333	20	at	at	IN
cord-015922-5wwy0m2k	333	21	regional	regional	JJ
cord-015922-5wwy0m2k	333	22	reference	reference	NN
cord-015922-5wwy0m2k	333	23	laboratories	laboratory	NNS
cord-015922-5wwy0m2k	333	24	,	,	,
cord-015922-5wwy0m2k	333	25	but	but	CC
cord-015922-5wwy0m2k	333	26	voriconazole	voriconazole	NN
cord-015922-5wwy0m2k	333	27	use	use	NN
cord-015922-5wwy0m2k	333	28	should	should	MD
cord-015922-5wwy0m2k	333	29	be	be	VB
cord-015922-5wwy0m2k	333	30	considered	consider	VBN
cord-015922-5wwy0m2k	333	31	.	.	.
cord-015922-5wwy0m2k	334	1	When	when	WRB
cord-015922-5wwy0m2k	334	2	therapy	therapy	NN
cord-015922-5wwy0m2k	334	3	for	for	IN
cord-015922-5wwy0m2k	334	4	the	the	DT
cord-015922-5wwy0m2k	334	5	endemic	endemic	JJ
cord-015922-5wwy0m2k	334	6	mycoses	mycose	NNS
cord-015922-5wwy0m2k	334	7	is	be	VBZ
cord-015922-5wwy0m2k	334	8	indicated	indicate	VBN
cord-015922-5wwy0m2k	334	9	,	,	,
cord-015922-5wwy0m2k	334	10	initial	initial	JJ
cord-015922-5wwy0m2k	334	11	treatment	treatment	NN
cord-015922-5wwy0m2k	334	12	(	(	-LRB-
cord-015922-5wwy0m2k	334	13	induction	induction	NN
cord-015922-5wwy0m2k	334	14	therapy	therapy	NN
cord-015922-5wwy0m2k	334	15	)	)	-RRB-
cord-015922-5wwy0m2k	334	16	with	with	IN
cord-015922-5wwy0m2k	334	17	an	an	DT
cord-015922-5wwy0m2k	334	18	amphotericin	amphotericin	NN
cord-015922-5wwy0m2k	334	19	preparation	preparation	NN
cord-015922-5wwy0m2k	334	20	should	should	MD
cord-015922-5wwy0m2k	334	21	be	be	VB
cord-015922-5wwy0m2k	334	22	considered	consider	VBN
cord-015922-5wwy0m2k	334	23	,	,	,
cord-015922-5wwy0m2k	334	24	followed	follow	VBN
cord-015922-5wwy0m2k	334	25	by	by	IN
cord-015922-5wwy0m2k	334	26	a	a	DT
cord-015922-5wwy0m2k	334	27	prolonged	prolonged	JJ
cord-015922-5wwy0m2k	334	28	course	course	NN
cord-015922-5wwy0m2k	334	29	of	of	IN
cord-015922-5wwy0m2k	334	30	consolidative	consolidative	JJ
cord-015922-5wwy0m2k	334	31	therapy	therapy	NN
cord-015922-5wwy0m2k	334	32	with	with	IN
cord-015922-5wwy0m2k	334	33	an	an	DT
cord-015922-5wwy0m2k	334	34	oral	oral	JJ
cord-015922-5wwy0m2k	334	35	azole	azole	NN
cord-015922-5wwy0m2k	334	36	.	.	.
cord-015922-5wwy0m2k	335	1	Cryptococcal	cryptococcal	JJ
cord-015922-5wwy0m2k	335	2	disease	disease	NN
cord-015922-5wwy0m2k	335	3	should	should	MD
cord-015922-5wwy0m2k	335	4	be	be	VB
cord-015922-5wwy0m2k	335	5	treated	treat	VBN
cord-015922-5wwy0m2k	335	6	initially	initially	RB
cord-015922-5wwy0m2k	335	7	with	with	IN
cord-015922-5wwy0m2k	335	8	an	an	DT
cord-015922-5wwy0m2k	335	9	amphotericin	amphotericin	NN
cord-015922-5wwy0m2k	335	10	preparation	preparation	NN
cord-015922-5wwy0m2k	335	11	,	,	,
cord-015922-5wwy0m2k	335	12	CNS	CNS	NNP
cord-015922-5wwy0m2k	335	13	involvement	involvement	NN
cord-015922-5wwy0m2k	335	14	should	should	MD
cord-015922-5wwy0m2k	335	15	be	be	VB
cord-015922-5wwy0m2k	335	16	excluded	exclude	VBN
cord-015922-5wwy0m2k	335	17	by	by	IN
cord-015922-5wwy0m2k	335	18	cerebrospinal	cerebrospinal	JJ
cord-015922-5wwy0m2k	335	19	fluid	fluid	JJ
cord-015922-5wwy0m2k	335	20	sampling	sampling	NN
cord-015922-5wwy0m2k	335	21	,	,	,
cord-015922-5wwy0m2k	335	22	and	and	CC
cord-015922-5wwy0m2k	335	23	the	the	DT
cord-015922-5wwy0m2k	335	24	use	use	NN
cord-015922-5wwy0m2k	335	25	of	of	IN
cord-015922-5wwy0m2k	335	26	flucytosine	flucytosine	NN
cord-015922-5wwy0m2k	335	27	should	should	MD
cord-015922-5wwy0m2k	335	28	be	be	VB
cord-015922-5wwy0m2k	335	29	considered	consider	VBN
cord-015922-5wwy0m2k	335	30	if	if	IN
cord-015922-5wwy0m2k	335	31	present	present	JJ
cord-015922-5wwy0m2k	335	32	.	.	.
cord-015922-5wwy0m2k	336	1	Pneumocystis	Pneumocystis	NNP
cord-015922-5wwy0m2k	336	2	jiroveci	jiroveci	NNP
cord-015922-5wwy0m2k	336	3	,	,	,
cord-015922-5wwy0m2k	336	4	formerly	formerly	RB
cord-015922-5wwy0m2k	336	5	carinii	carinii	FW
cord-015922-5wwy0m2k	336	6	,	,	,
cord-015922-5wwy0m2k	336	7	is	be	VBZ
cord-015922-5wwy0m2k	336	8	a	a	DT
cord-015922-5wwy0m2k	336	9	ubiquitous	ubiquitous	JJ
cord-015922-5wwy0m2k	336	10	environmental	environmental	JJ
cord-015922-5wwy0m2k	336	11	organism	organism	NN
cord-015922-5wwy0m2k	336	12	which	which	WDT
cord-015922-5wwy0m2k	336	13	is	be	VBZ
cord-015922-5wwy0m2k	336	14	an	an	DT
cord-015922-5wwy0m2k	336	15	important	important	JJ
cord-015922-5wwy0m2k	336	16	cause	cause	NN
cord-015922-5wwy0m2k	336	17	of	of	IN
cord-015922-5wwy0m2k	336	18	pneumonia	pneumonia	NN
cord-015922-5wwy0m2k	336	19	in	in	IN
cord-015922-5wwy0m2k	336	20	patients	patient	NNS
cord-015922-5wwy0m2k	336	21	who	who	WP
cord-015922-5wwy0m2k	336	22	are	be	VBP
cord-015922-5wwy0m2k	336	23	immunosuppressed	immunosuppressed	JJ
cord-015922-5wwy0m2k	336	24	,	,	,
cord-015922-5wwy0m2k	336	25	such	such	JJ
cord-015922-5wwy0m2k	336	26	as	as	IN
cord-015922-5wwy0m2k	336	27	those	those	DT
cord-015922-5wwy0m2k	336	28	who	who	WP
cord-015922-5wwy0m2k	336	29	have	have	VBP
cord-015922-5wwy0m2k	336	30	undergone	undergo	VBN
cord-015922-5wwy0m2k	336	31	an	an	DT
cord-015922-5wwy0m2k	336	32	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	336	33	,	,	,
cord-015922-5wwy0m2k	336	34	on	on	IN
cord-015922-5wwy0m2k	336	35	chronic	chronic	JJ
cord-015922-5wwy0m2k	336	36	prednisone	prednisone	NN
cord-015922-5wwy0m2k	336	37	(	(	-LRB-
cord-015922-5wwy0m2k	336	38	typically	typically	RB
cord-015922-5wwy0m2k	336	39	>	>	XX
cord-015922-5wwy0m2k	336	40	20	20	CD
cord-015922-5wwy0m2k	336	41	mg	mg	NN
cord-015922-5wwy0m2k	336	42	per	per	IN
cord-015922-5wwy0m2k	336	43	day	day	NN
cord-015922-5wwy0m2k	336	44	)	)	-RRB-
cord-015922-5wwy0m2k	336	45	or	or	CC
cord-015922-5wwy0m2k	336	46	with	with	IN
cord-015922-5wwy0m2k	336	47	advanced	advanced	JJ
cord-015922-5wwy0m2k	336	48	HIV	HIV	NNP
cord-015922-5wwy0m2k	336	49	infection	infection	NN
cord-015922-5wwy0m2k	336	50	.	.	.
cord-015922-5wwy0m2k	337	1	PCP	PCP	NNP
cord-015922-5wwy0m2k	337	2	infection	infection	NN
cord-015922-5wwy0m2k	337	3	typically	typically	RB
cord-015922-5wwy0m2k	337	4	presents	present	VBZ
cord-015922-5wwy0m2k	337	5	as	as	IN
cord-015922-5wwy0m2k	337	6	an	an	DT
cord-015922-5wwy0m2k	337	7	interstitial	interstitial	JJ
cord-015922-5wwy0m2k	337	8	pneumonitis	pneumonitis	NN
cord-015922-5wwy0m2k	337	9	with	with	IN
cord-015922-5wwy0m2k	337	10	marked	marked	JJ
cord-015922-5wwy0m2k	337	11	hypoxemia	hypoxemia	NN
cord-015922-5wwy0m2k	337	12	.	.	.
cord-015922-5wwy0m2k	338	1	Severe	severe	JJ
cord-015922-5wwy0m2k	338	2	infection	infection	NN
cord-015922-5wwy0m2k	338	3	can	can	MD
cord-015922-5wwy0m2k	338	4	be	be	VB
cord-015922-5wwy0m2k	338	5	life	life	NN
cord-015922-5wwy0m2k	338	6	threatening	threaten	VBG
cord-015922-5wwy0m2k	338	7	.	.	.
cord-015922-5wwy0m2k	339	1	Fortunately	fortunately	RB
cord-015922-5wwy0m2k	339	2	,	,	,
cord-015922-5wwy0m2k	339	3	universal	universal	JJ
cord-015922-5wwy0m2k	339	4	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	339	5	of	of	IN
cord-015922-5wwy0m2k	339	6	high	high	JJ
cord-015922-5wwy0m2k	339	7	risk	risk	NN
cord-015922-5wwy0m2k	339	8	patients	patient	NNS
cord-015922-5wwy0m2k	339	9	during	during	IN
cord-015922-5wwy0m2k	339	10	the	the	DT
cord-015922-5wwy0m2k	339	11	high	high	JJ
cord-015922-5wwy0m2k	339	12	risk	risk	NN
cord-015922-5wwy0m2k	339	13	periods	period	NNS
cord-015922-5wwy0m2k	339	14	with	with	IN
cord-015922-5wwy0m2k	339	15	trimethoprim	trimethoprim	NNP
cord-015922-5wwy0m2k	339	16	-	-	HYPH
cord-015922-5wwy0m2k	339	17	sulfamethoxazole	sulfamethoxazole	NNP
cord-015922-5wwy0m2k	339	18	has	have	VBZ
cord-015922-5wwy0m2k	339	19	markedly	markedly	RB
cord-015922-5wwy0m2k	339	20	decreased	decrease	VBN
cord-015922-5wwy0m2k	339	21	this	this	DT
cord-015922-5wwy0m2k	339	22	complication	complication	NN
cord-015922-5wwy0m2k	339	23	.	.	.
cord-015922-5wwy0m2k	340	1	However	however	RB
cord-015922-5wwy0m2k	340	2	,	,	,
cord-015922-5wwy0m2k	340	3	intolerance	intolerance	NN
cord-015922-5wwy0m2k	340	4	to	to	IN
cord-015922-5wwy0m2k	340	5	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	340	6	,	,	,
cord-015922-5wwy0m2k	340	7	use	use	NN
cord-015922-5wwy0m2k	340	8	of	of	IN
cord-015922-5wwy0m2k	340	9	second	second	JJ
cord-015922-5wwy0m2k	340	10	line	line	NN
cord-015922-5wwy0m2k	340	11	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	340	12	agents	agent	NNS
cord-015922-5wwy0m2k	340	13	(	(	-LRB-
cord-015922-5wwy0m2k	340	14	e.g.	e.g.	RB
cord-015922-5wwy0m2k	340	15	,	,	,
cord-015922-5wwy0m2k	340	16	dapsone	dapsone	NN
cord-015922-5wwy0m2k	340	17	,	,	,
cord-015922-5wwy0m2k	340	18	pentamidine	pentamidine	NNP
cord-015922-5wwy0m2k	340	19	,	,	,
cord-015922-5wwy0m2k	340	20	or	or	CC
cord-015922-5wwy0m2k	340	21	atovaquone	atovaquone	NNP
cord-015922-5wwy0m2k	340	22	)	)	-RRB-
cord-015922-5wwy0m2k	340	23	,	,	,
cord-015922-5wwy0m2k	340	24	poor	poor	JJ
cord-015922-5wwy0m2k	340	25	medication	medication	NN
cord-015922-5wwy0m2k	340	26	compliance	compliance	NN
cord-015922-5wwy0m2k	340	27	or	or	CC
cord-015922-5wwy0m2k	340	28	failure	failure	NN
cord-015922-5wwy0m2k	340	29	to	to	TO
cord-015922-5wwy0m2k	340	30	re	re	VB
cord-015922-5wwy0m2k	340	31	-	-	JJ
cord-015922-5wwy0m2k	340	32	institute	institute	JJ
cord-015922-5wwy0m2k	340	33	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	340	34	in	in	IN
cord-015922-5wwy0m2k	340	35	the	the	DT
cord-015922-5wwy0m2k	340	36	setting	setting	NN
cord-015922-5wwy0m2k	340	37	of	of	IN
cord-015922-5wwy0m2k	340	38	augmented	augment	VBN
cord-015922-5wwy0m2k	340	39	immunosuppression	immunosuppression	NN
cord-015922-5wwy0m2k	340	40	(	(	-LRB-
cord-015922-5wwy0m2k	340	41	e.g.	e.g.	RB
cord-015922-5wwy0m2k	340	42	,	,	,
cord-015922-5wwy0m2k	340	43	treatment	treatment	NN
cord-015922-5wwy0m2k	340	44	of	of	IN
cord-015922-5wwy0m2k	340	45	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	340	46	)	)	-RRB-
cord-015922-5wwy0m2k	340	47	are	be	VBP
cord-015922-5wwy0m2k	340	48	common	common	JJ
cord-015922-5wwy0m2k	340	49	reasons	reason	NNS
cord-015922-5wwy0m2k	340	50	why	why	WRB
cord-015922-5wwy0m2k	340	51	cases	case	NNS
cord-015922-5wwy0m2k	340	52	still	still	RB
cord-015922-5wwy0m2k	340	53	occur	occur	VBP
cord-015922-5wwy0m2k	340	54	.	.	.
cord-015922-5wwy0m2k	341	1	Several	several	JJ
cord-015922-5wwy0m2k	341	2	important	important	JJ
cord-015922-5wwy0m2k	341	3	issues	issue	NNS
cord-015922-5wwy0m2k	341	4	must	must	MD
cord-015922-5wwy0m2k	341	5	be	be	VB
cord-015922-5wwy0m2k	341	6	addressed	address	VBN
cord-015922-5wwy0m2k	341	7	after	after	IN
cord-015922-5wwy0m2k	341	8	successful	successful	JJ
cord-015922-5wwy0m2k	341	9	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	341	10	to	to	TO
cord-015922-5wwy0m2k	341	11	minimize	minimize	VB
cord-015922-5wwy0m2k	341	12	infectious	infectious	JJ
cord-015922-5wwy0m2k	341	13	complications	complication	NNS
cord-015922-5wwy0m2k	341	14	.	.	.
cord-015922-5wwy0m2k	342	1	First	first	RB
cord-015922-5wwy0m2k	342	2	,	,	,
cord-015922-5wwy0m2k	342	3	it	-PRON-	PRP
cord-015922-5wwy0m2k	342	4	is	be	VBZ
cord-015922-5wwy0m2k	342	5	important	important	JJ
cord-015922-5wwy0m2k	342	6	to	to	TO
cord-015922-5wwy0m2k	342	7	avoid	avoid	VB
cord-015922-5wwy0m2k	342	8	exposure	exposure	NN
cord-015922-5wwy0m2k	342	9	to	to	IN
cord-015922-5wwy0m2k	342	10	pathogens	pathogen	NNS
cord-015922-5wwy0m2k	342	11	,	,	,
cord-015922-5wwy0m2k	342	12	especially	especially	RB
cord-015922-5wwy0m2k	342	13	when	when	WRB
cord-015922-5wwy0m2k	342	14	the	the	DT
cord-015922-5wwy0m2k	342	15	immunosuppressive	immunosuppressive	JJ
cord-015922-5wwy0m2k	342	16	therapy	therapy	NN
cord-015922-5wwy0m2k	342	17	to	to	TO
cord-015922-5wwy0m2k	342	18	prevent	prevent	VB
cord-015922-5wwy0m2k	342	19	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	342	20	is	be	VBZ
cord-015922-5wwy0m2k	342	21	the	the	DT
cord-015922-5wwy0m2k	342	22	highest	high	JJS
cord-015922-5wwy0m2k	342	23	.	.	.
cord-015922-5wwy0m2k	343	1	This	this	DT
cord-015922-5wwy0m2k	343	2	includes	include	VBZ
cord-015922-5wwy0m2k	343	3	avoiding	avoid	VBG
cord-015922-5wwy0m2k	343	4	gardening	gardening	NN
cord-015922-5wwy0m2k	343	5	and	and	CC
cord-015922-5wwy0m2k	343	6	soil	soil	NN
cord-015922-5wwy0m2k	343	7	exposures	exposure	NNS
cord-015922-5wwy0m2k	343	8	,	,	,
cord-015922-5wwy0m2k	343	9	mold	mold	NN
cord-015922-5wwy0m2k	343	10	exposures	exposure	NNS
cord-015922-5wwy0m2k	343	11	such	such	JJ
cord-015922-5wwy0m2k	343	12	as	as	IN
cord-015922-5wwy0m2k	343	13	cleaning	clean	VBG
cord-015922-5wwy0m2k	343	14	out	out	RP
cord-015922-5wwy0m2k	343	15	damp	damp	JJ
cord-015922-5wwy0m2k	343	16	basements	basement	NNS
cord-015922-5wwy0m2k	343	17	or	or	CC
cord-015922-5wwy0m2k	343	18	smoking	smoking	NN
cord-015922-5wwy0m2k	343	19	marijuana	marijuana	NN
cord-015922-5wwy0m2k	343	20	,	,	,
cord-015922-5wwy0m2k	343	21	individuals	individual	NNS
cord-015922-5wwy0m2k	343	22	with	with	IN
cord-015922-5wwy0m2k	343	23	active	active	JJ
cord-015922-5wwy0m2k	343	24	respiratory	respiratory	JJ
cord-015922-5wwy0m2k	343	25	infections	infection	NNS
cord-015922-5wwy0m2k	343	26	,	,	,
cord-015922-5wwy0m2k	343	27	especially	especially	RB
cord-015922-5wwy0m2k	343	28	children	child	NNS
cord-015922-5wwy0m2k	343	29	,	,	,
cord-015922-5wwy0m2k	343	30	and	and	CC
cord-015922-5wwy0m2k	343	31	avoiding	avoid	VBG
cord-015922-5wwy0m2k	343	32	enteric	enteric	JJ
cord-015922-5wwy0m2k	343	33	pathogens	pathogen	NNS
cord-015922-5wwy0m2k	343	34	.	.	.
cord-015922-5wwy0m2k	344	1	Second	second	JJ
cord-015922-5wwy0m2k	344	2	,	,	,
cord-015922-5wwy0m2k	344	3	optimal	optimal	JJ
cord-015922-5wwy0m2k	344	4	treatment	treatment	NN
cord-015922-5wwy0m2k	344	5	or	or	CC
cord-015922-5wwy0m2k	344	6	monitoring	monitoring	NN
cord-015922-5wwy0m2k	344	7	for	for	IN
cord-015922-5wwy0m2k	344	8	latent	latent	JJ
cord-015922-5wwy0m2k	344	9	infections	infection	NNS
cord-015922-5wwy0m2k	344	10	such	such	JJ
cord-015922-5wwy0m2k	344	11	as	as	IN
cord-015922-5wwy0m2k	344	12	herpesviruses	herpesviruses	NNP
cord-015922-5wwy0m2k	344	13	,	,	,
cord-015922-5wwy0m2k	344	14	hepatitis	hepatitis	NN
cord-015922-5wwy0m2k	344	15	viruses	virus	NNS
cord-015922-5wwy0m2k	344	16	and	and	CC
cord-015922-5wwy0m2k	344	17	prior	prior	JJ
cord-015922-5wwy0m2k	344	18	granulomatous	granulomatous	JJ
cord-015922-5wwy0m2k	344	19	diseases	disease	NNS
cord-015922-5wwy0m2k	344	20	(	(	-LRB-
cord-015922-5wwy0m2k	344	21	e.g.	e.g.	RB
cord-015922-5wwy0m2k	344	22	,	,	,
cord-015922-5wwy0m2k	344	23	Mycobacterium	Mycobacterium	NNP
cord-015922-5wwy0m2k	344	24	tuberculosis	tuberculosis	NN
cord-015922-5wwy0m2k	344	25	)	)	-RRB-
cord-015922-5wwy0m2k	344	26	.	.	.
cord-015922-5wwy0m2k	345	1	Those	those	DT
cord-015922-5wwy0m2k	345	2	patients	patient	NNS
cord-015922-5wwy0m2k	345	3	with	with	IN
cord-015922-5wwy0m2k	345	4	a	a	DT
cord-015922-5wwy0m2k	345	5	positive	positive	JJ
cord-015922-5wwy0m2k	345	6	test	test	NN
cord-015922-5wwy0m2k	345	7	for	for	IN
cord-015922-5wwy0m2k	345	8	latent	latent	JJ
cord-015922-5wwy0m2k	345	9	tuberculosis	tuberculosis	NN
cord-015922-5wwy0m2k	345	10	should	should	MD
cord-015922-5wwy0m2k	345	11	receive	receive	VB
cord-015922-5wwy0m2k	345	12	secondary	secondary	JJ
cord-015922-5wwy0m2k	345	13	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	345	14	,	,	,
cord-015922-5wwy0m2k	345	15	which	which	WDT
cord-015922-5wwy0m2k	345	16	typically	typically	RB
cord-015922-5wwy0m2k	345	17	is	be	VBZ
cord-015922-5wwy0m2k	345	18	begun	begin	VBN
cord-015922-5wwy0m2k	345	19	within	within	IN
cord-015922-5wwy0m2k	345	20	one	one	CD
cord-015922-5wwy0m2k	345	21	month	month	NN
cord-015922-5wwy0m2k	345	22	post	post	NN
cord-015922-5wwy0m2k	345	23	-	-	NN
cord-015922-5wwy0m2k	345	24	transplantation	transplantation	NN
cord-015922-5wwy0m2k	345	25	,	,	,
cord-015922-5wwy0m2k	345	26	after	after	IN
cord-015922-5wwy0m2k	345	27	the	the	DT
cord-015922-5wwy0m2k	345	28	acute	acute	JJ
cord-015922-5wwy0m2k	345	29	regimen	regimen	NN
cord-015922-5wwy0m2k	345	30	toxicities	toxicity	NNS
cord-015922-5wwy0m2k	345	31	associated	associate	VBN
cord-015922-5wwy0m2k	345	32	with	with	IN
cord-015922-5wwy0m2k	345	33	transplantation	transplantation	NN
cord-015922-5wwy0m2k	345	34	have	have	VBP
cord-015922-5wwy0m2k	345	35	subsided	subside	VBN
cord-015922-5wwy0m2k	345	36	,	,	,
cord-015922-5wwy0m2k	345	37	when	when	WRB
cord-015922-5wwy0m2k	345	38	screening	screening	NN
cord-015922-5wwy0m2k	345	39	and	and	CC
cord-015922-5wwy0m2k	345	40	preventive	preventive	JJ
cord-015922-5wwy0m2k	345	41	treatment	treatment	NN
cord-015922-5wwy0m2k	345	42	have	have	VBP
cord-015922-5wwy0m2k	345	43	not	not	RB
cord-015922-5wwy0m2k	345	44	occurred	occur	VBN
cord-015922-5wwy0m2k	345	45	previous	previous	JJ
cord-015922-5wwy0m2k	345	46	to	to	IN
cord-015922-5wwy0m2k	345	47	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	345	48	.	.	.
cord-015922-5wwy0m2k	346	1	The	the	DT
cord-015922-5wwy0m2k	346	2	first	first	JJ
cord-015922-5wwy0m2k	346	3	line	line	NN
cord-015922-5wwy0m2k	346	4	therapy	therapy	NN
cord-015922-5wwy0m2k	346	5	for	for	IN
cord-015922-5wwy0m2k	346	6	secondary	secondary	JJ
cord-015922-5wwy0m2k	346	7	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	346	8	is	be	VBZ
cord-015922-5wwy0m2k	346	9	isoniazid	isoniazid	JJ
cord-015922-5wwy0m2k	346	10	for	for	IN
cord-015922-5wwy0m2k	346	11	nine	nine	CD
cord-015922-5wwy0m2k	346	12	months	month	NNS
cord-015922-5wwy0m2k	346	13	.	.	.
cord-015922-5wwy0m2k	347	1	However	however	RB
cord-015922-5wwy0m2k	347	2	,	,	,
cord-015922-5wwy0m2k	347	3	in	in	IN
cord-015922-5wwy0m2k	347	4	patients	patient	NNS
cord-015922-5wwy0m2k	347	5	with	with	IN
cord-015922-5wwy0m2k	347	6	significant	significant	JJ
cord-015922-5wwy0m2k	347	7	hepatic	hepatic	JJ
cord-015922-5wwy0m2k	347	8	dysfunction	dysfunction	NN
cord-015922-5wwy0m2k	347	9	or	or	CC
cord-015922-5wwy0m2k	347	10	peripheral	peripheral	JJ
cord-015922-5wwy0m2k	347	11	neuropathy	neuropathy	NN
cord-015922-5wwy0m2k	347	12	alternative	alternative	JJ
cord-015922-5wwy0m2k	347	13	regimens	regimen	NNS
cord-015922-5wwy0m2k	347	14	need	need	VBP
cord-015922-5wwy0m2k	347	15	to	to	TO
cord-015922-5wwy0m2k	347	16	be	be	VB
cord-015922-5wwy0m2k	347	17	considered	consider	VBN
cord-015922-5wwy0m2k	347	18	.	.	.
cord-015922-5wwy0m2k	348	1	Rifamycin	Rifamycin	NNP
cord-015922-5wwy0m2k	348	2	-	-	HYPH
cord-015922-5wwy0m2k	348	3	based	base	VBN
cord-015922-5wwy0m2k	348	4	regimens	regimen	NNS
cord-015922-5wwy0m2k	348	5	are	be	VBP
cord-015922-5wwy0m2k	348	6	difficult	difficult	JJ
cord-015922-5wwy0m2k	348	7	given	give	VBN
cord-015922-5wwy0m2k	348	8	the	the	DT
cord-015922-5wwy0m2k	348	9	potential	potential	JJ
cord-015922-5wwy0m2k	348	10	hepatotoxicity	hepatotoxicity	NN
cord-015922-5wwy0m2k	348	11	,	,	,
cord-015922-5wwy0m2k	348	12	as	as	RB
cord-015922-5wwy0m2k	348	13	well	well	RB
cord-015922-5wwy0m2k	348	14	as	as	IN
cord-015922-5wwy0m2k	348	15	the	the	DT
cord-015922-5wwy0m2k	348	16	significant	significant	JJ
cord-015922-5wwy0m2k	348	17	drug	drug	NN
cord-015922-5wwy0m2k	348	18	interactions	interaction	NNS
cord-015922-5wwy0m2k	348	19	,	,	,
cord-015922-5wwy0m2k	348	20	especially	especially	RB
cord-015922-5wwy0m2k	348	21	with	with	IN
cord-015922-5wwy0m2k	348	22	concomitant	concomitant	JJ
cord-015922-5wwy0m2k	348	23	use	use	NN
cord-015922-5wwy0m2k	348	24	of	of	IN
cord-015922-5wwy0m2k	348	25	a	a	DT
cord-015922-5wwy0m2k	348	26	calcineurin	calcineurin	NN
cord-015922-5wwy0m2k	348	27	or	or	CC
cord-015922-5wwy0m2k	348	28	an	an	DT
cord-015922-5wwy0m2k	348	29	azole	azole	NN
cord-015922-5wwy0m2k	348	30	.	.	.
cord-015922-5wwy0m2k	349	1	A	a	DT
cord-015922-5wwy0m2k	349	2	quinolone	quinolone	NN
cord-015922-5wwy0m2k	349	3	,	,	,
cord-015922-5wwy0m2k	349	4	such	such	JJ
cord-015922-5wwy0m2k	349	5	as	as	IN
cord-015922-5wwy0m2k	349	6	levofloxacin	levofloxacin	NNS
cord-015922-5wwy0m2k	349	7	,	,	,
cord-015922-5wwy0m2k	349	8	with	with	IN
cord-015922-5wwy0m2k	349	9	ethambutol	ethambutol	NNP
cord-015922-5wwy0m2k	349	10	may	may	MD
cord-015922-5wwy0m2k	349	11	be	be	VB
cord-015922-5wwy0m2k	349	12	considered	consider	VBN
cord-015922-5wwy0m2k	349	13	.	.	.
cord-015922-5wwy0m2k	350	1	When	when	WRB
cord-015922-5wwy0m2k	350	2	a	a	DT
cord-015922-5wwy0m2k	350	3	mycobateriologically	mycobateriologically	RB
cord-015922-5wwy0m2k	350	4	static	static	JJ
cord-015922-5wwy0m2k	350	5	regimen	regimen	NN
cord-015922-5wwy0m2k	350	6	is	be	VBZ
cord-015922-5wwy0m2k	350	7	chosen	choose	VBN
cord-015922-5wwy0m2k	350	8	,	,	,
cord-015922-5wwy0m2k	350	9	the	the	DT
cord-015922-5wwy0m2k	350	10	duration	duration	NN
cord-015922-5wwy0m2k	350	11	of	of	IN
cord-015922-5wwy0m2k	350	12	therapy	therapy	NN
cord-015922-5wwy0m2k	350	13	often	often	RB
cord-015922-5wwy0m2k	350	14	must	must	MD
cord-015922-5wwy0m2k	350	15	be	be	VB
cord-015922-5wwy0m2k	350	16	extended	extend	VBN
cord-015922-5wwy0m2k	350	17	with	with	IN
cord-015922-5wwy0m2k	350	18	some	some	DT
cord-015922-5wwy0m2k	350	19	using	use	VBG
cord-015922-5wwy0m2k	350	20	this	this	DT
cord-015922-5wwy0m2k	350	21	combination	combination	NN
cord-015922-5wwy0m2k	350	22	for	for	IN
cord-015922-5wwy0m2k	350	23	18	18	CD
cord-015922-5wwy0m2k	350	24	months	month	NNS
cord-015922-5wwy0m2k	350	25	as	as	IN
cord-015922-5wwy0m2k	350	26	secondary	secondary	JJ
cord-015922-5wwy0m2k	350	27	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	350	28	(	(	-LRB-
cord-015922-5wwy0m2k	350	29	Table	Table	NNP
cord-015922-5wwy0m2k	350	30	19	19	CD
cord-015922-5wwy0m2k	350	31	-	-	SYM
cord-015922-5wwy0m2k	350	32	2	2	CD
cord-015922-5wwy0m2k	350	33	)	)	-RRB-
cord-015922-5wwy0m2k	350	34	.	.	.
cord-015922-5wwy0m2k	351	1	Third	third	RB
cord-015922-5wwy0m2k	351	2	,	,	,
cord-015922-5wwy0m2k	351	3	optimizing	optimize	VBG
cord-015922-5wwy0m2k	351	4	vaccinations	vaccination	NNS
cord-015922-5wwy0m2k	351	5	for	for	IN
cord-015922-5wwy0m2k	351	6	routine	routine	JJ
cord-015922-5wwy0m2k	351	7	pathogens	pathogen	NNS
cord-015922-5wwy0m2k	351	8	such	such	JJ
cord-015922-5wwy0m2k	351	9	as	as	IN
cord-015922-5wwy0m2k	351	10	diphtheria	diphtheria	NN
cord-015922-5wwy0m2k	351	11	,	,	,
cord-015922-5wwy0m2k	351	12	tetanus	tetanus	NN
cord-015922-5wwy0m2k	351	13	,	,	,
cord-015922-5wwy0m2k	351	14	pertussis	pertussis	NN
cord-015922-5wwy0m2k	351	15	,	,	,
cord-015922-5wwy0m2k	351	16	influenza	influenza	NN
cord-015922-5wwy0m2k	351	17	and	and	CC
cord-015922-5wwy0m2k	351	18	pneumococcus	pneumococcus	NNP
cord-015922-5wwy0m2k	351	19	(	(	-LRB-
cord-015922-5wwy0m2k	351	20	Table	Table	NNP
cord-015922-5wwy0m2k	351	21	19	19	CD
cord-015922-5wwy0m2k	351	22	-	-	SYM
cord-015922-5wwy0m2k	351	23	3	3	CD
cord-015922-5wwy0m2k	351	24	)	)	-RRB-
cord-015922-5wwy0m2k	351	25	.	.	.
cord-015922-5wwy0m2k	352	1	This	this	DT
cord-015922-5wwy0m2k	352	2	optimal	optimal	JJ
cord-015922-5wwy0m2k	352	3	timing	timing	NN
cord-015922-5wwy0m2k	352	4	of	of	IN
cord-015922-5wwy0m2k	352	5	re	re	NN
cord-015922-5wwy0m2k	352	6	-	-	NN
cord-015922-5wwy0m2k	352	7	vaccination	vaccination	NN
cord-015922-5wwy0m2k	352	8	depends	depend	VBZ
cord-015922-5wwy0m2k	352	9	on	on	IN
cord-015922-5wwy0m2k	352	10	the	the	DT
cord-015922-5wwy0m2k	352	11	nature	nature	NN
cord-015922-5wwy0m2k	352	12	of	of	IN
cord-015922-5wwy0m2k	352	13	the	the	DT
cord-015922-5wwy0m2k	352	14	transplant	transplant	NN
cord-015922-5wwy0m2k	352	15	,	,	,
cord-015922-5wwy0m2k	352	16	with	with	IN
cord-015922-5wwy0m2k	352	17	earlier	early	JJR
cord-015922-5wwy0m2k	352	18	re	re	NN
cord-015922-5wwy0m2k	352	19	-	-	NN
cord-015922-5wwy0m2k	352	20	vaccination	vaccination	NN
cord-015922-5wwy0m2k	352	21	schedules	schedule	NNS
cord-015922-5wwy0m2k	352	22	being	be	VBG
cord-015922-5wwy0m2k	352	23	considered	consider	VBN
cord-015922-5wwy0m2k	352	24	in	in	IN
cord-015922-5wwy0m2k	352	25	the	the	DT
cord-015922-5wwy0m2k	352	26	nonmyeloablative	nonmyeloablative	JJ
cord-015922-5wwy0m2k	352	27	setting	setting	NN
cord-015922-5wwy0m2k	352	28	.	.	.
cord-015922-5wwy0m2k	353	1	Fourth	fourth	JJ
cord-015922-5wwy0m2k	353	2	,	,	,
cord-015922-5wwy0m2k	353	3	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	353	4	for	for	IN
cord-015922-5wwy0m2k	353	5	PCP	PCP	NNP
cord-015922-5wwy0m2k	353	6	,	,	,
cord-015922-5wwy0m2k	353	7	which	which	WDT
cord-015922-5wwy0m2k	353	8	is	be	VBZ
cord-015922-5wwy0m2k	353	9	typically	typically	RB
cord-015922-5wwy0m2k	353	10	continued	continue	VBN
cord-015922-5wwy0m2k	353	11	for	for	IN
cord-015922-5wwy0m2k	353	12	approximately	approximately	RB
cord-015922-5wwy0m2k	353	13	one	one	CD
cord-015922-5wwy0m2k	353	14	year	year	NN
cord-015922-5wwy0m2k	353	15	or	or	CC
cord-015922-5wwy0m2k	353	16	until	until	IN
cord-015922-5wwy0m2k	353	17	the	the	DT
cord-015922-5wwy0m2k	353	18	immunosuppressive	immunosuppressive	JJ
cord-015922-5wwy0m2k	353	19	medications	medication	NNS
cord-015922-5wwy0m2k	353	20	are	be	VBP
cord-015922-5wwy0m2k	353	21	tapered	taper	VBN
cord-015922-5wwy0m2k	353	22	off	off	RP
cord-015922-5wwy0m2k	353	23	.	.	.
cord-015922-5wwy0m2k	354	1	The	the	DT
cord-015922-5wwy0m2k	354	2	optimal	optimal	JJ
cord-015922-5wwy0m2k	354	3	medication	medication	NN
cord-015922-5wwy0m2k	354	4	to	to	TO
cord-015922-5wwy0m2k	354	5	use	use	VB
cord-015922-5wwy0m2k	354	6	for	for	IN
cord-015922-5wwy0m2k	354	7	PCP	PCP	NNP
cord-015922-5wwy0m2k	354	8	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	354	9	is	be	VBZ
cord-015922-5wwy0m2k	354	10	trimethoprimsulfamethoxazole	trimethoprimsulfamethoxazole	NNP
cord-015922-5wwy0m2k	354	11	which	which	WDT
cord-015922-5wwy0m2k	354	12	offers	offer	VBZ
cord-015922-5wwy0m2k	354	13	some	some	DT
cord-015922-5wwy0m2k	354	14	protection	protection	NN
cord-015922-5wwy0m2k	354	15	for	for	IN
cord-015922-5wwy0m2k	354	16	a	a	DT
cord-015922-5wwy0m2k	354	17	variety	variety	NN
cord-015922-5wwy0m2k	354	18	of	of	IN
cord-015922-5wwy0m2k	354	19	other	other	JJ
cord-015922-5wwy0m2k	354	20	important	important	JJ
cord-015922-5wwy0m2k	354	21	pathogens	pathogen	NNS
cord-015922-5wwy0m2k	354	22	including	include	VBG
cord-015922-5wwy0m2k	354	23	Pneumococcus	Pneumococcus	NNP
cord-015922-5wwy0m2k	354	24	,	,	,
cord-015922-5wwy0m2k	354	25	Hemophillus	Hemophillus	NNP
cord-015922-5wwy0m2k	354	26	influenza	influenza	NN
cord-015922-5wwy0m2k	354	27	,	,	,
cord-015922-5wwy0m2k	354	28	Nocardia	Nocardia	NNP
cord-015922-5wwy0m2k	354	29	sp	sp	NNP
cord-015922-5wwy0m2k	354	30	.	.	NNP
cord-015922-5wwy0m2k	354	31	,	,	,
cord-015922-5wwy0m2k	355	1	Toxoplasma	Toxoplasma	NNP
cord-015922-5wwy0m2k	355	2	,	,	,
cord-015922-5wwy0m2k	355	3	Listeria	Listeria	NNP
cord-015922-5wwy0m2k	355	4	,	,	,
cord-015922-5wwy0m2k	355	5	Salmonella	Salmonella	NNP
cord-015922-5wwy0m2k	355	6	sp	sp	NNP
cord-015922-5wwy0m2k	355	7	.	.	NNP
cord-015922-5wwy0m2k	355	8	,	,	,
cord-015922-5wwy0m2k	355	9	and	and	CC
cord-015922-5wwy0m2k	355	10	other	other	JJ
cord-015922-5wwy0m2k	355	11	enteric	enteric	JJ
cord-015922-5wwy0m2k	355	12	bacterial	bacterial	JJ
cord-015922-5wwy0m2k	355	13	pathogens	pathogen	NNS
cord-015922-5wwy0m2k	355	14	.	.	.
cord-015922-5wwy0m2k	356	1	If	if	IN
cord-015922-5wwy0m2k	356	2	trimethoprim	trimethoprim	NNP
cord-015922-5wwy0m2k	356	3	-	-	HYPH
cord-015922-5wwy0m2k	356	4	sulfamethoxazole	sulfamethoxazole	NNP
cord-015922-5wwy0m2k	356	5	is	be	VBZ
cord-015922-5wwy0m2k	356	6	not	not	RB
cord-015922-5wwy0m2k	356	7	tolerated	tolerate	VBN
cord-015922-5wwy0m2k	356	8	due	due	IN
cord-015922-5wwy0m2k	356	9	to	to	IN
cord-015922-5wwy0m2k	356	10	significant	significant	JJ
cord-015922-5wwy0m2k	356	11	renal	renal	JJ
cord-015922-5wwy0m2k	356	12	dysfunction	dysfunction	NN
cord-015922-5wwy0m2k	356	13	or	or	CC
cord-015922-5wwy0m2k	356	14	bone	bone	NN
cord-015922-5wwy0m2k	356	15	marrow	marrow	NN
cord-015922-5wwy0m2k	356	16	suppression	suppression	NN
cord-015922-5wwy0m2k	356	17	,	,	,
cord-015922-5wwy0m2k	356	18	then	then	RB
cord-015922-5wwy0m2k	356	19	alternative	alternative	JJ
cord-015922-5wwy0m2k	356	20	agents	agent	NNS
cord-015922-5wwy0m2k	356	21	for	for	IN
cord-015922-5wwy0m2k	356	22	PCP	PCP	NNP
cord-015922-5wwy0m2k	356	23	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	356	24	include	include	VBP
cord-015922-5wwy0m2k	356	25	dapsone	dapsone	NN
cord-015922-5wwy0m2k	356	26	,	,	,
cord-015922-5wwy0m2k	356	27	atovaquone	atovaquone	NNP
cord-015922-5wwy0m2k	356	28	or	or	CC
cord-015922-5wwy0m2k	356	29	aerosolized	aerosolize	VBN
cord-015922-5wwy0m2k	356	30	pentamidine	pentamidine	NN
cord-015922-5wwy0m2k	356	31	;	;	:
cord-015922-5wwy0m2k	356	32	however	however	RB
cord-015922-5wwy0m2k	356	33	,	,	,
cord-015922-5wwy0m2k	356	34	none	none	NN
cord-015922-5wwy0m2k	356	35	of	of	IN
cord-015922-5wwy0m2k	356	36	these	these	DT
cord-015922-5wwy0m2k	356	37	second	second	JJ
cord-015922-5wwy0m2k	356	38	line	line	NN
cord-015922-5wwy0m2k	356	39	agents	agent	NNS
cord-015922-5wwy0m2k	356	40	afford	afford	VBP
cord-015922-5wwy0m2k	356	41	the	the	DT
cord-015922-5wwy0m2k	356	42	broad	broad	JJ
cord-015922-5wwy0m2k	356	43	microbial	microbial	JJ
cord-015922-5wwy0m2k	356	44	protection	protection	NN
cord-015922-5wwy0m2k	356	45	which	which	WDT
cord-015922-5wwy0m2k	356	46	trimethoprim	trimethoprim	NNP
cord-015922-5wwy0m2k	356	47	-	-	HYPH
cord-015922-5wwy0m2k	356	48	sulfamethoxazole	sulfamethoxazole	NNP
cord-015922-5wwy0m2k	356	49	affords	afford	VBZ
cord-015922-5wwy0m2k	356	50	.	.	.
cord-015922-5wwy0m2k	357	1	And	and	CC
cord-015922-5wwy0m2k	357	2	lastly	lastly	RB
cord-015922-5wwy0m2k	357	3	,	,	,
cord-015922-5wwy0m2k	357	4	herpes	herpes	NN
cord-015922-5wwy0m2k	357	5	group	group	NN
cord-015922-5wwy0m2k	357	6	viral	viral	JJ
cord-015922-5wwy0m2k	357	7	prevention	prevention	NN
cord-015922-5wwy0m2k	357	8	which	which	WDT
cord-015922-5wwy0m2k	357	9	should	should	MD
cord-015922-5wwy0m2k	357	10	include	include	VB
cord-015922-5wwy0m2k	357	11	acyclovir	acyclovir	NNP
cord-015922-5wwy0m2k	357	12	to	to	TO
cord-015922-5wwy0m2k	357	13	prevent	prevent	VB
cord-015922-5wwy0m2k	357	14	HSV	HSV	NNP
cord-015922-5wwy0m2k	357	15	and	and	CC
cord-015922-5wwy0m2k	357	16	VZV	VZV	NNP
cord-015922-5wwy0m2k	357	17	and	and	CC
cord-015922-5wwy0m2k	357	18	systematic	systematic	JJ
cord-015922-5wwy0m2k	357	19	monitoring	monitoring	NN
cord-015922-5wwy0m2k	357	20	for	for	IN
cord-015922-5wwy0m2k	357	21	CMV	CMV	NNP
cord-015922-5wwy0m2k	357	22	,	,	,
cord-015922-5wwy0m2k	357	23	in	in	IN
cord-015922-5wwy0m2k	357	24	the	the	DT
cord-015922-5wwy0m2k	357	25	allogeneic	allogeneic	NN
cord-015922-5wwy0m2k	357	26	setting	setting	NN
cord-015922-5wwy0m2k	357	27	,	,	,
cord-015922-5wwy0m2k	357	28	with	with	IN
cord-015922-5wwy0m2k	357	29	early	early	JJ
cord-015922-5wwy0m2k	357	30	use	use	NN
cord-015922-5wwy0m2k	357	31	of	of	IN
cord-015922-5wwy0m2k	357	32	a	a	DT
cord-015922-5wwy0m2k	357	33	CMV	CMV	NNP
cord-015922-5wwy0m2k	357	34	active	active	JJ
cord-015922-5wwy0m2k	357	35	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	357	36	if	if	IN
cord-015922-5wwy0m2k	357	37	evidence	evidence	NN
cord-015922-5wwy0m2k	357	38	for	for	IN
cord-015922-5wwy0m2k	357	39	CMV	CMV	NNP
cord-015922-5wwy0m2k	357	40	activation	activation	NN
cord-015922-5wwy0m2k	357	41	or	or	CC
cord-015922-5wwy0m2k	357	42	disease	disease	NN
cord-015922-5wwy0m2k	357	43	is	be	VBZ
cord-015922-5wwy0m2k	357	44	observed	observe	VBN
cord-015922-5wwy0m2k	357	45	.	.	.
cord-015922-5wwy0m2k	358	1	Prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	358	2	must	must	MD
cord-015922-5wwy0m2k	358	3	be	be	VB
cord-015922-5wwy0m2k	358	4	re	re	VBN
cord-015922-5wwy0m2k	358	5	-	-	VBN
cord-015922-5wwy0m2k	358	6	assessed	assess	VBN
cord-015922-5wwy0m2k	358	7	in	in	IN
cord-015922-5wwy0m2k	358	8	the	the	DT
cord-015922-5wwy0m2k	358	9	setting	setting	NN
cord-015922-5wwy0m2k	358	10	of	of	IN
cord-015922-5wwy0m2k	358	11	persistent	persistent	JJ
cord-015922-5wwy0m2k	358	12	or	or	CC
cord-015922-5wwy0m2k	358	13	augmented	augment	VBN
cord-015922-5wwy0m2k	358	14	immunosuppression	immunosuppression	NN
cord-015922-5wwy0m2k	358	15	,	,	,
cord-015922-5wwy0m2k	358	16	such	such	JJ
cord-015922-5wwy0m2k	358	17	as	as	IN
cord-015922-5wwy0m2k	358	18	in	in	IN
cord-015922-5wwy0m2k	358	19	the	the	DT
cord-015922-5wwy0m2k	358	20	setting	setting	NN
cord-015922-5wwy0m2k	358	21	of	of	IN
cord-015922-5wwy0m2k	358	22	clinically	clinically	RB
cord-015922-5wwy0m2k	358	23	significant	significant	JJ
cord-015922-5wwy0m2k	358	24	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	358	25	,	,	,
cord-015922-5wwy0m2k	358	26	regardless	regardless	RB
cord-015922-5wwy0m2k	358	27	of	of	IN
cord-015922-5wwy0m2k	358	28	time	time	NN
cord-015922-5wwy0m2k	358	29	since	since	IN
cord-015922-5wwy0m2k	358	30	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	358	31	.	.	.
cord-015922-5wwy0m2k	359	1	Medication	medication	NN
cord-015922-5wwy0m2k	359	2	doses	dose	NNS
cord-015922-5wwy0m2k	359	3	may	may	MD
cord-015922-5wwy0m2k	359	4	need	need	VB
cord-015922-5wwy0m2k	359	5	to	to	TO
cord-015922-5wwy0m2k	359	6	be	be	VB
cord-015922-5wwy0m2k	359	7	adjusted	adjust	VBN
cord-015922-5wwy0m2k	359	8	for	for	IN
cord-015922-5wwy0m2k	359	9	renal	renal	JJ
cord-015922-5wwy0m2k	359	10	dysfunction	dysfunction	NN
cord-015922-5wwy0m2k	359	11	.	.	.
cord-015922-5wwy0m2k	360	1	*	*	NFP
cord-015922-5wwy0m2k	360	2	Trimethoprim	Trimethoprim	NNP
cord-015922-5wwy0m2k	360	3	-	-	HYPH
cord-015922-5wwy0m2k	360	4	sulfamethoxazole	sulfamethoxazole	NNP
cord-015922-5wwy0m2k	360	5	affords	afford	VBZ
cord-015922-5wwy0m2k	360	6	modest	modest	JJ
cord-015922-5wwy0m2k	360	7	protection	protection	NN
cord-015922-5wwy0m2k	360	8	for	for	IN
cord-015922-5wwy0m2k	360	9	a	a	DT
cord-015922-5wwy0m2k	360	10	broad	broad	JJ
cord-015922-5wwy0m2k	360	11	array	array	NN
cord-015922-5wwy0m2k	360	12	of	of	IN
cord-015922-5wwy0m2k	360	13	potential	potential	JJ
cord-015922-5wwy0m2k	360	14	environmental	environmental	JJ
cord-015922-5wwy0m2k	360	15	and	and	CC
cord-015922-5wwy0m2k	360	16	community	community	NN
cord-015922-5wwy0m2k	360	17	pathogens	pathogen	NNS
cord-015922-5wwy0m2k	360	18	including	include	VBG
cord-015922-5wwy0m2k	360	19	:	:	:
cord-015922-5wwy0m2k	361	1	Nocardia	Nocardia	NNP
cord-015922-5wwy0m2k	361	2	sp	sp	NN
cord-015922-5wwy0m2k	361	3	,	,	,
cord-015922-5wwy0m2k	361	4	toxoplasmosis	toxoplasmosis	NN
cord-015922-5wwy0m2k	361	5	,	,	,
cord-015922-5wwy0m2k	361	6	pneumococci	pneumococcus	NNS
cord-015922-5wwy0m2k	361	7	,	,	,
cord-015922-5wwy0m2k	361	8	H	H	NNP
cord-015922-5wwy0m2k	361	9	influenza	influenza	NN
cord-015922-5wwy0m2k	361	10	,	,	,
cord-015922-5wwy0m2k	361	11	listeria	listeria	NN
cord-015922-5wwy0m2k	361	12	,	,	,
cord-015922-5wwy0m2k	361	13	shigella	shigella	NNP
cord-015922-5wwy0m2k	361	14	,	,	,
cord-015922-5wwy0m2k	361	15	and	and	CC
cord-015922-5wwy0m2k	361	16	slamonella	slamonella	NNP
cord-015922-5wwy0m2k	361	17	sp	sp	NNP
cord-015922-5wwy0m2k	361	18	.	.	.
cord-015922-5wwy0m2k	362	1	*	*	NFP
cord-015922-5wwy0m2k	362	2	*	*	NFP
cord-015922-5wwy0m2k	362	3	Alternatively	alternatively	RB
cord-015922-5wwy0m2k	362	4	preemptive	preemptive	JJ
cord-015922-5wwy0m2k	362	5	monitoring	monitoring	NN
cord-015922-5wwy0m2k	362	6	with	with	IN
cord-015922-5wwy0m2k	362	7	serial	serial	JJ
cord-015922-5wwy0m2k	362	8	viral	viral	JJ
cord-015922-5wwy0m2k	362	9	antigen	antigen	NN
cord-015922-5wwy0m2k	362	10	or	or	CC
cord-015922-5wwy0m2k	362	11	viral	viral	JJ
cord-015922-5wwy0m2k	362	12	load	load	NN
cord-015922-5wwy0m2k	362	13	assays	assay	NNS
cord-015922-5wwy0m2k	362	14	can	can	MD
cord-015922-5wwy0m2k	362	15	be	be	VB
cord-015922-5wwy0m2k	362	16	considered	consider	VBN
cord-015922-5wwy0m2k	362	17	.	.	.
cord-015922-5wwy0m2k	363	1	*	*	NFP
cord-015922-5wwy0m2k	363	2	*	*	NFP
cord-015922-5wwy0m2k	363	3	*	*	NFP
cord-015922-5wwy0m2k	363	4	For	for	IN
cord-015922-5wwy0m2k	363	5	those	those	DT
cord-015922-5wwy0m2k	363	6	with	with	IN
cord-015922-5wwy0m2k	363	7	evidence	evidence	NN
cord-015922-5wwy0m2k	363	8	of	of	IN
cord-015922-5wwy0m2k	363	9	prior	prior	JJ
cord-015922-5wwy0m2k	363	10	HBV	HBV	NNP
cord-015922-5wwy0m2k	363	11	infection	infection	NN
cord-015922-5wwy0m2k	363	12	(	(	-LRB-
cord-015922-5wwy0m2k	363	13	e.g.	e.g.	RB
cord-015922-5wwy0m2k	363	14	,	,	,
cord-015922-5wwy0m2k	363	15	Hepatitis	Hepatitis	NNP
cord-015922-5wwy0m2k	363	16	B	B	NNP
cord-015922-5wwy0m2k	363	17	core	core	NN
cord-015922-5wwy0m2k	363	18	antibody	antibody	NN
cord-015922-5wwy0m2k	363	19	positive	positive	JJ
cord-015922-5wwy0m2k	363	20	)	)	-RRB-
cord-015922-5wwy0m2k	363	21	,	,	,
cord-015922-5wwy0m2k	363	22	consider	consider	VB
cord-015922-5wwy0m2k	363	23	monitoring	monitor	VBG
cord-015922-5wwy0m2k	363	24	HBV	HBV	NNP
cord-015922-5wwy0m2k	363	25	viral	viral	JJ
cord-015922-5wwy0m2k	363	26	load	load	NN
cord-015922-5wwy0m2k	363	27	for	for	IN
cord-015922-5wwy0m2k	363	28	evidence	evidence	NN
cord-015922-5wwy0m2k	363	29	of	of	IN
cord-015922-5wwy0m2k	363	30	reactivation	reactivation	NN
cord-015922-5wwy0m2k	363	31	periodically	periodically	RB
cord-015922-5wwy0m2k	363	32	.	.	.
cord-015922-5wwy0m2k	364	1	If	if	IN
cord-015922-5wwy0m2k	364	2	reactivation	reactivation	NN
cord-015922-5wwy0m2k	364	3	is	be	VBZ
cord-015922-5wwy0m2k	364	4	detected	detect	VBN
cord-015922-5wwy0m2k	364	5	then	then	RB
cord-015922-5wwy0m2k	364	6	consider	consider	VB
cord-015922-5wwy0m2k	364	7	treatment	treatment	NN
cord-015922-5wwy0m2k	364	8	if	if	IN
cord-015922-5wwy0m2k	364	9	persistent	persistent	JJ
cord-015922-5wwy0m2k	364	10	HBV	HBV	NNP
cord-015922-5wwy0m2k	364	11	viremia	viremia	NN
cord-015922-5wwy0m2k	364	12	detected	detect	VBD
cord-015922-5wwy0m2k	364	13	.	.	.
cord-015922-5wwy0m2k	365	1	Specific	specific	JJ
cord-015922-5wwy0m2k	365	2	HBV	HBV	NNP
cord-015922-5wwy0m2k	365	3	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	365	4	therapy	therapy	NN
cord-015922-5wwy0m2k	365	5	is	be	VBZ
cord-015922-5wwy0m2k	365	6	discussed	discuss	VBN
cord-015922-5wwy0m2k	365	7	in	in	IN
cord-015922-5wwy0m2k	365	8	the	the	DT
cord-015922-5wwy0m2k	365	9	text	text	NN
cord-015922-5wwy0m2k	365	10	.	.	.
cord-015922-5wwy0m2k	366	1	*	*	NFP
cord-015922-5wwy0m2k	366	2	*	*	NFP
cord-015922-5wwy0m2k	366	3	*	*	NFP
cord-015922-5wwy0m2k	366	4	*	*	NFP
cord-015922-5wwy0m2k	366	5	Pre	pre	JJ
cord-015922-5wwy0m2k	366	6	-	-	JJ
cord-015922-5wwy0m2k	366	7	transplant	transplant	JJ
cord-015922-5wwy0m2k	366	8	secondary	secondary	JJ
cord-015922-5wwy0m2k	366	9	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	366	10	for	for	IN
cord-015922-5wwy0m2k	366	11	MTb	MTb	NNS
cord-015922-5wwy0m2k	366	12	is	be	VBZ
cord-015922-5wwy0m2k	366	13	preferred	prefer	VBN
cord-015922-5wwy0m2k	366	14	.	.	.
cord-015922-5wwy0m2k	367	1	*	*	NFP
cord-015922-5wwy0m2k	367	2	*	*	NFP
cord-015922-5wwy0m2k	367	3	*	*	NFP
cord-015922-5wwy0m2k	367	4	*	*	NFP
cord-015922-5wwy0m2k	367	5	*	*	NFP
cord-015922-5wwy0m2k	367	6	Decision	decision	NN
cord-015922-5wwy0m2k	367	7	for	for	IN
cord-015922-5wwy0m2k	367	8	systemic	systemic	JJ
cord-015922-5wwy0m2k	367	9	azole	azole	NNP
cord-015922-5wwy0m2k	367	10	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	367	11	should	should	MD
cord-015922-5wwy0m2k	367	12	be	be	VB
cord-015922-5wwy0m2k	367	13	based	base	VBN
cord-015922-5wwy0m2k	367	14	on	on	IN
cord-015922-5wwy0m2k	367	15	local	local	JJ
cord-015922-5wwy0m2k	367	16	epidemiology	epidemiology	NN
cord-015922-5wwy0m2k	367	17	of	of	IN
cord-015922-5wwy0m2k	367	18	invasive	invasive	JJ
cord-015922-5wwy0m2k	367	19	fungal	fungal	JJ
cord-015922-5wwy0m2k	367	20	infections	infection	NNS
cord-015922-5wwy0m2k	367	21	.	.	.
cord-015922-5wwy0m2k	368	1	Consider	consider	VB
cord-015922-5wwy0m2k	368	2	posaconazole	posaconazole	NN
cord-015922-5wwy0m2k	368	3	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	368	4	in	in	IN
cord-015922-5wwy0m2k	368	5	the	the	DT
cord-015922-5wwy0m2k	368	6	setting	setting	NN
cord-015922-5wwy0m2k	368	7	of	of	IN
cord-015922-5wwy0m2k	368	8	significant	significant	JJ
cord-015922-5wwy0m2k	368	9	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	368	10	(	(	-LRB-
cord-015922-5wwy0m2k	368	11	e.g.	e.g.	RB
cord-015922-5wwy0m2k	368	12	,	,	,
cord-015922-5wwy0m2k	368	13	Grade	Grade	NNP
cord-015922-5wwy0m2k	368	14	3	3	CD
cord-015922-5wwy0m2k	368	15	or	or	CC
cord-015922-5wwy0m2k	368	16	4	4	CD
cord-015922-5wwy0m2k	368	17	)	)	-RRB-
cord-015922-5wwy0m2k	368	18	and	and	CC
cord-015922-5wwy0m2k	368	19	its	-PRON-	PRP$
cord-015922-5wwy0m2k	368	20	therapy	therapy	NN
cord-015922-5wwy0m2k	368	21	.	.	.
cord-015922-5wwy0m2k	369	1	Drug	drug	NN
cord-015922-5wwy0m2k	369	2	interactions	interaction	NNS
cord-015922-5wwy0m2k	369	3	must	must	MD
cord-015922-5wwy0m2k	369	4	be	be	VB
cord-015922-5wwy0m2k	369	5	carefully	carefully	RB
cord-015922-5wwy0m2k	369	6	managed	manage	VBN
cord-015922-5wwy0m2k	369	7	both	both	CC
cord-015922-5wwy0m2k	369	8	with	with	IN
cord-015922-5wwy0m2k	369	9	initiation	initiation	NN
cord-015922-5wwy0m2k	369	10	and	and	CC
cord-015922-5wwy0m2k	369	11	cessation	cessation	NN
cord-015922-5wwy0m2k	369	12	of	of	IN
cord-015922-5wwy0m2k	369	13	azole	azole	NNP
cord-015922-5wwy0m2k	369	14	therapy	therapy	NN
cord-015922-5wwy0m2k	369	15	.	.	.
cord-015922-5wwy0m2k	370	1	An	an	DT
cord-015922-5wwy0m2k	370	2	important	important	JJ
cord-015922-5wwy0m2k	370	3	aspect	aspect	NN
cord-015922-5wwy0m2k	370	4	of	of	IN
cord-015922-5wwy0m2k	370	5	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	370	6	therapy	therapy	NN
cord-015922-5wwy0m2k	370	7	in	in	IN
cord-015922-5wwy0m2k	370	8	the	the	DT
cord-015922-5wwy0m2k	370	9	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	370	10	patient	patient	NN
cord-015922-5wwy0m2k	370	11	is	be	VBZ
cord-015922-5wwy0m2k	370	12	the	the	DT
cord-015922-5wwy0m2k	370	13	management	management	NN
cord-015922-5wwy0m2k	370	14	of	of	IN
cord-015922-5wwy0m2k	370	15	drug	drug	NN
cord-015922-5wwy0m2k	370	16	interactions	interaction	NNS
cord-015922-5wwy0m2k	370	17	,	,	,
cord-015922-5wwy0m2k	370	18	especially	especially	RB
cord-015922-5wwy0m2k	370	19	between	between	IN
cord-015922-5wwy0m2k	370	20	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	370	21	agents	agent	NNS
cord-015922-5wwy0m2k	370	22	(	(	-LRB-
cord-015922-5wwy0m2k	370	23	e.g.	e.g.	RB
cord-015922-5wwy0m2k	370	24	,	,	,
cord-015922-5wwy0m2k	370	25	azoles	azole	NNS
cord-015922-5wwy0m2k	370	26	,	,	,
cord-015922-5wwy0m2k	370	27	macrolides	macrolides	NNP
cord-015922-5wwy0m2k	370	28	)	)	-RRB-
cord-015922-5wwy0m2k	370	29	and	and	CC
cord-015922-5wwy0m2k	370	30	the	the	DT
cord-015922-5wwy0m2k	370	31	immunosuppressive	immunosuppressive	JJ
cord-015922-5wwy0m2k	370	32	medications	medication	NNS
cord-015922-5wwy0m2k	370	33	(	(	-LRB-
cord-015922-5wwy0m2k	370	34	e.g.	e.g.	RB
cord-015922-5wwy0m2k	370	35	,	,	,
cord-015922-5wwy0m2k	370	36	calcineurin	calcineurin	NNP
cord-015922-5wwy0m2k	370	37	inhibitors	inhibitor	NNS
cord-015922-5wwy0m2k	370	38	,	,	,
cord-015922-5wwy0m2k	370	39	sirolimus	sirolimus	NNP
cord-015922-5wwy0m2k	370	40	)	)	-RRB-
cord-015922-5wwy0m2k	370	41	used	use	VBD
cord-015922-5wwy0m2k	370	42	to	to	TO
cord-015922-5wwy0m2k	370	43	prevent	prevent	VB
cord-015922-5wwy0m2k	370	44	and	and	CC
cord-015922-5wwy0m2k	370	45	treat	treat	VB
cord-015922-5wwy0m2k	370	46	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	370	47	.	.	.
cord-015922-5wwy0m2k	371	1	There	there	EX
cord-015922-5wwy0m2k	371	2	are	be	VBP
cord-015922-5wwy0m2k	371	3	three	three	CD
cord-015922-5wwy0m2k	371	4	important	important	JJ
cord-015922-5wwy0m2k	371	5	categories	category	NNS
cord-015922-5wwy0m2k	371	6	of	of	IN
cord-015922-5wwy0m2k	371	7	interaction	interaction	NN
cord-015922-5wwy0m2k	371	8	to	to	TO
cord-015922-5wwy0m2k	371	9	pay	pay	VB
cord-015922-5wwy0m2k	371	10	particular	particular	JJ
cord-015922-5wwy0m2k	371	11	attention	attention	NN
cord-015922-5wwy0m2k	371	12	to	to	IN
cord-015922-5wwy0m2k	371	13	,	,	,
cord-015922-5wwy0m2k	371	14	two	two	CD
cord-015922-5wwy0m2k	371	15	of	of	IN
cord-015922-5wwy0m2k	371	16	which	which	WDT
cord-015922-5wwy0m2k	371	17	are	be	VBP
cord-015922-5wwy0m2k	371	18	related	relate	VBN
cord-015922-5wwy0m2k	371	19	to	to	IN
cord-015922-5wwy0m2k	371	20	the	the	DT
cord-015922-5wwy0m2k	371	21	major	major	JJ
cord-015922-5wwy0m2k	371	22	route	route	NN
cord-015922-5wwy0m2k	371	23	of	of	IN
cord-015922-5wwy0m2k	371	24	drug	drug	NN
cord-015922-5wwy0m2k	371	25	metabolism	metabolism	NN
cord-015922-5wwy0m2k	371	26	for	for	IN
cord-015922-5wwy0m2k	371	27	the	the	DT
cord-015922-5wwy0m2k	371	28	calcineurin	calcineurin	NNP
cord-015922-5wwy0m2k	371	29	inhibitors	inhibitor	NNS
cord-015922-5wwy0m2k	371	30	,	,	,
cord-015922-5wwy0m2k	371	31	hepatic	hepatic	JJ
cord-015922-5wwy0m2k	371	32	cytochrome	cytochrome	NN
cord-015922-5wwy0m2k	371	33	P450	p450	JJ
cord-015922-5wwy0m2k	371	34	enzymatic	enzymatic	JJ
cord-015922-5wwy0m2k	371	35	metabolism	metabolism	NN
cord-015922-5wwy0m2k	371	36	.	.	.
cord-015922-5wwy0m2k	372	1	These	these	DT
cord-015922-5wwy0m2k	372	2	interactions	interaction	NNS
cord-015922-5wwy0m2k	372	3	are	be	VBP
cord-015922-5wwy0m2k	372	4	as	as	IN
cord-015922-5wwy0m2k	372	5	follows	follow	VBZ
cord-015922-5wwy0m2k	372	6	:	:	:
cord-015922-5wwy0m2k	372	7	1	1	LS
cord-015922-5wwy0m2k	372	8	)	)	-RRB-
cord-015922-5wwy0m2k	372	9	certain	certain	JJ
cord-015922-5wwy0m2k	372	10	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	372	11	agents	agent	NNS
cord-015922-5wwy0m2k	372	12	(	(	-LRB-
cord-015922-5wwy0m2k	372	13	most	most	RBS
cord-015922-5wwy0m2k	372	14	notably	notably	RB
cord-015922-5wwy0m2k	372	15	the	the	DT
cord-015922-5wwy0m2k	372	16	macrolides	macrolide	NNS
cord-015922-5wwy0m2k	372	17	[	[	-LRB-
cord-015922-5wwy0m2k	372	18	eryth	eryth	NN
cord-015922-5wwy0m2k	372	19	romycin	romycin	NNS
cord-015922-5wwy0m2k	372	20	>	>	XX
cord-015922-5wwy0m2k	373	1	clarithromycin	clarithromycin	NNP
cord-015922-5wwy0m2k	374	1	>	>	XX
cord-015922-5wwy0m2k	375	1	azithromycin	azithromycin	NNP
cord-015922-5wwy0m2k	375	2	]	]	-RRB-
cord-015922-5wwy0m2k	375	3	and	and	CC
cord-015922-5wwy0m2k	375	4	the	the	DT
cord-015922-5wwy0m2k	375	5	azoles	azole	NNS
cord-015922-5wwy0m2k	375	6	[	[	-LRB-
cord-015922-5wwy0m2k	375	7	ketoconazole	ketoconazole	RB
cord-015922-5wwy0m2k	375	8	>	>	XX
cord-015922-5wwy0m2k	376	1	itraco	itraco	NNP
cord-015922-5wwy0m2k	376	2	nazole	nazole	NNP
cord-015922-5wwy0m2k	377	1	>	>	XX
cord-015922-5wwy0m2k	378	1	voriconazole	voriconazole	NNP
cord-015922-5wwy0m2k	378	2	>	>	XX
cord-015922-5wwy0m2k	378	3	fluconazole	fluconazole	NNP
cord-015922-5wwy0m2k	378	4	]	]	-RRB-
cord-015922-5wwy0m2k	378	5	)	)	-RRB-
cord-015922-5wwy0m2k	378	6	will	will	MD
cord-015922-5wwy0m2k	378	7	downregulate	downregulate	VB
cord-015922-5wwy0m2k	378	8	the	the	DT
cord-015922-5wwy0m2k	378	9	metabolism	metabolism	NN
cord-015922-5wwy0m2k	378	10	of	of	IN
cord-015922-5wwy0m2k	378	11	the	the	DT
cord-015922-5wwy0m2k	378	12	calcineurin	calcineurin	NN
cord-015922-5wwy0m2k	378	13	inhibitors	inhibitor	NNS
cord-015922-5wwy0m2k	378	14	,	,	,
cord-015922-5wwy0m2k	378	15	resulting	result	VBG
cord-015922-5wwy0m2k	378	16	in	in	IN
cord-015922-5wwy0m2k	378	17	elevated	elevated	JJ
cord-015922-5wwy0m2k	378	18	blood	blood	NN
cord-015922-5wwy0m2k	378	19	levels	level	NNS
cord-015922-5wwy0m2k	378	20	of	of	IN
cord-015922-5wwy0m2k	378	21	active	active	JJ
cord-015922-5wwy0m2k	378	22	drug	drug	NN
cord-015922-5wwy0m2k	378	23	,	,	,
cord-015922-5wwy0m2k	378	24	and	and	CC
cord-015922-5wwy0m2k	378	25	an	an	DT
cord-015922-5wwy0m2k	378	26	increased	increase	VBN
cord-015922-5wwy0m2k	378	27	risk	risk	NN
cord-015922-5wwy0m2k	378	28	of	of	IN
cord-015922-5wwy0m2k	378	29	nephrotoxicity	nephrotoxicity	NN
cord-015922-5wwy0m2k	378	30	,	,	,
cord-015922-5wwy0m2k	378	31	as	as	RB
cord-015922-5wwy0m2k	378	32	well	well	RB
cord-015922-5wwy0m2k	378	33	as	as	IN
cord-015922-5wwy0m2k	378	34	over	over	IN
cord-015922-5wwy0m2k	378	35	-	-	HYPH
cord-015922-5wwy0m2k	378	36	immunosuppression	immunosuppression	NN
cord-015922-5wwy0m2k	378	37	and	and	CC
cord-015922-5wwy0m2k	378	38	an	an	DT
cord-015922-5wwy0m2k	378	39	increased	increase	VBN
cord-015922-5wwy0m2k	378	40	incidence	incidence	NN
cord-015922-5wwy0m2k	378	41	of	of	IN
cord-015922-5wwy0m2k	378	42	opportunistic	opportunistic	JJ
cord-015922-5wwy0m2k	378	43	infection	infection	NN
cord-015922-5wwy0m2k	378	44	;	;	:
cord-015922-5wwy0m2k	379	1	2	2	LS
cord-015922-5wwy0m2k	379	2	)	)	-RRB-
cord-015922-5wwy0m2k	379	3	certain	certain	JJ
cord-015922-5wwy0m2k	379	4	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	379	5	agents	agent	NNS
cord-015922-5wwy0m2k	379	6	(	(	-LRB-
cord-015922-5wwy0m2k	379	7	such	such	JJ
cord-015922-5wwy0m2k	379	8	as	as	IN
cord-015922-5wwy0m2k	379	9	rifampin	rifampin	NN
cord-015922-5wwy0m2k	379	10	and	and	CC
cord-015922-5wwy0m2k	379	11	rifabutin	rifabutin	NNS
cord-015922-5wwy0m2k	379	12	)	)	-RRB-
cord-015922-5wwy0m2k	379	13	upregulate	upregulate	VBP
cord-015922-5wwy0m2k	379	14	metabolism	metabolism	NN
cord-015922-5wwy0m2k	379	15	of	of	IN
cord-015922-5wwy0m2k	379	16	the	the	DT
cord-015922-5wwy0m2k	379	17	calcineurin	calcineurin	NNP
cord-015922-5wwy0m2k	379	18	inhibitors	inhibitor	NNS
cord-015922-5wwy0m2k	379	19	,	,	,
cord-015922-5wwy0m2k	379	20	leading	lead	VBG
cord-015922-5wwy0m2k	379	21	to	to	IN
cord-015922-5wwy0m2k	379	22	a	a	DT
cord-015922-5wwy0m2k	379	23	fall	fall	NN
cord-015922-5wwy0m2k	379	24	in	in	IN
cord-015922-5wwy0m2k	379	25	blood	blood	NN
cord-015922-5wwy0m2k	379	26	levels	level	NNS
cord-015922-5wwy0m2k	379	27	and	and	CC
cord-015922-5wwy0m2k	379	28	an	an	DT
cord-015922-5wwy0m2k	379	29	increased	increase	VBN
cord-015922-5wwy0m2k	379	30	risk	risk	NN
cord-015922-5wwy0m2k	379	31	of	of	IN
cord-015922-5wwy0m2k	379	32	GvHD	GvHD	NNP
cord-015922-5wwy0m2k	379	33	,	,	,
cord-015922-5wwy0m2k	379	34	and	and	CC
cord-015922-5wwy0m2k	379	35	3	3	LS
cord-015922-5wwy0m2k	379	36	)	)	-RRB-
cord-015922-5wwy0m2k	379	37	therapeutic	therapeutic	JJ
cord-015922-5wwy0m2k	379	38	blood	blood	NN
cord-015922-5wwy0m2k	379	39	levels	level	NNS
cord-015922-5wwy0m2k	379	40	of	of	IN
cord-015922-5wwy0m2k	379	41	the	the	DT
cord-015922-5wwy0m2k	379	42	calcineurin	calcineurin	NN
cord-015922-5wwy0m2k	379	43	inhibitors	inhibitor	NNS
cord-015922-5wwy0m2k	379	44	,	,	,
cord-015922-5wwy0m2k	379	45	when	when	WRB
cord-015922-5wwy0m2k	379	46	combined	combine	VBN
cord-015922-5wwy0m2k	379	47	with	with	IN
cord-015922-5wwy0m2k	379	48	such	such	JJ
cord-015922-5wwy0m2k	379	49	drugs	drug	NNS
cord-015922-5wwy0m2k	379	50	as	as	IN
cord-015922-5wwy0m2k	379	51	amphotericin	amphotericin	NNS
cord-015922-5wwy0m2k	379	52	B	b	NN
cord-015922-5wwy0m2k	379	53	,	,	,
cord-015922-5wwy0m2k	379	54	aminoglycosides	aminoglycoside	NNS
cord-015922-5wwy0m2k	379	55	and	and	CC
cord-015922-5wwy0m2k	379	56	vancomycin	vancomycin	NN
cord-015922-5wwy0m2k	379	57	,	,	,
cord-015922-5wwy0m2k	379	58	can	can	MD
cord-015922-5wwy0m2k	379	59	cause	cause	VB
cord-015922-5wwy0m2k	379	60	significant	significant	JJ
cord-015922-5wwy0m2k	379	61	renal	renal	JJ
cord-015922-5wwy0m2k	379	62	toxicity	toxicity	NN
cord-015922-5wwy0m2k	379	63	.	.	.
cord-015922-5wwy0m2k	380	1	HSCT	HSCT	NNP
cord-015922-5wwy0m2k	380	2	has	have	VBZ
cord-015922-5wwy0m2k	380	3	become	become	VBN
cord-015922-5wwy0m2k	380	4	one	one	CD
cord-015922-5wwy0m2k	380	5	of	of	IN
cord-015922-5wwy0m2k	380	6	the	the	DT
cord-015922-5wwy0m2k	380	7	great	great	JJ
cord-015922-5wwy0m2k	380	8	success	success	NN
cord-015922-5wwy0m2k	380	9	stories	story	NNS
cord-015922-5wwy0m2k	380	10	of	of	IN
cord-015922-5wwy0m2k	380	11	modern	modern	JJ
cord-015922-5wwy0m2k	380	12	medicine	medicine	NN
cord-015922-5wwy0m2k	380	13	.	.	.
cord-015922-5wwy0m2k	381	1	It	-PRON-	PRP
cord-015922-5wwy0m2k	381	2	is	be	VBZ
cord-015922-5wwy0m2k	381	3	the	the	DT
cord-015922-5wwy0m2k	381	4	therapy	therapy	NN
cord-015922-5wwy0m2k	381	5	of	of	IN
cord-015922-5wwy0m2k	381	6	choice	choice	NN
cord-015922-5wwy0m2k	381	7	for	for	IN
cord-015922-5wwy0m2k	381	8	an	an	DT
cord-015922-5wwy0m2k	381	9	increasing	increase	VBG
cord-015922-5wwy0m2k	381	10	number	number	NN
cord-015922-5wwy0m2k	381	11	of	of	IN
cord-015922-5wwy0m2k	381	12	conditions	condition	NNS
cord-015922-5wwy0m2k	381	13	,	,	,
cord-015922-5wwy0m2k	381	14	including	include	VBG
cord-015922-5wwy0m2k	381	15	a	a	DT
cord-015922-5wwy0m2k	381	16	variety	variety	NN
cord-015922-5wwy0m2k	381	17	of	of	IN
cord-015922-5wwy0m2k	381	18	cancers	cancer	NNS
cord-015922-5wwy0m2k	381	19	,	,	,
cord-015922-5wwy0m2k	381	20	bone	bone	NN
cord-015922-5wwy0m2k	381	21	marrow	marrow	NN
cord-015922-5wwy0m2k	381	22	failure	failure	NN
cord-015922-5wwy0m2k	381	23	states	state	NNS
cord-015922-5wwy0m2k	381	24	,	,	,
cord-015922-5wwy0m2k	381	25	congenital	congenital	JJ
cord-015922-5wwy0m2k	381	26	immunodeficiencies	immunodeficiency	NNS
cord-015922-5wwy0m2k	381	27	,	,	,
cord-015922-5wwy0m2k	381	28	metabolic	metabolic	JJ
cord-015922-5wwy0m2k	381	29	disorders	disorder	NNS
cord-015922-5wwy0m2k	381	30	and	and	CC
cord-015922-5wwy0m2k	381	31	even	even	RB
cord-015922-5wwy0m2k	381	32	as	as	IN
cord-015922-5wwy0m2k	381	33	a	a	DT
cord-015922-5wwy0m2k	381	34	means	means	NN
cord-015922-5wwy0m2k	381	35	for	for	IN
cord-015922-5wwy0m2k	381	36	introducing	introduce	VBG
cord-015922-5wwy0m2k	381	37	new	new	JJ
cord-015922-5wwy0m2k	381	38	genes	gene	NNS
cord-015922-5wwy0m2k	381	39	.	.	.
cord-015922-5wwy0m2k	382	1	The	the	DT
cord-015922-5wwy0m2k	382	2	major	major	JJ
cord-015922-5wwy0m2k	382	3	hurdle	hurdle	NN
cord-015922-5wwy0m2k	382	4	in	in	IN
cord-015922-5wwy0m2k	382	5	most	most	JJS
cord-015922-5wwy0m2k	382	6	of	of	IN
cord-015922-5wwy0m2k	382	7	these	these	DT
cord-015922-5wwy0m2k	382	8	attempts	attempt	NNS
cord-015922-5wwy0m2k	382	9	,	,	,
cord-015922-5wwy0m2k	382	10	however	however	RB
cord-015922-5wwy0m2k	382	11	,	,	,
cord-015922-5wwy0m2k	382	12	remains	remain	VBZ
cord-015922-5wwy0m2k	382	13	infection	infection	NN
cord-015922-5wwy0m2k	382	14	.	.	.
cord-015922-5wwy0m2k	383	1	Bacterial	bacterial	JJ
cord-015922-5wwy0m2k	383	2	and	and	CC
cord-015922-5wwy0m2k	383	3	fungal	fungal	JJ
cord-015922-5wwy0m2k	383	4	sepsis	sepsis	NN
cord-015922-5wwy0m2k	383	5	,	,	,
cord-015922-5wwy0m2k	383	6	as	as	RB
cord-015922-5wwy0m2k	383	7	well	well	RB
cord-015922-5wwy0m2k	383	8	as	as	IN
cord-015922-5wwy0m2k	383	9	herpes	herpes	NN
cord-015922-5wwy0m2k	383	10	group	group	NN
cord-015922-5wwy0m2k	383	11	viral	viral	JJ
cord-015922-5wwy0m2k	383	12	infection	infection	NN
cord-015922-5wwy0m2k	383	13	and	and	CC
cord-015922-5wwy0m2k	383	14	community	community	NN
cord-015922-5wwy0m2k	383	15	-	-	HYPH
cord-015922-5wwy0m2k	383	16	acquired	acquire	VBN
cord-015922-5wwy0m2k	383	17	respiratory	respiratory	JJ
cord-015922-5wwy0m2k	383	18	virus	virus	NN
cord-015922-5wwy0m2k	383	19	infection	infection	NN
cord-015922-5wwy0m2k	383	20	threaten	threaten	VBP
cord-015922-5wwy0m2k	383	21	the	the	DT
cord-015922-5wwy0m2k	383	22	well	well	RB
cord-015922-5wwy0m2k	383	23	-	-	HYPH
cord-015922-5wwy0m2k	383	24	being	being	NN
cord-015922-5wwy0m2k	383	25	of	of	IN
cord-015922-5wwy0m2k	383	26	these	these	DT
cord-015922-5wwy0m2k	383	27	patients	patient	NNS
cord-015922-5wwy0m2k	383	28	.	.	.
cord-015922-5wwy0m2k	384	1	There	there	EX
cord-015922-5wwy0m2k	384	2	are	be	VBP
cord-015922-5wwy0m2k	384	3	two	two	CD
cord-015922-5wwy0m2k	384	4	phases	phase	NNS
cord-015922-5wwy0m2k	384	5	of	of	IN
cord-015922-5wwy0m2k	384	6	the	the	DT
cord-015922-5wwy0m2k	384	7	post	post	JJ
cord-015922-5wwy0m2k	384	8	-	-	JJ
cord-015922-5wwy0m2k	384	9	transplant	transplant	JJ
cord-015922-5wwy0m2k	384	10	course	course	NN
cord-015922-5wwy0m2k	384	11	when	when	WRB
cord-015922-5wwy0m2k	384	12	the	the	DT
cord-015922-5wwy0m2k	384	13	patient	patient	NN
cord-015922-5wwy0m2k	384	14	is	be	VBZ
cord-015922-5wwy0m2k	384	15	at	at	IN
cord-015922-5wwy0m2k	384	16	particular	particular	JJ
cord-015922-5wwy0m2k	384	17	risk	risk	NN
cord-015922-5wwy0m2k	384	18	:	:	:
cord-015922-5wwy0m2k	384	19	preengraftment	preengraftment	NNP
cord-015922-5wwy0m2k	384	20	with	with	IN
cord-015922-5wwy0m2k	384	21	profound	profound	JJ
cord-015922-5wwy0m2k	384	22	granulocytopenia	granulocytopenia	NNP
cord-015922-5wwy0m2k	384	23	and	and	CC
cord-015922-5wwy0m2k	384	24	mucositis	mucositis	NNP
cord-015922-5wwy0m2k	384	25	,	,	,
cord-015922-5wwy0m2k	384	26	and	and	CC
cord-015922-5wwy0m2k	384	27	post	post	JJ
cord-015922-5wwy0m2k	384	28	-	-	NN
cord-015922-5wwy0m2k	384	29	engraftment	engraftment	JJ
cord-015922-5wwy0m2k	384	30	when	when	WRB
cord-015922-5wwy0m2k	384	31	GVHD	GVHD	NNP
cord-015922-5wwy0m2k	384	32	and	and	CC
cord-015922-5wwy0m2k	384	33	its	-PRON-	PRP$
cord-015922-5wwy0m2k	384	34	therapy	therapy	NN
cord-015922-5wwy0m2k	384	35	render	render	VBP
cord-015922-5wwy0m2k	384	36	the	the	DT
cord-015922-5wwy0m2k	384	37	patient	patient	NN
cord-015922-5wwy0m2k	384	38	vulnerable	vulnerable	JJ
cord-015922-5wwy0m2k	384	39	to	to	IN
cord-015922-5wwy0m2k	384	40	both	both	CC
cord-015922-5wwy0m2k	384	41	fungal	fungal	JJ
cord-015922-5wwy0m2k	384	42	and	and	CC
cord-015922-5wwy0m2k	384	43	viral	viral	JJ
cord-015922-5wwy0m2k	384	44	infection	infection	NN
cord-015922-5wwy0m2k	384	45	.	.	.
cord-015922-5wwy0m2k	385	1	New	new	JJ
cord-015922-5wwy0m2k	385	2	preventative	preventative	JJ
cord-015922-5wwy0m2k	385	3	strategies	strategy	NNS
cord-015922-5wwy0m2k	385	4	are	be	VBP
cord-015922-5wwy0m2k	385	5	being	be	VBG
cord-015922-5wwy0m2k	385	6	formulated	formulate	VBN
cord-015922-5wwy0m2k	385	7	involving	involve	VBG
cord-015922-5wwy0m2k	385	8	both	both	CC
cord-015922-5wwy0m2k	385	9	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	385	10	and	and	CC
cord-015922-5wwy0m2k	385	11	preemptive	preemptive	JJ
cord-015922-5wwy0m2k	385	12	therapy	therapy	NN
cord-015922-5wwy0m2k	385	13	.	.	.
cord-015922-5wwy0m2k	386	1	Similarly	similarly	RB
cord-015922-5wwy0m2k	386	2	,	,	,
cord-015922-5wwy0m2k	386	3	new	new	JJ
cord-015922-5wwy0m2k	386	4	non	non	JJ
cord-015922-5wwy0m2k	386	5	-	-	JJ
cord-015922-5wwy0m2k	386	6	culture	culture	JJ
cord-015922-5wwy0m2k	386	7	diagnostic	diagnostic	JJ
cord-015922-5wwy0m2k	386	8	approaches	approach	NNS
cord-015922-5wwy0m2k	386	9	that	that	WDT
cord-015922-5wwy0m2k	386	10	rely	rely	VBP
cord-015922-5wwy0m2k	386	11	on	on	IN
cord-015922-5wwy0m2k	386	12	antigen	antigen	NN
cord-015922-5wwy0m2k	386	13	detection	detection	NN
cord-015922-5wwy0m2k	386	14	or	or	CC
cord-015922-5wwy0m2k	386	15	PCR	PCR	NNP
cord-015922-5wwy0m2k	386	16	detection	detection	NN
cord-015922-5wwy0m2k	386	17	of	of	IN
cord-015922-5wwy0m2k	386	18	microbial	microbial	JJ
cord-015922-5wwy0m2k	386	19	DNA	dna	NN
cord-015922-5wwy0m2k	386	20	are	be	VBP
cord-015922-5wwy0m2k	386	21	being	be	VBG
cord-015922-5wwy0m2k	386	22	developed	develop	VBN
cord-015922-5wwy0m2k	386	23	.	.	.
cord-015922-5wwy0m2k	387	1	New	new	JJ
cord-015922-5wwy0m2k	387	2	therapies	therapy	NNS
cord-015922-5wwy0m2k	387	3	,	,	,
cord-015922-5wwy0m2k	387	4	both	both	CC
cord-015922-5wwy0m2k	387	5	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	387	6	and	and	CC
cord-015922-5wwy0m2k	387	7	antifungal	antifungal	JJ
cord-015922-5wwy0m2k	387	8	,	,	,
cord-015922-5wwy0m2k	387	9	have	have	VBP
cord-015922-5wwy0m2k	387	10	emerged	emerge	VBN
cord-015922-5wwy0m2k	387	11	.	.	.
cord-015922-5wwy0m2k	388	1	These	these	DT
cord-015922-5wwy0m2k	388	2	should	should	MD
cord-015922-5wwy0m2k	388	3	prompt	prompt	VB
cord-015922-5wwy0m2k	388	4	much	much	RB
cord-015922-5wwy0m2k	388	5	more	more	RBR
cord-015922-5wwy0m2k	388	6	effective	effective	JJ
cord-015922-5wwy0m2k	388	7	prevention	prevention	NN
cord-015922-5wwy0m2k	388	8	and	and	CC
cord-015922-5wwy0m2k	388	9	therapeutic	therapeutic	JJ
cord-015922-5wwy0m2k	388	10	strategies	strategy	NNS
cord-015922-5wwy0m2k	388	11	.	.	.
cord-015922-5wwy0m2k	388	12	 	 	_SP
cord-015922-5wwy0m2k	389	1	Infection	infection	NN
cord-015922-5wwy0m2k	389	2	in	in	IN
cord-015922-5wwy0m2k	389	3	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	389	4	stem	stem	NN
cord-015922-5wwy0m2k	389	5	cell	cell	NN
cord-015922-5wwy0m2k	389	6	tansplantation	tansplantation	NN
cord-015922-5wwy0m2k	389	7	Quantitative	quantitative	JJ
cord-015922-5wwy0m2k	389	8	relationships	relationship	NNS
cord-015922-5wwy0m2k	389	9	between	between	IN
cord-015922-5wwy0m2k	389	10	circulating	circulate	VBG
cord-015922-5wwy0m2k	389	11	leukocytes	leukocyte	NNS
cord-015922-5wwy0m2k	389	12	and	and	CC
cord-015922-5wwy0m2k	389	13	infection	infection	NN
cord-015922-5wwy0m2k	389	14	in	in	IN
cord-015922-5wwy0m2k	389	15	patients	patient	NNS
cord-015922-5wwy0m2k	389	16	with	with	IN
cord-015922-5wwy0m2k	389	17	acute	acute	JJ
cord-015922-5wwy0m2k	389	18	leukemia	leukemia	NN
cord-015922-5wwy0m2k	389	19	Guidelines	guideline	NNS
cord-015922-5wwy0m2k	389	20	for	for	IN
cord-015922-5wwy0m2k	389	21	preventing	prevent	VBG
cord-015922-5wwy0m2k	389	22	opportunistic	opportunistic	JJ
cord-015922-5wwy0m2k	389	23	infections	infection	NNS
cord-015922-5wwy0m2k	389	24	among	among	IN
cord-015922-5wwy0m2k	389	25	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	389	26	stem	stem	NN
cord-015922-5wwy0m2k	389	27	cell	cell	NN
cord-015922-5wwy0m2k	389	28	transplant	transplant	NN
cord-015922-5wwy0m2k	389	29	recipients	recipient	NNS
cord-015922-5wwy0m2k	389	30	Preventing	prevent	VBG
cord-015922-5wwy0m2k	389	31	opportunistic	opportunistic	JJ
cord-015922-5wwy0m2k	389	32	infections	infection	NNS
cord-015922-5wwy0m2k	389	33	after	after	IN
cord-015922-5wwy0m2k	389	34	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	389	35	stem	stem	NN
cord-015922-5wwy0m2k	389	36	cell	cell	NN
cord-015922-5wwy0m2k	389	37	transplantation	transplantation	NN
cord-015922-5wwy0m2k	389	38	:	:	:
cord-015922-5wwy0m2k	389	39	the	the	DT
cord-015922-5wwy0m2k	389	40	Centers	Centers	NNPS
cord-015922-5wwy0m2k	389	41	for	for	IN
cord-015922-5wwy0m2k	389	42	Disease	Disease	NNP
cord-015922-5wwy0m2k	389	43	Control	Control	NNP
cord-015922-5wwy0m2k	389	44	and	and	CC
cord-015922-5wwy0m2k	389	45	Prevention	Prevention	NNP
cord-015922-5wwy0m2k	389	46	,	,	,
cord-015922-5wwy0m2k	389	47	Infectious	Infectious	NNP
cord-015922-5wwy0m2k	389	48	Diseases	Diseases	NNPS
cord-015922-5wwy0m2k	389	49	Society	Society	NNP
cord-015922-5wwy0m2k	389	50	of	of	IN
cord-015922-5wwy0m2k	389	51	America	America	NNP
cord-015922-5wwy0m2k	389	52	,	,	,
cord-015922-5wwy0m2k	389	53	and	and	CC
cord-015922-5wwy0m2k	389	54	American	American	NNP
cord-015922-5wwy0m2k	389	55	Society	Society	NNP
cord-015922-5wwy0m2k	389	56	for	for	IN
cord-015922-5wwy0m2k	389	57	Blood	blood	NN
cord-015922-5wwy0m2k	389	58	and	and	CC
cord-015922-5wwy0m2k	389	59	Marrow	Marrow	NNP
cord-015922-5wwy0m2k	389	60	Transplantation	Transplantation	NNP
cord-015922-5wwy0m2k	389	61	Practice	Practice	NNP
cord-015922-5wwy0m2k	389	62	Guidelines	Guidelines	NNPS
cord-015922-5wwy0m2k	389	63	and	and	CC
cord-015922-5wwy0m2k	389	64	beyond	beyond	RB
cord-015922-5wwy0m2k	389	65	.	.	.
cord-015922-5wwy0m2k	390	1	Hematology	Hematology	NNP
cord-015922-5wwy0m2k	390	2	/	/	,
cord-015922-5wwy0m2k	390	3	the	the	DT
cord-015922-5wwy0m2k	390	4	Education	Education	NNP
cord-015922-5wwy0m2k	390	5	Program	Program	NNP
cord-015922-5wwy0m2k	390	6	of	of	IN
cord-015922-5wwy0m2k	390	7	the	the	DT
cord-015922-5wwy0m2k	390	8	Invasive	invasive	JJ
cord-015922-5wwy0m2k	390	9	aspergillus	aspergillus	NN
cord-015922-5wwy0m2k	390	10	infection	infection	NN
cord-015922-5wwy0m2k	390	11	:	:	:
cord-015922-5wwy0m2k	390	12	possible	possible	JJ
cord-015922-5wwy0m2k	390	13	nonward	nonward	NN
cord-015922-5wwy0m2k	390	14	common	common	JJ
cord-015922-5wwy0m2k	390	15	source	source	NN
cord-015922-5wwy0m2k	390	16	within	within	IN
cord-015922-5wwy0m2k	390	17	the	the	DT
cord-015922-5wwy0m2k	390	18	hospital	hospital	NN
cord-015922-5wwy0m2k	390	19	environment	environment	NN
cord-015922-5wwy0m2k	390	20	Septicemia	septicemia	NN
cord-015922-5wwy0m2k	390	21	and	and	CC
cord-015922-5wwy0m2k	390	22	shock	shock	NN
cord-015922-5wwy0m2k	390	23	syndrome	syndrome	NN
cord-015922-5wwy0m2k	390	24	due	due	IN
cord-015922-5wwy0m2k	390	25	to	to	IN
cord-015922-5wwy0m2k	390	26	viridans	viridans	NNP
cord-015922-5wwy0m2k	390	27	streptococci	streptococcus	NNS
cord-015922-5wwy0m2k	390	28	:	:	:
cord-015922-5wwy0m2k	390	29	a	a	DT
cord-015922-5wwy0m2k	390	30	case	case	NN
cord-015922-5wwy0m2k	390	31	-	-	HYPH
cord-015922-5wwy0m2k	390	32	control	control	NN
cord-015922-5wwy0m2k	390	33	study	study	NN
cord-015922-5wwy0m2k	390	34	of	of	IN
cord-015922-5wwy0m2k	390	35	predisposing	predisposing	JJ
cord-015922-5wwy0m2k	390	36	factors	factor	NNS
cord-015922-5wwy0m2k	390	37	Introduction	introduction	NN
cord-015922-5wwy0m2k	390	38	to	to	IN
cord-015922-5wwy0m2k	390	39	marrow	marrow	NN
cord-015922-5wwy0m2k	390	40	and	and	CC
cord-015922-5wwy0m2k	390	41	blood	blood	NN
cord-015922-5wwy0m2k	390	42	stem	stem	NN
cord-015922-5wwy0m2k	390	43	cell	cell	NN
cord-015922-5wwy0m2k	390	44	transplantation	transplantation	NN
cord-015922-5wwy0m2k	390	45	Infectious	infectious	JJ
cord-015922-5wwy0m2k	390	46	complications	complication	NNS
cord-015922-5wwy0m2k	390	47	associated	associate	VBN
cord-015922-5wwy0m2k	390	48	with	with	IN
cord-015922-5wwy0m2k	390	49	alemtuzumab	alemtuzumab	JJ
cord-015922-5wwy0m2k	390	50	use	use	NN
cord-015922-5wwy0m2k	390	51	for	for	IN
cord-015922-5wwy0m2k	390	52	lymphoproliferative	lymphoproliferative	JJ
cord-015922-5wwy0m2k	390	53	disorders	disorder	NNS
cord-015922-5wwy0m2k	391	1	Infliximab	Infliximab	NNP
cord-015922-5wwy0m2k	391	2	use	use	VBP
cord-015922-5wwy0m2k	391	3	in	in	IN
cord-015922-5wwy0m2k	391	4	patients	patient	NNS
cord-015922-5wwy0m2k	391	5	with	with	IN
cord-015922-5wwy0m2k	391	6	severe	severe	JJ
cord-015922-5wwy0m2k	391	7	graftversus	graftversus	NN
cord-015922-5wwy0m2k	391	8	-	-	HYPH
cord-015922-5wwy0m2k	391	9	host	host	NN
cord-015922-5wwy0m2k	391	10	disease	disease	NN
cord-015922-5wwy0m2k	391	11	and	and	CC
cord-015922-5wwy0m2k	391	12	other	other	JJ
cord-015922-5wwy0m2k	391	13	emerging	emerge	VBG
cord-015922-5wwy0m2k	391	14	risk	risk	NN
cord-015922-5wwy0m2k	391	15	factors	factor	NNS
cord-015922-5wwy0m2k	391	16	of	of	IN
cord-015922-5wwy0m2k	391	17	non	non	JJ
cord-015922-5wwy0m2k	391	18	-	-	JJ
cord-015922-5wwy0m2k	391	19	Candida	candida	JJ
cord-015922-5wwy0m2k	391	20	invasive	invasive	JJ
cord-015922-5wwy0m2k	391	21	fungal	fungal	JJ
cord-015922-5wwy0m2k	391	22	infections	infection	NNS
cord-015922-5wwy0m2k	391	23	in	in	IN
cord-015922-5wwy0m2k	391	24	allogeneic	allogeneic	JJ
cord-015922-5wwy0m2k	391	25	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	391	26	stem	stem	NN
cord-015922-5wwy0m2k	391	27	cell	cell	NN
cord-015922-5wwy0m2k	391	28	transplant	transplant	NN
cord-015922-5wwy0m2k	391	29	recipients	recipient	NNS
cord-015922-5wwy0m2k	391	30	:	:	:
cord-015922-5wwy0m2k	391	31	a	a	DT
cord-015922-5wwy0m2k	391	32	cohort	cohort	NN
cord-015922-5wwy0m2k	391	33	study	study	NN
cord-015922-5wwy0m2k	391	34	Risks	risk	NNS
cord-015922-5wwy0m2k	391	35	and	and	CC
cord-015922-5wwy0m2k	391	36	outcomes	outcome	NNS
cord-015922-5wwy0m2k	391	37	of	of	IN
cord-015922-5wwy0m2k	391	38	invasive	invasive	JJ
cord-015922-5wwy0m2k	391	39	fungal	fungal	JJ
cord-015922-5wwy0m2k	391	40	infections	infection	NNS
cord-015922-5wwy0m2k	391	41	in	in	IN
cord-015922-5wwy0m2k	391	42	recipients	recipient	NNS
cord-015922-5wwy0m2k	391	43	of	of	IN
cord-015922-5wwy0m2k	391	44	allogeneic	allogeneic	NN
cord-015922-5wwy0m2k	391	45	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	391	46	stem	stem	NN
cord-015922-5wwy0m2k	391	47	cell	cell	NN
cord-015922-5wwy0m2k	391	48	transplants	transplant	NNS
cord-015922-5wwy0m2k	391	49	after	after	IN
cord-015922-5wwy0m2k	391	50	nonmyeloablative	nonmyeloablative	JJ
cord-015922-5wwy0m2k	391	51	conditioning	conditioning	NN
cord-015922-5wwy0m2k	391	52	Invasive	invasive	JJ
cord-015922-5wwy0m2k	391	53	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	391	54	following	follow	VBG
cord-015922-5wwy0m2k	391	55	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	391	56	cell	cell	NN
cord-015922-5wwy0m2k	391	57	transplantation	transplantation	NN
cord-015922-5wwy0m2k	391	58	:	:	:
cord-015922-5wwy0m2k	391	59	outcomes	outcome	NNS
cord-015922-5wwy0m2k	391	60	and	and	CC
cord-015922-5wwy0m2k	391	61	prognostic	prognostic	JJ
cord-015922-5wwy0m2k	391	62	factors	factor	NNS
cord-015922-5wwy0m2k	391	63	associated	associate	VBN
cord-015922-5wwy0m2k	391	64	with	with	IN
cord-015922-5wwy0m2k	391	65	mortality	mortality	NN
cord-015922-5wwy0m2k	391	66	Galactomannan	Galactomannan	NNP
cord-015922-5wwy0m2k	391	67	and	and	CC
cord-015922-5wwy0m2k	391	68	computed	compute	VBD
cord-015922-5wwy0m2k	391	69	tomography	tomography	NN
cord-015922-5wwy0m2k	391	70	-	-	HYPH
cord-015922-5wwy0m2k	391	71	based	base	VBN
cord-015922-5wwy0m2k	391	72	preemptive	preemptive	JJ
cord-015922-5wwy0m2k	391	73	antifungal	antifungal	JJ
cord-015922-5wwy0m2k	391	74	therapy	therapy	NN
cord-015922-5wwy0m2k	391	75	in	in	IN
cord-015922-5wwy0m2k	391	76	neutropenic	neutropenic	JJ
cord-015922-5wwy0m2k	391	77	patients	patient	NNS
cord-015922-5wwy0m2k	391	78	at	at	IN
cord-015922-5wwy0m2k	391	79	high	high	JJ
cord-015922-5wwy0m2k	391	80	risk	risk	NN
cord-015922-5wwy0m2k	391	81	for	for	IN
cord-015922-5wwy0m2k	391	82	invasive	invasive	JJ
cord-015922-5wwy0m2k	391	83	fungal	fungal	JJ
cord-015922-5wwy0m2k	391	84	infection	infection	NN
cord-015922-5wwy0m2k	391	85	:	:	:
cord-015922-5wwy0m2k	392	1	a	a	DT
cord-015922-5wwy0m2k	392	2	prospective	prospective	JJ
cord-015922-5wwy0m2k	392	3	feasibility	feasibility	NN
cord-015922-5wwy0m2k	392	4	study	study	NN
cord-015922-5wwy0m2k	392	5	Levofloxacin	Levofloxacin	NNP
cord-015922-5wwy0m2k	392	6	to	to	TO
cord-015922-5wwy0m2k	392	7	prevent	prevent	VB
cord-015922-5wwy0m2k	392	8	bacterial	bacterial	JJ
cord-015922-5wwy0m2k	392	9	infection	infection	NN
cord-015922-5wwy0m2k	392	10	in	in	IN
cord-015922-5wwy0m2k	392	11	patients	patient	NNS
cord-015922-5wwy0m2k	392	12	with	with	IN
cord-015922-5wwy0m2k	392	13	cancer	cancer	NN
cord-015922-5wwy0m2k	392	14	and	and	CC
cord-015922-5wwy0m2k	392	15	neutropenia	neutropenia	NN
cord-015922-5wwy0m2k	392	16	Antibacterial	antibacterial	JJ
cord-015922-5wwy0m2k	392	17	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	392	18	after	after	IN
cord-015922-5wwy0m2k	392	19	chemotherapy	chemotherapy	NN
cord-015922-5wwy0m2k	392	20	for	for	IN
cord-015922-5wwy0m2k	392	21	solid	solid	JJ
cord-015922-5wwy0m2k	392	22	tumors	tumor	NNS
cord-015922-5wwy0m2k	392	23	and	and	CC
cord-015922-5wwy0m2k	392	24	lymphomas	lymphoma	NNS
cord-015922-5wwy0m2k	392	25	Prophylactic	prophylactic	JJ
cord-015922-5wwy0m2k	392	26	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	392	27	agents	agent	NNS
cord-015922-5wwy0m2k	392	28	and	and	CC
cord-015922-5wwy0m2k	392	29	the	the	DT
cord-015922-5wwy0m2k	392	30	importance	importance	NN
cord-015922-5wwy0m2k	392	31	of	of	IN
cord-015922-5wwy0m2k	392	32	fitness	fitness	NN
cord-015922-5wwy0m2k	392	33	Changing	change	VBG
cord-015922-5wwy0m2k	392	34	epidemiology	epidemiology	NN
cord-015922-5wwy0m2k	392	35	of	of	IN
cord-015922-5wwy0m2k	392	36	infections	infection	NNS
cord-015922-5wwy0m2k	392	37	in	in	IN
cord-015922-5wwy0m2k	392	38	patients	patient	NNS
cord-015922-5wwy0m2k	392	39	with	with	IN
cord-015922-5wwy0m2k	392	40	neutropenia	neutropenia	NN
cord-015922-5wwy0m2k	392	41	and	and	CC
cord-015922-5wwy0m2k	392	42	cancer	cancer	NN
cord-015922-5wwy0m2k	392	43	:	:	:
cord-015922-5wwy0m2k	392	44	emphasis	emphasis	NN
cord-015922-5wwy0m2k	392	45	on	on	IN
cord-015922-5wwy0m2k	392	46	gram	gram	NN
cord-015922-5wwy0m2k	392	47	-	-	HYPH
cord-015922-5wwy0m2k	392	48	positive	positive	JJ
cord-015922-5wwy0m2k	392	49	and	and	CC
cord-015922-5wwy0m2k	392	50	resistant	resistant	JJ
cord-015922-5wwy0m2k	392	51	bacteria	bacteria	NNS
cord-015922-5wwy0m2k	392	52	Outcomes	outcome	NNS
cord-015922-5wwy0m2k	392	53	of	of	IN
cord-015922-5wwy0m2k	392	54	bacteremia	bacteremia	NN
cord-015922-5wwy0m2k	392	55	in	in	IN
cord-015922-5wwy0m2k	392	56	patients	patient	NNS
cord-015922-5wwy0m2k	392	57	with	with	IN
cord-015922-5wwy0m2k	392	58	cancer	cancer	NN
cord-015922-5wwy0m2k	392	59	and	and	CC
cord-015922-5wwy0m2k	392	60	neutropenia	neutropenia	NN
cord-015922-5wwy0m2k	392	61	:	:	:
cord-015922-5wwy0m2k	392	62	observations	observation	NNS
cord-015922-5wwy0m2k	392	63	from	from	IN
cord-015922-5wwy0m2k	392	64	two	two	CD
cord-015922-5wwy0m2k	392	65	decades	decade	NNS
cord-015922-5wwy0m2k	392	66	of	of	IN
cord-015922-5wwy0m2k	392	67	epidemiological	epidemiological	JJ
cord-015922-5wwy0m2k	392	68	and	and	CC
cord-015922-5wwy0m2k	392	69	clinical	clinical	JJ
cord-015922-5wwy0m2k	392	70	trials	trial	NNS
cord-015922-5wwy0m2k	392	71	Escherichia	Escherichia	NNP
cord-015922-5wwy0m2k	392	72	coli	coli	NNS
cord-015922-5wwy0m2k	392	73	resistant	resistant	JJ
cord-015922-5wwy0m2k	392	74	to	to	IN
cord-015922-5wwy0m2k	392	75	fluoroquinolones	fluoroquinolone	NNS
cord-015922-5wwy0m2k	392	76	in	in	IN
cord-015922-5wwy0m2k	392	77	patients	patient	NNS
cord-015922-5wwy0m2k	392	78	with	with	IN
cord-015922-5wwy0m2k	392	79	cancer	cancer	NN
cord-015922-5wwy0m2k	392	80	and	and	CC
cord-015922-5wwy0m2k	392	81	neutropenia	neutropenia	NN
cord-015922-5wwy0m2k	392	82	Ceftazidime	Ceftazidime	NNP
cord-015922-5wwy0m2k	392	83	combined	combine	VBD
cord-015922-5wwy0m2k	392	84	with	with	IN
cord-015922-5wwy0m2k	392	85	a	a	DT
cord-015922-5wwy0m2k	392	86	short	short	JJ
cord-015922-5wwy0m2k	392	87	or	or	CC
cord-015922-5wwy0m2k	392	88	long	long	JJ
cord-015922-5wwy0m2k	392	89	course	course	NN
cord-015922-5wwy0m2k	392	90	of	of	IN
cord-015922-5wwy0m2k	392	91	amikacin	amikacin	NN
cord-015922-5wwy0m2k	392	92	for	for	IN
cord-015922-5wwy0m2k	392	93	empirical	empirical	JJ
cord-015922-5wwy0m2k	392	94	therapy	therapy	NN
cord-015922-5wwy0m2k	392	95	of	of	IN
cord-015922-5wwy0m2k	392	96	gram	gram	JJ
cord-015922-5wwy0m2k	392	97	-	-	HYPH
cord-015922-5wwy0m2k	392	98	negative	negative	JJ
cord-015922-5wwy0m2k	392	99	bacteremia	bacteremia	NN
cord-015922-5wwy0m2k	392	100	in	in	IN
cord-015922-5wwy0m2k	392	101	cancer	cancer	NN
cord-015922-5wwy0m2k	392	102	patients	patient	NNS
cord-015922-5wwy0m2k	392	103	with	with	IN
cord-015922-5wwy0m2k	392	104	granulocytopenia	granulocytopenia	NNP
cord-015922-5wwy0m2k	392	105	.	.	.
cord-015922-5wwy0m2k	393	1	The	the	DT
cord-015922-5wwy0m2k	393	2	EORTC	EORTC	NNP
cord-015922-5wwy0m2k	393	3	International	International	NNP
cord-015922-5wwy0m2k	393	4	Antimicrobial	Antimicrobial	NNP
cord-015922-5wwy0m2k	393	5	Therapy	Therapy	NNP
cord-015922-5wwy0m2k	393	6	Cooperative	Cooperative	NNP
cord-015922-5wwy0m2k	393	7	Group	Group	NNP
cord-015922-5wwy0m2k	393	8	Gram	Gram	NNP
cord-015922-5wwy0m2k	393	9	-	-	HYPH
cord-015922-5wwy0m2k	393	10	positive	positive	JJ
cord-015922-5wwy0m2k	393	11	infections	infection	NNS
cord-015922-5wwy0m2k	393	12	and	and	CC
cord-015922-5wwy0m2k	393	13	the	the	DT
cord-015922-5wwy0m2k	393	14	use	use	NN
cord-015922-5wwy0m2k	393	15	of	of	IN
cord-015922-5wwy0m2k	393	16	vancomycin	vancomycin	NN
cord-015922-5wwy0m2k	393	17	in	in	IN
cord-015922-5wwy0m2k	393	18	550	550	CD
cord-015922-5wwy0m2k	393	19	episodes	episode	NNS
cord-015922-5wwy0m2k	393	20	of	of	IN
cord-015922-5wwy0m2k	393	21	fever	fever	NN
cord-015922-5wwy0m2k	393	22	and	and	CC
cord-015922-5wwy0m2k	393	23	neutropenia	neutropenia	NN
cord-015922-5wwy0m2k	393	24	guidelines	guideline	NNS
cord-015922-5wwy0m2k	393	25	for	for	IN
cord-015922-5wwy0m2k	393	26	the	the	DT
cord-015922-5wwy0m2k	393	27	use	use	NN
cord-015922-5wwy0m2k	393	28	of	of	IN
cord-015922-5wwy0m2k	393	29	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	393	30	agents	agent	NNS
cord-015922-5wwy0m2k	393	31	in	in	IN
cord-015922-5wwy0m2k	393	32	neutropenic	neutropenic	JJ
cord-015922-5wwy0m2k	393	33	patients	patient	NNS
cord-015922-5wwy0m2k	393	34	with	with	IN
cord-015922-5wwy0m2k	393	35	cancer	cancer	NN
cord-015922-5wwy0m2k	393	36	Duration	duration	NN
cord-015922-5wwy0m2k	393	37	of	of	IN
cord-015922-5wwy0m2k	393	38	empiric	empiric	JJ
cord-015922-5wwy0m2k	393	39	antibiotic	antibiotic	JJ
cord-015922-5wwy0m2k	393	40	therapy	therapy	NN
cord-015922-5wwy0m2k	393	41	in	in	IN
cord-015922-5wwy0m2k	393	42	granulocytopenic	granulocytopenic	NN
cord-015922-5wwy0m2k	393	43	patients	patient	NNS
cord-015922-5wwy0m2k	393	44	with	with	IN
cord-015922-5wwy0m2k	393	45	cancer	cancer	NN
cord-015922-5wwy0m2k	393	46	Guidelines	guideline	NNS
cord-015922-5wwy0m2k	393	47	for	for	IN
cord-015922-5wwy0m2k	393	48	the	the	DT
cord-015922-5wwy0m2k	393	49	prevention	prevention	NN
cord-015922-5wwy0m2k	393	50	of	of	IN
cord-015922-5wwy0m2k	393	51	intravascular	intravascular	JJ
cord-015922-5wwy0m2k	393	52	catheter	catheter	NN
cord-015922-5wwy0m2k	393	53	-	-	HYPH
cord-015922-5wwy0m2k	393	54	related	relate	VBN
cord-015922-5wwy0m2k	393	55	infections	infection	NNS
cord-015922-5wwy0m2k	393	56	.	.	.
cord-015922-5wwy0m2k	394	1	The	the	DT
cord-015922-5wwy0m2k	394	2	Hospital	Hospital	NNP
cord-015922-5wwy0m2k	394	3	Infection	Infection	NNP
cord-015922-5wwy0m2k	394	4	Control	Control	NNP
cord-015922-5wwy0m2k	394	5	Practices	Practices	NNPS
cord-015922-5wwy0m2k	394	6	Advisory	Advisory	NNP
cord-015922-5wwy0m2k	394	7	Committee	Committee	NNP
cord-015922-5wwy0m2k	394	8	Palifermin	Palifermin	NNP
cord-015922-5wwy0m2k	394	9	for	for	IN
cord-015922-5wwy0m2k	394	10	oral	oral	JJ
cord-015922-5wwy0m2k	394	11	mucositis	mucositis	NN
cord-015922-5wwy0m2k	394	12	after	after	IN
cord-015922-5wwy0m2k	394	13	intensive	intensive	JJ
cord-015922-5wwy0m2k	394	14	therapy	therapy	NN
cord-015922-5wwy0m2k	394	15	for	for	IN
cord-015922-5wwy0m2k	394	16	hematologic	hematologic	JJ
cord-015922-5wwy0m2k	394	17	cancers	cancer	NNS
cord-015922-5wwy0m2k	395	1	The	the	DT
cord-015922-5wwy0m2k	395	2	use	use	NN
cord-015922-5wwy0m2k	395	3	of	of	IN
cord-015922-5wwy0m2k	395	4	intravenous	intravenous	JJ
cord-015922-5wwy0m2k	395	5	immune	immune	JJ
cord-015922-5wwy0m2k	395	6	globulin	globulin	NN
cord-015922-5wwy0m2k	395	7	in	in	IN
cord-015922-5wwy0m2k	395	8	immunodeficiency	immunodeficiency	NN
cord-015922-5wwy0m2k	395	9	diseases	disease	NNS
cord-015922-5wwy0m2k	396	1	A	a	DT
cord-015922-5wwy0m2k	396	2	controlled	control	VBN
cord-015922-5wwy0m2k	396	3	trial	trial	NN
cord-015922-5wwy0m2k	396	4	of	of	IN
cord-015922-5wwy0m2k	396	5	long	long	JJ
cord-015922-5wwy0m2k	396	6	-	-	HYPH
cord-015922-5wwy0m2k	396	7	term	term	NN
cord-015922-5wwy0m2k	396	8	administration	administration	NN
cord-015922-5wwy0m2k	396	9	of	of	IN
cord-015922-5wwy0m2k	396	10	intravenous	intravenous	JJ
cord-015922-5wwy0m2k	396	11	immunoglobulin	immunoglobulin	NN
cord-015922-5wwy0m2k	396	12	to	to	TO
cord-015922-5wwy0m2k	396	13	prevent	prevent	VB
cord-015922-5wwy0m2k	396	14	late	late	JJ
cord-015922-5wwy0m2k	396	15	infection	infection	NN
cord-015922-5wwy0m2k	396	16	and	and	CC
cord-015922-5wwy0m2k	396	17	chronic	chronic	JJ
cord-015922-5wwy0m2k	396	18	graft	graft	NN
cord-015922-5wwy0m2k	396	19	-	-	HYPH
cord-015922-5wwy0m2k	396	20	vs.-host	vs.-host	NN
cord-015922-5wwy0m2k	396	21	disease	disease	NN
cord-015922-5wwy0m2k	396	22	after	after	IN
cord-015922-5wwy0m2k	396	23	marrow	marrow	NN
cord-015922-5wwy0m2k	396	24	transplantation	transplantation	NN
cord-015922-5wwy0m2k	396	25	:	:	:
cord-015922-5wwy0m2k	396	26	clinical	clinical	JJ
cord-015922-5wwy0m2k	396	27	outcome	outcome	NN
cord-015922-5wwy0m2k	396	28	and	and	CC
cord-015922-5wwy0m2k	396	29	effect	effect	NN
cord-015922-5wwy0m2k	396	30	on	on	IN
cord-015922-5wwy0m2k	396	31	subsequent	subsequent	JJ
cord-015922-5wwy0m2k	396	32	immune	immune	JJ
cord-015922-5wwy0m2k	396	33	recovery	recovery	NN
cord-015922-5wwy0m2k	397	1	The	the	DT
cord-015922-5wwy0m2k	397	2	therapeutic	therapeutic	JJ
cord-015922-5wwy0m2k	397	3	prescription	prescription	NN
cord-015922-5wwy0m2k	397	4	for	for	IN
cord-015922-5wwy0m2k	397	5	the	the	DT
cord-015922-5wwy0m2k	397	6	organ	organ	NN
cord-015922-5wwy0m2k	397	7	transplant	transplant	NN
cord-015922-5wwy0m2k	397	8	recipient	recipient	NN
cord-015922-5wwy0m2k	397	9	:	:	:
cord-015922-5wwy0m2k	397	10	the	the	DT
cord-015922-5wwy0m2k	397	11	linkage	linkage	NN
cord-015922-5wwy0m2k	397	12	of	of	IN
cord-015922-5wwy0m2k	397	13	immunosuppression	immunosuppression	NN
cord-015922-5wwy0m2k	397	14	and	and	CC
cord-015922-5wwy0m2k	397	15	antimicrobial	antimicrobial	JJ
cord-015922-5wwy0m2k	397	16	strategies	strategy	NNS
cord-015922-5wwy0m2k	397	17	Cytomegalovirus	Cytomegalovirus	NNP
cord-015922-5wwy0m2k	397	18	in	in	IN
cord-015922-5wwy0m2k	397	19	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	397	20	stem	stem	NN
cord-015922-5wwy0m2k	397	21	cell	cell	NN
cord-015922-5wwy0m2k	397	22	transplant	transplant	NN
cord-015922-5wwy0m2k	397	23	recipients	recipient	NNS
cord-015922-5wwy0m2k	397	24	:	:	:
cord-015922-5wwy0m2k	397	25	Current	current	JJ
cord-015922-5wwy0m2k	397	26	status	status	NN
cord-015922-5wwy0m2k	397	27	,	,	,
cord-015922-5wwy0m2k	397	28	known	know	VBN
cord-015922-5wwy0m2k	397	29	challenges	challenge	NNS
cord-015922-5wwy0m2k	397	30	,	,	,
cord-015922-5wwy0m2k	397	31	and	and	CC
cord-015922-5wwy0m2k	397	32	future	future	JJ
cord-015922-5wwy0m2k	397	33	strategies	strategy	NNS
cord-015922-5wwy0m2k	397	34	Sirolimus	Sirolimus	NNP
cord-015922-5wwy0m2k	397	35	-	-	HYPH
cord-015922-5wwy0m2k	397	36	based	base	VBN
cord-015922-5wwy0m2k	397	37	graft	graft	NN
cord-015922-5wwy0m2k	397	38	-	-	HYPH
cord-015922-5wwy0m2k	397	39	versus	versus	IN
cord-015922-5wwy0m2k	397	40	-	-	HYPH
cord-015922-5wwy0m2k	397	41	host	host	NN
cord-015922-5wwy0m2k	397	42	disease	disease	NN
cord-015922-5wwy0m2k	397	43	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	397	44	protects	protect	VBZ
cord-015922-5wwy0m2k	397	45	against	against	IN
cord-015922-5wwy0m2k	397	46	cytomegalovirus	cytomegalovirus	JJ
cord-015922-5wwy0m2k	397	47	reactivation	reactivation	NN
cord-015922-5wwy0m2k	397	48	after	after	IN
cord-015922-5wwy0m2k	397	49	allogeneic	allogeneic	NN
cord-015922-5wwy0m2k	397	50	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	397	51	stem	stem	NN
cord-015922-5wwy0m2k	397	52	cell	cell	NN
cord-015922-5wwy0m2k	397	53	transplantation	transplantation	NN
cord-015922-5wwy0m2k	397	54	:	:	:
cord-015922-5wwy0m2k	397	55	a	a	DT
cord-015922-5wwy0m2k	397	56	cohort	cohort	NN
cord-015922-5wwy0m2k	397	57	analysis	analysis	NN
cord-015922-5wwy0m2k	397	58	Risk	risk	NN
cord-015922-5wwy0m2k	397	59	factors	factor	NNS
cord-015922-5wwy0m2k	397	60	for	for	IN
cord-015922-5wwy0m2k	397	61	cytomegalovirus	cytomegalovirus	JJ
cord-015922-5wwy0m2k	397	62	infection	infection	NN
cord-015922-5wwy0m2k	397	63	after	after	IN
cord-015922-5wwy0m2k	397	64	human	human	JJ
cord-015922-5wwy0m2k	397	65	marrow	marrow	NN
cord-015922-5wwy0m2k	397	66	transplantation	transplantation	NN
cord-015922-5wwy0m2k	397	67	Transfusion	Transfusion	NNP
cord-015922-5wwy0m2k	397	68	-	-	HYPH
cord-015922-5wwy0m2k	397	69	transmitted	transmit	VBN
cord-015922-5wwy0m2k	397	70	cytomegalovirus	cytomegalovirus	JJ
cord-015922-5wwy0m2k	397	71	infection	infection	NN
cord-015922-5wwy0m2k	397	72	after	after	IN
cord-015922-5wwy0m2k	397	73	receipt	receipt	NN
cord-015922-5wwy0m2k	397	74	of	of	IN
cord-015922-5wwy0m2k	397	75	leukoreduced	leukoreduced	JJ
cord-015922-5wwy0m2k	397	76	blood	blood	NN
cord-015922-5wwy0m2k	397	77	products	product	NNS
cord-015922-5wwy0m2k	397	78	Incidence	incidence	NN
cord-015922-5wwy0m2k	397	79	and	and	CC
cord-015922-5wwy0m2k	397	80	outcome	outcome	NN
cord-015922-5wwy0m2k	397	81	of	of	IN
cord-015922-5wwy0m2k	397	82	bacterial	bacterial	JJ
cord-015922-5wwy0m2k	397	83	and	and	CC
cord-015922-5wwy0m2k	397	84	fungal	fungal	JJ
cord-015922-5wwy0m2k	397	85	infections	infection	NNS
cord-015922-5wwy0m2k	397	86	following	follow	VBG
cord-015922-5wwy0m2k	397	87	nonmyeloablative	nonmyeloablative	NNP
cord-015922-5wwy0m2k	397	88	compared	compare	VBN
cord-015922-5wwy0m2k	397	89	with	with	IN
cord-015922-5wwy0m2k	397	90	myeloablative	myeloablative	JJ
cord-015922-5wwy0m2k	397	91	allogeneic	allogeneic	JJ
cord-015922-5wwy0m2k	397	92	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	397	93	stem	stem	NN
cord-015922-5wwy0m2k	397	94	cell	cell	NN
cord-015922-5wwy0m2k	397	95	transplantation	transplantation	NN
cord-015922-5wwy0m2k	397	96	:	:	:
cord-015922-5wwy0m2k	397	97	a	a	DT
cord-015922-5wwy0m2k	397	98	matched	match	VBN
cord-015922-5wwy0m2k	397	99	control	control	NN
cord-015922-5wwy0m2k	397	100	study	study	NN
cord-015922-5wwy0m2k	397	101	Pharmacokinetics	Pharmacokinetics	NNP
cord-015922-5wwy0m2k	397	102	of	of	IN
cord-015922-5wwy0m2k	397	103	ganciclovir	ganciclovir	NNP
cord-015922-5wwy0m2k	397	104	after	after	IN
cord-015922-5wwy0m2k	397	105	oral	oral	JJ
cord-015922-5wwy0m2k	397	106	valganciclovir	valganciclovir	NNP
cord-015922-5wwy0m2k	397	107	versus	versus	IN
cord-015922-5wwy0m2k	397	108	intravenous	intravenous	JJ
cord-015922-5wwy0m2k	397	109	ganciclovir	ganciclovir	NNS
cord-015922-5wwy0m2k	397	110	in	in	IN
cord-015922-5wwy0m2k	397	111	allogeneic	allogeneic	NN
cord-015922-5wwy0m2k	397	112	stem	stem	NN
cord-015922-5wwy0m2k	397	113	cell	cell	NN
cord-015922-5wwy0m2k	397	114	transplant	transplant	NN
cord-015922-5wwy0m2k	397	115	patients	patient	NNS
cord-015922-5wwy0m2k	397	116	with	with	IN
cord-015922-5wwy0m2k	397	117	graft	graft	NN
cord-015922-5wwy0m2k	397	118	-	-	HYPH
cord-015922-5wwy0m2k	397	119	versus	versus	IN
cord-015922-5wwy0m2k	397	120	-	-	HYPH
cord-015922-5wwy0m2k	397	121	host	host	NN
cord-015922-5wwy0m2k	397	122	disease	disease	NN
cord-015922-5wwy0m2k	397	123	of	of	IN
cord-015922-5wwy0m2k	397	124	the	the	DT
cord-015922-5wwy0m2k	397	125	gastrointestinal	gastrointestinal	JJ
cord-015922-5wwy0m2k	397	126	tract	tract	NN
cord-015922-5wwy0m2k	397	127	Oral	oral	JJ
cord-015922-5wwy0m2k	397	128	valganciclovir	valganciclovir	NNS
cord-015922-5wwy0m2k	397	129	leads	lead	VBZ
cord-015922-5wwy0m2k	397	130	to	to	IN
cord-015922-5wwy0m2k	397	131	higher	high	JJR
cord-015922-5wwy0m2k	397	132	exposure	exposure	NN
cord-015922-5wwy0m2k	397	133	to	to	IN
cord-015922-5wwy0m2k	397	134	ganciclovir	ganciclovir	NNS
cord-015922-5wwy0m2k	397	135	than	than	IN
cord-015922-5wwy0m2k	397	136	intravenous	intravenous	JJ
cord-015922-5wwy0m2k	397	137	ganciclovir	ganciclovir	NNS
cord-015922-5wwy0m2k	397	138	in	in	IN
cord-015922-5wwy0m2k	397	139	patients	patient	NNS
cord-015922-5wwy0m2k	397	140	following	follow	VBG
cord-015922-5wwy0m2k	397	141	allogeneic	allogeneic	IN
cord-015922-5wwy0m2k	397	142	stem	stem	NN
cord-015922-5wwy0m2k	397	143	cell	cell	NN
cord-015922-5wwy0m2k	397	144	transplantation	transplantation	NN
cord-015922-5wwy0m2k	397	145	Early	early	JJ
cord-015922-5wwy0m2k	397	146	treatment	treatment	NN
cord-015922-5wwy0m2k	397	147	with	with	IN
cord-015922-5wwy0m2k	397	148	ganciclovir	ganciclovir	NNS
cord-015922-5wwy0m2k	397	149	to	to	TO
cord-015922-5wwy0m2k	397	150	prevent	prevent	VB
cord-015922-5wwy0m2k	397	151	cytomegalovirus	cytomegalovirus	NN
cord-015922-5wwy0m2k	397	152	disease	disease	NN
cord-015922-5wwy0m2k	397	153	after	after	IN
cord-015922-5wwy0m2k	397	154	allogeneic	allogeneic	NN
cord-015922-5wwy0m2k	397	155	bone	bone	NN
cord-015922-5wwy0m2k	397	156	marrow	marrow	NN
cord-015922-5wwy0m2k	397	157	transplantation	transplantation	NN
cord-015922-5wwy0m2k	397	158	Ganciclovir	Ganciclovir	NNP
cord-015922-5wwy0m2k	397	159	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	397	160	to	to	TO
cord-015922-5wwy0m2k	397	161	prevent	prevent	VB
cord-015922-5wwy0m2k	397	162	cytomegalovirus	cytomegalovirus	NN
cord-015922-5wwy0m2k	397	163	disease	disease	NN
cord-015922-5wwy0m2k	397	164	after	after	IN
cord-015922-5wwy0m2k	397	165	allogeneic	allogeneic	NN
cord-015922-5wwy0m2k	397	166	marrow	marrow	NN
cord-015922-5wwy0m2k	397	167	transplant	transplant	NN
cord-015922-5wwy0m2k	397	168	Cytomegalovirus	Cytomegalovirus	NNP
cord-015922-5wwy0m2k	397	169	pp65	pp65	NNP
cord-015922-5wwy0m2k	397	170	antigenemia	antigenemia	NNP
cord-015922-5wwy0m2k	397	171	-	-	HYPH
cord-015922-5wwy0m2k	397	172	guided	guide	VBN
cord-015922-5wwy0m2k	397	173	early	early	JJ
cord-015922-5wwy0m2k	397	174	treatment	treatment	NN
cord-015922-5wwy0m2k	397	175	with	with	IN
cord-015922-5wwy0m2k	397	176	ganciclovir	ganciclovir	NNP
cord-015922-5wwy0m2k	397	177	versus	versus	IN
cord-015922-5wwy0m2k	397	178	ganciclovir	ganciclovir	NNP
cord-015922-5wwy0m2k	397	179	at	at	IN
cord-015922-5wwy0m2k	397	180	engraftment	engraftment	NN
cord-015922-5wwy0m2k	397	181	after	after	IN
cord-015922-5wwy0m2k	397	182	allogeneic	allogeneic	NN
cord-015922-5wwy0m2k	397	183	marrow	marrow	NN
cord-015922-5wwy0m2k	397	184	transplantation	transplantation	NN
cord-015922-5wwy0m2k	397	185	:	:	:
cord-015922-5wwy0m2k	397	186	a	a	DT
cord-015922-5wwy0m2k	397	187	randomized	randomized	JJ
cord-015922-5wwy0m2k	397	188	double	double	JJ
cord-015922-5wwy0m2k	397	189	-	-	HYPH
cord-015922-5wwy0m2k	397	190	blind	blind	JJ
cord-015922-5wwy0m2k	397	191	study	study	NN
cord-015922-5wwy0m2k	397	192	Polymerase	Polymerase	NNP
cord-015922-5wwy0m2k	397	193	chain	chain	NN
cord-015922-5wwy0m2k	397	194	reaction	reaction	NN
cord-015922-5wwy0m2k	397	195	monitoring	monitoring	NN
cord-015922-5wwy0m2k	397	196	reduces	reduce	VBZ
cord-015922-5wwy0m2k	397	197	the	the	DT
cord-015922-5wwy0m2k	397	198	incidence	incidence	NN
cord-015922-5wwy0m2k	397	199	of	of	IN
cord-015922-5wwy0m2k	397	200	cytomegalovirus	cytomegalovirus	JJ
cord-015922-5wwy0m2k	397	201	disease	disease	NN
cord-015922-5wwy0m2k	397	202	and	and	CC
cord-015922-5wwy0m2k	397	203	the	the	DT
cord-015922-5wwy0m2k	397	204	duration	duration	NN
cord-015922-5wwy0m2k	397	205	and	and	CC
cord-015922-5wwy0m2k	397	206	side	side	NN
cord-015922-5wwy0m2k	397	207	effects	effect	NNS
cord-015922-5wwy0m2k	397	208	of	of	IN
cord-015922-5wwy0m2k	397	209	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	397	210	therapy	therapy	NN
cord-015922-5wwy0m2k	397	211	after	after	IN
cord-015922-5wwy0m2k	397	212	bone	bone	NN
cord-015922-5wwy0m2k	397	213	marrow	marrow	NN
cord-015922-5wwy0m2k	397	214	transplantation	transplantation	NN
cord-015922-5wwy0m2k	397	215	Successful	successful	JJ
cord-015922-5wwy0m2k	397	216	modification	modification	NN
cord-015922-5wwy0m2k	397	217	of	of	IN
cord-015922-5wwy0m2k	397	218	a	a	DT
cord-015922-5wwy0m2k	397	219	pp65	pp65	NNP
cord-015922-5wwy0m2k	397	220	antigenemia	antigenemia	NNP
cord-015922-5wwy0m2k	397	221	-	-	HYPH
cord-015922-5wwy0m2k	397	222	based	base	VBN
cord-015922-5wwy0m2k	397	223	early	early	JJ
cord-015922-5wwy0m2k	397	224	treatment	treatment	NN
cord-015922-5wwy0m2k	397	225	strategy	strategy	NN
cord-015922-5wwy0m2k	397	226	for	for	IN
cord-015922-5wwy0m2k	397	227	prevention	prevention	NN
cord-015922-5wwy0m2k	397	228	of	of	IN
cord-015922-5wwy0m2k	397	229	cytomegalovirus	cytomegalovirus	JJ
cord-015922-5wwy0m2k	397	230	disease	disease	NN
cord-015922-5wwy0m2k	397	231	in	in	IN
cord-015922-5wwy0m2k	397	232	allogeneic	allogeneic	NN
cord-015922-5wwy0m2k	397	233	marrow	marrow	NN
cord-015922-5wwy0m2k	397	234	transplant	transplant	NN
cord-015922-5wwy0m2k	397	235	recipients	recipient	NNS
cord-015922-5wwy0m2k	397	236	Risk	risk	NN
cord-015922-5wwy0m2k	397	237	factors	factor	NNS
cord-015922-5wwy0m2k	397	238	for	for	IN
cord-015922-5wwy0m2k	397	239	treatment	treatment	NN
cord-015922-5wwy0m2k	397	240	failures	failure	NNS
cord-015922-5wwy0m2k	397	241	in	in	IN
cord-015922-5wwy0m2k	397	242	patients	patient	NNS
cord-015922-5wwy0m2k	397	243	receiving	receive	VBG
cord-015922-5wwy0m2k	397	244	PCR	PCR	NNP
cord-015922-5wwy0m2k	397	245	-	-	HYPH
cord-015922-5wwy0m2k	397	246	based	base	VBN
cord-015922-5wwy0m2k	397	247	preemptive	preemptive	JJ
cord-015922-5wwy0m2k	397	248	therapy	therapy	NN
cord-015922-5wwy0m2k	397	249	for	for	IN
cord-015922-5wwy0m2k	397	250	CMV	CMV	NNP
cord-015922-5wwy0m2k	397	251	infection	infection	NN
cord-015922-5wwy0m2k	398	1	Preemptive	preemptive	JJ
cord-015922-5wwy0m2k	398	2	therapy	therapy	NN
cord-015922-5wwy0m2k	398	3	in	in	IN
cord-015922-5wwy0m2k	398	4	immunocompromised	immunocompromised	JJ
cord-015922-5wwy0m2k	398	5	hosts	host	NNS
cord-015922-5wwy0m2k	398	6	Epstein	Epstein	NNP
cord-015922-5wwy0m2k	398	7	-	-	HYPH
cord-015922-5wwy0m2k	398	8	Barr	Barr	NNP
cord-015922-5wwy0m2k	398	9	virus	virus	NN
cord-015922-5wwy0m2k	398	10	and	and	CC
cord-015922-5wwy0m2k	398	11	lymphoproliferatic	lymphoproliferatic	JJ
cord-015922-5wwy0m2k	398	12	disorders	disorder	NNS
cord-015922-5wwy0m2k	398	13	after	after	IN
cord-015922-5wwy0m2k	398	14	transplantation	transplantation	NN
cord-015922-5wwy0m2k	399	1	CD20	CD20	NNP
cord-015922-5wwy0m2k	399	2	monoclonal	monoclonal	JJ
cord-015922-5wwy0m2k	399	3	antibody	antibody	NN
cord-015922-5wwy0m2k	399	4	(	(	-LRB-
cord-015922-5wwy0m2k	399	5	rituximab	rituximab	NN
cord-015922-5wwy0m2k	399	6	)	)	-RRB-
cord-015922-5wwy0m2k	399	7	for	for	IN
cord-015922-5wwy0m2k	399	8	therapy	therapy	NN
cord-015922-5wwy0m2k	399	9	of	of	IN
cord-015922-5wwy0m2k	399	10	Epstein	Epstein	NNP
cord-015922-5wwy0m2k	399	11	-	-	HYPH
cord-015922-5wwy0m2k	399	12	Barr	Barr	NNP
cord-015922-5wwy0m2k	399	13	virus	virus	NN
cord-015922-5wwy0m2k	399	14	lymphoma	lymphoma	NN
cord-015922-5wwy0m2k	399	15	after	after	IN
cord-015922-5wwy0m2k	399	16	hemopoietic	hemopoietic	JJ
cord-015922-5wwy0m2k	399	17	stem	stem	NN
cord-015922-5wwy0m2k	399	18	-	-	HYPH
cord-015922-5wwy0m2k	399	19	cell	cell	NN
cord-015922-5wwy0m2k	399	20	transplantation	transplantation	NN
cord-015922-5wwy0m2k	399	21	Anti	anti	NN
cord-015922-5wwy0m2k	399	22	-	-	NNP
cord-015922-5wwy0m2k	399	23	B	b	NN
cord-015922-5wwy0m2k	399	24	-	-	HYPH
cord-015922-5wwy0m2k	399	25	cell	cell	NN
cord-015922-5wwy0m2k	399	26	monoclonal	monoclonal	JJ
cord-015922-5wwy0m2k	399	27	antibodies	antibody	NNS
cord-015922-5wwy0m2k	399	28	in	in	IN
cord-015922-5wwy0m2k	399	29	the	the	DT
cord-015922-5wwy0m2k	399	30	treatment	treatment	NN
cord-015922-5wwy0m2k	399	31	of	of	IN
cord-015922-5wwy0m2k	399	32	severe	severe	JJ
cord-015922-5wwy0m2k	399	33	B	b	NN
cord-015922-5wwy0m2k	399	34	-	-	HYPH
cord-015922-5wwy0m2k	399	35	cell	cell	NN
cord-015922-5wwy0m2k	399	36	lymphoproliferative	lymphoproliferative	JJ
cord-015922-5wwy0m2k	399	37	syndrome	syndrome	NN
cord-015922-5wwy0m2k	399	38	following	follow	VBG
cord-015922-5wwy0m2k	399	39	bone	bone	NN
cord-015922-5wwy0m2k	399	40	marrow	marrow	NN
cord-015922-5wwy0m2k	399	41	and	and	CC
cord-015922-5wwy0m2k	399	42	organ	organ	NN
cord-015922-5wwy0m2k	399	43	transplantation	transplantation	NN
cord-015922-5wwy0m2k	399	44	Oral	oral	JJ
cord-015922-5wwy0m2k	399	45	acyclovir	acyclovir	NNP
cord-015922-5wwy0m2k	399	46	for	for	IN
cord-015922-5wwy0m2k	399	47	the	the	DT
cord-015922-5wwy0m2k	399	48	long	long	JJ
cord-015922-5wwy0m2k	399	49	-	-	HYPH
cord-015922-5wwy0m2k	399	50	term	term	NN
cord-015922-5wwy0m2k	399	51	suppression	suppression	NN
cord-015922-5wwy0m2k	399	52	of	of	IN
cord-015922-5wwy0m2k	399	53	varcella	varcella	NNP
cord-015922-5wwy0m2k	399	54	zoster	zoster	NNP
cord-015922-5wwy0m2k	399	55	virus	virus	NN
cord-015922-5wwy0m2k	399	56	infection	infection	NN
cord-015922-5wwy0m2k	399	57	after	after	IN
cord-015922-5wwy0m2k	399	58	marrow	marrow	NN
cord-015922-5wwy0m2k	399	59	transplantation	transplantation	NN
cord-015922-5wwy0m2k	400	1	The	the	DT
cord-015922-5wwy0m2k	400	2	effectiveness	effectiveness	NN
cord-015922-5wwy0m2k	400	3	of	of	IN
cord-015922-5wwy0m2k	400	4	the	the	DT
cord-015922-5wwy0m2k	400	5	varicella	varicella	NN
cord-015922-5wwy0m2k	400	6	vaccine	vaccine	NN
cord-015922-5wwy0m2k	400	7	in	in	IN
cord-015922-5wwy0m2k	400	8	clinical	clinical	JJ
cord-015922-5wwy0m2k	400	9	practice	practice	NN
cord-015922-5wwy0m2k	401	1	Postexposure	postexposure	NN
cord-015922-5wwy0m2k	401	2	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	401	3	of	of	IN
cord-015922-5wwy0m2k	401	4	varicella	varicella	NN
cord-015922-5wwy0m2k	401	5	in	in	IN
cord-015922-5wwy0m2k	401	6	family	family	NN
cord-015922-5wwy0m2k	401	7	contact	contact	NN
cord-015922-5wwy0m2k	401	8	by	by	IN
cord-015922-5wwy0m2k	401	9	oral	oral	JJ
cord-015922-5wwy0m2k	401	10	acyclovir	acyclovir	NNP
cord-015922-5wwy0m2k	401	11	Varicella	Varicella	NNP
cord-015922-5wwy0m2k	401	12	-	-	HYPH
cord-015922-5wwy0m2k	401	13	zoster	zoster	NN
cord-015922-5wwy0m2k	401	14	virus	virus	NN
cord-015922-5wwy0m2k	401	15	infection	infection	NN
cord-015922-5wwy0m2k	401	16	in	in	IN
cord-015922-5wwy0m2k	401	17	adult	adult	NN
cord-015922-5wwy0m2k	401	18	patients	patient	NNS
cord-015922-5wwy0m2k	401	19	after	after	IN
cord-015922-5wwy0m2k	401	20	unrelated	unrelated	JJ
cord-015922-5wwy0m2k	401	21	cord	cord	NN
cord-015922-5wwy0m2k	401	22	blood	blood	NN
cord-015922-5wwy0m2k	401	23	transplantation	transplantation	NN
cord-015922-5wwy0m2k	401	24	:	:	:
cord-015922-5wwy0m2k	401	25	a	a	DT
cord-015922-5wwy0m2k	401	26	single	single	JJ
cord-015922-5wwy0m2k	401	27	institute	institute	NN
cord-015922-5wwy0m2k	401	28	experience	experience	NN
cord-015922-5wwy0m2k	401	29	in	in	IN
cord-015922-5wwy0m2k	401	30	Japan	Japan	NNP
cord-015922-5wwy0m2k	401	31	Clinical	clinical	JJ
cord-015922-5wwy0m2k	401	32	outcomes	outcome	NNS
cord-015922-5wwy0m2k	401	33	of	of	IN
cord-015922-5wwy0m2k	401	34	human	human	JJ
cord-015922-5wwy0m2k	401	35	herpesvirus	herpesvirus	NN
cord-015922-5wwy0m2k	401	36	6	6	CD
cord-015922-5wwy0m2k	401	37	reactivation	reactivation	NN
cord-015922-5wwy0m2k	401	38	after	after	IN
cord-015922-5wwy0m2k	401	39	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	401	40	stem	stem	NN
cord-015922-5wwy0m2k	401	41	cell	cell	NN
cord-015922-5wwy0m2k	401	42	transplantation	transplantation	NN
cord-015922-5wwy0m2k	401	43	A	a	DT
cord-015922-5wwy0m2k	401	44	population	population	NN
cord-015922-5wwy0m2k	401	45	-	-	HYPH
cord-015922-5wwy0m2k	401	46	based	base	VBN
cord-015922-5wwy0m2k	401	47	study	study	NN
cord-015922-5wwy0m2k	401	48	of	of	IN
cord-015922-5wwy0m2k	401	49	primary	primary	JJ
cord-015922-5wwy0m2k	401	50	human	human	JJ
cord-015922-5wwy0m2k	401	51	herpesvirus	herpesvirus	NN
cord-015922-5wwy0m2k	401	52	6	6	CD
cord-015922-5wwy0m2k	401	53	infection	infection	NN
cord-015922-5wwy0m2k	401	54	MR	MR	NNP
cord-015922-5wwy0m2k	401	55	imaging	imaging	NN
cord-015922-5wwy0m2k	401	56	of	of	IN
cord-015922-5wwy0m2k	401	57	human	human	JJ
cord-015922-5wwy0m2k	401	58	herpesvirus-6-associated	herpesvirus-6-associate	VBN
cord-015922-5wwy0m2k	401	59	encephalitis	encephalitis	RB
cord-015922-5wwy0m2k	401	60	in	in	IN
cord-015922-5wwy0m2k	401	61	4	4	CD
cord-015922-5wwy0m2k	401	62	patients	patient	NNS
cord-015922-5wwy0m2k	401	63	with	with	IN
cord-015922-5wwy0m2k	401	64	anterograde	anterograde	JJ
cord-015922-5wwy0m2k	401	65	amnesia	amnesia	NN
cord-015922-5wwy0m2k	401	66	after	after	IN
cord-015922-5wwy0m2k	401	67	allogeneic	allogeneic	NN
cord-015922-5wwy0m2k	401	68	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	401	69	stem	stem	NN
cord-015922-5wwy0m2k	401	70	-	-	HYPH
cord-015922-5wwy0m2k	401	71	cell	cell	NN
cord-015922-5wwy0m2k	401	72	transplantation	transplantation	NN
cord-015922-5wwy0m2k	401	73	Post	post	NN
cord-015922-5wwy0m2k	401	74	-	-	JJ
cord-015922-5wwy0m2k	401	75	transplant	transplant	JJ
cord-015922-5wwy0m2k	401	76	acute	acute	JJ
cord-015922-5wwy0m2k	401	77	limbic	limbic	JJ
cord-015922-5wwy0m2k	401	78	encephalitis	encephalitis	RB
cord-015922-5wwy0m2k	401	79	:	:	:
cord-015922-5wwy0m2k	401	80	clinical	clinical	JJ
cord-015922-5wwy0m2k	401	81	features	feature	NNS
cord-015922-5wwy0m2k	401	82	and	and	CC
cord-015922-5wwy0m2k	401	83	relationship	relationship	NN
cord-015922-5wwy0m2k	401	84	to	to	IN
cord-015922-5wwy0m2k	401	85	HHV6	HHV6	NNP
cord-015922-5wwy0m2k	401	86	Human	Human	NNP
cord-015922-5wwy0m2k	401	87	herpesvirus	herpesvirus	NN
cord-015922-5wwy0m2k	401	88	6	6	CD
cord-015922-5wwy0m2k	401	89	variant	variant	NN
cord-015922-5wwy0m2k	401	90	B	b	NN
cord-015922-5wwy0m2k	401	91	infection	infection	NN
cord-015922-5wwy0m2k	401	92	in	in	IN
cord-015922-5wwy0m2k	401	93	adult	adult	NN
cord-015922-5wwy0m2k	401	94	patients	patient	NNS
cord-015922-5wwy0m2k	401	95	after	after	IN
cord-015922-5wwy0m2k	401	96	unrelated	unrelated	JJ
cord-015922-5wwy0m2k	401	97	cord	cord	NN
cord-015922-5wwy0m2k	401	98	blood	blood	NN
cord-015922-5wwy0m2k	401	99	transplantation	transplantation	NN
cord-015922-5wwy0m2k	401	100	Community	Community	NNP
cord-015922-5wwy0m2k	401	101	respiratory	respiratory	JJ
cord-015922-5wwy0m2k	401	102	virus	virus	NN
cord-015922-5wwy0m2k	401	103	infections	infection	NNS
cord-015922-5wwy0m2k	401	104	among	among	IN
cord-015922-5wwy0m2k	401	105	hospitalized	hospitalize	VBN
cord-015922-5wwy0m2k	401	106	adult	adult	NN
cord-015922-5wwy0m2k	401	107	bone	bone	NN
cord-015922-5wwy0m2k	401	108	marrow	marrow	NN
cord-015922-5wwy0m2k	401	109	transplant	transplant	NN
cord-015922-5wwy0m2k	401	110	recipients	recipient	NNS
cord-015922-5wwy0m2k	401	111	Phase	Phase	NNP
cord-015922-5wwy0m2k	401	112	1	1	CD
cord-015922-5wwy0m2k	401	113	evaluation	evaluation	NN
cord-015922-5wwy0m2k	401	114	of	of	IN
cord-015922-5wwy0m2k	401	115	the	the	DT
cord-015922-5wwy0m2k	401	116	respiratory	respiratory	JJ
cord-015922-5wwy0m2k	401	117	syncytial	syncytial	JJ
cord-015922-5wwy0m2k	401	118	virus	virus	NN
cord-015922-5wwy0m2k	401	119	-	-	HYPH
cord-015922-5wwy0m2k	401	120	specific	specific	JJ
cord-015922-5wwy0m2k	401	121	monoclonal	monoclonal	JJ
cord-015922-5wwy0m2k	401	122	antibody	antibody	NN
cord-015922-5wwy0m2k	401	123	palivizumab	palivizumab	NNS
cord-015922-5wwy0m2k	401	124	in	in	IN
cord-015922-5wwy0m2k	401	125	recipients	recipient	NNS
cord-015922-5wwy0m2k	401	126	of	of	IN
cord-015922-5wwy0m2k	401	127	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	401	128	stem	stem	NN
cord-015922-5wwy0m2k	401	129	cell	cell	NN
cord-015922-5wwy0m2k	401	130	transplants	transplant	NNS
cord-015922-5wwy0m2k	401	131	Detection	detection	NN
cord-015922-5wwy0m2k	401	132	of	of	IN
cord-015922-5wwy0m2k	401	133	rhinovirus	rhinovirus	NN
cord-015922-5wwy0m2k	401	134	RNA	RNA	NNP
cord-015922-5wwy0m2k	401	135	in	in	IN
cord-015922-5wwy0m2k	401	136	bronchoalveolar	bronchoalveolar	NNP
cord-015922-5wwy0m2k	401	137	lavage	lavage	NN
cord-015922-5wwy0m2k	401	138	in	in	IN
cord-015922-5wwy0m2k	401	139	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	401	140	stem	stem	NN
cord-015922-5wwy0m2k	401	141	cell	cell	NN
cord-015922-5wwy0m2k	401	142	transplant	transplant	NN
cord-015922-5wwy0m2k	401	143	recipients	recipient	NNS
cord-015922-5wwy0m2k	401	144	with	with	IN
cord-015922-5wwy0m2k	401	145	pneumonia	pneumonia	NN
cord-015922-5wwy0m2k	401	146	Rhinovirus	Rhinovirus	NNP
cord-015922-5wwy0m2k	401	147	infections	infection	NNS
cord-015922-5wwy0m2k	401	148	in	in	IN
cord-015922-5wwy0m2k	401	149	myelosuppressed	myelosuppressed	JJ
cord-015922-5wwy0m2k	401	150	adult	adult	NN
cord-015922-5wwy0m2k	401	151	blood	blood	NN
cord-015922-5wwy0m2k	401	152	and	and	CC
cord-015922-5wwy0m2k	401	153	marrow	marrow	NN
cord-015922-5wwy0m2k	401	154	transplant	transplant	NN
cord-015922-5wwy0m2k	401	155	recipients	recipient	NNS
cord-015922-5wwy0m2k	401	156	Community	Community	NNP
cord-015922-5wwy0m2k	401	157	respiratory	respiratory	JJ
cord-015922-5wwy0m2k	401	158	virus	virus	NN
cord-015922-5wwy0m2k	401	159	infections	infection	NNS
cord-015922-5wwy0m2k	401	160	in	in	IN
cord-015922-5wwy0m2k	401	161	transplant	transplant	NN
cord-015922-5wwy0m2k	401	162	recipients	recipient	NNS
cord-015922-5wwy0m2k	401	163	Palivizumab	Palivizumab	NNP
cord-015922-5wwy0m2k	401	164	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	401	165	to	to	TO
cord-015922-5wwy0m2k	401	166	prevent	prevent	VB
cord-015922-5wwy0m2k	401	167	respiratory	respiratory	JJ
cord-015922-5wwy0m2k	401	168	syncytial	syncytial	JJ
cord-015922-5wwy0m2k	401	169	virus	virus	NN
cord-015922-5wwy0m2k	401	170	mortality	mortality	NN
cord-015922-5wwy0m2k	401	171	after	after	IN
cord-015922-5wwy0m2k	401	172	pediatric	pediatric	JJ
cord-015922-5wwy0m2k	401	173	bone	bone	NN
cord-015922-5wwy0m2k	401	174	marrow	marrow	NN
cord-015922-5wwy0m2k	401	175	transplantation	transplantation	NN
cord-015922-5wwy0m2k	401	176	:	:	:
cord-015922-5wwy0m2k	401	177	a	a	DT
cord-015922-5wwy0m2k	401	178	decision	decision	NN
cord-015922-5wwy0m2k	401	179	analysis	analysis	NN
cord-015922-5wwy0m2k	401	180	model	model	NN
cord-015922-5wwy0m2k	401	181	Influenza	Influenza	NNP
cord-015922-5wwy0m2k	401	182	infections	infection	NNS
cord-015922-5wwy0m2k	401	183	after	after	IN
cord-015922-5wwy0m2k	401	184	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	401	185	stem	stem	NN
cord-015922-5wwy0m2k	401	186	cell	cell	NN
cord-015922-5wwy0m2k	401	187	transplantation	transplantation	NN
cord-015922-5wwy0m2k	401	188	:	:	:
cord-015922-5wwy0m2k	401	189	risk	risk	NN
cord-015922-5wwy0m2k	401	190	factors	factor	NNS
cord-015922-5wwy0m2k	401	191	,	,	,
cord-015922-5wwy0m2k	401	192	mortality	mortality	NN
cord-015922-5wwy0m2k	401	193	,	,	,
cord-015922-5wwy0m2k	401	194	and	and	CC
cord-015922-5wwy0m2k	401	195	the	the	DT
cord-015922-5wwy0m2k	401	196	effect	effect	NN
cord-015922-5wwy0m2k	401	197	of	of	IN
cord-015922-5wwy0m2k	401	198	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	401	199	therapy	therapy	NN
cord-015922-5wwy0m2k	401	200	Hemorrhagic	hemorrhagic	NN
cord-015922-5wwy0m2k	401	201	cystitis	cystitis	NN
cord-015922-5wwy0m2k	401	202	in	in	IN
cord-015922-5wwy0m2k	401	203	adults	adult	NNS
cord-015922-5wwy0m2k	401	204	after	after	IN
cord-015922-5wwy0m2k	401	205	unrelated	unrelated	JJ
cord-015922-5wwy0m2k	401	206	cord	cord	NN
cord-015922-5wwy0m2k	401	207	blood	blood	NN
cord-015922-5wwy0m2k	401	208	transplantation	transplantation	NN
cord-015922-5wwy0m2k	401	209	:	:	:
cord-015922-5wwy0m2k	401	210	a	a	DT
cord-015922-5wwy0m2k	401	211	single	single	JJ
cord-015922-5wwy0m2k	401	212	-	-	HYPH
cord-015922-5wwy0m2k	401	213	institution	institution	NN
cord-015922-5wwy0m2k	401	214	experience	experience	NN
cord-015922-5wwy0m2k	401	215	in	in	IN
cord-015922-5wwy0m2k	401	216	Japan	Japan	NNP
cord-015922-5wwy0m2k	401	217	Assessment	Assessment	NNP
cord-015922-5wwy0m2k	401	218	of	of	IN
cord-015922-5wwy0m2k	401	219	disseminated	disseminate	VBN
cord-015922-5wwy0m2k	401	220	adenovirus	adenovirus	NN
cord-015922-5wwy0m2k	401	221	infections	infection	NNS
cord-015922-5wwy0m2k	401	222	using	use	VBG
cord-015922-5wwy0m2k	401	223	quantitative	quantitative	JJ
cord-015922-5wwy0m2k	401	224	plasma	plasma	NN
cord-015922-5wwy0m2k	401	225	PCR	PCR	NNP
cord-015922-5wwy0m2k	401	226	in	in	IN
cord-015922-5wwy0m2k	401	227	adult	adult	NN
cord-015922-5wwy0m2k	401	228	allogeneic	allogeneic	NN
cord-015922-5wwy0m2k	401	229	stem	stem	NN
cord-015922-5wwy0m2k	401	230	cell	cell	NN
cord-015922-5wwy0m2k	401	231	transplant	transplant	NN
cord-015922-5wwy0m2k	401	232	recipients	recipient	NNS
cord-015922-5wwy0m2k	401	233	receiving	receive	VBG
cord-015922-5wwy0m2k	401	234	reduced	reduce	VBN
cord-015922-5wwy0m2k	401	235	intensity	intensity	NN
cord-015922-5wwy0m2k	401	236	or	or	CC
cord-015922-5wwy0m2k	401	237	myeloablative	myeloablative	JJ
cord-015922-5wwy0m2k	401	238	conditioning	conditioning	NN
cord-015922-5wwy0m2k	401	239	Cidofovir	Cidofovir	NNP
cord-015922-5wwy0m2k	401	240	for	for	IN
cord-015922-5wwy0m2k	401	241	adenovirus	adenovirus	NN
cord-015922-5wwy0m2k	401	242	infections	infection	NNS
cord-015922-5wwy0m2k	401	243	after	after	IN
cord-015922-5wwy0m2k	401	244	allogeneic	allogeneic	JJ
cord-015922-5wwy0m2k	401	245	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	401	246	stem	stem	NN
cord-015922-5wwy0m2k	401	247	cell	cell	NN
cord-015922-5wwy0m2k	401	248	transplantation	transplantation	NN
cord-015922-5wwy0m2k	401	249	:	:	:
cord-015922-5wwy0m2k	401	250	a	a	DT
cord-015922-5wwy0m2k	401	251	survey	survey	NN
cord-015922-5wwy0m2k	401	252	by	by	IN
cord-015922-5wwy0m2k	401	253	the	the	DT
cord-015922-5wwy0m2k	401	254	Infectious	Infectious	NNP
cord-015922-5wwy0m2k	401	255	Diseases	Diseases	NNPS
cord-015922-5wwy0m2k	401	256	Working	Working	NNP
cord-015922-5wwy0m2k	401	257	Party	Party	NNP
cord-015922-5wwy0m2k	401	258	of	of	IN
cord-015922-5wwy0m2k	401	259	the	the	DT
cord-015922-5wwy0m2k	401	260	European	European	NNP
cord-015922-5wwy0m2k	401	261	Group	Group	NNP
cord-015922-5wwy0m2k	401	262	for	for	IN
cord-015922-5wwy0m2k	401	263	Blood	Blood	NNP
cord-015922-5wwy0m2k	401	264	and	and	CC
cord-015922-5wwy0m2k	401	265	Marrow	Marrow	NNP
cord-015922-5wwy0m2k	401	266	Transplantation	Transplantation	NNP
cord-015922-5wwy0m2k	401	267	Parainfluenza	Parainfluenza	NNP
cord-015922-5wwy0m2k	401	268	virus	virus	NN
cord-015922-5wwy0m2k	401	269	infections	infection	NNS
cord-015922-5wwy0m2k	401	270	after	after	IN
cord-015922-5wwy0m2k	401	271	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	401	272	stem	stem	NN
cord-015922-5wwy0m2k	401	273	cell	cell	NN
cord-015922-5wwy0m2k	401	274	transplantation	transplantation	NN
cord-015922-5wwy0m2k	401	275	:	:	:
cord-015922-5wwy0m2k	401	276	risk	risk	NN
cord-015922-5wwy0m2k	401	277	factors	factor	NNS
cord-015922-5wwy0m2k	401	278	,	,	,
cord-015922-5wwy0m2k	401	279	response	response	NN
cord-015922-5wwy0m2k	401	280	to	to	IN
cord-015922-5wwy0m2k	401	281	antiviral	antiviral	JJ
cord-015922-5wwy0m2k	401	282	therapy	therapy	NN
cord-015922-5wwy0m2k	401	283	,	,	,
cord-015922-5wwy0m2k	401	284	and	and	CC
cord-015922-5wwy0m2k	401	285	effect	effect	NN
cord-015922-5wwy0m2k	401	286	on	on	IN
cord-015922-5wwy0m2k	401	287	transplant	transplant	NN
cord-015922-5wwy0m2k	401	288	outcome	outcome	NN
cord-015922-5wwy0m2k	401	289	Respiratory	respiratory	JJ
cord-015922-5wwy0m2k	401	290	disease	disease	NN
cord-015922-5wwy0m2k	401	291	due	due	JJ
cord-015922-5wwy0m2k	401	292	to	to	IN
cord-015922-5wwy0m2k	401	293	parainfluenza	parainfluenza	NNP
cord-015922-5wwy0m2k	401	294	virus	virus	NN
cord-015922-5wwy0m2k	401	295	in	in	IN
cord-015922-5wwy0m2k	401	296	adult	adult	NN
cord-015922-5wwy0m2k	401	297	bone	bone	NN
cord-015922-5wwy0m2k	401	298	marrow	marrow	NN
cord-015922-5wwy0m2k	401	299	transplant	transplant	NN
cord-015922-5wwy0m2k	401	300	recipients	recipient	NNS
cord-015922-5wwy0m2k	402	1	Ciprofloxacin	Ciprofloxacin	NNP
cord-015922-5wwy0m2k	402	2	decreased	decrease	VBD
cord-015922-5wwy0m2k	402	3	polyoma	polyoma	NNP
cord-015922-5wwy0m2k	402	4	BK	BK	NNP
cord-015922-5wwy0m2k	402	5	virus	virus	NN
cord-015922-5wwy0m2k	402	6	load	load	NN
cord-015922-5wwy0m2k	402	7	in	in	IN
cord-015922-5wwy0m2k	402	8	patients	patient	NNS
cord-015922-5wwy0m2k	402	9	who	who	WP
cord-015922-5wwy0m2k	402	10	underwent	undergo	VBD
cord-015922-5wwy0m2k	402	11	allogeneic	allogeneic	JJ
cord-015922-5wwy0m2k	402	12	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	402	13	stem	stem	NN
cord-015922-5wwy0m2k	402	14	cell	cell	NN
cord-015922-5wwy0m2k	402	15	transplantation	transplantation	NN
cord-015922-5wwy0m2k	402	16	Influence	influence	NN
cord-015922-5wwy0m2k	402	17	of	of	IN
cord-015922-5wwy0m2k	402	18	human	human	JJ
cord-015922-5wwy0m2k	402	19	immunodeficiency	immunodeficiency	NN
cord-015922-5wwy0m2k	402	20	virus	virus	NN
cord-015922-5wwy0m2k	402	21	infection	infection	NN
cord-015922-5wwy0m2k	402	22	on	on	IN
cord-015922-5wwy0m2k	402	23	the	the	DT
cord-015922-5wwy0m2k	402	24	course	course	NN
cord-015922-5wwy0m2k	402	25	of	of	IN
cord-015922-5wwy0m2k	402	26	hepatitis	hepatitis	NN
cord-015922-5wwy0m2k	402	27	C	C	NNP
cord-015922-5wwy0m2k	402	28	virus	virus	NN
cord-015922-5wwy0m2k	402	29	infection	infection	NN
cord-015922-5wwy0m2k	402	30	:	:	:
cord-015922-5wwy0m2k	402	31	a	a	DT
cord-015922-5wwy0m2k	402	32	meta	meta	JJ
cord-015922-5wwy0m2k	402	33	-	-	HYPH
cord-015922-5wwy0m2k	402	34	analysis	analysis	NN
cord-015922-5wwy0m2k	402	35	A	a	DT
cord-015922-5wwy0m2k	402	36	long	long	JJ
cord-015922-5wwy0m2k	402	37	-	-	HYPH
cord-015922-5wwy0m2k	402	38	term	term	NN
cord-015922-5wwy0m2k	402	39	follow	follow	NN
cord-015922-5wwy0m2k	402	40	-	-	HYPH
cord-015922-5wwy0m2k	402	41	up	up	NN
cord-015922-5wwy0m2k	402	42	study	study	NN
cord-015922-5wwy0m2k	402	43	on	on	IN
cord-015922-5wwy0m2k	402	44	hepatitis	hepatitis	NNP
cord-015922-5wwy0m2k	402	45	B	B	NNP
cord-015922-5wwy0m2k	402	46	surface	surface	NN
cord-015922-5wwy0m2k	402	47	antigen	antigen	NN
cord-015922-5wwy0m2k	402	48	-	-	HYPH
cord-015922-5wwy0m2k	402	49	positive	positive	JJ
cord-015922-5wwy0m2k	402	50	patients	patient	NNS
cord-015922-5wwy0m2k	402	51	undergoing	undergo	VBG
cord-015922-5wwy0m2k	402	52	allogeneic	allogeneic	IN
cord-015922-5wwy0m2k	402	53	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	402	54	stem	stem	NN
cord-015922-5wwy0m2k	402	55	cell	cell	NN
cord-015922-5wwy0m2k	402	56	transplantation	transplantation	NN
cord-015922-5wwy0m2k	402	57	Effectiveness	Effectiveness	NNP
cord-015922-5wwy0m2k	402	58	of	of	IN
cord-015922-5wwy0m2k	402	59	prophylactic	prophylactic	JJ
cord-015922-5wwy0m2k	402	60	Anti	Anti	NNP
cord-015922-5wwy0m2k	402	61	-	-	JJ
cord-015922-5wwy0m2k	402	62	HBV	HBV	NNP
cord-015922-5wwy0m2k	402	63	therapy	therapy	NN
cord-015922-5wwy0m2k	402	64	in	in	IN
cord-015922-5wwy0m2k	402	65	allogeneic	allogeneic	JJ
cord-015922-5wwy0m2k	402	66	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	402	67	stem	stem	NN
cord-015922-5wwy0m2k	402	68	cell	cell	NN
cord-015922-5wwy0m2k	402	69	transplantation	transplantation	NN
cord-015922-5wwy0m2k	402	70	with	with	IN
cord-015922-5wwy0m2k	402	71	HBsAg	hbsag	ADD
cord-015922-5wwy0m2k	402	72	positive	positive	JJ
cord-015922-5wwy0m2k	402	73	donors	donor	NNS
cord-015922-5wwy0m2k	402	74	Peginterferon	Peginterferon	NNP
cord-015922-5wwy0m2k	402	75	Alfa-2a	Alfa-2a	NNP
cord-015922-5wwy0m2k	402	76	,	,	,
cord-015922-5wwy0m2k	402	77	lamivudine	lamivudine	JJ
cord-015922-5wwy0m2k	402	78	,	,	,
cord-015922-5wwy0m2k	402	79	and	and	CC
cord-015922-5wwy0m2k	402	80	the	the	DT
cord-015922-5wwy0m2k	402	81	combination	combination	NN
cord-015922-5wwy0m2k	402	82	for	for	IN
cord-015922-5wwy0m2k	402	83	HBeAg	hbeag	CD
cord-015922-5wwy0m2k	402	84	-	-	HYPH
cord-015922-5wwy0m2k	402	85	positive	positive	JJ
cord-015922-5wwy0m2k	402	86	chronic	chronic	NN
cord-015922-5wwy0m2k	402	87	hepatitis	hepatitis	NN
cord-015922-5wwy0m2k	402	88	B	B	NNP
cord-015922-5wwy0m2k	402	89	Entecavir	Entecavir	NNP
cord-015922-5wwy0m2k	402	90	versus	versus	IN
cord-015922-5wwy0m2k	402	91	lamivudine	lamivudine	NN
cord-015922-5wwy0m2k	402	92	for	for	IN
cord-015922-5wwy0m2k	402	93	patients	patient	NNS
cord-015922-5wwy0m2k	402	94	with	with	IN
cord-015922-5wwy0m2k	402	95	HBeAg	hbeag	CD
cord-015922-5wwy0m2k	402	96	-	-	HYPH
cord-015922-5wwy0m2k	402	97	negative	negative	JJ
cord-015922-5wwy0m2k	402	98	chronic	chronic	JJ
cord-015922-5wwy0m2k	402	99	hepatitis	hepatitis	NN
cord-015922-5wwy0m2k	402	100	B	B	NNP
cord-015922-5wwy0m2k	402	101	A	a	DT
cord-015922-5wwy0m2k	402	102	comparison	comparison	NN
cord-015922-5wwy0m2k	402	103	of	of	IN
cord-015922-5wwy0m2k	402	104	entecavir	entecavir	NNP
cord-015922-5wwy0m2k	402	105	and	and	CC
cord-015922-5wwy0m2k	402	106	lamivudine	lamivudine	NNP
cord-015922-5wwy0m2k	402	107	for	for	IN
cord-015922-5wwy0m2k	402	108	HBeAg	hbeag	CD
cord-015922-5wwy0m2k	402	109	-	-	HYPH
cord-015922-5wwy0m2k	402	110	positive	positive	JJ
cord-015922-5wwy0m2k	402	111	chronic	chronic	NN
cord-015922-5wwy0m2k	402	112	hepatitis	hepatitis	NN
cord-015922-5wwy0m2k	402	113	B	B	NNP
cord-015922-5wwy0m2k	402	114	Long	long	JJ
cord-015922-5wwy0m2k	402	115	-	-	HYPH
cord-015922-5wwy0m2k	402	116	term	term	NN
cord-015922-5wwy0m2k	402	117	therapy	therapy	NN
cord-015922-5wwy0m2k	402	118	with	with	IN
cord-015922-5wwy0m2k	402	119	adefovir	adefovir	NNP
cord-015922-5wwy0m2k	403	1	dipivoxil	dipivoxil	NNP
cord-015922-5wwy0m2k	403	2	for	for	IN
cord-015922-5wwy0m2k	403	3	HBeAg	hbeag	CD
cord-015922-5wwy0m2k	403	4	-	-	HYPH
cord-015922-5wwy0m2k	403	5	negative	negative	JJ
cord-015922-5wwy0m2k	403	6	chronic	chronic	JJ
cord-015922-5wwy0m2k	403	7	hepatitis	hepatitis	NN
cord-015922-5wwy0m2k	403	8	B	B	NNP
cord-015922-5wwy0m2k	403	9	Long	long	JJ
cord-015922-5wwy0m2k	403	10	-	-	HYPH
cord-015922-5wwy0m2k	403	11	term	term	NN
cord-015922-5wwy0m2k	403	12	outcome	outcome	NN
cord-015922-5wwy0m2k	403	13	of	of	IN
cord-015922-5wwy0m2k	403	14	hepatitis	hepatitis	NN
cord-015922-5wwy0m2k	403	15	C	C	NNP
cord-015922-5wwy0m2k	403	16	infection	infection	NN
cord-015922-5wwy0m2k	403	17	after	after	IN
cord-015922-5wwy0m2k	403	18	bone	bone	NN
cord-015922-5wwy0m2k	403	19	marrow	marrow	NN
cord-015922-5wwy0m2k	403	20	transplantation	transplantation	NN
cord-015922-5wwy0m2k	404	1	Hepatitis	hepatitis	NN
cord-015922-5wwy0m2k	404	2	reactivation	reactivation	NN
cord-015922-5wwy0m2k	404	3	and	and	CC
cord-015922-5wwy0m2k	404	4	liver	liver	NN
cord-015922-5wwy0m2k	404	5	failure	failure	NN
cord-015922-5wwy0m2k	404	6	in	in	IN
cord-015922-5wwy0m2k	404	7	haemopoietic	haemopoietic	JJ
cord-015922-5wwy0m2k	404	8	stem	stem	NN
cord-015922-5wwy0m2k	404	9	cell	cell	NN
cord-015922-5wwy0m2k	404	10	transplants	transplant	NNS
cord-015922-5wwy0m2k	404	11	for	for	IN
cord-015922-5wwy0m2k	404	12	hepatitis	hepatitis	NN
cord-015922-5wwy0m2k	404	13	B	B	NNP
cord-015922-5wwy0m2k	404	14	virus	virus	NN
cord-015922-5wwy0m2k	404	15	(	(	-LRB-
cord-015922-5wwy0m2k	404	16	HBV)/hepatitis	HBV)/hepatitis	NNP
cord-015922-5wwy0m2k	404	17	C	C	NNP
cord-015922-5wwy0m2k	404	18	virus	virus	NN
cord-015922-5wwy0m2k	404	19	(	(	-LRB-
cord-015922-5wwy0m2k	404	20	HCV	HCV	NNP
cord-015922-5wwy0m2k	404	21	)	)	-RRB-
cord-015922-5wwy0m2k	404	22	positive	positive	JJ
cord-015922-5wwy0m2k	404	23	recipients	recipient	NNS
cord-015922-5wwy0m2k	404	24	:	:	:
cord-015922-5wwy0m2k	405	1	a	a	DT
cord-015922-5wwy0m2k	405	2	retrospective	retrospective	JJ
cord-015922-5wwy0m2k	405	3	study	study	NN
cord-015922-5wwy0m2k	405	4	by	by	IN
cord-015922-5wwy0m2k	405	5	the	the	DT
cord-015922-5wwy0m2k	405	6	Italian	italian	JJ
cord-015922-5wwy0m2k	405	7	group	group	NN
cord-015922-5wwy0m2k	405	8	for	for	IN
cord-015922-5wwy0m2k	405	9	blood	blood	NN
cord-015922-5wwy0m2k	405	10	and	and	CC
cord-015922-5wwy0m2k	405	11	marrow	marrow	NN
cord-015922-5wwy0m2k	405	12	transplantation	transplantation	NN
cord-015922-5wwy0m2k	405	13	Hepatitis	Hepatitis	NNP
cord-015922-5wwy0m2k	405	14	C	C	NNP
cord-015922-5wwy0m2k	405	15	virus	virus	NN
cord-015922-5wwy0m2k	405	16	infection	infection	NN
cord-015922-5wwy0m2k	405	17	is	be	VBZ
cord-015922-5wwy0m2k	405	18	a	a	DT
cord-015922-5wwy0m2k	405	19	risk	risk	NN
cord-015922-5wwy0m2k	405	20	factor	factor	NN
cord-015922-5wwy0m2k	405	21	for	for	IN
cord-015922-5wwy0m2k	405	22	liver	liver	NN
cord-015922-5wwy0m2k	405	23	failure	failure	NN
cord-015922-5wwy0m2k	405	24	from	from	IN
cord-015922-5wwy0m2k	405	25	veno	veno	NNP
cord-015922-5wwy0m2k	405	26	-	-	HYPH
cord-015922-5wwy0m2k	405	27	occlusive	occlusive	JJ
cord-015922-5wwy0m2k	405	28	disease	disease	NN
cord-015922-5wwy0m2k	405	29	after	after	IN
cord-015922-5wwy0m2k	405	30	bone	bone	NN
cord-015922-5wwy0m2k	405	31	marrow	marrow	NN
cord-015922-5wwy0m2k	405	32	transplantation	transplantation	NN
cord-015922-5wwy0m2k	405	33	Guidelines	guideline	NNS
cord-015922-5wwy0m2k	405	34	for	for	IN
cord-015922-5wwy0m2k	405	35	treatment	treatment	NN
cord-015922-5wwy0m2k	405	36	of	of	IN
cord-015922-5wwy0m2k	405	37	candidiasis	candidiasis	NN
cord-015922-5wwy0m2k	406	1	Should	Should	MD
cord-015922-5wwy0m2k	406	2	vascular	vascular	JJ
cord-015922-5wwy0m2k	406	3	catheters	catheter	NNS
cord-015922-5wwy0m2k	406	4	be	be	VB
cord-015922-5wwy0m2k	406	5	removed	remove	VBN
cord-015922-5wwy0m2k	406	6	from	from	IN
cord-015922-5wwy0m2k	406	7	all	all	DT
cord-015922-5wwy0m2k	406	8	patients	patient	NNS
cord-015922-5wwy0m2k	406	9	with	with	IN
cord-015922-5wwy0m2k	406	10	candidemia	candidemia	NN
cord-015922-5wwy0m2k	406	11	?	?	.
cord-015922-5wwy0m2k	407	1	An	an	DT
cord-015922-5wwy0m2k	407	2	evidence	evidence	NN
cord-015922-5wwy0m2k	407	3	-	-	HYPH
cord-015922-5wwy0m2k	407	4	based	base	VBN
cord-015922-5wwy0m2k	407	5	review	review	NN
cord-015922-5wwy0m2k	407	6	Efficacy	Efficacy	NNP
cord-015922-5wwy0m2k	407	7	and	and	CC
cord-015922-5wwy0m2k	407	8	safety	safety	NN
cord-015922-5wwy0m2k	407	9	of	of	IN
cord-015922-5wwy0m2k	407	10	fluconazole	fluconazole	NN
cord-015922-5wwy0m2k	407	11	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	407	12	for	for	IN
cord-015922-5wwy0m2k	407	13	fungal	fungal	JJ
cord-015922-5wwy0m2k	407	14	infections	infection	NNS
cord-015922-5wwy0m2k	407	15	after	after	IN
cord-015922-5wwy0m2k	407	16	marrow	marrow	NN
cord-015922-5wwy0m2k	407	17	transplantation	transplantation	NN
cord-015922-5wwy0m2k	407	18	-	-	:
cord-015922-5wwy0m2k	407	19	a	a	DT
cord-015922-5wwy0m2k	407	20	prospective	prospective	NN
cord-015922-5wwy0m2k	407	21	,	,	,
cord-015922-5wwy0m2k	407	22	randomized	randomized	JJ
cord-015922-5wwy0m2k	407	23	,	,	,
cord-015922-5wwy0m2k	407	24	double	double	JJ
cord-015922-5wwy0m2k	407	25	-	-	HYPH
cord-015922-5wwy0m2k	407	26	blind	blind	JJ
cord-015922-5wwy0m2k	407	27	study	study	NN
cord-015922-5wwy0m2k	408	1	A	a	DT
cord-015922-5wwy0m2k	408	2	controlled	control	VBN
cord-015922-5wwy0m2k	408	3	trial	trial	NN
cord-015922-5wwy0m2k	408	4	of	of	IN
cord-015922-5wwy0m2k	408	5	fluconazole	fluconazole	NN
cord-015922-5wwy0m2k	408	6	to	to	TO
cord-015922-5wwy0m2k	408	7	prevent	prevent	VB
cord-015922-5wwy0m2k	408	8	fungal	fungal	JJ
cord-015922-5wwy0m2k	408	9	infections	infection	NNS
cord-015922-5wwy0m2k	408	10	in	in	IN
cord-015922-5wwy0m2k	408	11	patients	patient	NNS
cord-015922-5wwy0m2k	408	12	undergoing	undergo	VBG
cord-015922-5wwy0m2k	408	13	bone	bone	NN
cord-015922-5wwy0m2k	408	14	marrow	marrow	NN
cord-015922-5wwy0m2k	408	15	transplantation	transplantation	NN
cord-015922-5wwy0m2k	408	16	Infections	infection	NNS
cord-015922-5wwy0m2k	408	17	in	in	IN
cord-015922-5wwy0m2k	408	18	the	the	DT
cord-015922-5wwy0m2k	408	19	neutropenic	neutropenic	JJ
cord-015922-5wwy0m2k	408	20	patient	patient	JJ
cord-015922-5wwy0m2k	408	21	-	-	HYPH
cord-015922-5wwy0m2k	408	22	new	new	JJ
cord-015922-5wwy0m2k	408	23	views	view	NNS
cord-015922-5wwy0m2k	408	24	of	of	IN
cord-015922-5wwy0m2k	408	25	an	an	DT
cord-015922-5wwy0m2k	408	26	old	old	JJ
cord-015922-5wwy0m2k	408	27	problem	problem	NN
cord-015922-5wwy0m2k	408	28	.	.	.
cord-015922-5wwy0m2k	409	1	Hematology	Hematology	NNP
cord-015922-5wwy0m2k	409	2	/	/	,
cord-015922-5wwy0m2k	409	3	the	the	DT
cord-015922-5wwy0m2k	409	4	Education	Education	NNP
cord-015922-5wwy0m2k	409	5	Program	Program	NNP
cord-015922-5wwy0m2k	409	6	of	of	IN
cord-015922-5wwy0m2k	409	7	the	the	DT
cord-015922-5wwy0m2k	409	8	Fungal	fungal	JJ
cord-015922-5wwy0m2k	409	9	infections	infection	NNS
cord-015922-5wwy0m2k	409	10	in	in	IN
cord-015922-5wwy0m2k	409	11	granulocytopenic	granulocytopenic	NN
cord-015922-5wwy0m2k	409	12	patients	patient	NNS
cord-015922-5wwy0m2k	409	13	:	:	:
cord-015922-5wwy0m2k	409	14	current	current	JJ
cord-015922-5wwy0m2k	409	15	approaches	approach	NNS
cord-015922-5wwy0m2k	409	16	to	to	IN
cord-015922-5wwy0m2k	409	17	classifications	classification	NNS
cord-015922-5wwy0m2k	409	18	,	,	,
cord-015922-5wwy0m2k	409	19	diagnosis	diagnosis	NN
cord-015922-5wwy0m2k	409	20	Candidemia	Candidemia	NNP
cord-015922-5wwy0m2k	409	21	in	in	IN
cord-015922-5wwy0m2k	409	22	immunocompromised	immunocompromised	JJ
cord-015922-5wwy0m2k	409	23	patients	patient	NNS
cord-015922-5wwy0m2k	410	1	Infections	infection	NNS
cord-015922-5wwy0m2k	410	2	due	due	JJ
cord-015922-5wwy0m2k	410	3	to	to	IN
cord-015922-5wwy0m2k	410	4	resistant	resistant	JJ
cord-015922-5wwy0m2k	410	5	Candida	Candida	NNP
cord-015922-5wwy0m2k	410	6	species	specie	NNS
cord-015922-5wwy0m2k	410	7	in	in	IN
cord-015922-5wwy0m2k	410	8	patients	patient	NNS
cord-015922-5wwy0m2k	410	9	with	with	IN
cord-015922-5wwy0m2k	410	10	cancer	cancer	NN
cord-015922-5wwy0m2k	410	11	who	who	WP
cord-015922-5wwy0m2k	410	12	are	be	VBP
cord-015922-5wwy0m2k	410	13	receiving	receive	VBG
cord-015922-5wwy0m2k	410	14	chemotherapy	chemotherapy	NN
cord-015922-5wwy0m2k	410	15	Prospective	prospective	JJ
cord-015922-5wwy0m2k	410	16	study	study	NN
cord-015922-5wwy0m2k	410	17	of	of	IN
cord-015922-5wwy0m2k	410	18	Candida	Candida	NNP
cord-015922-5wwy0m2k	410	19	endophthalmitis	endophthalmitis	NN
cord-015922-5wwy0m2k	410	20	in	in	IN
cord-015922-5wwy0m2k	410	21	hospitalized	hospitalize	VBN
cord-015922-5wwy0m2k	410	22	patients	patient	NNS
cord-015922-5wwy0m2k	410	23	with	with	IN
cord-015922-5wwy0m2k	410	24	candidemia	candidemia	NNP
cord-015922-5wwy0m2k	410	25	Risk	Risk	NNP
cord-015922-5wwy0m2k	410	26	factors	factor	NNS
cord-015922-5wwy0m2k	410	27	for	for	IN
cord-015922-5wwy0m2k	410	28	hepatosplenic	hepatosplenic	JJ
cord-015922-5wwy0m2k	410	29	abscesses	abscess	NNS
cord-015922-5wwy0m2k	410	30	in	in	IN
cord-015922-5wwy0m2k	410	31	patients	patient	NNS
cord-015922-5wwy0m2k	410	32	with	with	IN
cord-015922-5wwy0m2k	410	33	acute	acute	JJ
cord-015922-5wwy0m2k	410	34	leukemia	leukemia	NN
cord-015922-5wwy0m2k	410	35	receiving	receive	VBG
cord-015922-5wwy0m2k	410	36	empiric	empiric	JJ
cord-015922-5wwy0m2k	410	37	azole	azole	NNP
cord-015922-5wwy0m2k	410	38	treatment	treatment	NN
cord-015922-5wwy0m2k	410	39	Practice	Practice	NNP
cord-015922-5wwy0m2k	410	40	guidelines	guideline	NNS
cord-015922-5wwy0m2k	410	41	for	for	IN
cord-015922-5wwy0m2k	410	42	the	the	DT
cord-015922-5wwy0m2k	410	43	treatment	treatment	NN
cord-015922-5wwy0m2k	410	44	of	of	IN
cord-015922-5wwy0m2k	410	45	candidiasis	candidiasi	NNS
cord-015922-5wwy0m2k	410	46	.	.	.
cord-015922-5wwy0m2k	411	1	Infectious	Infectious	NNP
cord-015922-5wwy0m2k	411	2	Diseases	Diseases	NNPS
cord-015922-5wwy0m2k	411	3	Society	Society	NNP
cord-015922-5wwy0m2k	411	4	of	of	IN
cord-015922-5wwy0m2k	411	5	America	America	NNP
cord-015922-5wwy0m2k	411	6	Disseminated	disseminate	VBN
cord-015922-5wwy0m2k	411	7	trichosporonosis	trichosporonosis	NN
cord-015922-5wwy0m2k	411	8	caused	cause	VBN
cord-015922-5wwy0m2k	411	9	by	by	IN
cord-015922-5wwy0m2k	411	10	Trichosporon	Trichosporon	NNP
cord-015922-5wwy0m2k	411	11	loubieri	loubieri	NN
cord-015922-5wwy0m2k	411	12	Micafungin	Micafungin	NNP
cord-015922-5wwy0m2k	411	13	versus	versus	IN
cord-015922-5wwy0m2k	411	14	fluconazole	fluconazole	NN
cord-015922-5wwy0m2k	411	15	for	for	IN
cord-015922-5wwy0m2k	411	16	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	411	17	against	against	IN
cord-015922-5wwy0m2k	411	18	invasive	invasive	JJ
cord-015922-5wwy0m2k	411	19	fungal	fungal	JJ
cord-015922-5wwy0m2k	411	20	infections	infection	NNS
cord-015922-5wwy0m2k	411	21	during	during	IN
cord-015922-5wwy0m2k	411	22	neutropenia	neutropenia	NN
cord-015922-5wwy0m2k	411	23	in	in	IN
cord-015922-5wwy0m2k	411	24	patients	patient	NNS
cord-015922-5wwy0m2k	411	25	undergoing	undergo	VBG
cord-015922-5wwy0m2k	411	26	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	411	27	stem	stem	NN
cord-015922-5wwy0m2k	411	28	cell	cell	NN
cord-015922-5wwy0m2k	411	29	transplantation	transplantation	NN
cord-015922-5wwy0m2k	411	30	Caspofungin	Caspofungin	NNP
cord-015922-5wwy0m2k	411	31	versus	versus	IN
cord-015922-5wwy0m2k	411	32	liposomal	liposomal	JJ
cord-015922-5wwy0m2k	411	33	amphotericin	amphotericin	NNS
cord-015922-5wwy0m2k	411	34	B	B	NNP
cord-015922-5wwy0m2k	411	35	for	for	IN
cord-015922-5wwy0m2k	411	36	empirical	empirical	JJ
cord-015922-5wwy0m2k	411	37	antifungal	antifungal	JJ
cord-015922-5wwy0m2k	411	38	therapy	therapy	NN
cord-015922-5wwy0m2k	411	39	in	in	IN
cord-015922-5wwy0m2k	411	40	patients	patient	NNS
cord-015922-5wwy0m2k	411	41	with	with	IN
cord-015922-5wwy0m2k	411	42	persistent	persistent	JJ
cord-015922-5wwy0m2k	411	43	fever	fever	NN
cord-015922-5wwy0m2k	411	44	and	and	CC
cord-015922-5wwy0m2k	411	45	neutropenia	neutropenia	NN
cord-015922-5wwy0m2k	411	46	Breakthrough	Breakthrough	NNP
cord-015922-5wwy0m2k	411	47	trichosporonosis	trichosporonosis	NN
cord-015922-5wwy0m2k	411	48	in	in	IN
cord-015922-5wwy0m2k	411	49	patients	patient	NNS
cord-015922-5wwy0m2k	411	50	with	with	IN
cord-015922-5wwy0m2k	411	51	hematologic	hematologic	JJ
cord-015922-5wwy0m2k	411	52	malignancies	malignancy	NNS
cord-015922-5wwy0m2k	411	53	receiving	receive	VBG
cord-015922-5wwy0m2k	411	54	micafungin	micafungin	NNP
cord-015922-5wwy0m2k	411	55	Epidemiology	Epidemiology	NNP
cord-015922-5wwy0m2k	411	56	of	of	IN
cord-015922-5wwy0m2k	411	57	Aspergillus	Aspergillus	NNP
cord-015922-5wwy0m2k	411	58	infections	infection	NNS
cord-015922-5wwy0m2k	411	59	in	in	IN
cord-015922-5wwy0m2k	411	60	a	a	DT
cord-015922-5wwy0m2k	411	61	large	large	JJ
cord-015922-5wwy0m2k	411	62	cohort	cohort	NN
cord-015922-5wwy0m2k	411	63	of	of	IN
cord-015922-5wwy0m2k	411	64	patients	patient	NNS
cord-015922-5wwy0m2k	411	65	undergoing	undergo	VBG
cord-015922-5wwy0m2k	411	66	bone	bone	NN
cord-015922-5wwy0m2k	411	67	marrow	marrow	NN
cord-015922-5wwy0m2k	411	68	transplantation	transplantation	NN
cord-015922-5wwy0m2k	411	69	Candidemia	Candidemia	NNP
cord-015922-5wwy0m2k	411	70	in	in	IN
cord-015922-5wwy0m2k	411	71	allogeneic	allogeneic	NN
cord-015922-5wwy0m2k	411	72	blood	blood	NN
cord-015922-5wwy0m2k	411	73	and	and	CC
cord-015922-5wwy0m2k	411	74	marrow	marrow	NN
cord-015922-5wwy0m2k	411	75	transplant	transplant	NN
cord-015922-5wwy0m2k	411	76	recipients	recipient	NNS
cord-015922-5wwy0m2k	411	77	:	:	:
cord-015922-5wwy0m2k	411	78	evolution	evolution	NN
cord-015922-5wwy0m2k	411	79	of	of	IN
cord-015922-5wwy0m2k	411	80	risk	risk	NN
cord-015922-5wwy0m2k	411	81	factors	factor	NNS
cord-015922-5wwy0m2k	411	82	after	after	IN
cord-015922-5wwy0m2k	411	83	the	the	DT
cord-015922-5wwy0m2k	411	84	adoption	adoption	NN
cord-015922-5wwy0m2k	411	85	of	of	IN
cord-015922-5wwy0m2k	411	86	prophylactic	prophylactic	JJ
cord-015922-5wwy0m2k	411	87	fluconazole	fluconazole	NNP
cord-015922-5wwy0m2k	411	88	Prevention	Prevention	NNP
cord-015922-5wwy0m2k	411	89	and	and	CC
cord-015922-5wwy0m2k	411	90	early	early	JJ
cord-015922-5wwy0m2k	411	91	treatment	treatment	NN
cord-015922-5wwy0m2k	411	92	of	of	IN
cord-015922-5wwy0m2k	411	93	invasive	invasive	JJ
cord-015922-5wwy0m2k	411	94	fungal	fungal	JJ
cord-015922-5wwy0m2k	411	95	infection	infection	NN
cord-015922-5wwy0m2k	411	96	in	in	IN
cord-015922-5wwy0m2k	411	97	patients	patient	NNS
cord-015922-5wwy0m2k	411	98	with	with	IN
cord-015922-5wwy0m2k	411	99	cancer	cancer	NN
cord-015922-5wwy0m2k	411	100	and	and	CC
cord-015922-5wwy0m2k	411	101	neutropenia	neutropenia	NN
cord-015922-5wwy0m2k	411	102	and	and	CC
cord-015922-5wwy0m2k	411	103	in	in	IN
cord-015922-5wwy0m2k	411	104	stem	stem	NN
cord-015922-5wwy0m2k	411	105	cell	cell	NN
cord-015922-5wwy0m2k	411	106	transplant	transplant	NN
cord-015922-5wwy0m2k	411	107	recipients	recipient	NNS
cord-015922-5wwy0m2k	411	108	in	in	IN
cord-015922-5wwy0m2k	411	109	the	the	DT
cord-015922-5wwy0m2k	411	110	era	era	NN
cord-015922-5wwy0m2k	411	111	of	of	IN
cord-015922-5wwy0m2k	411	112	newer	new	JJR
cord-015922-5wwy0m2k	411	113	broad	broad	JJ
cord-015922-5wwy0m2k	411	114	-	-	HYPH
cord-015922-5wwy0m2k	411	115	spectrum	spectrum	NN
cord-015922-5wwy0m2k	411	116	antifungal	antifungal	JJ
cord-015922-5wwy0m2k	411	117	agents	agent	NNS
cord-015922-5wwy0m2k	411	118	and	and	CC
cord-015922-5wwy0m2k	411	119	diagnostic	diagnostic	JJ
cord-015922-5wwy0m2k	411	120	adjuncts	adjunct	NNS
cord-015922-5wwy0m2k	412	1	Defining	define	VBG
cord-015922-5wwy0m2k	412	2	opportunistic	opportunistic	JJ
cord-015922-5wwy0m2k	412	3	invasive	invasive	JJ
cord-015922-5wwy0m2k	412	4	fungal	fungal	JJ
cord-015922-5wwy0m2k	412	5	infections	infection	NNS
cord-015922-5wwy0m2k	412	6	in	in	IN
cord-015922-5wwy0m2k	412	7	immunocompromised	immunocompromised	JJ
cord-015922-5wwy0m2k	412	8	patients	patient	NNS
cord-015922-5wwy0m2k	412	9	with	with	IN
cord-015922-5wwy0m2k	412	10	cancer	cancer	NN
cord-015922-5wwy0m2k	412	11	and	and	CC
cord-015922-5wwy0m2k	412	12	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	412	13	stem	stem	NN
cord-015922-5wwy0m2k	412	14	cell	cell	NN
cord-015922-5wwy0m2k	412	15	transplants	transplant	NNS
cord-015922-5wwy0m2k	412	16	:	:	:
cord-015922-5wwy0m2k	413	1	an	an	DT
cord-015922-5wwy0m2k	413	2	international	international	JJ
cord-015922-5wwy0m2k	413	3	consensus	consensus	NN
cord-015922-5wwy0m2k	413	4	Should	Should	MD
cord-015922-5wwy0m2k	413	5	the	the	DT
cord-015922-5wwy0m2k	413	6	consensus	consensus	NN
cord-015922-5wwy0m2k	413	7	guidelines	guideline	NNS
cord-015922-5wwy0m2k	413	8	'	'	POS
cord-015922-5wwy0m2k	413	9	specific	specific	JJ
cord-015922-5wwy0m2k	413	10	criteria	criterion	NNS
cord-015922-5wwy0m2k	413	11	for	for	IN
cord-015922-5wwy0m2k	413	12	the	the	DT
cord-015922-5wwy0m2k	413	13	diagnosis	diagnosis	NN
cord-015922-5wwy0m2k	413	14	of	of	IN
cord-015922-5wwy0m2k	413	15	invasive	invasive	JJ
cord-015922-5wwy0m2k	413	16	fungal	fungal	JJ
cord-015922-5wwy0m2k	413	17	infection	infection	NN
cord-015922-5wwy0m2k	413	18	be	be	VB
cord-015922-5wwy0m2k	413	19	changed	change	VBN
cord-015922-5wwy0m2k	413	20	?	?	.
cord-015922-5wwy0m2k	414	1	Reactivity	reactivity	NN
cord-015922-5wwy0m2k	414	2	of	of	IN
cord-015922-5wwy0m2k	414	3	(	(	-LRB-
cord-015922-5wwy0m2k	414	4	1->3)-beta	1->3)-beta	CD
cord-015922-5wwy0m2k	414	5	-	-	HYPH
cord-015922-5wwy0m2k	414	6	d	d	NN
cord-015922-5wwy0m2k	414	7	-	-	HYPH
cord-015922-5wwy0m2k	414	8	glucan	glucan	JJ
cord-015922-5wwy0m2k	414	9	assay	assay	NN
cord-015922-5wwy0m2k	414	10	with	with	IN
cord-015922-5wwy0m2k	414	11	commonly	commonly	RB
cord-015922-5wwy0m2k	414	12	used	use	VBN
cord-015922-5wwy0m2k	414	13	intravenous	intravenous	JJ
cord-015922-5wwy0m2k	414	14	antimicrobials	antimicrobial	NNS
cord-015922-5wwy0m2k	414	15	Increasing	increase	VBG
cord-015922-5wwy0m2k	414	16	volume	volume	NN
cord-015922-5wwy0m2k	414	17	and	and	CC
cord-015922-5wwy0m2k	414	18	changing	change	VBG
cord-015922-5wwy0m2k	414	19	characteristics	characteristic	NNS
cord-015922-5wwy0m2k	414	20	of	of	IN
cord-015922-5wwy0m2k	414	21	invasive	invasive	JJ
cord-015922-5wwy0m2k	414	22	pulmonary	pulmonary	JJ
cord-015922-5wwy0m2k	414	23	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	414	24	on	on	IN
cord-015922-5wwy0m2k	414	25	sequential	sequential	JJ
cord-015922-5wwy0m2k	414	26	thoracic	thoracic	JJ
cord-015922-5wwy0m2k	414	27	computed	compute	VBN
cord-015922-5wwy0m2k	414	28	tomography	tomography	NN
cord-015922-5wwy0m2k	414	29	scans	scan	NNS
cord-015922-5wwy0m2k	414	30	in	in	IN
cord-015922-5wwy0m2k	414	31	patients	patient	NNS
cord-015922-5wwy0m2k	414	32	with	with	IN
cord-015922-5wwy0m2k	414	33	neutropenia	neutropenia	NN
cord-015922-5wwy0m2k	414	34	Empiric	Empiric	NNP
cord-015922-5wwy0m2k	414	35	antibiotic	antibiotic	JJ
cord-015922-5wwy0m2k	414	36	and	and	CC
cord-015922-5wwy0m2k	414	37	antifungal	antifungal	JJ
cord-015922-5wwy0m2k	414	38	therapy	therapy	NN
cord-015922-5wwy0m2k	414	39	for	for	IN
cord-015922-5wwy0m2k	414	40	cancer	cancer	NN
cord-015922-5wwy0m2k	414	41	patients	patient	NNS
cord-015922-5wwy0m2k	414	42	with	with	IN
cord-015922-5wwy0m2k	414	43	prolonged	prolonged	JJ
cord-015922-5wwy0m2k	414	44	fever	fever	NN
cord-015922-5wwy0m2k	414	45	and	and	CC
cord-015922-5wwy0m2k	414	46	granulocytopenia	granulocytopenia	NNP
cord-015922-5wwy0m2k	414	47	Empiric	Empiric	NNP
cord-015922-5wwy0m2k	414	48	antifungal	antifungal	JJ
cord-015922-5wwy0m2k	414	49	therapy	therapy	NN
cord-015922-5wwy0m2k	414	50	in	in	IN
cord-015922-5wwy0m2k	414	51	febrile	febrile	JJ
cord-015922-5wwy0m2k	414	52	granulocytopenic	granulocytopenic	NN
cord-015922-5wwy0m2k	414	53	patients	patient	NNS
cord-015922-5wwy0m2k	414	54	.	.	.
cord-015922-5wwy0m2k	415	1	EORTC	EORTC	NNP
cord-015922-5wwy0m2k	415	2	International	International	NNP
cord-015922-5wwy0m2k	415	3	Antimicrobial	Antimicrobial	NNP
cord-015922-5wwy0m2k	415	4	Therapy	Therapy	NNP
cord-015922-5wwy0m2k	415	5	Cooperative	Cooperative	NNP
cord-015922-5wwy0m2k	415	6	Group	Group	NNP
cord-015922-5wwy0m2k	415	7	Liposomal	Liposomal	NNP
cord-015922-5wwy0m2k	415	8	amphotericin	amphotericin	NNS
cord-015922-5wwy0m2k	415	9	B	b	NN
cord-015922-5wwy0m2k	415	10	for	for	IN
cord-015922-5wwy0m2k	415	11	empirical	empirical	JJ
cord-015922-5wwy0m2k	415	12	therapy	therapy	NN
cord-015922-5wwy0m2k	415	13	in	in	IN
cord-015922-5wwy0m2k	415	14	patients	patient	NNS
cord-015922-5wwy0m2k	415	15	with	with	IN
cord-015922-5wwy0m2k	415	16	persistent	persistent	JJ
cord-015922-5wwy0m2k	415	17	fever	fever	NN
cord-015922-5wwy0m2k	415	18	and	and	CC
cord-015922-5wwy0m2k	415	19	neutropenia	neutropenia	NN
cord-015922-5wwy0m2k	415	20	.	.	.
cord-015922-5wwy0m2k	416	1	National	National	NNP
cord-015922-5wwy0m2k	416	2	Institute	Institute	NNP
cord-015922-5wwy0m2k	416	3	of	of	IN
cord-015922-5wwy0m2k	416	4	Allergy	Allergy	NNP
cord-015922-5wwy0m2k	416	5	and	and	CC
cord-015922-5wwy0m2k	416	6	Infectious	Infectious	NNP
cord-015922-5wwy0m2k	416	7	Diseases	Diseases	NNPS
cord-015922-5wwy0m2k	417	1	Mycoses	Mycoses	NNP
cord-015922-5wwy0m2k	417	2	Study	Study	NNP
cord-015922-5wwy0m2k	417	3	Group	Group	NNP
cord-015922-5wwy0m2k	417	4	Voriconazole	Voriconazole	NNP
cord-015922-5wwy0m2k	417	5	compared	compare	VBN
cord-015922-5wwy0m2k	417	6	with	with	IN
cord-015922-5wwy0m2k	417	7	liposomal	liposomal	JJ
cord-015922-5wwy0m2k	417	8	amphotericin	amphotericin	NNS
cord-015922-5wwy0m2k	417	9	B	b	NN
cord-015922-5wwy0m2k	417	10	for	for	IN
cord-015922-5wwy0m2k	417	11	empirical	empirical	JJ
cord-015922-5wwy0m2k	417	12	antifungal	antifungal	JJ
cord-015922-5wwy0m2k	417	13	therapy	therapy	NN
cord-015922-5wwy0m2k	417	14	in	in	IN
cord-015922-5wwy0m2k	417	15	patients	patient	NNS
cord-015922-5wwy0m2k	417	16	with	with	IN
cord-015922-5wwy0m2k	417	17	neutropenia	neutropenia	NN
cord-015922-5wwy0m2k	417	18	and	and	CC
cord-015922-5wwy0m2k	417	19	persistent	persistent	JJ
cord-015922-5wwy0m2k	417	20	fever	fever	NN
cord-015922-5wwy0m2k	417	21	Voriconazole	Voriconazole	NNP
cord-015922-5wwy0m2k	417	22	versus	versus	IN
cord-015922-5wwy0m2k	417	23	amphotericin	amphotericin	NNS
cord-015922-5wwy0m2k	417	24	B	b	NN
cord-015922-5wwy0m2k	417	25	for	for	IN
cord-015922-5wwy0m2k	417	26	primary	primary	JJ
cord-015922-5wwy0m2k	417	27	therapy	therapy	NN
cord-015922-5wwy0m2k	417	28	of	of	IN
cord-015922-5wwy0m2k	417	29	invasive	invasive	JJ
cord-015922-5wwy0m2k	417	30	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	417	31	Voriconazole	Voriconazole	NNP
cord-015922-5wwy0m2k	417	32	and	and	CC
cord-015922-5wwy0m2k	417	33	sirolimus	sirolimus	NNP
cord-015922-5wwy0m2k	417	34	coadministration	coadministration	NN
cord-015922-5wwy0m2k	417	35	after	after	IN
cord-015922-5wwy0m2k	417	36	allogeneic	allogeneic	JJ
cord-015922-5wwy0m2k	417	37	hematopoietic	hematopoietic	JJ
cord-015922-5wwy0m2k	417	38	stem	stem	NN
cord-015922-5wwy0m2k	417	39	cell	cell	NN
cord-015922-5wwy0m2k	417	40	transplantation	transplantation	NN
cord-015922-5wwy0m2k	417	41	Torsades	Torsades	NNP
cord-015922-5wwy0m2k	417	42	de	de	IN
cord-015922-5wwy0m2k	417	43	pointes	pointes	FW
cord-015922-5wwy0m2k	417	44	associated	associate	VBN
cord-015922-5wwy0m2k	417	45	with	with	IN
cord-015922-5wwy0m2k	417	46	voriconazole	voriconazole	NNP
cord-015922-5wwy0m2k	417	47	use	use	VBP
cord-015922-5wwy0m2k	417	48	Salvage	salvage	NN
cord-015922-5wwy0m2k	417	49	therapy	therapy	NN
cord-015922-5wwy0m2k	417	50	with	with	IN
cord-015922-5wwy0m2k	417	51	voriconazole	voriconazole	NN
cord-015922-5wwy0m2k	417	52	for	for	IN
cord-015922-5wwy0m2k	417	53	invasive	invasive	JJ
cord-015922-5wwy0m2k	417	54	fungal	fungal	JJ
cord-015922-5wwy0m2k	417	55	infections	infection	NNS
cord-015922-5wwy0m2k	417	56	in	in	IN
cord-015922-5wwy0m2k	417	57	patients	patient	NNS
cord-015922-5wwy0m2k	417	58	failing	fail	VBG
cord-015922-5wwy0m2k	417	59	or	or	CC
cord-015922-5wwy0m2k	417	60	intolerant	intolerant	JJ
cord-015922-5wwy0m2k	417	61	to	to	IN
cord-015922-5wwy0m2k	417	62	standard	standard	JJ
cord-015922-5wwy0m2k	417	63	antifungal	antifungal	JJ
cord-015922-5wwy0m2k	417	64	therapy	therapy	NN
cord-015922-5wwy0m2k	417	65	Posaconazole	Posaconazole	NNP
cord-015922-5wwy0m2k	417	66	or	or	CC
cord-015922-5wwy0m2k	417	67	fluconazole	fluconazole	NN
cord-015922-5wwy0m2k	417	68	for	for	IN
cord-015922-5wwy0m2k	417	69	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	417	70	in	in	IN
cord-015922-5wwy0m2k	417	71	severe	severe	JJ
cord-015922-5wwy0m2k	417	72	graft	graft	NN
cord-015922-5wwy0m2k	417	73	-	-	HYPH
cord-015922-5wwy0m2k	417	74	versus	versus	IN
cord-015922-5wwy0m2k	417	75	-	-	HYPH
cord-015922-5wwy0m2k	417	76	host	host	NN
cord-015922-5wwy0m2k	417	77	disease	disease	NN
cord-015922-5wwy0m2k	417	78	Posaconazole	Posaconazole	NNP
cord-015922-5wwy0m2k	417	79	vs.	vs.	IN
cord-015922-5wwy0m2k	417	80	fluconazole	fluconazole	NNP
cord-015922-5wwy0m2k	417	81	or	or	CC
cord-015922-5wwy0m2k	417	82	itraconazole	itraconazole	NNP
cord-015922-5wwy0m2k	417	83	prophylaxis	prophylaxis	NN
cord-015922-5wwy0m2k	417	84	in	in	IN
cord-015922-5wwy0m2k	417	85	patients	patient	NNS
cord-015922-5wwy0m2k	417	86	with	with	IN
cord-015922-5wwy0m2k	417	87	neutropenia	neutropenia	NN
cord-015922-5wwy0m2k	417	88	Prophylaxis	Prophylaxis	NNP
cord-015922-5wwy0m2k	417	89	and	and	CC
cord-015922-5wwy0m2k	417	90	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	417	91	-	-	,
cord-015922-5wwy0m2k	417	92	has	have	VBZ
cord-015922-5wwy0m2k	417	93	the	the	DT
cord-015922-5wwy0m2k	417	94	principle	principle	NN
cord-015922-5wwy0m2k	417	95	been	be	VBN
cord-015922-5wwy0m2k	417	96	proven	prove	VBN
cord-015922-5wwy0m2k	417	97	?	?	.
cord-015922-5wwy0m2k	418	1	Posaconazole	Posaconazole	NNP
cord-015922-5wwy0m2k	418	2	as	as	IN
cord-015922-5wwy0m2k	418	3	salvage	salvage	NN
cord-015922-5wwy0m2k	418	4	therapy	therapy	NN
cord-015922-5wwy0m2k	418	5	for	for	IN
cord-015922-5wwy0m2k	419	1	zygomycosis	zygomycosis	NNP
cord-015922-5wwy0m2k	419	2	Posaconazole	Posaconazole	NNP
cord-015922-5wwy0m2k	419	3	is	be	VBZ
cord-015922-5wwy0m2k	419	4	effective	effective	JJ
cord-015922-5wwy0m2k	419	5	as	as	IN
cord-015922-5wwy0m2k	419	6	salvage	salvage	NN
cord-015922-5wwy0m2k	419	7	therapy	therapy	NN
cord-015922-5wwy0m2k	419	8	in	in	IN
cord-015922-5wwy0m2k	419	9	zygomycosis	zygomycosis	NNP
cord-015922-5wwy0m2k	419	10	:	:	:
cord-015922-5wwy0m2k	419	11	a	a	DT
cord-015922-5wwy0m2k	419	12	retrospective	retrospective	JJ
cord-015922-5wwy0m2k	419	13	summary	summary	NN
cord-015922-5wwy0m2k	419	14	of	of	IN
cord-015922-5wwy0m2k	419	15	91	91	CD
cord-015922-5wwy0m2k	419	16	cases	case	NNS
cord-015922-5wwy0m2k	419	17	Treatment	treatment	NN
cord-015922-5wwy0m2k	419	18	of	of	IN
cord-015922-5wwy0m2k	419	19	invasive	invasive	JJ
cord-015922-5wwy0m2k	419	20	aspergillosis	aspergillosis	NN
cord-015922-5wwy0m2k	419	21	with	with	IN
cord-015922-5wwy0m2k	419	22	posaconazole	posaconazole	NNP
cord-015922-5wwy0m2k	419	23	in	in	IN
cord-015922-5wwy0m2k	419	24	patients	patient	NNS
cord-015922-5wwy0m2k	419	25	who	who	WP
cord-015922-5wwy0m2k	419	26	are	be	VBP
cord-015922-5wwy0m2k	419	27	refractory	refractory	JJ
cord-015922-5wwy0m2k	419	28	to	to	IN
cord-015922-5wwy0m2k	419	29	or	or	CC
cord-015922-5wwy0m2k	419	30	intolerant	intolerant	JJ
cord-015922-5wwy0m2k	419	31	of	of	IN
cord-015922-5wwy0m2k	419	32	conventional	conventional	JJ
cord-015922-5wwy0m2k	419	33	therapy	therapy	NN
cord-015922-5wwy0m2k	419	34	:	:	:
cord-015922-5wwy0m2k	419	35	an	an	DT
cord-015922-5wwy0m2k	419	36	externally	externally	RB
cord-015922-5wwy0m2k	419	37	controlled	control	VBN
cord-015922-5wwy0m2k	419	38	trial	trial	NN
cord-015922-5wwy0m2k	419	39	We	-PRON-	PRP
cord-015922-5wwy0m2k	419	40	would	would	MD
cord-015922-5wwy0m2k	419	41	like	like	VB
cord-015922-5wwy0m2k	419	42	to	to	TO
cord-015922-5wwy0m2k	419	43	thank	thank	VB
cord-015922-5wwy0m2k	419	44	Robert	Robert	NNP
cord-015922-5wwy0m2k	419	45	H	H	NNP
cord-015922-5wwy0m2k	419	46	Rubin	Rubin	NNP
cord-015922-5wwy0m2k	419	47	,	,	,
cord-015922-5wwy0m2k	419	48	M.D.	M.D.	NNP
cord-015922-5wwy0m2k	419	49	for	for	IN
cord-015922-5wwy0m2k	419	50	the	the	DT
cord-015922-5wwy0m2k	419	51	many	many	JJ
cord-015922-5wwy0m2k	419	52	years	year	NNS
cord-015922-5wwy0m2k	419	53	of	of	IN
cord-015922-5wwy0m2k	419	54	advice	advice	NN
cord-015922-5wwy0m2k	419	55	and	and	CC
cord-015922-5wwy0m2k	419	56	teaching	teaching	NN
cord-015922-5wwy0m2k	419	57	,	,	,
cord-015922-5wwy0m2k	419	58	and	and	CC
cord-015922-5wwy0m2k	419	59	for	for	IN
cord-015922-5wwy0m2k	419	60	critically	critically	RB
cord-015922-5wwy0m2k	419	61	reviewing	review	VBG
cord-015922-5wwy0m2k	419	62	this	this	DT
cord-015922-5wwy0m2k	419	63	work	work	NN
cord-015922-5wwy0m2k	419	64	.	.	.